,id,ticker,title,category,content,date,provider,url,article_id
181076,402592,ABT,Abbott Q4 top line up 7   non GAAP EPS up 17 ,news,"Abbott Laboratories  ABT  Q4 results  Revenues   8 314M   7 1    Nutrition   1 868M   5 2    Diagnostics   2 058M   5 0    Established Pharmaceuticals   1 174M   7 8    Medical Devices   3 204M   9 7   
Net Income   1 049M   60 4    EPS   0 59   59 5    non GAAP Net Income   1 705M   18 1    non GAAP EPS   0 95   17 3   
2020 Guidance  GAAP EPS   2 35   2 45  Non GAAP EPS   3 55   3 65 
Q1 Guidance  GAAP EPS   0 40   0 42  Non GAAP EPS   0 69   0 71 
Shares are up 1  premarket ",2020-01-22,Seeking Alpha,https://invst.ly/plbny,2064815
181077,402593,ABT,Here s Why Investors Really Liked Abbott Labs  Q4 Earnings Results,news,"It s fair to say that Abbott Laboratories   NYSE ABT  stock performance in 2019 was good but not great  Shares jumped more than 20  last year while lagging well behind the 29  gain delivered by the S P 500 index  But Abbott is off to a great start in 2020 
The global healthcare leader announced its fourth quarter results on Wednesday before the market opened  There was a lot for investors to like with its latest quarterly update 

By the numbers
Abbott reported Q4 revenue of  8 3 billion  a solid 7 1  year over year increase  This also topped the consensus analysts  estimate of  8 26 billion 
The company announced Q4 diluted earnings per share from continuing operations of  0 59 based on generally accepted accounting principles  GAAP   This reflected a 59 5  jump from the  0 37 per share posted in the year ago period 
Abbott s adjusted diluted EPS for the fourth quarter came in at  0 95 per share  up from  0 81 in the prior year period  This met the average analyst earnings estimate 
Behind the numbers
The Q4 sales growth looks even more impressive when adjusted for foreign exchange fluctuations  The company said that its sales increased by 8 5  year over year on a constant currency basis and excluding the impact of discontinued operations 
All three of Abbott s business segments delivered solid growth  The company s medical devices unit was the biggest winner  with revenue jumping 9 7  year over year to  3 2 billion thanks to double digit organic sales growth in its diabetes care  electrophysiology  heart failure  and structural heart businesses 
Sales for the company s established pharmaceuticals segment increased 7 8  over the prior year period to nearly  1 2 billion  Improving performances in Asia and Latin America drove this growth  
Abbott s nutrition and diagnostics segments trailed with year over year revenue growth of 5 2  and 5   respectively  Total Q4 revenue for the company s diagnostics segment was nearly  2 1 billion  with the Alinity line of diagnostic instruments contributing significantly to growth  The nutrition segment raked in  1 9 billion  with stronger growth in the adult market driven largely by Abbott s Ensure and Glucerna brands 
The company s bottom line improvement was even better than its sales mainly because operating costs increased at a slower pace than sales did  In addition  Abbott s interest expense and tax expense decreased significantly from the prior year period 
Looking ahead
Management anticipates full year 2020 organic sales growth to come in between 7  and 8   with GAAP EPS between  2 35 and  2 45  Adjusted diluted EPS is expected to be between  3 55 and  3 65  For the first quarter of 2020  the company is anticipating EPS between  0 40 and  0 42  with adjusted EPS between  0 69 and  0 71 
CEO Miles White said that Abbott s focus on organic growth is  driving top tier performance   He added that the company is  entering 2020 with very good momentum and targeting continued strong growth   
Abbott remains one of the top blue chip stocks on the market  with solid growth and an attractive dividend  With the potential for Food and Drug Administration clearance of the company s new version of its Freestyle Libre continuous glucose monitoring system in the near future and positive Q4 results under its belt  Abbott has a pretty good chance to deliver an even better performance in 2020 than it did last year ",2020-01-22,The Motley Fool,https://invst.ly/plgiw,2065200
181078,402594,ABT,Abbott Laboratories Beats Revenue Expectations With Balanced Growth,news,"Abbott Laboratories  NYSE ABT  released its fourth quarter  report Wednesday morning  beating expectations for revenue and meeting its guidance for earnings per share  Shares were up by about 3  on the news 
For the quarter  revenue rose by 7 1  year over year to  8 31 billion  compared to analysts  consensus estimate of  8 26 billion  and was up 8 5  after excluding foreign currency effects and a discontinued business  Adjusted earnings per share were up 17 3  to  0 95  precisely hitting the midpoint of the guidance range management provided three months ago 
Abbott s largest segment  medical devices  provided its strongest sales gain    11 3   excluding foreign currency impacts  Sales of the company s continuous glucose monitoring system  FreeStyle Libre  increased 62   and sales of the MitraClip heart valve implant product grew 29  

Abbott s other three segments delivered solid growth as well  led by its branded generic drug business targeted at emerging markets  which had organic growth of 10   The diagnostics unit s sales grew by 6 4   and the nutrition segment had organic sales growth of 5 8  
Management s newly released guidance for 2020 forecasts sales growth of between 7  and 8   excluding currency impacts  which is above the 6 4  growth that analysts have been modeling  The company expects adjusted EPS for the year to fall in the  3 55 to  3 65 range  which would be growth of 11  at the midpoint  That s consistent with analysts  consensus estimate 
Abbott s well managed  diversified healthcare business is a model of consistency  hitting its guidance quarter after quarter  and the market is applauding that quality today  to the benefit of shareholders in this Dividend Aristocrat ",2020-01-22,The Motley Fool,https://invst.ly/pli83,2065325
181079,402595,ABT,Abbott Laboratories  ABT  Q4 2019 Earnings Call Transcript,news,"Abbott Laboratories  NYSE ABT Q4 2019 Earnings CallJan 22  2020  9 30 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorGood morning and thank you for standing by  welcome to Abbott s Fourth Quarter 2019 Earnings Conference Call   Operator Instructions  With the exception of any participants  questions asked during the question and answer session  the entire call  including the question and answer session is material copyrighted by Abbott  It cannot be recorded or rebroadcast without Abbott s expressed written permission I would now like to introduce Mr  Scott Leinenweber  Vice President  Investor Relations  Licensing and Acquisitions Scott Leinenweber    Vice President of Investor Relations  Licensing and AcquisitionsGood morning and thank you for joining us  With me today are Miles White  Chairman of the Board and Chief Executive Officer  Robert Ford  President and Chief Operating Officer  and Brian Yoor  Executive Vice President  Finance and Chief Financial Officer  Miles will provide opening remarks  Brian will discuss our performance and outlook in more detail  Following their comments  we ll take your questions Before we get started  some statements made today may be forward looking for purposes of the Private Securities Litigation Reform Act of 1995  including the expected financial results for 2020  Abbott cautions that these forward looking statements are subject to risk and uncertainties that may cause actual results to differ materially from those indicated in the forward looking statements  Economic  competitive  governmental  technological and other factors that may affect Abbott s operations are discussed in Item 1A  Risk Factors to our annual report on Securities and Exchange Commission Form 10 K for the year ended December 31st  2018 Abbott undertakes no obligation to release publicly any revisions to forward looking statements as a result of subsequent events or developments except as required by law  Please note that financial results and guidance provided on the call today for sales  EPS and line items of the P L will be for continuing operations only  On today s conference call as in the past non GAAP financial measures will be used to help investors understand Abbott s ongoing business performance  These non GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today  which are available on our website at abbott com  Unless otherwise noted  our commentary on sales growth refers to organic sales growth  which is defined in our earnings news release issued earlier today With that I will now turn the call over to Miles Miles D  White    Chairman and Chief Executive OfficerOkay  Thanks  Scott  Good morning  2019 was another highly successful year for Abbott  Our focused execution resulted in strong financial performance  including ongoing earnings per share of  3 24 reflecting 12 5  growth on an absolute basis and even higher growth when excluding the impact of currency  All four of our businesses performed well contributing to full year organic sales growth of more than 7 5  which is above the guidance range we set at the beginning of last year  The successful year was capped off by a strong fourth quarter with organic sales growth of 8 5   including double digit sales growth in Medical Devices  Established Pharmaceuticals and Core Laboratory Diagnostics  along with ongoing EPS growth of more than 17  Our consistent strong performance demonstrates that our business model is working exactly as intended  We ve built the Company very deliberately through a multi year process to deliver superior results for years to come  We ve shaped our businesses to align with important trends to make sure we re in the right places with the right products and we ve targeted businesses that are focused on some of the world s greatest healthcare concerns  for example  diabetes and cardiovascular disease are two of the most significant healthcare challenges of our lifetime  They are chronic  long lasting and dramatically increasing in prevalence around the world Nearly every healthcare decision begins with a diagnostic test  And this testing not only occurs in the traditional hospital setting  but also increasingly at alternate sites such as physicians  offices  pharmacies and even at home  Proper nutrition is the foundational element of good health across every stage of life  Whether you re a newborn baby  a child striving to grow  or an aging adult working to overcome a health condition  And access to healthcare continues to expand rapidly in emerging markets were 85  of the world s population resides We shaped our Company to achieve scale and leadership positions in all of these areas  The investments we ve made and our focus on execution are working  Our product pipelines are strong  our operating culture is strong and we re well positioned to achieve sustainable strong growth for years to come For 2020 we re forecasting another year of top tier financial performance  As we announced this morning we forecast organic sales growth of 7  to 8   and adjusted earnings per share of  3 55 to  3 65  reflecting double digit growth I ll now provide a brief overview of our 2019 results and 2020 outlook for each business  and I ll start with Diagnostics  where sales grew 6 5  in the fourth quarter led by double digit growth in core laboratory testing  The rollout of Alinity continues to go well in Europe where we re winning new business at a high rate and successfully renewing existing contracts that come up for bid  We continue to expand our rollout of Alinity systems across multiple key markets including US  where last year we obtained FDA approval of Alinity for blood and plasma screening and have made significant progress obtaining regulatory approvals for a critical mass of our immunoassay and clinical chemistry test menu I ll turn now to Nutrition  where sales increased 6  in the quarter  led by strong growth across several countries and segments of our business  including Southeast Asia and Latin America  across both Pediatric and Adult Nutrition as well as above market growth in the US  In Pediatric Nutrition growth was driven by PediaSure  our nutrition solutions to help kids grow and thrive  and Pedialyte  our oral rehydration product which continues to see unprecedented uptick with both children and adults  In Adult Nutrition  global growth of 10  in the fourth quarter was led by Ensure  our leading complete and balanced nutrition brand and Glucerna our leading brand for people with diabetes Moving now to Medical Devices  where sales increased nearly 11 5  in the fourth quarter led by double digit growth in Structural Heart  Diabetes Care  Electrophysiology and Heart Failure  In Structural Heart  sales increased 17  in the fourth quarter  Over the last couple of years  our portfolio and long term growth opportunities in this area have strengthened considerably  We ve been building our position organically in this area for quite some time  when in 2017  the combination with St  Jude created what I d now consider a best in class Structural Heart portfolio MitraClip  our market leading device for the minimally invasive treatment of mitral regurgitation or a leaky heart valve is the cornerstone of our portfolio with annual sales this past year of nearly  700 million  growing 30   Last year  we obtained an important new indication in the US that significantly expands the number of people that can be treated with MitraClip  And just last week  we announced that we are initiating a clinical trial that offers the potential to expand the treatable patient population even further Beyond MitraClip  several exciting technologies are expected to emerge from our Structural Heart pipeline in 2020  including CE Mark approvals for TriClip  a first of its kind technology to repair leaky tricuspid heart valves and for Tendyne  which targets replacement of the mitral valve  as well as US approval of Portico for Transcatheter Aortic Valve Replacement Turning now to Diabetes Care where sales increased nearly 35  in the quarter led by FreeStyle Libre  our revolutionary continuous glucose monitoring system  Several years back we saw an opportunity to approach continuous glucose monitoring or CGM in a fundamentally different manner compared to others in the space  We challenged ourselves to rethink existing paradigms as we sought to develop a solution that would truly benefit the mass population of people living with diabetes around the world  That aspiration influenced every aspect of Libre  highly accurate  simple to use  particularly affordable and easy for patients to access The results of our unique approach have been remarkable by any measure  Libre has quickly become the global market leading wearable CGM  Its user base has roughly doubled each year to its current level of approximately 2 million users globally  including the highest user base among CGMs in the US  Reimbursement coverage has ramped up quickly around the world as payers increasingly recognize its highly differentiated value proposition  And it s only CGM that s widely available through the pharmacy channel  which is a significant benefit for patients as it simplifies the process of acquiring the product In 2019  Libre achieved full year sales approaching  2 billion  an increase of 70  versus the prior year  And importantly  as we plan for the substantial growth opportunity to come  we significantly expanded our manufacturing capacity to keep up with anticipated demand for this life changing technology Now  I ll wrap up with Established Pharmaceuticals or EPD  where sales increased 10  in the quarter led by growth across several geographies in Latin America and Asia  For the full year  sales increased 7  for the second year in a row  as this business continues to execute its unique branded generic strategy in emerging markets  These markets are growing rapidly  their populations are aging  their middle classes are expanding and healthcare spending is increasing due to improving access to healthcare  Our strategy to build a significant presence and scale in these markets is unique and continues to result in strong growth So in summary  this was another highly successful year with strong performance across our businesses  We continue to strengthen our leadership positions in some of the largest and fastest growing areas in healthcare and we re entering 2020 with great momentum across our businesses and targeting another year of strong organic sales growth and double digit EPS growth I ll now turn the call over to Brian to discuss our 2019 results and 2020 outlook in more detail  Brian Brian B  Yoor    Executive Vice President of Finance and Chief Financial OfficerThanks  Miles  As Scott mentioned earlier  please note that all references to sales growth rates unless otherwise noted are on an organic basis which is consistent with our previous guidance Turning to our results  Sales for the fourth quarter increased 8 5   Exchange had an unfavorable year over year impact of 1 4  on fourth quarter sales  Regarding other aspects of the P L  the adjusted gross margin ratio was 59 4  of sales  adjusted R D investment was 6 7  of sales and adjusted SG A expense was 28 3  of sales  The fourth quarter adjusted tax rate was 12 8  lower than our previous full year guidance of around 14 5   due to continued implementation of and adaptation to the US tax reform regulations  Our fourth quarter tax rate reflects the aggregate adjustment to achieve our full year revised effective tax rate of 14  Turning to our outlook for the full year 2020  today we issued guidance for adjusted earnings per share of  3 55 to  3 65  For the full year we forecast organic sales growth of 7  to 8   And based on current rates  we would expect exchange to have a negative impact of around 0 05  on our full year reported sales  We forecast an adjusted gross margin ratio of around 59  of sales for the full year  which reflects underlying gross margin improvement across our businesses  offset by the impact of investments to support the rapid market adoption of our Alinity diagnostic systems  investments in Libre and MitraClip manufacturing capacity expansions and the impact of currency mix  We forecast adjusted R D investment of approximately 7  of sales and adjusted SG A expense of around 29 5  of sales  We forecast net interest expense of around  515 million and non operating income around  200 million  Lastly  we forecast an adjusted tax rate of 13 5  to 14  for the full year 2020 Turning to our outlook for the first quarter  We forecast adjusted EPS of  0 69 to  0 71 which reflects double digit growth  We forecast organic sales growth of around 7  and at current rates would expect exchange to have a negative impact of a little more than 1  on our first quarter reported sales  We forecast an adjusted gross margin ratio of somewhat above 58 5  of sales  adjusted R D investment of somewhat above 7  of sales and adjusted SG A expense of around 32  of sales  Lastly  we forecast net interest expense of around  130 million in the first quarter Before we open the call for questions  I ll now provide a quick overview of our first quarter and full year organic sales growth outlook by business  For Established Pharmaceuticals  we forecast mid to high single digit growth for both the first quarter and the full year  In Nutrition  we forecast growth of around 4  for the full year and growth of 3  to 4  for the first quarter  In Diagnostics  we forecast mid to high single digit growth for both the first quarter and full year  and in Medical Devices  we forecast double digit growth similar to last year for both the first quarter and full year With that  we will now open the call for questions Questions and Answers OperatorThank you   Operator Instructions  And our first question comes from Bob Hopkins from Bank of America  Your line is open Bob Hopkins    Bank of America Merrill Lynch    AnalystGreat  Thanks for taking the question  So I guess  first  Miles congratulations on such an incredible run of 20 plus years of value creation  obviously incredibly impressive track record  And in light of that the first question  I d love to ask  both you and Robert to comment on a topic  that I know is on the minds of most investors from a big picture perspective and that is the durability of the incredible 7  revenue growth outlook that you guys have expressed for 2020 and beyond  And the main reason I want to ask that question is that when you take a step back  there is no other company in med tech modeling anything close to that kind of growth off of that large of a base  especially for multiple years  So Miles for you  I guess  just if you wouldn t mind providing some big picture thoughts on that durability topic  And then for Robert maybe getting a little bit more specific on the product areas that give you the confidence long term and whether or not M A or divestitures could play a slightly bigger role going forward to help you maintain that level of growth  Thank you Miles D  White    Chairman and Chief Executive OfficerBob  this is Miles  There is a temptation to sort of say something that sticks my successor with just unbelievable goals for the future  etc   is overwhelming  So I m going to speak first  Seriously  we have been building what we ve got here for an extended period of time  It didn t just happen  It s not based on a single driving product or driving business  It s actually quite broad based across all of our businesses  And while you know  a lot of people have commented to me or us that gee  you get the lot of big numbers and you know hard for a big company to grow  etc  We don t actually feel like that big a company And we don t necessarily feel even though we ve got leading positions in so many of our businesses  We don t actually feel like a lot of big numbers is working against us  We feel like the opportunity for growth  if you ve got an innovative pipeline and you re in markets  where there is a natural tailwind of growth demographically or from an innovation standpoint and so on  yeah  I don t really think that this whole notion of gee  our size or big numbers applies  If we were a tech company  you wouldn t be asking us that  because we d be too small So  you know  I think if we look at the size of the opportunities where we place the Company and its businesses and the portfolio of products and geographies and so forth  I think there is enormous market opportunity that s untapped  And I think there is enormous penetration to be tapped  and I think there are some obvious examples out there  And fortunately in all of our businesses  I think every one of them is innovating and creating new products and innovating to replace older products in a way that s really never been true before and it s across the board  And so as we look forward to that and model it  we think our growth rates are sustainable  How far out are they sustainable  I don t know  but years anyway And are we going to have speed bumps  We re going to have speed bumps of our own making  we re going to have speed bumps from trade  we re going to have speed bumps from exchange  we re going to have speed bumps in any number of ways  as all companies have and do and yet we    and we have them now  and we re still growing at a very healthy strong rate  And I credit the innovation pipeline  some smart acquisitions at the right time  with the right businesses  the right strategies  the right fits  I credit the execution of our organization and the culture of execution that is here  I have super confidence in my successor  no qualms  The minute you retire everybody thinks you ought to diversify your holdings  because you re too concentrated in one thing  I only wish I had more And I ll remind them every day that I m a shareholder  but which he knows  but I have nothing but confidence in the pipeline  the management  the products  the strategies and the new leader  who is going to take over from me  I have tremendous confidence in Robert  and he s got all the abilities  all the skills  etc  So we can keep talking about the lot of big numbers and gee  how do you grow on this base  We don t feel slowed or anything by that  We feel like we ve got tremendous opportunity to sustain our growth rates Robert B  Ford    President and Chief Operating OfficerYeah  Bob  this is Robert here  As you re aware  under Miles  leadership last 20 plus years  Abbott has been reshaped several times  I was close to him and to the Board when we went through this last reshaping of the Company to really position and align our businesses to kind of high growth markets  geographies  etc  And as Miles said  it wasn t just the acquisition piece of it  which was important  but it was also how we looked at our internal R D  our internal innovation  how we thought about it  So obviously with the transition here to CEO  there s the natural question of the incoming  Do they think differently  Is there a change in strategy  Is a different way of thinking  And I can tell you  I m very much aligned with Miles We see things very similar  as it relates to our strategy  how we operate  the philosophy of the Company  the vision we have for Abbott  And in the last 18 months for me  in particular to be kind of close to Miles during this transition period  being closer to him with his mentorship and learning how he has been able to kind of create value as you referenced in the beginning there  that leaves me with my number 1 priority to do that is to really execute as Miles said on these organic growth opportunities we have  And we have multiple growth drivers as you know  Bob that  in my opinion they re in their very early stages  whether it s Libre  the Alinity rollout  our rejuvenated cardiovascular portfolio  I think we ve got a great opportunity in our adult International Nutrition business  our branded generic pharmaceutical business in the emerging markets  which is a very unique strategy So I look at all of that and I think your question how sustainable is this  I think all these opportunities are in the early stages here  and it s really going to be up to me and the team here to make sure that we maximize on all of these opportunities  So we ve got a portfolio that s aligned to the biggest areas of medical need  attractive geographies  As Miles said about the pipeline  it s a very rich pipeline  We talk about how this pipeline has evolved  and how we haven t seen as rich as a pipeline at Abbott in a long time  and it s a nice cadence also  It s not just a kind of won and done  We ve got multiple kind of rollouts here Our operate    the way we operate is very strong  Miles talked about our culture  We set high aspirations for ourselves  and we do have a culture of accountability  of execution  and then you layer that in with 100 000 of the colleagues around the world that are passionate  they care about what they re doing  they believe in what we re doing  they believe in our strategy  I think we ve got all the elements here to be able to sustain this kind of growth rate going forward Bob Hopkins    Bank of America Merrill Lynch    AnalystGreat  That s super helpful  Just one super short follow up on Diabetes  Robert  if you wouldn t mind just giving us a quick update on Libre 2 timelines and your thoughts there  And then if you re willing to give us a sense for in your 2020 guidance  what sort of growth assumption are you making for Libre in 2020  Thank you Robert B  Ford    President and Chief Operating OfficerSure  So on Libre 2  specifically last October  I mentioned that we were working through a handful of issues  Quite frankly  we encounter this handful of issues in other parts of our business too  so it s nothing that s for us is terribly surprising  It s normal  I m not going to go into any of the real specifics here  But what I will say  Bob  is that since that time in October  I m very pleased with the progress that we ve made  And I continue to be very confident in Libre 2 and its performance and the product itself and its iCGM label So regarding the guidance on Libre 2  what I can tell you is that we ve got a lot of growth  We    our guidance contemplates  Phonetic  a lot of Libre growth  So we re not necessarily differentiating here between one and two  But if you look at our Q4  we had a great Q4 with Libre and that s without Libre 2 in the US  It was a great way to exit and to enter 2020  As Miles said  we re the market leader in CGM in revenue and in the amount of patients  and we re growing at twice the rate Our strategy here  has always been Miles talked about challenging some of the paradigms  It has always been from the moment we launched  to look at this as a more kind of consumer  retail  kind of web shop online play here  So when you look at our Q4  you don t see that kind of big Q4 spike and then drop in Q1  which you usually see from kind of medical benefit DME products  Our growth is very kind of consistent and sequential The US has done very well in the year  Obviously  we want to do better  but we exited the year with well over 0 5 million patients in the US  We set up some goals for 2019  as it relates to distribution  payer coverage in the US  formulary positions  And we exited 2019 exactly where we wanted to be  with all of those goals  all favorable to Libre So  our focus in the US in 2020 here is really to take advantage of what we ve established in terms of the infrastructure and drive demand  So you ll see more TV advertising  you ll see more sales force expansion  you ll see more partnerships and execution of those partnerships  you ll see more sampling  And I think that  that same momentum that you see in the US is also there in our international markets  which is obviously a much larger base for us  and we saw great momentum in Q4 So our 2020 here is really focusing on international markets as expanding Libre into geographies that we haven t yet launched  We were capacity constrained in 2019 to the several markets that we haven t launched  and we put in place now plans to roll Libre into those new geographies and rollout Libre 2 into some of those Libre 1 markets One thing I think is important to kind of put front and center here is the clinical aspect of Libre  It is the most studied CGM right now  And if you look at the data  whether it s our data  whether it s real world evidence data  whether it s third party government sponsored trials  they all say the same thing  which is people that use Libre have better outcomes  They live better  They have let    their A1c drops  Their hypo drops  Their rate of hospitalization goes down  So that the value proposition that we ve always envisioned for Libre not only is it intact  but we actually see it growing  It s an easy to use  intuitive  consumer friendly product that delivers the outcomes that are real and measurable and it s priced for mass adoption  it s affordable We always saw the therapy benefit not only for type 1s and for pumpers  we saw this therapy benefit for people that were on one shot a day insulin  oral med patients  So we always looked at this market to be 80 million to 100 million people  Now  is it going to penetrate all the 100 million people  That might be a little bit too aspirational  But what I would say  is it more than 2 million  3 million  5 million  10 million people  Absolutely  And that s how we re building our strategy  investing in the product  investing in the awareness and investing in the scalability  so we can capitalize on this opportunity Bob Hopkins    Bank of America Merrill Lynch    AnalystThank you OperatorThank you  And our next question comes from Robbie Marcus from J P  Morgan  Your line is open Robert Marcus    J P  Morgan    AnalystThanks for taking the question  I ll echo Bob s sentiment  Miles  sorry to see you go  but we re very happy to have someone so confident as Robert step in  Maybe if we could turn to Structural Heart  I was wondering if you could give an update on where we are with reimbursement and MitraClip  And then also a bit more broadly  Miles  you talked about some of the new product launches we re going to see in 2020  Maybe you could just walk us through those and the expectations throughout the year Robert B  Ford    President and Chief Operating OfficerSure  Robbie  I ll take that  On MitraClip listen  we had a great quarter  had a great year  and as Miles said in his comments about  700 million product growing at 30   And the interesting thing here is that the penetration of the therapy is only at about 5   right  So we see a long opportunity  I talked about MitraClip being a multi year  multi billion dollar opportunity here And there s several elements to that  CMS reimbursement is an important building block  We expect that some time in Q2  But I ve always said that it was more than just the CMS reimbursement for the indication expansion we got  We know that we need to be able to penetrate the therapy  We need to open new centers  make it more available  To do that  we need to hire more reps  invest in field clinical teams to be able to get that penetration  And we ve also invested in a lot of clinical evidence and building clinical evidence here  we just recently announced our study to investigate MitraClip in moderate risk surgical patients So again  we ve been investing to build this market and obviously MitraClip gets a lot of attention in the Structural Heart portfolio  But if I take a step back here  I think it s important that we look at  we ve always seen valvular heart disease as a big opportunity for Abbott  whether it s the demographics  whether it s the medical need  And we saw this unique opportunity with the St  Jude acquisition to put together our MitraClip capabilities with the portfolio  St  Jude and really create a stand alone business unit that was best in class for Structural Heart  And we did that and it s been about two years that we ve done that  And I    I think we re seeing really the impact of the effect of a dedicated team  R D  clinical  and we ve got a nice cadence of products coming out this year as a result of that work We ve got two new CE approvals that we expect this year  Miles mentioned them  TriClip  This is a modified version of our MitraClip to treat the leaky heart valve  We believe it s a big opportunity  because the therapy    if mitral therapy is low  tricuspid leaky valve treatment or repair is even lower  So we know that    we know how to build this  We did it with mitral  and we re going to go about doing it the same way  building the capability  the clinical evidence Another big opportunity we have is with Tendyne  This will be the first minimally invasive mitral replacement valve  So if you think about our team right now  we ve built a lot of competency on mitral repair  and now we re going to put in the hands of this team not only the opportunity to offer repair  but also a replacement solution that s minimally invasive  And I think there is a great opportunity for us in that space too  Both those products are enrolling here in the US  So we do plan to bring those to the US On the aortic side  we ve made investments on Portico  We knew that we needed to make some clinical and some R D investments here to increase the competitiveness of the system  and we like the data  We think there is going to be a segment of the population  segment of the market that we will be able to compete effectively  It s under FDA review  and we expect approval shortly And then finally on our Structural intervention  this is a part of the portfolio that doesn t get a lot of attention here  but it s about a quarter of our Structural Heart business  It s growing double digit  We ve got great products there  We ve seen a great ramp up with our stroke prevention technology  with PFO  our congenital business  and Amulet  which is right now under clinical evaluation in the US for treatment of LAA So I take a step back here  I said  yeah  MitraClip is a big growth driver  and we got a lot of things going right there  We re making the right investments from a clinical  from a commercial perspective  But I look at the portfolio that s been built here and I m very excited  it s very complete  it s very differentiated and there is a nice cadence  Robbie  to the launches Robert Marcus    J P  Morgan    AnalystGreat  I appreciate that  And maybe just a quick follow up  Alinity still hasn t really start its launch in the US  yeah  you put up 13  growth in Core Lab in the fourth quarter  How should we be thinking about the impact in 2020 from Alinity both in the US and outside the US Robert B  Ford    President and Chief Operating OfficerYeah  I think that we re going to continue to see this kind of rollout of the Alinity platform  The challenge we had a little bit in the US and Miles talked about the progress we made is that  when we launched it in Europe  we had a more complete kind of assay menu  And that allowed us to more    with more intentionality go after the market  the existing accounts  new accounts And then the US  we ve now achieved  let s say a critical mass of assay menu  test panel etc   that allows us to have that same kind of intentionality we had in Europe  have that same intentionality move into the US  Q4  we did have some capital sales  so that brings up the growth rate a little bit  But I think you re going to see the same kind of growth rate in the US  the same kind of ramp up that we saw in Europe Robert Marcus    J P  Morgan    AnalystThanks a lot OperatorThank you  And our next question comes from David Lewis from Morgan Stanley  Your line is open David Lewis    Morgan Stanley    AnalystGood morning  I don t want to sound like a broken record  but I ll reiterate Miles  there s some fairly significant and unique value creation over these last 20 years  So congratulations again on behalf of shareholders  Robert and Miles just starting off with a couple of businesses that had lagged in 2019 that are actually showing some improvement here in the back half of  19  which were Neuromodulation and CRM  some pretty decent improvement  specifically in the fourth quarter  I mean  Robert  you can just talk through what specific changes have been made in those two businesses  And how you re thinking about the outlook or sustainability of those franchises into 2020  And then I have a quick follow up Robert B  Ford    President and Chief Operating OfficerSure  So let s start over with Neuro then  I mean I think we had a tough year  full year in Neuro  when we came into the year  we talked about some of the challenges we were up against  And there are really two we had  obviously the sales force expansion and some of the disruption that  that created  But we felt it was important to do  to make that sales force expansion  And then some of the market declines that we saw  We re kind of seeing double digit growths and beginning of the year kind of saw that go to flat and even negative growth rate So I think the sales force expansion piece  we kind of got past that in the middle of the year  It s a unique selling model  about 30  to 35  of our sales team in the US was new  was under a year  So we spend a lot of time getting them up to speed  not only with their territories  but how to go about the selling process  etc  And I think that s    that s largely behind us  Now obviously if you look at the sales reps  the ones that have 7 to 10 years of experience  they re much more productive than the ones that have got 12 months  but we re seeing a nice steady ramp up in terms of the productivity of those new sales reps And the other thing we talked about was how innovation and new product launches could kind of fuel the market growth  And I think you saw that in Q4 not only with us  but even with some of the other players in the market come out with new product launches  at least what I see now from some of the pre announcements having kind of an impact there And so we came out with our product launch  Proclaim XR early in Q4  and I think you saw the impact of that in Q4  I think it s a modest    it was a modest improvement  we expect more  And a lot of our focus here in 2020 is going to be to ensure that this new sales team has got innovation to sell  So we re expanding our MRI portfolio  We know we need to do  We re launching a new radio frequency ablation generator  This is an important part of our customers  practices  and we felt that we weren t as competitive with our offering there So we developed a new system that will be rolling out this year  And we also believe that programming and connectivity    connectivity to devices  consumer devices is an important aspect  patient adoption of the therapy  So we ll continue to work on how we integrate to implant the device into those    those more consumer products  So we ve got a nice cadence of rollouts there And on the CRM side  we talked about this in the beginning of last year  we had    we encountered some challenges  And we felt that one of the things that we needed to do for the CRM side was to make sure  it got more focus and more attention  not only from    not only from me obviously  but from the management team  So we made an organizational structure change  Q1 of last year  which got finalized in Q2  where we separated the CRM business from the EP  Phonetic  business And we didn t do it just from a field sales perspective  we did it up really across all functions  So we have a dedicated CRM business unit with a dedicated leader  R D  etc  And I think you ve seen some of the output of that focus in the second half of the year  I would like to see a couple more quarters strung together  So that s what we re aspiring here too But I think one of the biggest impact of that focus obviously  the field has an impact  but I m more excited about the focus on the R D side  I think we had to kind of slowed down our R D innovation over here and that focus  that dedicated business unit focus  I think you ll see the output of that  not only in 2020  we have a couple of product launches in the US  new ICD  and in Europe also  but we ve got plans for a nice cadence of innovation in  21 and  22  So I m excited about kind of what we ve done there  Obviously  it s early innings in terms of this business unit we ll be creating  but I like what I see David Lewis    Morgan Stanley    AnalystOkay  And just two quick follow ups for me  Just Robert on MitraClip  is there a specific embedded assumption in the guidance for MitraClip  And how acutely do you think we see that recovery in the back half  And then your margin guidance about 50 basis points is a little lower than 2019 consistent with our numbers  but if you could just highlight two or three of the examples of significant reinvestment for growth in 2020 that would be super helpful  Thanks so much Robert B  Ford    President and Chief Operating OfficerSo I just    on your question about MitraClip recovering growth  and I think we ve been pretty strong in our growth rate  The US has done very well  And what we saw in the international market  if that s what you re referring to  we did see that kind of impact of the    some of the studies that came out in Europe impact us in the first quarter  but every quarter sequentially flat  We ve seen improvement  and I think we ve passed    we ve passed that on Regarding the guidance  I mean we ve got a lot of growth  As I said with Libre  we ve got a lot of growth here  We ve contemplated  as I said  CMS approval  but I have been fairly consistent with the CMS approval is going to be an important aspect here  but it s not just that  right  It s the    we ve been showing really strong growth in the US even without the reimbursement  and that s a result of the investments that we ve been making both in the field and clinical perspective  And I m sorry what was the other question Brian B  Yoor    Executive Vice President of Finance and Chief Financial OfficerIt was on    it was on margin expansion  I ll start off by saying this margin improvement is an ongoing focus for us David  it has been and will continue to be whether that s gross margin  whether that s the leverage we continue to get in SG A  And yes  notably  we did see that this year  You may be off just a little bit from our modelling  the foreign currency mix  we have a little bit of a headwind next year  but we have our gross margin expansion plan underlying But keep in mind as Robert said  with these investments that we re doing for growth  whether that s continued Libre expansion  whether that s the most recent MitraClip expansion we announced  as well as the unprecedented uptake of Alinity  that s presenting a little bit of a headwind  but that s a good news item in the short term and longer term  You ll continue to see those gross margins expand  as we look out over the years David Lewis    Morgan Stanley    AnalystGreat  Thanks so much OperatorThank you  Our next question comes from Vijay Kumar from Evercore  Your line is open Vijay Kumar    Evercore ISI    AnalystThanks  guys  Congrats on a really nice springs here  Phonetic   One may be on Nutrition  the adult side has come in really strong  I know  China has been a bit of a bother with some regulation    regulatory changes a couple of years ago  Could you comment on what you re seeing in China  is Adult Nutrition back  Is    has something changed in China for you guys Robert B  Ford    President and Chief Operating OfficerWell  listen we achieved a pretty strong growth rate in Q4 and that s despite some of the softness that we did see in China  We talked a little bit about it in Q3  Vijay  We ve seen some improvement  but some of those dynamics are still there  whether it s the birth rate or some of the kind of competitive intensity  We have obviously developed a plan here  as were going into Q4 and going into 2020 here  a big part of that strategy to address some of those competitive dynamics there is innovation and product launches and we put a plan together here We got a nice steady stream of    cadence of launches in China  But I do think that it does point out to the strength of our Nutrition business that we re able to post this kind of growth rate despite still some continued softness in China  And I think that speaks to the strength of the business  Miles talked about we had some very strong growth in South  Southeast Asia and Latin America on both sides of the business  Pediatric and Adult  And I don t think that    I think it shows this    China is an important market for us for sure  It has our intentions    our attention  But we re not overly reliant on it Vijay Kumar    Evercore ISI    AnalystYeah  That s helpful  Robert  And one on Diagnostics  I know flu has been the topic du jour  Just curious what that means for Diagnostics  On the Core Lab side  Alinity  really strong trends  You spoke about continued share gains in Europe  I m just curious where we are in  on the US side  Have you    is the win rate on the US side comparable to Europe or is that something that we should be expecting for the back half heading into  20   21  Phonetic  Robert B  Ford    President and Chief Operating OfficerYeah  As I said  in Europe  I think we ve had kind of good success in Europe  We talked about winning new businesses at that 50  rate  The renewals of our existing business  where we re trailing nearly    nearly all of that business  And I think in the US right now  it might be a little bit too early  just because you don t we really didn t have the intentionality the launch that we had in Europe  Now that we ve got a more complete menu  I think our ability to compete and our competitive fitness  let s call it that way in the US increases to the same level that we ve had in Europe Vijay Kumar    Evercore ISI    AnalystGreat  Thank you  guys OperatorThank you  And our next question comes from Larry Biegelsen from Wells Fargo  Your line is open Larry Biegelsen    Wells Fargo    AnalystGood morning  Thanks for taking the question  Congrats on another really strong quarter  And Miles  I ll echo what the other    the other comments and add that I ll miss interacting with you on these calls  always insightful and fun  Just two quick questions  One  maybe for Robert on capital allocation  I know I ve asked this on a few calls before  but you guys have paid down a lot of debt recently  Are you  Robert maybe thinking about M A a little bit differently  Should we expect more tuck ins in 2020  And I just have one quick follow up Robert B  Ford    President and Chief Operating OfficerSure  I think what you ll see is the same philosophy  the same framework that we ve had for this year  which is a very kind of balanced approach  As you ve said  a lot of our focus  the last couple of years has been to pay down debt  We paid down close to  10 billion over the last two years  Our net debt to EBITDA ratio is around 1 5 now  And we ve got kind of payments that are due in the next few years and that s all kind of contemplated in our capital plan The other thing we re always going to have a mindful eye here  Larry is ensuring that a portion of that capital goes back to our shareholders  Our dividend is a big part of our identity  We ve increased our dividend for 47 consecutive years  This year we just announced a 13  increase  So    and we announced also at the end of last year  our share repurchase about  3 billion  We do that from time to time mainly to kind of offset dilution We ll also look at our growth opportunities  and we ve talked a lot about them whether it s the rollout of Alinity  whether it s the manufacturing expansion of Libre  We just announced in Q4  a new manufacturing site  a second manufacturing site for MitraClip  Those are all great returns for our shareholders in terms of the return of that capital And then on the M A side  we re now looking to do any deals right now  I think the framework that Miles has always worked is true to me  which is you know it needs to meet our threshold of it being strategic or  and at the same time opportunistic  And we ve been looking at a lot  but we re always studying  we re always looking  and I haven t seen anything crossing the radar here that kind of falls in    falls into those two    those two buckets  But we re always going to keep looking  as we ve always done Larry Biegelsen    Wells Fargo    AnalystPerfect  And then just one housekeeping for Brian  and Brian congratulations on your retirement and I ll miss you as well  Just FX on the    on EPS  the impact in 2020  Thanks for taking the questions Robert B  Ford    President and Chief Operating OfficerThe impact of what  EPS FX Brian B  Yoor    Executive Vice President of Finance and Chief Financial OfficerFX  it s around  0 05  Larry Larry Biegelsen    Wells Fargo    AnalystThanks  Brian Brian B  Yoor    Executive Vice President of Finance and Chief Financial OfficerBased on the mix  you got it OperatorThank you  And our next question comes from Rick Wise from Stifel  Your line is open Rick Wise    Stifel Nicolaus    AnalystGood morning  everybody  Maybe I ll start off with EPD  EPD  Rob  it s always a little bit of a black box to us Medical Device and after all just said to me  I won t drag everybody else into it  You re clearly doing exceptionally well  strong fourth quarter  and you re saying mid to high single digits for 2020  But maybe just give us a little update some of the key drivers  What could gets you to the upper end of your range  And maybe some of the challenges  just give us some perspective about what you re thinking about for 2020 Robert B  Ford    President and Chief Operating OfficerSure  I heard this comment a couple of times now about kind of EPD or pharma business kind of being a black box or not as transparent and as not as understanding  I mean I will say here  the biggest focus of this business is taking opportunity of the geographic dynamics  right  You can either have a proprietary pharmaceutical business a little bit more higher cost versus pure generic business  which is obviously very cheap Our branded generic business kind of sits between those two book ins  I come from an emerging market  so I can tell you that when we buy medications  it s not reimbursed  So you pay for it out of pocket and you re willing to pay a little bit of a premium to ensure that what you re getting is high quality product  And I think that s what this business has been built on is taking advantage of that dynamic of this population in these markets growing with their disposable income and allocating some of that to their healthcare costs on brands that they trust  And that s what we ve been building over these years  A key driver of this strategy here is you need to be  you need to have the breadth and the depth in your therapy classes So we have comprehensive portfolios in the geographies that we re competing  They re deep in each therapy class  You need to be omnichannel  you need to be present in the doctor s office  you need to be present in the pharmacy  you need to be able to kind of communicate directly with the consumer and you need to be local  You need to have a local R D or engine organization and manufacturing to be able to move fast with the opportunities that you see  And I think that s at the core of our strategy One of the challenges in this business  as Miles has always said is the FX piece of it  but the performance growth  we expect it to be in this kind of high single digit growth  and a big driver of that is being in the right markets  with the right infrastructure  with the right products  with the depth and the focus on execution Rick Wise    Stifel Nicolaus    AnalystGreat  And turning to two other areas  Heart Failure business has done a great job  How sustainable is the robust growth we ve seen  And maybe talk a little bit about the implications of the less invasive surgical approach for HeartMate 3  what that might mean  And just last maybe touch a little bit on Alere  It s been a little bit of an disappointment  What are the next steps  Help us understand what s going on  And where we go from here with Alere  Thank you so much Robert B  Ford    President and Chief Operating OfficerSure  On Heart Failure  I mean we had a very successful 2019  We achieved the destination therapy indication for HeartMate 3 at the end of  18  So that rolled into  19  So you saw the growth rate of about 20  here  Rick  that growth is predominantly driven by share gains and specifically here in the US  So we exited 2019  Our estimation right now is through our internal data north of 80  So as we go into 2020  we expect that to not be at that 20  rate now and to mirror more of what the market is growing  which is we expect to be in that mid single digit range  But I do believe that we ve got a lot of opportunity  I talked about cadence of innovation in our products and one product that s comped pretty quiet  but we ve done a really good job there  which is CardioMEMS CardioMEMS is now close to  100 million  It s growing 30   We continue to enrolled in our guide HF trial that s going to be used to open an NCD  but the outcomes there are also extremely meaningful in terms of hospitalization reductions  etc  So I think that will be kind of our next driver of growth in Heart Failure  and I m very pleased with what the team has been able to build in that business Going to your question on Alere  It s been a little bit of a    we ll call it like a mixed bag here  We ve had some businesses that we brought into Abbott  and I think we ve done very well with them  We ve accelerated their performance  If I look at the infectious disease portfolio in our developed markets  that s done very well  Yeah  of course there is some opportunity there with the flu season  But I think the team has done a really good job here expanding the portfolio and looking at those that installed base beyond just a flu test  And our cardiometabolic business has done very well too  growing in the high single digits  low double digits So I think those two businesses  we ve done a really good job with  and I think the team has done a good job on the cost side with the synergies too  But you have pointed out that there are some parts in the business here  where we were not pleased with  we re not satisfied  Our emerging market Infectious Disease segment had a tough 2019  part of that is kind of NGO purchasing cycles and dynamics in certain markets  but we ve got to do better than that  And we ve implemented a strategy here to really look at other emerging markets outside of the African continent here and build the value proposition of those tests in other emerging markets In our toxicology business too  I don t think we ve been able to kind of fully maximize the value there and that one there has got a lot of attention too  So we had a good Q4  a lot of focus here  a lot of good growth in the US  and I think part of that was a little bit of the flu  But if we can get these two business here  our emerging markets and our toxicology business to execute on the plans that we put in place for them  I think you ll see that is kind of a mid growth  a mid single digit kind of growth business for us But I look at the trend and the dynamics of these products for the opportunities we have  the strategy to get into these businesses is still very much intact also  Miles talked about more and more testing move into alternative channels  We continue to see that  and we re targeting steady improvement here  But I think the long term growth opportunity because of that trend is very positive Rick Wise    Stifel Nicolaus    AnalystThanks and congratulations Scott Leinenweber    Vice President of Investor Relations  Licensing and AcquisitionsThanks  operator  We ll take one more question OperatorThank you  And our final question comes from Kristen Stewart from Barclays  Your line is open Kristen Stewart    Barclays    AnalystHi  thanks so much for taking my question  Congratulations Miles on your retirement and Brian  I hope your next chapter is a positive one as well  Just I guess a couple of cleanup questions  In terms of the  I guess PHP product  I was just wondering if you can maybe update us on just the timelines there for expected launch And then also for Amulet as well just kind of expectations for a launch just to get some timelines  And then also  I think you Robert had also mentioned just some products within the CRM business launching there  Could you just maybe update us on expectations for that franchise  I think you mentioned a new ICD platform and some other milestones to expect within the CRM portfolio  Thanks Robert B  Ford    President and Chief Operating OfficerSo sure  on PHP and Amulet  I mean those are still I d say a couple of years away  So we re still in kind of clinical evaluation of that  We ll then kind of put the information together  submit to the FDA  So I d say you kind of have normal timelines over there  So you can look at it about a couple    a couple of years away On the CRM side  like I said  I think the biggest opportunity we had when we changed the structure was to kind of get the innovation going  So we ve got two product launches  we ve got a new version of    new update to our implantable cardiac monitor planned for this year  We ve got a new ICD planned again for both US and Europe  And our growth expectations here are to be    to do better than what we ve been doing  steady sequential improvement  We ve had some challenges  and I think that these products here will allow us to continue that sequential improvement  Yeah  So I ll   Kristen Stewart    Barclays    AnalystPerfect  And then  I forgot  Phonetic  Robert B  Ford    President and Chief Operating OfficerGo ahead Kristen Stewart    Barclays    AnalystI was just going to say and do you see any opportunities  I think Bob had mentioned this  but any opportunities just in terms of divestitures within Medical Devices or elsewhere within the portfolio or some smaller tuck in  I know you said  it didn t sound like you were going to do any larger scale M A  but just more product lines to bring into the portfolio from a more of a tuck in acquisition from technology earlier stage Robert B  Ford    President and Chief Operating OfficerYeah  Listen if I take that and just talk about our model  we have a diversified model  I fundamentally believe in our diversified model  I think you ve seen sequential improvement in all four areas over the last couple of years from a big picture perspective  Now when you go into each one of them  can you find some areas that we can do better  and we should do better  Yeah  we can and we ve talked about some of those today  But that doesn t mean that we don t think they re great opportunities that just means that we need to focus on doing better and executing better on that  So as I look at these four businesses  I like the businesses we have Kristen Stewart    Barclays    AnalystOkay  perfect  Thank you very much Miles D  White    Chairman and Chief Executive OfficerOkay  This is Miles again  I ll wrap up and close for us  So first of all  thank you all very much for your very kind comments  And on behalf of both Brian and I    well  speak and tell you that it s been a great honor and a great pleasure for us to lead our Company  It s been a tremendous experience  I feel like I ve had two or three careers here in the last 21 years and probably have Brian was estimating this morning this was our 85th or 86th earnings call  And therefore  I can t tell you that I know yeah  whether I m going to miss him  but I m sure had a lot of them  And they re always challenging  they re always interesting opportunities to converse with you about the prospects of the Company and so forth I feel like I leave the Company in perhaps its best position ever in terms of products and growth  future opportunities  etc   as I said at the beginning  I m very pleased with the succession and the management team that s here  It s not just the CEO that s changing  the CFO is changing and Bob Funck  who s our long time Abbott employee and he s been our Controller for a number of years and been in some of the most challenging jobs at Abbott and so forth  will be an absolutely superb successor to Brian You know that a lot of our management team has changed over the last couple of years as we move to a next generation of leaders and managers in the Company  And I think it s a great mix of people that are homegrown and also have come to us either through St  Jude or other outside places and we re just really happy with the team  we ve got  the pipelines we ve got  the positions we ve got  We think our success is sustainable  And I think the track record that we ve laid down over the last years has been recognized that way  and we re appreciative of the recognition that all of you have given As I commented tongue in cheek  as a significant shareholder of the Company  I ll obviously be watching closely  And especially in the    the immediate future  as the Chairman So with that  we ll close the call  Thank you all very much  and thanks for all your support Scott Leinenweber    Vice President of Investor Relations  Licensing and AcquisitionsVery good  Thank you  operator  and thank you for all of your questions  This now concludes Abbott s conference call  A webcast replay of this call will be available after 11 00 AM Central Time today on Abbott s Investor Relation website at abbottinvestor com  Thank you for joining us today Operator Operator Closing Remarks Duration  62 minutesCall participants Scott Leinenweber    Vice President of Investor Relations  Licensing and AcquisitionsMiles D  White    Chairman and Chief Executive OfficerBrian B  Yoor    Executive Vice President of Finance and Chief Financial OfficerRobert B  Ford    President and Chief Operating OfficerBob Hopkins    Bank of America Merrill Lynch    AnalystRobert Marcus    J P  Morgan    AnalystDavid Lewis    Morgan Stanley    AnalystVijay Kumar    Evercore ISI    AnalystLarry Biegelsen    Wells Fargo    AnalystRick Wise    Stifel Nicolaus    AnalystKristen Stewart    Barclays    Analyst
More ABT analysis
All earnings call transcripts",2020-01-22,The Motley Fool,https://invst.ly/plj17,2065386
181080,402596,ABT,Why Abbott Laboratories Just Became an Even Better Buy,news,"Abbott Laboratories  NYSE ABT  has been a great buy for many years  The healthcare stock has made investors rich in a number of ways  While it may pay a modest dividend  the annual increases to its payouts for more than 40 years has made it an exceptionally good long term buy 
The returns shareholders have earned over the years from simply holding its shares have been very strong  In 2019  Abbott s stock was up 20   a little better than the 18  returns investors would have earned by holding the Health Care Select Sector SPDR Fund 
As good of a buy as Abbott has been  it just got even better 
The company showed strong sales growth in 2019
Abbott released its fourth quarter earnings on Jan  22  and the numbers were very strong  Revenue of  8 31 billion was up 7 1  in Q4  which was good enough to beat analyst expectations of  8 26 billion  Meanwhile  diluted earnings per share  EPS  of  0 95 were in line with Wall Street s expectations as well 
The company s overall performance was even stronger when looking at its organic growth rate  which factors out the effect of foreign exchange as well as non core business in the nutrition segment that Abbott discontinued in 2018  Organic growth in Q4 was 8 5  and two segments were up by double digits  Medical devices rose by 11 3  and pharmaceuticals grew by 10   Medical device sales were also up 10 5  for the entire year when looking at its organic numbers 

Abbott s bottom line was even more impressive
Revenue was strong  but what really stood out was the jump in earnings  The company s net earnings of  1 05 billion were up 61  from the prior year quarter when Abbott earned  654 million  Small wins along the way  such as fewer expenses related to interest and debt  saved the company  36 million  while the net effect of foreign exchange added  2 million to its bottom line compared to a loss of  26 million a year ago  That s  62 million in cost reductions  that alone would have been good enough for a 10  improvement from last year s bottom line 
However  the biggest gains were in the company s operating income where Abbott was able to squeeze out more from its top line  Operating expenses  including cost of goods sold  rose at a rate of 4 9   slightly below the 7 1  increase that the company saw in its top line  That helped Abbott s operating income rise by  224 million 
It was the same story when looking at the company s full year results  as Abbott s revenue growth of 4 3  was well above the 1 7  increase that its operating expenses rose by  leaving more of the top line to trickle through to the bottom  As a result  full year earnings were also up an impressive 56  year over year 
It s expecting another good year in 2020
With a stellar 2019 on the books  Abbott is expecting another strong showing this year  In its full year guidance for 2020  the company is projecting that organic growth will again fall between 7  to 8   In 2019  organic growth for the year came in at 7 7  
On the earnings side  the company is expecting diluted EPS of between  2 35 and  2 45  That would be another double digit improvement from the company s diluted EPS of  2 06 in 2019  
It s hard not to like Abbott 
At a forward price to earnings ratio of 22 and a price to book multiple of around five  Abbott is not a cheap stock for value investors  However  given the growth the company has demonstrated and its numbers being weighed down by foreign exchange  there s reason to be optimstic that it can build on these results not just for one year but many years down the road 
It s a sign of good management that a company can grow sales and at the same time bring its costs down  But given that the company has been able to increase its dividend payments for decades  it may not be all that surprising that Abbott is such a quality stock to invest in  With good revenue diversification and multiple segments showing strong sales growth  the healthcare stock is a good option for risk averse investors who may be concerned that a recession is around the corner and are in search of a quality dividend ",2020-02-03,The Motley Fool,https://invst.ly/pqg8u,2074498
181097,402613,ABT,Better Buy  Abbott Laboratories vs  Pfizer,news,"Investors looking for large cap  dividend paying healthcare stocks have plenty of options  Whether it s large scale drug manufacturers or medical technology providers  there s enough choice to suit whatever you re looking for 
Abbott Laboratories  NYSE ABT  and Pfizer  NYSE PFE  both have large market valuations  solid dividends  and a strong track record of success  However  they operate in different areas of the healthcare market  with Abbott developing diagnostic equipment while Pfizer focuses on developing new pharmaceutical candidates 
If you had to choose between the two  however  which is the better investment 

Big changes for Pfizer on the horizon
The upcoming year is going to bring quite a few changes for Pfizer  and that has many investors on edge  The company s new CEO  Albert Bourla  is implementing a major shift in corporate strategy  focusing on higher margin products by spinning off well known drug brands that have been dragging down revenue growth 
Earlier in July  Pfizer announced that it was selling its non patent drug unit  Upjohn  to Mylan  creating a new company called Viatris in the process  Viatris will be home to a number of well known drug brands that have been decent revenue drivers  although their growth rates have slowed down  
If shedding its Upjohn drug collection wasn t a big enough change  Pfizer also announced that it will combine its consumer healthcare unit with GlaxoSmithKline s own equivalent business to create a separate entity for over the counter products  While Pfizer s consumer healthcare division wasn t that large  and it still will retain a 32  stake in the new joint venture  it will mean the loss of some well known products  most notably Advil 
Pfizer will be going back to basics  so to speak  focusing on developing new drug candidates as well as marketing its existing lineup of rapidly growing blockbuster candidates  This includes a cancer drug called Inlyta  a rare heart disease treatment called Vyndaqel  and immunology drug Xeljanz  All three drugs have seen very strong growth rates  with Inlyta up 240   Vyndaqel up 325   and Xeljanz up 40  year over year in terms of sales  
The company s best drug candidates  an anticoagulant called Eliquis and a breast cancer drug called lbrance  are also still staying with Pfizer  Both drugs are the primary revenue sources for their respective areas    internal medicine and oncology    and collectively account for 18  of Pfizer s total revenue 
Overall  Pfizer s facing a big shift  but it s likely to emerge from it as a more focused and efficient drug developer than it s been in many years 
Abbott s consistent growth from a diverse business
In contrast to Pfizer  Abbott has stayed relatively the same for the past few years  Ever since splitting from AbbVie in 2013  the company has done quite well for itself  Doubling in stock price  delivering consecutive double digit growth rates  and all the while maintaining a consistently increasing dividend is quite an impressive achievement  considering its large size 
Unlike Pfizer  Abbott isn t a new drug developer  Instead  its main revenue source comes from the sale of medical diagnostics equipment and devices  primarily in the realm of cardiovascular disease but also other conditions  such as diabetes  Thanks to some major acquisitions  including a  25 billion buyout of rival medical device maker St  Jude Medical in 2016  Abbott s medical device sales have seen high single digit growth in what s already the company s largest business segment 
While medical device sales are Abbott s bread and butter  its total revenue is split among four main business areas  One of these is Abbott s nutritionals business  which primarily provides formulas for infants and small children  The company also has its own generic drug business  which sells branded generic versions of drugs whose patents have expired  These two businesses accounted for 24  and 14  of Abbott s 2018 revenue  In comparison  Abbot s medical device segment accounts for 37  of the company s revenue  while its second largest business  diagnostics  accounted for 25  of 2018 income  
Comparing financials
Both Pfizer and Abbott are large cap stocks  with market caps around  216 billion and  154 billion  respectively  As it turns out  both companies have relatively similar financial metrics 
Looking at their price to sales  P S  ratios shows that Pfizer trades at 4 25  while Abbott comes in at 4 93  That s pretty much in line with most other large cap healthcare stocks  with Johnson   Johnson trading at 4 8 times sales  while Amgen trades at a 6 39 P S ratio  
While Abbott ended up taking on a significant amount of debt to fund its acquisitions  the company has done a good job paying off its debt since then  Long term liabilities have fallen from  27 billion in Q4 2017 to  17 6 billion in Q3 2019  a 35  decline in just two years  In comparison  Pfizer s debt has grown a little over that same period  from  31 8 billion to its current  36 0 billion  
What s the verdict 
Pfizer and Abbott have quite a few differences  despite their similarities  Pfizer is undergoing some major changes  spinning off many of its older  stagnating drug brands to focus on developing and marketing its portfolio of high growth drug candidates  So far  the drug lineup that Pfizer s holding on to right now has seen very impressive growth rates  some even in the triple digits 
On the other hand  Abbott embodies the philosophy of  slow and steady wins the race   The company has maintained a more than reasonable growth rate over a long period and is likely to continue doing what it s already doing 
There s a strong case to be made for both companies  but if I had to choose  I d lean a bit more toward Pfizer  While Abbott might be a better investment for a hands off investor looking for a safe and secure stock  Pfizer s move to focus on its high growth drug segment gives the stock major upside potential in the next year or two  Both companies  however  are good investments and should have a lot going for them in the future ",2020-01-02,The Motley Fool,https://invst.ly/pccsn,2051185
181098,402614,ABT,Where Will Abbott Laboratories Be in 5 Years ,news,"Abbott Laboratories  NYSE ABT  has been one of the better performing large cap healthcare stocks on the market  although many years ago the company was going through a major change  Back in 2013  Abbott s drug business ended up splitting off from the firm to form a separate company called AbbVie  In this split  AbbVie maintained ownership of a number of blockbuster drugs  the most notable being Humira 
Despite the loss of these blockbuster drugs and their impressive revenue figures  Abbott has grown at a steady rate  With the company s market cap more than doubling over the past few years and now reaching  154 5 billion  how much more room does Abbott Laboratories have to grow  Most would agree that the company s future remains bright  although growth might slow down 
To get an idea of where Abbott will be in five years  let s look into what s fueled its impressive growth over the past few years and what s going on now 

Abbott s track record of success
The history of Abbott Laboratories goes back to 1888  when Wallace Calvin Abbott started it as a one man operation  Forty one years later  the company went public on the Chicago Stock Exchange in 1929  Since then  it has become one of the top dividend stocks in the country  with a 95 year history of paying out dividends and a 47 year period of consecutively increasing its payouts 
Abbott s largest business is its medical device segment  which includes medical devices for patients with cardiovascular disease and diabetes  This division accounted for 37  of the company s 2018 revenue  approximately  11 4 billion in total 
What s particularly impressive is that the annual growth rate of Abbott s medical device business has consistently hovered near the 10  mark  thanks to some of Abbott s recent acquisitions  The most notable one was the  25 billion St  Jude Medical acquisition in 2016  another medical device maker that created devices in the cardiovascular and diabetes markets 
Abbott s next two drivers of revenue are its diagnostics segment and nutrition business  which accounted for 25  and 24   respectively  of its 2018 revenue  However  Abbott has its own established pharmaceutical business  as well  selling branded generic drugs that  while not as exciting  still remain a lucrative market  This segment accounted for 14  of Abbott s 2018 revenues 
Recent financial results
Looking at Abbott s Q3 2019 quarterly results  there aren t any major warning signs to be found  Total third quarter revenue came in at  8 1 billion  with  5 2 billion coming from international markets  The best single business segment for Abbott has been its international medical device business  which reported an impressive 14 3  increase in organic sales  compared to Q3 2018 
Overall  all of Abbott s business segments have been doing well  with net income increasing by 70 3  over the past year from  563 million in Q3 2018 to  960 million as of the current quarter  Medical device sales rose by 10 6  compared to Q3 2018  while established pharmaceuticals  diagnostics  and nutrition all rose by 7 9   6 6   and 3 8   respectively  All these results are pretty much in line with analyst estimates  and Abbott s management expects to hit the upper end of its guidance target for the end of the year 
As for specific product lines that are doing well  Abbott s Freestyle Libre continuous glucose monitoring  CGM  technology  which helps manage glucose levels for people with diabetes  saw sales jump by 67 6  over the past year  making it one of the fastest growing products in Abbott s lineup  The company also has a new MitraClip product  which is used by heart surgeons in repairing the mitral valve  which plays a crucial role in moving blood in and out of the heart  Sales have gone up by 31 9  since Q3 2018  
Abbott made a couple of major acquisitions over the past few years  In 2017  it paid a sum of  30 billion to buy St  Jude Medical and diagnostic test maker Alere  Since then  however  the company has continually paid off much of its long term debt  which has decreased from  27 2 billion in Q4 2017 to  17 6 billion as of Q3 2019 
Specific predictions for 2025
One thing to note is the planned departure of Abbott s longtime CEO Miles White  With 21 years under his belt as the chief executive for the company  it s reasonable to attribute a good portion of Abbott s steady success to his leadership  Replacing him will be Robert Ford  Abbott s current Chief Operating Officer  who was named by White as his top pick for who to replace him  Ford is only 48 so it wouldn t be surprising if he stays in this role well into 2025 and beyond  
In terms of specific segment predictions  medical device sales will remain Abbott s bread and butter  and will likely continue to grow at a faster rate than major competitors  Johnson   Johnson and Medtronic both have larger medical device businesses than Abbott  However  both of these company s businesses are growing at a slower rate  Johnson   Johnson saw 5 3  growth in its medical device business over the past year  excluding acquisitions and divestitures   less than half of Abbott s 10 6  growth rate  Medtronic grew even less  only a 4 1  increase in organic sales  
By 2025  I predict that Abbott will continue to gobble up market share from its larger competitors thanks to its faster growth rate  but still won t eclipse either Johnson   Johnson or Medtronic in this area just yet  Annual medical device sales of as much as  22 billion is possible by the end of 2025  but even a more conservative  17 billion would be impressive
As for its second biggest segment  established pharmaceuticals  Abbott falls quite a bit short when compared to the size of other company s established pharmaceutical businesses  such as Sanofi and Pfizer  Considering that Abbott is a medical device maker first and foremost  this isn t really surprising  What is impressive  however  is that Abbott s business is growing where others are shrinking  Sanofi s established pharmaceuticals business revenue shrank from  13 5 billion to  12 2 billion between 2016 and 2018  while Pfizer s fell from  11 2 billion to  10 5 billion over the same period  Abbott s  on the other hand  grew from  3 9 billion to  4 4 billion between those two years  
Abbott won t eclipse these drugmakers any time soon  but by 2025  it will have grown by a fair bit assuming its current growth rate stays the same  It wouldn t be surprising if revenues from this business segment cracks  7 billion annually 

What s the verdict on Abbott 
There s not much to say that s negative about Abbott  It s a large cap healthcare stock that s been around for many decades  so it s impressive that the company is growing its revenues this quickly while providing a consistent dividend 
Over the next five years  I expect the company to continue to increase sales  pay off debt  and widen its net margin  While the stock doubled between 2014 and 2019  I m not sure if it s going to do so again by 2025 or if growth will slow down a little  especially since doubling again would put the company s market cap at a whopping  300 billion  What is clear  however  is that this healthcare giant shows no sign that it will stop growing anytime soon ",2020-01-18,The Motley Fool,https://invst.ly/pjndb,2062576
181099,402615,ABT,Better Buy  Abbott Laboratories vs  AbbVie,news,"You d have to rank Abbott Laboratories   NYSE ABT  spin off of AbbVie  NYSE ABBV  in 2013 as one of the best corporate moves of the last decade  Since the separation  Abbott s share price has soared 184   while AbbVie stock is up 158  
Which stock is the better pick now for long term investors  Here s how Abbott and AbbVie stack up against each other 

The case for Abbott Labs
Abbott Labs focuses on four key markets  The company makes the most money selling cardiovascular and neuromodulation products  It also has big businesses that sell nutritional products and diagnostics systems  In addition  Abbott retained an established pharmaceuticals unit after its spin off of AbbVie that focuses primarily on emerging markets  
The company continues to deliver solid growth  with revenue rising 5 5  in the third quarter and earnings jumping 12  from the prior year  Abbott s biggest segment is also its fastest growing business  Its cardiovascular and neuromodulation products unit achieved 10 6  organic growth in the last quarter 
Wall Street analysts think that Abbott will be able to deliver average annual earnings growth of more than 11  over the next five years  The company has several growth drivers that should make this possible  including its Alinity diagnostic systems  HeartMate 3 left ventricular assist devices  MitraClip mitral regurgitation devices  and FreeStyle Libre continuous glucose monitoring  CGM  systems 
On top of this strong growth  Abbott also pays a nice dividend    it currently yields nearly 1 7   And in December  Abbott increased its dividend for the 48th consecutive year 
All of this great growth has given Abbott a somewhat pricey valuation  though  Shares currently trade at around 24 times expected earnings  But with Abbott s great prospects and strong dividend track record  paying a premium for this blue chip stock is to be expected 
The case for AbbVie
AbbVie claimed all of the prescription drugs with higher growth prospects when it was spun off  The most important of these drugs was Humira  which still ranks as the best selling drug in the world and is likely to remain in the top two until 2024 
However  Humira now faces biosimilar competition in Europe  with biosimilars on their way to the U S  market in 2023  AbbVie can t rely on the blockbuster drug for growth as it has in the past  The good news is that the company has a strong lineup  including cancer drugs Imbruvica and Venclexta along with new immunology drugs Rinvoq and Skyrizi 
But with analysts expecting weak average annual earnings growth of less than 4  over the next five years as Humira s sales wane  AbbVie knew it needed to do something different  That s why the drugmaker is acquiring Allergan  NYSE AGN  for  63 billion  The deal will bring the enormously successful Botox into AbbVie s arsenal along with promising newer drugs including Vraylar 
While AbbVie s growth prospects are somewhat shaky  its dividend definitely isn t  The company s dividend yield stands at a mouthwatering 5 4   making AbbVie one of the most attractive high yield dividend stocks on the market 
AbbVie s shares trade at only 9 4 times expected earnings  one of the lowest valuations among big healthcare stocks  However  the valuation isn t as appealing when looking over a longer period  with Humira facing the prospect of slumping sales in the wake of biosimilar competition in the U S  market  Still  though  with the company s terrific dividend and modest growth prospects that should be bolstered with the Allergan acquisition  many investors will likely think that the price is right for AbbVie 
Better buy
Which stock is the better pick  My answer is that it depends on your investing goals 
Growth investors will prefer Abbott Labs  The company should enjoy a big sales boost if and when the FDA clears the way for the new version of FreeStyle Libre to hit the U S  market  However  I think that income investors will prefer AbbVie s sizzling yield  Even with the company s Humira challenges  my view is that AbbVie will keep the dividends flowing and growing for a long time to come ",2020-01-19,The Motley Fool,https://invst.ly/pjxcr,2062736
181100,402616,ABT,Abbott Laboratories Q4 2019 Earnings Preview,news,"Abbott Laboratories  NYSE ABT  is scheduled to announce Q4 earnings results on Wednesday  January 22nd  before market open 
The consensus EPS Estimate is  0 95   17 3  Y Y  and the consensus Revenue Estimate is  8 26B   6 3  Y Y  
Over the last 2 years  abt has beaten EPS estimates 63  of the time and has beaten revenue estimates 63  of the time 
Over the last 3 months  EPS estimates have seen 1 upward revision and 2 downward  Revenue estimates have seen 1 upward revision  and 3 downward ",2020-01-21,Seeking Alpha,https://invst.ly/pl04b,2064371
181101,402617,ABT,Abbott Laboratories EPS in line  beats on revenue,news,"Abbott Laboratories  NYSE ABT   Q4 Non GAAP EPS of  0 95 in line  GAAP EPS of  0 59 misses by  0 05 
Revenue of  8 31B   6 9  Y Y  beats by  50M 
Shares  0 13  PM 
Press Release",2020-01-22,Seeking Alpha,https://invst.ly/plbg7,2064800
181103,402619,ABT,Abbott quarterly profit soars 60 ,news," Reuters     Abbott Laboratories  Inc  N ABT  reported a 60  rise in fourth quarter profit on Wednesday  boosted by strong sales of its diabetes and heart devices 
The company s net earnings rose to  1 05 billion  or 59 cents per share  in the quarter ended Dec  31  from  654 million  or 37 cents per share  a year earlier 
Net sales of the medical device maker rose 7  to  8 31 billion ",2020-01-22,Reuters,https://www.investing.com/news/stock-market-news/abbott-quarterly-profit-soars-60-2064809,2064809
181122,402638,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 01  to trade at  81 85 by 15 28  19 28 GMT  on Friday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 3 50M  Abbott Labs has traded in a range of  81 83 to  84 23 on the day 
The stock has traded at  86 1300 at its highest and  81 8200 at its lowest during the past seven days ",2019-08-23,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1962514,1962514
181123,402639,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 09  to trade at  81 62 by 09 52  13 52 GMT  on Tuesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 421 18K  Abbott Labs has traded in a range of  81 57 to  83 52 on the day 
The stock has traded at  86 4300 at its highest and  81 5900 at its lowest during the past seven days ",2019-09-10,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1974512,1974512
181124,402640,ABT,Abbott Labs Rises 3 ,news,"Investing com   Abbott Labs  NYSE ABT  rose by 3 02  to trade at  84 31 by 13 50  17 50 GMT  on Monday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 1 94M  Abbott Labs has traded in a range of  82 23 to  84 32 on the day 
The stock has traded at  84 3100 at its highest and  81 4300 at its lowest during the past seven days ",2019-09-30,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-rises-3-1989254,1989254
181125,402641,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 03  to trade at  79 36 by 10 41  14 41 GMT  on Wednesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 1 01M  Abbott Labs has traded in a range of  79 34 to  81 48 on the day 
The stock has traded at  84 7700 at its highest and  79 3600 at its lowest during the past seven days ",2019-10-02,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1990875,1990875
181126,402642,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 05  to trade at  78 57 by 15 56  19 56 GMT  on Tuesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 4 67M  Abbott Labs has traded in a range of  78 56 to  80 28 on the day 
The stock has traded at  84 7700 at its highest and  78 5600 at its lowest during the past seven days ",2019-10-08,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1993544,1993544
181127,402643,ABT,Abbott Labs Rises 3 ,news,"Investing com   Abbott Labs  NYSE ABT  rose by 3 02  to trade at  82 23 by 13 50  17 50 GMT  on Tuesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 2 75M  Abbott Labs has traded in a range of  80 74 to  82 24 on the day 
The stock has traded at  82 2400 at its highest and  78 5100 at its lowest during the past seven days ",2019-10-15,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-rises-3-1996667,1996667
181128,402644,ABT,Abbott Labs Earnings inline  Revenue Misses In Q3,news,"Investing com   Abbott Labs  NYSE ABT  reported third quarter earnings  that matched analysts  expectations on Wednesday and revenue that fell short of forecasts 
The firm reported earnings per share of  0 84 on revenue of  8 08B  Analysts polled by Investing com forecast EPS of  0 84 on revenue of  8 11B  That compared to EPS of  0 75 on revenue of  7 66B in the same period a year earlier  The company had reported EPS of  0 82 on revenue of  7 98B in the previous quarter 
Abbott Labs shares gained 0 02  to trade at  82 00 in pre market trade following the report 
Abbott Labs follows other major Healthcare sector earnings this monthOn Tuesday  J J reported third quarter EPS of  2 12 on revenue of  20 73B  compared to forecasts of EPS of  2 on revenue of  20 1B 
Helen of Troy Ltd earnings beat analysts  expectations on October 8  with second quarter EPS of  2 24 on revenue of  414M  Investing com analysts expected EPS of  1 88 on revenue of  391 86M
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-10-16,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-earnings-inline-revenue-misses-in-q3-1997020,1997020
181143,402659,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 10  to trade at  76 66 by 13 04  17 04 GMT  on Tuesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 2 58M  Abbott Labs has traded in a range of  76 62 to  78 87 on the day 
The stock has traded at  79 6900 at its highest and  76 6300 at its lowest during the past seven days ",2019-05-07,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1859299,1859299
181144,402660,ABT,Abbott Labs Earnings Beat  Revenue Misses In Q2,news,"Investing com   Abbott Labs  NYSE ABT  reported second quarter earnings  that beat analysts  expectations on Wednesday and revenue that fell short of forecasts 
The firm reported earnings per share of  0 82 on revenue of  7 98B  Analysts polled by Investing com expected EPS of  0 8 on revenue of  8B  That compared to EPS of  0 73 on revenue of  7 77B in the same period a year earlier  The company had reported EPS of  0 63 on revenue of  7 54B in the previous quarter 

Abbott Labs follows other major Healthcare sector earnings this month
 On Tuesday  J J reported second quarter EPS of  2 58 on revenue of  20 56B  compared to forecasts of EPS of  2 44 on revenue of  20 29B 
Bayer AG PK earnings beat analysts  expectations on June 18  with second quarter EPS of  0 71 on revenue of  14 5B  Investing com analysts expected EPS of  0 69 on revenue of  14 17B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-07-17,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-earnings-beat-revenue-misses-in-q2-1925919,1925919
181146,402662,ABT,Abbott Labs Rises 3 ,news,"Investing com   Abbott Labs  NYSE ABT  rose by 3 38  to trade at  85 97 by 09 31  13 31 GMT  on Wednesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 196 82K  Abbott Labs has traded in a range of  85 87 to  86 19 on the day 
The stock has traded at  86 1900 at its highest and  82 9000 at its lowest during the past seven days ",2019-07-17,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-rises-3-1926100,1926100
181149,402665,ABT,Abbott hits record high as diabetes device fuels profit beat,news,"By Saumya Joseph  Manas Mishra and Julie Steenhuysen
 Reuters     Abbott Laboratories   N ABT  beat analysts  estimates for quarterly profit and lifted its full year earnings forecast on Wednesday  boosted by a near 64  jump in sales of its blood sugar monitoring device 
Shares rose 4  to a record high of  86 59  adding to the about 15  gain since the start of the year 
Abbott is betting on the device  FreeStyle Libre  and is working on newer versions to cushion slowing growth in some of its older products 
The continuous glucose monitor  which helps diabetics track blood sugar levels without having to prick their fingers  is used by more than 1 5 million people worldwide 
FreeStyle Libre 2  the next generation device  which is already approved in Europe  is now under U S  regulatory review 
To expand its reach  Abbott plans to ramp up manufacturing capacity for FreeStyle Libre by three to five times in the next few years  Reuters reported on Tuesday 
When asked on the conference call what that increased capacity could mean  Chief Executive Miles White said he sees potential for Libre to bring in annual sales of  5 billion  in a reasonable time  
Libre s sales are expected to reach  1 5 billion this year  the company has said 
Abbott is also focusing on another growth driver  MitraClip  Sales of the device used for heart valve repair jumped 26 7  to  169 million in the quarter 
Momentum continues for Abbott s key growth drivers and  we don t believe it is slowing down any time soon   BMO Capital Markets analyst Joanne Wuensch wrote in a client note 
Sales of FreeStyle Libre rose 63 9  on a reported basis to  433 million in the second quarter 
Total sales at the diabetes unit jumped 28 2  and helped Abbott s medical devices division report a 6 4  rise in revenue to  3 08 billion 
 For an interactive graphic on diabetes unit sales  click here   
Abbott raised its 2019 forecast for adjusted earnings from continuing operations to  3 21 to  3 27 per share  from its prior forecast of  3 15 to  3 25 per share 
The company s net earnings rose 37  to  1 billion in the second quarter ended June 30 
Excluding items  Abbott earned 82 cents per share  ahead of the average analyst estimate of 80 cents  according to IBES data from Refinitiv 
Net sales rose 2 7  to  7 98 billion  but missed estimates of  8 billion ",2019-07-17,Reuters,https://www.investing.com/news/stock-market-news/abbott-hits-record-high-as-diabetes-device-fuels-profit-beat-1926329,1926329
181150,402666,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 02  to trade at  83 23 by 14 43  18 43 GMT  on Monday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 2 34M  Abbott Labs has traded in a range of  83 22 to  84 88 on the day 
The stock has traded at  88 7300 at its highest and  83 2100 at its lowest during the past seven days ",2019-08-05,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1945940,1945940
181151,402667,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 02  to trade at  84 30 by 14 40  18 40 GMT  on Wednesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 1 82M  Abbott Labs has traded in a range of  84 26 to  86 31 on the day 
The stock has traded at  87 1000 at its highest and  82 3100 at its lowest during the past seven days ",2019-08-14,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1955263,1955263
181167,402683,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 04  to trade at  69 32 by 12 18  17 18 GMT  on Wednesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 3 90M  Abbott Labs has traded in a range of  69 31 to  71 55 on the day 
The stock has traded at  71 7400 at its highest and  68 1300 at its lowest during the past seven days ",2019-01-23,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1755235,1755235
181170,402686,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 04  to trade at  68 91 by 14 26  19 26 GMT  on Monday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 3 09M  Abbott Labs has traded in a range of  68 98 to  70 53 on the day 
The stock has traded at  71 7700 at its highest and  68 8900 at its lowest during the past seven days ",2019-01-28,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1760408,1760408
181171,402687,ABT,Intellia CEO not involved in Starboard s Bristol Myers board challenge,news,"By Greg Roumeliotis NEW YORK  Reuters    Intellia Therapeutics Inc Chief Executive John Leonard  who U S  drug maker Bristol Myers Squibb  NYSE BMY  Co said last week was nominated by hedge fund Starboard Value LP to sit on its board  is not affiliated with the effort  an Intellia spokeswoman said on Thursday   He is not involved  He has a very demanding job as our CEO and he is on other boards as well   Jennifer Mound Smoter  Intellia senior vice president for external affairs and communications  said in an interview after Reuters contacted Leonard   Smoter declined to offer an explanation on how Leonard s name was included in Starboard s slate of five directors to challenge Bristol Myers  board  Starboard declined to comment   Leonard is a seasoned pharmaceutical industry executive  having previously held senior positions at  Abbott Laboratories   NYSE ABT  and Abbvie Inc   Starboard s four other board nominees are Starboard Chief Executive Jeffrey Smith  Shulman Family Ventures managing partner Steven Shulman  Tyree   D Angelo Partners co CEO Michael Tyree  and Water Street Healthcare Partner Janet Vergis  according to a regulatory filing by Bristol Myers  Starboard s immediate goal is to muster enough Bristol Myers shareholder support to shoot down the company s  74 billion deal to acquire biotech  Celgene Corp   NASDAQ CELG   the New York based fund said on Thursday  If it succeeds  it will use the slate to challenge Bristol Myers  board  Starboard added  Starboard reported on Thursday it owned 4 4 million shares  or 0 3 percent  of Bristol s shares  A top Bristol Myers shareholder  Wellington Management  came out against the Celgene deal on Wednesday  criticizing it as too risky and expensive  Bristol Myers on Thursday defended the Celgene deal  through which it hopes to create a market leader in the lucrative treatment of cancer by combining two of the world s biggest selling portfolios of drugs that treat the disease  as well as adding assets in immunology and inflammation  Starboard has a track record of opposing deals  It tried to block Virginia based meat giant Smithfield Foods  sale to Chinese company Shuanghui International in 2013  as well as aircraft component maker Rockwell Collins  NYSE COL  Inc s acquisition of B E Aerospace two years ago  Both deals were done  Starboard has been seeking to burnish its credentials in the pharmaceutical sector  Perrigo Company Plc shares have lost more than a third of their value since the drug maker gave Starboard board representation in 2017  
Assertio Therapeutics Inc  previously known as Depomed  explored a sale three years ago under pressure from Starboard but did not reach any deal  Its shares have lost half their value since then ",2019-02-28,Reuters,https://www.investing.com/news/stock-market-news/intellia-ceo-not-involved-in-starboards-bristolmyers-board-challenge-1794860,1794860
181172,402688,ABT,Abbott Labs Earnings  Revenue Beat in Q1,news,"Investing com   Abbott Labs  NYSE ABT  reported first quarter earnings  that Beat analysts  expectations on Wednesday and revenue that topped forecasts 
The firm reported earnings per share of  0 63 on revenue of  7 54B  Analysts polled by Investing com forecast EPS of  0 61 on revenue of  7 47B  That compared to EPS of  0 59 on revenue of  7 39B in the same period a year earlier  The company had reported EPS of  0 81 on revenue of  7 77B in the previous quarter 
Abbott Labs shares gained 0 55  to trade at  76 80 in pre market trade following the report 
Abbott Labs follows other major Healthcare sector earnings this month
 On Tuesday  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 62B 
LivaNova PLC earnings missed analysts  expectations on February 27  with fourth quarter EPS of  0 95 on revenue of  297M  Investing com analysts expected EPS of  1 1 on revenue of  294 99M
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-04-17,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-earnings-revenue-beat-in-q1-1838438,1838438
181173,402689,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 18  to trade at  73 95 by 09 51  13 51 GMT  on Wednesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 1 16M  Abbott Labs has traded in a range of  73 14 to  76 19 on the day 
The stock has traded at  79 4200 at its highest and  73 2800 at its lowest during the past seven days ",2019-04-17,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1838634,1838634
181174,402690,ABT,StockBeat   UnitedHealth Deepens Losses as Fears Over Political Risk Rise,news,"Investing com   UnitedHealth Group fell deeper into the red Wednesday as analysts turned bearish on the stock in the wake of its CEO s warning on political risk 
UnitedHealth  NYSE UNH  CEO David Wichmann s warning on Tuesday that a Medicare for All system would destabilize the system put health care stocks on notice and prompted negative calls on the sector from analysts 
The stock fell as much as 5 7  before buyers came in and pared the loss to 2 9   The shares had lost 4  on Monday  
The measures proposed by Democrats would  surely jeopardize the relationship people have with their doctors  destabilize the nation s health system and limit the ability of clinicians to practice medicine at their best   Wichmann said   And the inherent cost burden would surely have a severe impact on the economy and jobs    all without fundamentally increasing access to care  
Citi lowered its price target for UnitedHealth to  247 from  288  citing concerns over government reforms including  regulatory uncertainties around Medicare for All and concerns around  point of sale  rebates  
The negative sentiment in the stock has overshadowed better than expected earnings from other health care companies and has pressured the health care sector overall  The Health Care Select Sector ETF  NYSE XLV  was off about 3 4  Wednesday afternoon  Up 8  on March 4  the ETF is now off 1 3  for the year 
Abbott Labs  NYSE ABT  fell 4   even as the company reported first quarter results that ttopped expectations 
The company reported earnings per share of  0 63 on revenue of  7 54 billion  above estimates from Investing com for earnings of  0 61 a share on revenue of  7 47 billion 
Johnson   Johnson  NYSE JNJ  bucked the trend lower as it continued to add to gains following its above consensus earnings reported a day earlier ",2019-04-17,Investing.com,https://www.investing.com/news/stock-market-news/stockbeat--unitedhealth-deepens-losses-as-fears-over-political-risk-rise-1838901,1838901
181193,402709,ABT,Abbott Labs Falls 4 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 51  to trade at  67 06 by 09 53  14 53 GMT  on Thursday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 825 37K  Abbott Labs has traded in a range of  67 01 to  68 84 on the day 
The stock has traded at  72 7600 at its highest and  65 4400 at its lowest during the past seven days ",2019-01-03,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-4-1736329,1736329
181194,402710,ABT,Abbott Labs Rises 3 ,news,"Investing com   Abbott Labs  NYSE ABT  rose by 3 04  to trade at  68 23 by 12 21  17 21 GMT  on Friday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 2 87M  Abbott Labs has traded in a range of  67 00 to  68 28 on the day 
The stock has traded at  72 7600 at its highest and  65 5000 at its lowest during the past seven days ",2019-01-04,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-rises-3-1737797,1737797
181195,402711,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 07  to trade at  67 01 by 11 47  16 47 GMT  on Tuesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 3 40M  Abbott Labs has traded in a range of  67 01 to  69 64 on the day 
The stock has traded at  72 7600 at its highest and  65 5000 at its lowest during the past seven days ",2019-01-08,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1741166,1741166
181196,402712,ABT,Top Picks 2019  AbbVie Inc  ABBV,news,"The population is aging at warp speed  A combination of longer lives and lower fertility rates have made the US and global populations older than ever before  forecasts Tom Hutchinson  a leading income expert and editor of Cabot Dividend Investor 
About a third of the US population is already over 50  and they won t be getting any younger  In fact  the fastest growing segment of the population is 65 and older as an average of 10 000 baby boomers turn 65 every single day  
What does this mean   It means you re likely to get stuck behind drivers who pull out onto the middle of the road and become stumped  But it also means that healthcare will be a booming growth industry  as older people simply require a lot more of it  That s a beautiful thing because the sector is already defensive and adding the growth quotient makes it irresistible 
There s a lot of ways to play healthcare  You can invest in everything from high flying biotechnology companies to the more stodgy big pharmaceutical companies   I like a company that combines both   the stability and high dividend yield of big pharma and the rapid growth of biotechnology 
AbbVie  NYSE ABBV  is a US based biopharmaceutical company specializing in cutting edge small molecule drugs   The company was spun off from pharmaceutical giant Abbott Labs  NYSE ABT  in 2013  but has already eclipsed its former parent company in size and is now the eighth largest drug company in the world 
Since the stock s IPO on December 21  2012 it has provided a phenomenal average annual return of 20    An initial  10 000 investment would now be worth over  31 000  with dividends reinvested  The dividend has more than doubled since 2014 and ABBV now yields a big fat 5  
The rapid growth has been achieved from its blockbuster biologic auto immune drug Humira  which is the world s number one drug by far with annual sales of over  20 billion  Humira accounts for over 50  of sales and faces increasing competition that will erode market share  However  AbbVie has a spectacular pipeline of new drugs that should more than offset the slippage 
According to market research firm EvaluatePharma  Abbvie has the second most valuable clinical pipeline across all of biopharma  It has 20 new products slated for launch by 2020 and 15 drugs and treatments that are already currently already in phase 3  the last step before the approval process  
Earnings over the next five years are expected to be even better than the last five  With a yield of 5 0   the stock has a spectacular track record and offers more growth and a higher dividend than any other big drug company 
Subscribe to Cabot Dividend Investor here ",2019-01-09,Money Show,https://www.investing.com/news/stock-market-news/top-picks-2019-abbvie-inc-abbv-1742083,1742083
181197,402713,ABT,Abbott Labs Rises 3 ,news,"Investing com   Abbott Labs  NYSE ABT  rose by 3 19  to trade at  70 45 by 15 09  20 09 GMT  on Tuesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 3 91M  Abbott Labs has traded in a range of  68 36 to  70 45 on the day 
The stock has traded at  70 4500 at its highest and  67 0000 at its lowest during the past seven days ",2019-01-15,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-rises-3-1747793,1747793
181198,402714,ABT,Top Picks 2019  Abbott Laboratories ABT,news,"If the 2018 market proved anything it is that you need to own stocks with an earnings backbone  That s because like the cream  great companies with strong earnings and strong products pipelines tend to quickly rise to the top  One such company is medical device maker  Abbott Laboratories   NYSE ABT   suggests Jim Woods  editor of Fast Money Alert 
The diversified medical device maker  whose products include blood glucose monitoring kits  nutritional healthcare products  diagnostic products and equipment  has seen strong EPS growth that s put it in the top quartile of all publicly traded companies  growth over the past two quarters and past several years  
That growth has been recognized by the fast money in 2018  as ABT s 2018 gain of nearly 27  puts it in the top 6  of price performers over the past year  it also pays a 1 8  dividend yield for even more upside   
One personal note here  I am about to get some firsthand knowledge of one very interesting new Abbot product called DRG therapy  This surgically implanted electronic stimulation device is used for chronic pain management  in my case injuries from years of martial arts  bodybuilding and military training  
The device delivers pain relief to a reported 74 2  of patients who suffer from complex regional pain syndrome  or CRPS  Hopefully  I will be in that near three quarters of patients with those positive results 
For Wall Street  the upside in Abbott has allowed it to trade well above its 200 day moving average in 2018  And despite the volatility we witnessed in most stocks during Q4  the shares ended the year back above its short term  50 day moving average at a time when most stocks were tanking 
I suspect the stock is just getting started  and in 2019  I think this healthcare standout is a good way to ease the 2018 portfolio pain  Disclosure  At the time of this writing  Jim Woods was long ABT in his Fast Money Alert advisory service 
Subscribe to Jim Woods Investing here ",2019-01-17,Money Show,https://www.investing.com/news/stock-market-news/top-picks-2019-abbott-laboratories-abt-1749643,1749643
181199,402715,ABT,Abbott Labs Earnings in Line  Revenue Misses In Q4,news,"Investing com   Abbott Labs  NYSE ABT  reported fourth quarter earnings  that matched analysts  expectations on Wednesday and revenue that fell short of forecasts 
The firm reported earnings per share of  0 81 on revenue of  7 77B  Analysts polled by Investing com forecast EPS of  0 81 on revenue of  7 81B  That compared to EPS of  0 74 on revenue of  7 59B in the same period a year earlier  The company had reported EPS of  0 75 on revenue of  7 66B in the previous quarter 
Abbott Labs shares gained 0 01  to trade at  71 50 in pre market trade following the report 
Abbott Labs follows other major Healthcare sector earnings this month
 On Tuesday  J J reported fourth quarter EPS of  1 97 on revenue of  20 39B  compared to forecasts of EPS of  1 95 on revenue of  20 2B 
McKesson earnings beat analyst s expectations on October 25  2018  with second quarter EPS of  3 6 on revenue of  53 08B  Investing com analysts expected EPS of  3 28 on revenue of  53 56B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-01-23,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-earnings-inline-revenue-misses-in-q4-1754727,1754727
181219,402735,ABT,Abbott Labs Earnings  Revenue beat in Q3,news,"Investing com   Abbott Labs  NYSE ABT  reported third quarter earnings  that beat analyst s expectations on Wednesday and revenue that topped forecasts 
The firm reported earnings per share of  0 75 on revenue of  7 66B  Analysts polled by Investing com anticipated EPS of  0 74 on revenue of  7 65B  That compared to EPS of  0 74 on revenue of  6 83B in the same period a year earlier The company had reported EPS of  0 73 on revenue of  7 77B in the previous quarter 
Abbott Labs shares slightly moved  0 48  to trade at  70 61 in pre market trade following the report 
For the year  Abbott Labs shares are up 21 91   outperforming the S P 500 which is up 4 7  year to date 
Abbott Labs follows other major Healthcare sector earnings this month
 On Tuesday  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 04B 
Cantel Medical earnings beat analyst s expectations on September 27  with fourth quarter EPS of  0 62 on revenue of  228 85M  Investing com analysts expected EPS of  0 58 on revenue of  225 98M
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-17,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-earnings-revenue-beat-in-q3-1647719,1647719
181220,402736,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 10  to trade at  68 05 by 13 19  17 19 GMT  on Thursday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 5 39M  Abbott Labs has traded in a range of  68 05 to  69 72 on the day 
The stock has traded at  71 2100 at its highest and  67 6500 at its lowest during the past seven days ",2018-10-18,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1650221,1650221
181221,402737,ABT,Abbott and AbbVie to pay  25M to settle TriCor case,news,Reuters reports that Abbott  NYSE ABT  and AbbVie  NYSE ABBV  have agreed to pay a total of  25M to settle a whistleblower lawsuit accusing the companies of an alleged kickback scheme to doctors aimed at driving prescriptions for cholesterol med TriCor  fenofibrate  and for allegedly promoting the drug for unapproved uses The suit was filed in 2009 by a former sales rep AbbVie was spun out of Abbott in 2013 Now read ,2018-10-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/abbott-and-abbvie-to-pay-25m-to-settle-tricor-case-1662405,1662405
181222,402738,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 04  to trade at  70 58 by 13 43  18 43 GMT  on Monday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 2 65M  Abbott Labs has traded in a range of  70 57 to  72 89 on the day 
The stock has traded at  73 0800 at its highest and  69 5900 at its lowest during the past seven days ",2018-11-12,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1684684,1684684
181223,402739,ABT,Abbott Labs Rises 3 ,news,"Investing com   Abbott Labs  NYSE ABT  rose by 3 21  to trade at  71 95 by 12 45  17 45 GMT  on Wednesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 2 78M  Abbott Labs has traded in a range of  70 10 to  71 95 on the day 
The stock has traded at  72 4100 at its highest and  67 8300 at its lowest during the past seven days ",2018-11-28,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-rises-3-1703715,1703715
181224,402740,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 04  to trade at  72 01 by 13 27  18 27 GMT  on Tuesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 2 98M  Abbott Labs has traded in a range of  71 97 to  74 25 on the day 
The stock has traded at  74 9200 at its highest and  68 3800 at its lowest during the past seven days ",2018-12-04,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1710611,1710611
181225,402741,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 02  to trade at  69 38 by 14 11  19 11 GMT  on Friday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 3 45M  Abbott Labs has traded in a range of  69 32 to  71 83 on the day 
The stock has traded at  74 9200 at its highest and  69 3200 at its lowest during the past seven days ",2018-12-07,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1715259,1715259
181228,402744,ABT,Abbott Labs Rises 3 ,news,"Investing com   Abbott Labs  NYSE ABT  rose by 3 07  to trade at  67 57 by 11 47  16 47 GMT  on Wednesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 2 45M  Abbott Labs has traded in a range of  65 90 to  67 57 on the day 
The stock has traded at  71 4700 at its highest and  65 4700 at its lowest during the past seven days ",2018-12-26,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-rises-3-1730977,1730977
181230,402746,ABT,Abbott Labs Falls 3 ,news,"Investing com   Abbott Labs  NYSE ABT  fell by 3 15  to trade at  70 06 by 09 52  14 52 GMT  on Wednesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 777 70K  Abbott Labs has traded in a range of  70 04 to  70 96 on the day 
The stock has traded at  72 7600 at its highest and  65 4400 at its lowest during the past seven days ",2019-01-02,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1735013,1735013
181252,402768,ABT,Abbott Labs Rises 3 35 ,news,"Investing com   Abbott Labs  NYSE ABT  rose by 3 35  to trade at  71 36 by 09 33  13 33 GMT  on Monday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was  511 07K  Abbott Labs has traded in a range of  70 41 to  71 38 on the day 
The stock has traded at  71 39 at its highest and  67 51 at its lowest during the past seven days ",2018-09-24,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-rises-335-1621248,1621248
181253,402769,ABT,Abbott Labs Falls 3  as Market Selloff Overshadows RBC Upgrade ,news,"Investing com   Shares of Abbott Labs fell Wednesday as broad market selling pressure weighed  even as RBC Capital Markets said the drug company was set to continue its string of  strong  quarterly results 
RBC upgraded its price target on Abbott s stock to  77 per share from  70  insisting that while the company will struggle to beat its first half organic growth of 7 5  in the third quarter   upside to consensus remains a distinct possibility  
RBC kept its investment rating on the stock at outperform and said Abbott s string of strong quarterly results was likely to continue 
The bullish note from RBC comes a week ahead of Abbot s third quarter results 
 Abbott Laboratories   NYSE ABT  fell by 3  to trade at  69 13 by 14 27  18 27 GMT  on Wednesday on the NYSE  The volume of Abbott Labs shares traded since the start of the session was 5 34 million  Abbott Labs has traded in a range of  69 09 to  71 21 on the day  The stock has traded at  74 05 at its highest and  69 10 at its lowest during the past seven days ",2018-10-10,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-falls-3-1639267,1639267
181254,402770,ABT,Abbott Labs Rises 3 ,news,"Investing com   Abbott Labs  NYSE ABT  rose by 3 01  to trade at  70 77 by 12 49  16 49 GMT  on Tuesday on the NYSE exchange 
The volume of Abbott Labs shares traded since the start of the session was 2 63M  Abbott Labs has traded in a range of  69 30 to  70 77 on the day 
The stock has traded at  72 3900 at its highest and  67 6500 at its lowest during the past seven days ",2018-10-16,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-rises-3-1646508,1646508
181269,402785,ABT,Abbott Labs tops profit estimates  raises full year earnings forecast,news," Reuters     Abbott Laboratories   NYSE ABT  raised its full year earnings forecast and reported a quarterly profit that beat analysts  estimates  powered by higher sales across its businesses  including its top earning medical device unit 
The diversified healthcare company said on Wednesday medical device sales rose 11 3 percent to  2 89 billion in the second quarter  ahead of the average analyst estimate of  2 66 billion 
The unit  which accounted for nearly 38 percent of the company s revenue last year  benefited from sales of its FreeStyle Libre device for diabetics that helps monitor blood sugar levels without the need to prick fingers frequently 
Abbott raised its full year forecast for adjusted earnings from continuing operations to between  2 85 per share and  2 91 per share  from a prior range of  2 80 to  2 90 
Excluding items  the company earned 73 cents per share  ahead of analysts  average estimate of 71 cents  according to Thomson Reuters I B E S 
Net sales rose 17 percent to  7 78 billion  above analysts  estimate of  7 71 billion 
Net earnings increased to  733 million  or 41 cents per share  in the second quarter ended June 30  from  283 million  or 16 cents per share  a year earlier 
The company s shares rose 2 percent to  64 10 in premarket trade ",2018-07-18,Reuters,https://www.investing.com/news/stock-market-news/abbott-labs-tops-profit-estimates-raises-fullyear-earnings-forecast-1534595,1534595
181282,402798,ABT,Key events next week   healthcare,news,Noteworthy events during the week of April 15   21 for healthcare investors Monday  4 16   FDA action date for Bristol Myers Squibb s  NYSE BMY  Opdivo Yervoy combo in intermediate poor risk renal cell carcinoma Bristol Myers Squibb investor event  review of data presented at the American Association for Cancer Research  AACR  Annual Meeting Universal Influenza Vaccines Conference  Lausanne  Switzerland  BiondVax Pharmaceuticals  NASDAQ BVXV   Mid stage M 001 data Tuesday  4 17   FDA action date for  Rigel Pharmaceuticals    NASDAQ RIGL  Tavalisse  fostamatinib  for chronic persistent immune thrombocytopenia FDA action date for  Ultragenyx  Pharmaceutical s  NASDAQ RARE  Crysvita  burosumab  for X linked hypophosphatemia Q1 earnings  premarket   UnitedHealth Group  NYSE UNH   Johnson   Johnson  NYSE JNJ  Wednesday  4 18   Abbott  NYSE ABT  Q1 results  premarket  Thursday  4 19   FDA advisory committee review of GW Pharmaceuticals   NASDAQ GWPH  cannabidiol oral solution for Lennox Gastaut or Dravet syndrome Revance Therapeutics  NASDAQ RVNC   Investor Day  NYC Saturday  4 21   European Congress of Clinical Microbiology and Infectious Diseases   ECCMID    Madrid  4 days   Motif bio  NASDAQ MTFB   Three iclaprim abstracts including P3 data vs  vancomycin in ABSSSI from Gram positive bacteria  Cidara Therapeutics  NASDAQ CDTX   Preclinical data on rezafungin  Achaogen  NASDAQ AKAO   Plazomicin data  SCYNEXIS  NASDAQ SCYX   SCY 078 data  Tetraphase Pharmaceuticals  NASDAQ TTPH   P3 eravacycline data   Cardiome Pharma   NASDAQ CRME   Data on Xydalba and Zevtera Mabelio  Paratek Pharmaceuticals  NASDAQ PRTK   P3 omadacycline data in ABSSSI  Nabriva Therapeutics  NASDAQ NBRV   Lefamulin data American Academy of Neurology Annual Meeting  Los Angeles  7 days    MediciNova   NASDAQ MNOV   P1b 2a data on MN 166 in ALS  BrainStorm Cell Therapeutics  NASDAQ BCLI   P2 NurOwn micro RNA biomarker data and ALSFR R subgroup analyses  Ovid Therapeutics  NASDAQ OVID   OV101 data  TAK 035 OV935 data  Intec Pharma  NASDAQ NTEC   P2 safety and PK data on Accordion Pill  GW Pharmaceuticals  GWPH   P3 Epidiolex data in Lennox Gastaut and Dravet  Adamas Pharmaceuticals  NASDAQ ADMS   GOCOVRI  amantadine  data Now read ,2018-04-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/key-events-next-week--healthcare-1393973,1393973
181283,402799,ABT,Abbott Laboratories beats by  0 01  beats on revenue,news,Abbott Laboratories   NYSE ABT   Q1 EPS of  0 59 beats by  0 01 Revenue of  7 39B   16 7  Y Y  beats by  100M Press ReleaseNow read ,2018-04-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/abbott-laboratories-beats-by-001-beats-on-revenue-1400652,1400652
181284,402800,ABT,Abbott sticks to earlier forecasts  disappoints investors,news,"By Manas Mishra  Reuters    Abbott Laboratories   N ABT  just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full year profit forecast some investors had expected would be raised  sending the healthcare company s shares lower  Some analysts also said a 6 9 percent rise in organic sales  which excludes the impact of foreign currency and certain divestitures and acquisitions  was just shy of a roughly 7 percent expected by investors  Thomson Reuters I B E S had no consensus estimate for the organic sales  Leerink analyst Danielle Antalffy said the miss  may limit upside to the shares today despite an otherwise very good quarter   Several other analysts said the company had failed to meet heightened expectations among investors   Abbott shares fell 2 7 percent to trade at  58 22 mid morning in New York   On a reported basis  Abbott s sales rose 16 7 percent to  7 39 billion  beating consensus expectations of  7 29 billion  according to Thomson Reuters I B E S   Excluding items  Abbott reported a profit of 59 cents per share against expectations of 58 cents per share   The company reiterated its full year 2018 forecast of adjusted earnings from continuing operation between  2 80 to  2 90 per share   It s all about the expectations   Evercore ISI analyst Vijay Kumar said  saying that investors may have been disappointed that the healthcare company only maintained its full year profit forecast   The company s first quarter results were helped by launches of new medical devices and a turnaround in its business that sells baby and adult nutritional supplements  Sales across all the company s business units  except in its established pharmaceuticals business  beat expectations   The established pharmaceuticals  which sells generic drugs in emerging growth countries such as India  raked in sales of 1 04 billion  but missed analysts  consensus estimates of  1 08 billion   The weak sales were due to a slowing market growth rate in Russia  Chief Executive Miles White said on a conference call    We seem to have a given market that affects our established pharmaceuticals or even our nutrition business from time to time somewhere  And in this particular case  it s Russia   White said  The company reported net earnings of  418 million  or 23 cents per share  in the quarter ended March 31  compared to  419 million  or 24 cents per share  a year earlier  
Profit from Abbott s medical device business   its largest division   continued to benefit from its  25 billion purchase of St  Jude Medical  and from new device launches  Sales for the unit rose 14 6 percent to  2 74 billion in the quarter ",2018-04-18,Reuters,https://www.investing.com/news/stock-market-news/abbott-labs-quarterly-revenue-rises-167-percent-1400651,1400651
181285,402801,ABT,7 Dividend ETFs That Offer Growth In 2020,opinion,In a low interest rate environment  dividend investing has been the hot spot and seems an excellent choice for 2020  Though the strategy doesn t offer dramatic price appreciation  it is a major source of consistent income for investors in any type of market Below we highlight some solid reasons to invest in this strategy Uneven Stock Market RallyThe stock market is currently hitting new record highs but 2020 is likely to be filled with volatility backed by Middle East tensions  trade uncertainty and U S  presidential election  The dividend focused products offer safety in the form of payouts and stability in the form of mature companies that are less volatile to large swings in stock prices  read    Additionally  the Fed vowed to keep interest rates steady in 2020 after three rates cut last year  This has raised the appeal for dividend strategies Dividend Payout to Top  500 BillionThe companies on the S P 500 are expected to return more money to shareholders through dividends than ever this year  Per Howard Silverblatt  senior index analyst at S P Dow Jones Indices  the dividend payout is expected to top  500 billion for the first time  At least 330 companies on the index are expected to raise their dividends based on their history and financial condition  Among the companies that recently announced plans to raise their dividends are Pfizer Inc    NYSE PFE    Abbott Laboratories   NYSE ABT   and AT T Inc   NYSE T   Notably  the first quarter is typically the busiest period for dividends as companies roll out their annual results and reward shareholders ahead of their annual meetings Solid Inflow in Q4Investors have been showing interest in dividend strategies  In the fourth quarter  they added more than  10 billion in new money to dividend focused ETFs  the highest period of inflows for 2019  according to Todd Rosenbluth  head of ETF and mutual fund research at CFRA  read    Invest in Dividend GrowthAlthough dividends have increased  the yields dropped to 1 80  at year end 2019 from 2 16  at the beginning as the S P 500 surged 29   according to FactSet  As such  honing in on dividend aristocrats could be the most beneficial way Dividend aristocrats are the blue chip dividend paying companies  which have a long history of raising dividend payments year over year  These tend to skew the portfolio to less volatile sectors and mature companies  Investors should note that the dividend aristocrat funds offer more dividend growth opportunities when compared to the other products in the space but might not necessarily have the highest yields  As a result  these products provide a nice combination of annual dividend growth and capital appreciation opportunity and are mainly suitable for risk adverse  long term investors How to Play Below we have presented a bunch of dividend aristocrats ETFs that have a Zacks ETF Rank  1  Strong Buy  or 2  Buy  or 3  Hold  Vanguard Dividend Appreciation ETF   ASX VIG  This is the largest and most popular ETF in the dividend space with AUM of  42 2 billion and average daily volume of about 1 1 million shares  The fund follows the NASDAQ US Dividend Achievers Select Index  which is composed of high quality stocks that have a record of raising dividends every year  It holds 182 securities in the basket and charges 6 bps in annual fees   VIG has a Zacks ETF Rank  1 with a Medium risk outlook  read    iShares Core Dividend Growth ETF This fund provides exposure to companies having a history of sustained dividend growth by tracking the Morningstar US Dividend Growth Index  Holding 478 stocks in its basket  the fund has AUM of  10 4 billion and trades in good volumes of about 1 3 million shares  It charges 8 bps in fees per year and has a Zacks ETF Rank  2 with a Medium risk outlook iShares Select Dividend ETF This fund provides exposure to the companies with a consistent 5 year history of dividend payments  It follows the Dow Jones U S  Select Dividend Index and holds 100 securities in its basket  The ETF has AUM of  18 5 billion and average daily volume of around 499 000 shares  It charges 39 bps in fees per year from investors and has a Zacks ETF Rank  3 with a Medium risk outlook SPDR S P Dividend ETF   TSX SDY  With AUM of  19 7 billion and average daily volume of 481 000 shares  this fund provides a well diversified exposure to 112 U S  stocks that have been consistently increasing their dividends every year for at least 20 years  This can be done by tracking the S P High Yield Dividend Aristocrats Index  The fund charges 35 bps in fees and has a Zacks ETF Rank  3 with a Medium risk outlook  Schwab U S  Dividend Equity ETF With AUM of  11 7 billion  this product offers exposure to 113 high dividend yielding U S  companies that have a record of consistent dividend payments supported by fundamental strength based on financial ratios and ample liquidity  This can be easily done by tracking the Dow Jones U S  Dividend 100 Index  The fund charges 6 bps in annual fees and trades in solid volume of around 782 000 shares a day  It has a Zacks ETF Rank  3 with a Medium risk outlook  read    ProShares S P 500 Aristocrats ETF   BO NOBL  This product provides exposure to companies that raised dividend payments annually for at least 25 years by tracking the S P 500 Dividend Aristocrats Index  It holds 58 securities in its basket and charges 35 bps in annual fees  NOBL has amassed  6 5 billion in its asset base and trades in a volume of around 459 000 shares a day on average  It has a Zacks ETF Rank  3 with a Medium risk outlook First Trust NASDAQ Rising Dividend Achievers ETF This fund provides exposure to a diversified portfolio of 51 companies with a history of paying dividends  It tracks the NASDAQ US Rising Dividend Achievers Index  charging investors 50 bps in annual fees  The ETF has accumulated  1 2 billion in its asset base and sees a good volume of 2020 000 shares a day on average  It has a Zacks ETF Rank  2 with a Medium risk outlook  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2020-01-13,Zacks Investment Research,https://www.investing.com/analysis/7-dividend-etfs-that-offer-growth-in-2020-200498683,200498683
181286,402802,ABT,Abbott  ABT  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"The market expects Abbott  ABT  to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended December 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on January 22  2020  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This maker of infant formula  medical devices and drugs is expected to post quarterly earnings of  0 95 per share in its upcoming report  which represents a year over year change of  17 3  
Revenues are expected to be  8 26 billion  up 6 4  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 93  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Abbott 
For Abbott  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 59  
On the other hand  the stock currently carries a Zacks Rank of  4 
So  this combination makes it difficult to conclusively predict that Abbott will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Abbott would post earnings of  0 84 per share when it actually produced earnings of  0 84  delivering no surprise 
Over the last four quarters  the company has beaten consensus EPS estimates two times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Abbott doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2020-01-15,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-reports-next-week-wall-street-expects-earnings-growth-200499058,200499058
181287,402803,ABT,Abbott  ABT  Q4 Earnings Match Estimates  Revenues Beat Mark,opinion,Abbott Laboratories   NYSE ABT   reported fourth quarter 2019 adjusted earnings from continuing operations of 95 cents per share  in line with the Zacks Consensus Estimate  Meanwhile  the bottom line improved 17 3  from the prior year quarter  Also  reported earnings from continuing operations came in at 59 cents  reflecting a 59 5  surge from the year ago quarter Further  full year adjusted earnings of  3 24 rose 12 5  from the year ago period  Meanwhile  the figure met the Zacks Consensus Estimate and also fell within the company s guided range of  3 23  3 25 Fourth quarter worldwide sales of  8 31 billion were up 7 1  year over year on a reported basis  The top line also exceeded the Zacks Consensus Estimate by 0 6  On an organic basis  adjusting the impact of foreign exchange along with the prior year s first  second and third quarter results for a non core business within U S  Adult Nutrition   sales increased 8 5  year over year in the reported quarter Abbott Laboratories Price  Consensus and EPS Surprise   For 2019  worldwide sales were  31 9 billion  up 4 3  on a reported basis and up 7 7  on an organic basis from 2018 levels  This was also slightly ahead of the Zacks Consensus Estimate of  31 85 billion Quarter in DetailAbbott operates through four segments  namely  Established Pharmaceuticals Division  EPD   Medical Devices  Nutrition and Diagnostics In the fourth quarter  EPD sales rose 7 8  on a reported basis  improved 10  on an organic basis  to  1 17 billion  Sales in the key emerging markets ascended 7  year over year on a reported basis  Organically  sales climbed 9 5  in this market Medical Devices business sales increased 9 7  on a reported basis to  3 2 billion  On an organic basis  sales grew 11 3   Double digit growth in Electrophysiology  Heart Failure  Structural Heart and Diabetes Care contributed to this upside Vascular sales reportedly  up 0 3  on an organic basis  dipped 0 8   Neuromodulation sales in the quarter were up 2  reportedly  up 3  organically   Rhythm Management sales were up 2 3  on a reported basis  up 3 7  organically  in the quarter Nutrition sales were up 5 2  year over year on a reported basis  up 5 8  on an organic basis  to  1 87 billion  Pediatric Nutrition sales inched up 2 8  on an organic basis  Adult Nutrition sales were up 9 9  organically Diagnostics sales were up 5  year over year on a reported basis  up 6 4  on an organic basis  to  2 06 billion  Core Laboratory Diagnostics sales grew 10  on an organic basis  led by above market growth in the United States and international markets  However  Molecular Diagnostics slipped 4 4  on an organic basis  Point of Care Diagnostics sales too slid 0 2  on an organic basis  Rapid Diagnostics sales improved 2 7  on an organic basis in the fourth quarter  driven by infectious disease testing in developed markets and cardio metabolic testing globally  partially offset by lower infectious disease testing sales in Africa 2020 GuidanceAbbott issued its 2020 guidance For the full year  adjusted earnings from continuing operations are expected in the band of  3 55  3 65  The Zacks Consensus Estimate of  3 61 lies within this projected range  Organic sales growth is projected in the range of 7 8   The Zacks Consensus Estimate for 2020 worldwide sales is pegged at  33 97 billion The company also provided its first quarter 2020 adjusted earnings per share outlook  It expects to report adjusted earnings from continuing operations in the bracket of 69 71 cents  The consensus mark of 72 cents surpasses this predicted range Our TakeAbbott exited 2019 on a mixed note with earnings meeting the Zacks Consensus Estimate and revenues exceeding the same Overall  we are optimistic about Abbott s strong and consistent EPD and Medical Devices performance organically  Particularly  Abbott has been riding high on a healthy growth graph within its Diabetes Care business  The company has been hogging the limelight for developments in the flagship  sensor based continuous glucose monitoring system  known as FreeStyle Libre System  Also  solid contributions from the company s other two businesses buoy investors  hopes  Moreover  the company s emerging market performance has been promising on the back of several strategic developments On the flip side  increasing currency headwinds and lower infectious disease testing sales in Africa significantly dented the company s international performance Zacks Rank   Key PicksCurrently  Abbott carries a Zacks Rank  4  Sell  Some better ranked stocks in the broader medical space are Haemonetics Corporation   NYSE HAE    Hill Rom Holdings  Inc    NYSE HRC   and Smith   Nephew  LON SN  plc   NYSE SNN    While Haemonetics sports a Zacks Rank  1  Strong Buy   the other two carry a Zacks Rank  2  Buy  You can see  The Zacks Consensus Estimate for Haemonetics  third quarter fiscal 2020 revenues is pegged at  255 4 million  suggesting an expected 3 2  growth rate from the prior year reported figure  The same for adjusted earnings per share is anticipated at 76 cents  implying a 20 6  improvement from the year ago reported number The Zacks Consensus Estimate for Hill Rom s first quarter fiscal 2020 revenues is pegged at  685 3 million  hinting at a 0 26  increase from the year earlier reported figure  The same for adjusted earnings per share stands at  1 08  indicating a 5 9  increase from the year ago reported figure The Zacks Consensus Estimate for Smith   Nephew s fourth quarter 2019 revenues is pegged at  1 4 billion  The same for adjusted earnings per share stands at  1 14 Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2020-01-21,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-q4-earnings-match-estimates-revenues-beat-mark-200500616,200500616
181308,402824,ABT,Abbott Laboratories Q4 revenues up 42   non GAAP EPS up 14   updates guidance,news,Abbott Laboratories   ABT  Q4 results  Revenues   7 589M   42 3    Nutrition   1 784M   42 3    Diagnostics   1 906M   51 7    Established Pharmaceuticals   1 145M  Medical Devices   2 737M   102 2   Operating Income   691M   27 1    Net Loss    864M   Loss Per Share    0 50   Non GAAP EPS   0 74   13 8   Q1 Guidance  GAAP EPS   0 16   0 18  Non GAAP EPS   0 57    0 59 2018 Guidance  GAAP EPS   1 22   1 32  Non GAAP EPS   2 80    2 90 Shares are up 3  premarket on light volume Now read ,2018-01-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/abbott-laboratories-q4-revenues-up-42-nongaap-eps-up-14-updates-guidance-1144497,1144497
181309,402825,ABT,Abbott results beat on strong medical device business,news," Reuters    Abbott Laboratories   N ABT  fourth quarter results topped analysts  estimates on Wednesday  boosted by strong sales in its medical devices and generics businesses  Shares of the diversified healthcare company  which also forecast better than expected full year adjusted earnings  jumped 1 8 percent to  60 30 before the bell  The company posted a net loss of  828 million  or 48 cents per share  mainly related to a  1 46 billion charge due to the recent U S  tax overhaul  Excluding items  Abbott reported a profit of 74 cents per share  Analysts on average were expecting a profit of 73 cents per share  according to Thomson Reuters I B E S  Profit from Abbott s medical device business   it s largest division   continued to benefit from its  25 billion purchase of St  Jude Medical  Sales for the unit rose 9 6 percent on an operational basis to  2 74 billion in the quarter ending Dec  31  Net sales rose 42 3 percent to  7 59 billion ahead of analysts  estimate of  7 39 billion  The company forecast full year adjusted profit of  2 80 to  2 90 per share  
Analysts were expecting a profit of  2 49 per share ",2018-01-24,Reuters,https://www.investing.com/news/stock-market-news/abbott-posts-quarterly-loss-on-14-billion-tax-charge-1144204,1144204
181310,402826,ABT,Abbott  ABT  Up 2 1  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Abbott  ABT   Shares have added about 2 1  in that time frame  underperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Abbott due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Abbott Posts In Line Q3 Earnings  Reports Strong Segmental SalesAbbott reported third quarter 2019 adjusted earnings from continuing operations of 84 cents per share  in line with the Zacks Consensus Estimate  The bottom line improved 12  from the prior year quarter  Reported earnings from continuing operations came in at 53 cents  showing a 70 9  surge from the year ago quarter Third quarter worldwide sales came in at  8 08 billion  up 5 5  year over year on a reported basis  The top line missed the Zacks Consensus Estimate by 0 2  On an organic basis  adjusting for the impact of foreign exchange along with the prior year first  second and third quarter results for a non core business within U S  Adult Nutrition   sales increased 7 6  year over year in the reported quarter Quarter in DetailAbbott operates through four segments  namely  Established Pharmaceuticals Division  EPD   Medical Devices  Nutrition and Diagnostics In the third quarter  EPD sales rose 4 4  on a reported basis  improved 7 9  on an organic basis  to  1 21 billion  This included a 3 5  adverse impact from currency fluctuations  Sales in the key emerging markets rose 2 8  year over year  excluding an adverse 4  impact of foreign exchange  Organically  sales climbed 6 8  in this market Medical Devices business sales increased 8 9  on a reported basis to  3 07 billion  On an organic basis  sales grew 10 6   Double digit growth in Electrophysiology  Heart Failure  Structural Heart and Diabetes Care contributed to the rise Cardiovascular and Neuromodulation sales reportedly  up 5 6  on an organic basis  rose 4 2  In Electrophysiology  growth was led by solid performance by cardiac diagnostic and ablation catheters Heart Failure sales growth was 23 2  organically  driven by strong market adoption of Abbott s HeartMate 3 left ventricular assist device following its FDA approval as a destination therapy in late 2018 Within Structural Heart  the company registered 16  organic growth on a year over year basis driven by Abbott s MitraClip device Diabetes Care sales improved 29 6   up 33 1  organically   buoyed by consistent consumer uptake of FreeStyle Libre  the revolutionary continuous glucose monitoring system of Abbott Nutrition sales were up a marginal 2  year over year on a reported basis  up 3 8  on an organic basis  to  1 87 billion  Pediatric Nutrition sales increased 1 4  on an organic basis  Adult Nutrition sales were up 6 9  organically Diagnostics sales were up 4 7  year over year on a reported basis  up 6 6  on an organic basis  to  1 91 billion  Core Laboratory Diagnostics sales grew 10 6  on an organic basis led by solid growth in the United States and international markets  Molecular Diagnostics slipped 6 4   on an organic basis  Point of Care Diagnostics sales were up 6 7  on an organic basis led by the company s i STAT handheld system in the United States and internationally  Rapid Diagnostics sales improved 0 8  on an organic basis in the third quarter led by infectious disease testing in developed markets and cardio metabolic testing globally 2019 GuidanceFor the full year  adjusted earnings from continuing operations have been lowered to a new band of  3 23 to  3 25 from the earlier  3 21  3 27  The Zacks Consensus Estimate of  3 24 lies within this projected range The company has also issued the fourth quarter 2019 adjusted earnings per share outlook  It expects to report adjusted earnings from continuing operations in the range of 94 96 cents  The consensus mark of 94 cents falls within the predicted range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
Currently  Abbott has an average Growth Score of C  a grade with the same score on the momentum front  Following the exact same course  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision has been net zero  Notably  Abbott has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-11-14,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-up-21-since-last-earnings-report-can-it-continue-200485631,200485631
181311,402827,ABT,The Zacks Analyst Blog Highlights  Facebook  Alibaba  Mastercard  Abbott Laboratories And Philip Morris International,opinion,For Immediate ReleaseChicago  IL   December 30  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Facebook   NASDAQ FB    Alibaba Group   NYSE BABA    Mastercard   NYSE MA    Abbott Laboratories   NYSE ABT   and Philip Morris International   NYSE PM   Here are highlights from Friday s Analyst Blog  Top Stock Reports for Facebook  Alibaba and MastercardThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Facebook  Alibaba Group and Mastercard  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Facebook s shares have outperformed the S P 500 year to date   58 5  vs   27 9    The Zacks analyst believes that growth in Instagram Stories and Feed  and Facebook News Feed is expected to aid mobile ad revenues The company s initiatives to improve privacy  transparency and authenticity of ads are likely to boost user trust and engagement  The launch of Facebook View app  Facebook Pay and catalogs in the WhatsApp Business app aimed at small businesses is noteworthy  Further  partnerships with ESPN and Fox for sports related streaming on Facebook Watch are a positive However  a persistent mix shift toward Stories is anticipated to hurt ARPU  Also  the company s rising regulatory headwinds  including the antitrust investigation and the EU s investigation of Libra  are concerns Shares of Alibaba have gained  29 4  in the past three months against the Zacks Internet Commerce industry s rise of  13 4   The Zacks analyst believes that Alibaba is benefiting from steady improvement in core commerce along with strong growth in metrics Further  Alibaba s strengthening cloud business with its expanding customer base continues to drive its performance  Its New Retail strategy is also gaining significant momentum in the market  This is aiding growth in its Tmall Import  Hema fresh food grocery business and Intime Department Stores Additionally  the consolidation of Ele me and Cainiao Network is acting as a tailwind  However  the company s increasing investments  uncertain economy and macro headwinds in China are major concerns  Also  rising competition poses a risk Mastercard s shares have gained  13 1  over the past six months against the Zacks Financial Transaction Services industry s rise of  8 4   The Zacks analyst believes that the company s revenues are gaining from higher switched transactions  increase in cross border volume and gross dollar volume Numerous acquisitions made over the years have fueled its inorganic growth  The company is benefiting from shifts in payments  from physical to digital  Investment in technology has also kept the company at the forefront of the rapidly changing payments industry  Its solid capital position enables investment in business The Zacks Consensus Estimate for current year earnings has been revised 1 1  upward over the last 60 days  However  escalating costs might put pressure on margins  In order to gain customers and new business  Mastercard has been incurring high levels of costs under rebates and incentives  which remain a concern Other noteworthy reports we are featuring today include Abbott Laboratories and Philip Morris International Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-12-29,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-facebook-alibaba-mastercard-abbott-laboratories-and-philip-morris-international-200495457,200495457
181327,402843,ABT,Abbott wins U S  antitrust approval to buy Alere with conditions,news,"By Diane Bartz WASHINGTON  Reuters     Abbott Laboratories   NYSE ABT  has won U S  antitrust approval to buy Alere Inc on condition that it sell two point of care medical testing businesses  the Federal Trade Commission said on Thursday  Canada also announced on Thursday that it had approved the proposed transaction on similar terms   Alere s shares were up 3 5 percent at  50 61 in mid afternoon trading on Thursday while Abbott was up 3 percent at  53 72   Abbott first offered to buy Alere in February 2016  but the deal ran into trouble because of issues related to the diagnostic maker s accounting and sales practices  The company finally agreed to buy Alere in April for about  5 3 billion  down from an initial  5 8 billion offer  Alere also agreed Thursday to pay more than  13 million to resolve Securities and Exchange Commission charges that it committed accounting fraud and made improper payments to foreign officials  To win the U S  antitrust approval  the FTC required Abbott to sell two types of point of care medical testing device businesses  which can be used in doctors  offices  hospitals and homes   The companies agreed to divest a blood gas testing system that measures the oxygen and carbon dioxide in the blood and a cardiac marker system used to determine quickly if a patient is having a heart attack or congestive heart failure  Siemens Aktiengesellschaft will buy the blood gas testing business  as well as two Alere facilities in Ottawa  Quidel Corp will buy the heart function testing system business as well as an Alere facility in San Diego  The deal will help Abbott expand in point of care diagnostic testing  a market that is growing as physicians increasingly adopt rapid tests that speed up treatment  Point of care tests provide results to doctors in a matter of minutes and can be conducted in the physician s office  an ambulance or even at home  Alere makes tests for infections such as HIV  tuberculosis  malaria and dengue  
Last year  Abbott agreed sell its medical optics division to Johnson   Johnson  NYSE JNJ  for  4 3 billion  and closed its  25 billion acquisition of St  Jude Medical this January ",2017-09-28,Reuters,https://www.investing.com/news/stock-market-news/abbott-wins-us-antitrust-approval-to-buy-alere-with-conditions-534317,534317
181328,402844,ABT,U S  pressing India to avoid capping medical device prices  allow withdrawals,news,"By Aditya Kalra NEW DELHI  Reuters    The United States is pressing India not to extend price caps on medical devices and wants New Delhi to allow firms to withdraw products from the market if they do not wish to sell at government determined rates  a U S  trade official told Reuters  Indian Prime Minister Narendra Modi s government has in recent months slashed prices of medical devices such as knee implants and heart stents by up to 75 percent to make them more affordable  But the  5 billion Indian medical technology industry   which counts U S  firms such as  Abbott Laboratories   N ABT   Boston Scientific Corp  N BSX  and Johnson   Johnson  N JNJ  as key players   has protested these moves  saying they hurt innovation  profits and future investment  A senior United States Trade Representative  USTR  official said they were pressing India to not extend price caps to other devices  allow for higher pricing for technologically advanced equipment and let companies withdraw their products if they wish to  India last month issued orders which effectively barred companies from any immediate withdrawals of heart stents or knee implants following price capping to ensure adequate supply of devices for patients  Abbott  for example  wants to withdraw one of its stents saying it s not commercially viable under government set prices  but India has rejected its plea   It is a principal concern for the United States   the U S  official said on condition of anonymity  India s trade ministry  which co chairs such discussions under the U S  India Trade Policy Forum did not respond to a request for comment  The federal drug pricing regulator referred questions to the department of pharmaceutical  which did not respond to queries  Modi  however  has previously said that providing affordable healthcare to patients takes precedence over the interests of companies   The government has equated high margins charged for some medical devices with  illegal profiteering   In some cases these margins can exceed 400 percent   The United States has been increasing pressure on India to revise its stance on price caps for medical devices  A person familiar with the matter said assistant USTR Mark Linscott and his delegation last month conveyed their concerns to Indian trade officials in New Delhi   In May  a group of U S  Congress members urged India to reconsider its decision to cap prices of stents  which are tiny wire mesh tubes used to treat blocked arteries   Tanoubi Ngangom  an associate fellow for healthcare at the New Delhi based Observer Research Foundation  said India must continue to develop policies based on its requirements and not succumb to diplomatic pressure  
 Indian government should retain a pro public health stance on pricing medical devices to ensure access to affordable healthcare   she said ",2017-10-04,Reuters,https://www.investing.com/news/stock-market-news/us-pressing-india-to-avoid-capping-medical-device-prices-allow-withdrawals-536472,536472
181329,402845,ABT,Abbott Laboratories Q3 revenues up 29   non GAAP EPS up 12   updates guidance,news,"Abbott Laboratories   ABT  Q3 results  Revenues   6 829M   28 8    Nutrition   1 768M   0 8    Diagnostics   1 279M   5 4    Established Pharmaceuticals   1 171M   15 7    Medical Devices   2 597M   98 2   
Operating Income   810M   9 7    Net Income   561M  EPS   0 32  Non GAAP EPS   0 66   11 9   
Q4 Guidance  GAAP EPS   0 28   0 30  Non GAAP EPS   0 72    0 74 
2017 Guidance  GAAP EPS   0 97   0 99  Non GAAP EPS   2 48    2 50 
Shares are up 1  on light volume 
Now read ",2017-10-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/abbott-laboratories-q3-revenues-up-29-nongaap-eps-up-12-updates-guidance-543409,543409
181330,402846,ABT,Options Red Hot Ahead Of Abbott Earnings,opinion,"The shares of healthcare stock  Abbott Laboratories   NYSE ABT  are up 2 6  at  81 87 just ahead of tomorrow s third quarter earnings    due out before the open tomorrow  Oct  16    after the board announced a share buyback plan of up to  3 billion  The company also announced a partnership with Tandem Diabetes Care  TNDM   which has the latter stock higher today  too  




What s more  the equity is set to take over its 20 day moving average for the first time in over a month  Since its late July  record peak of  88 76  the stock has cooled gradually  touching a four month low of  78 51 just last week  Since then  however  ABT has found support at its     a trendline that s had bullish implications for the equity in the past  
Options players have been extremely bullish ahead of earnings  with 5 74 calls bought for every put on the the International Securities Exchange  ISE   Cboe Options Exchange  CBOE   and NASDAQ OMX PHLX  PHLX  during the last 10 days    which sits higher than all other readings from the past year  
That being said  options are running hot today  with 8 778 calls and 4 037 puts across the tape so far    three times what s typically see at this point  The two most popular positions are the October 81 put  where positions are possibly being sold to open  followed by the October 82 and 83 50 calls 
Abbott s post earnings moves have been split during the last eight sessions  with the stock averaging a next day swing of 2 5   regardless of direction  This time around  the options pits are pricing in a slightly bigger move at 4 6  ",2019-10-16,Schaeffer's Investment Research,https://www.investing.com/analysis/options-redhot-ahead-of-abbott-earnings-200473776,200473776
181331,402847,ABT,Abbott  ABT  Meets Q3 Earnings Estimates,opinion,"Abbott  ABT  came out with quarterly earnings of  0 84 per share  in line with the Zacks Consensus Estimate  This compares to earnings of  0 75 per share a year ago  These figures are adjusted for non recurring items 
A quarter ago  it was expected that this maker of infant formula  medical devices and drugs would post earnings of  0 80 per share when it actually produced earnings of  0 82  delivering a surprise of 2 50  
Over the last four quarters  the company has surpassed consensus EPS estimates two times 
Abbott  which belongs to the Zacks Medical   Products industry  posted revenues of  8 08 billion for the quarter ended September 2019  missing the Zacks Consensus Estimate by 0 23   This compares to year ago revenues of  7 66 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Abbott shares have added about 13 3  since the beginning of the year versus the S P 500 s gain of 19 5  
What s Next for Abbott 
While Abbott has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Abbott was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 94 on  8 30 billion in revenues for the coming quarter and  3 24 on  31 92 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Products is currently in the top 44  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-meets-q3-earnings-estimates-200473897,200473897
181352,402868,ABT,Abbott lifts profit forecast as it integrates St  Jude deal,news, Reuters     Abbott Laboratories   N ABT  on Thursday raised its full year adjusted profit forecast as the diversified healthcare company gains from its  25 billion acquisition of medical devices maker St  Jude Medical earlier this year The company raised its full year adjusted earnings from continuing operations by 3 cents to a range of  2 43 per share to  2 53 per share  Abbott  which agreed to buy troubled diagnostics company  Alere Inc   N ALR  for a revised value of  5 30 billion in April  reported second quarter profit of 62 cents per share  edging past estimates by 1 cent  according to Thomson Reuters I B E S  Net sales rose to  6 64 billion from  5 33 billion  matching the analysts  average estimate  The company said sales growth was hurt by the implementation of a new tax regime in India  More than half of Abbott s revenue came from sales outside the United States in the latest quarter  Abbott s shares  already up 29 percent through Wednesday s close  gained 1 1 percent to  49 95 in premarket trading   This showing is sufficient to support the stock  especially given the improvements we expect for the St  Jude business over the next 12 months   Cowen   Co s Joshua Jennings wrote in a client note   Sales in Abbott s three core divisions   diagnostics  medical devices and branded generic pharmaceuticals   rose on a reported basis in the quarter  with nutritional products business the only laggard  Sales in medical devices  Abbott s largest division  surged about 89 percent to  2 60 billion   Global nutrition sales slipped 0 6 percent   The company s pediatric business has been under pressure since last year after China imposed new food safety regulations that required manufacturers to re register baby formulas with the government  Net profit from continuing operations more than halved to  270 million  or 15 cents per share  in the second quarter ended June 30 due to higher costs ,2017-07-20,Reuters,https://www.investing.com/news/stock-market-news/abbott's-quarterly-profit-halves-as-costs-soar-507800,507800
181353,402869,ABT,Abbott Diagnostics lands  252M managed equipment contract in Britain,news,Abbott s  NYSE ABT  Diagnostics unit inks a  252M managed equipment agreement with North West London Pathology  NWLP  under which Abbott will supply all analytical equipment and consumables  including the Alinity ci and Alinity h series of instruments  and AlinIQ  its informatics solution The contract was awarded through a competitive procurement process conducted by NWLP The partnership will manage 26M tests year  about 6  of the UK pathology market Now read ,2017-08-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/abbott-diagnostics-lands-252m-managed-equipment-contract-in-britain-518696,518696
181354,402870,ABT,Abbott releases new round of cyber updates for St  Jude pacemakers,news,"By Michael Erman NEW YORK  Reuters     Abbott Laboratories   NYSE ABT  said on Tuesday it would issue updates to reduce the risk of its St  Jude heart implants being hacked and to warn patients that the devices  batteries may run down earlier than expected  It was the second round of updates for the heart implants that Abbott has announced since buying medical device maker St  Jude Medical earlier this year  The U S  government launched a probe last year of claims the devices were vulnerable to potentially life threatening hacks that could cause implanted devices to pace at potentially dangerous rates or cause them to fail by draining their batteries  The company also identified a separate problem with lithium batteries in its heart devices last year  St  Jude recalled some of its 400 000 implanted heart devices last October due to risk of premature battery depletion  which was linked to two deaths in Europe   The U S  Food and Drug Administration said then that hospitals should return unused devices and warned patients with an already implanted device to seek immediate medical attention if they get a low battery alert   Abbott is resolving all old St  Jude Medical issues   Abbott spokeswoman Candace Steele Flippin said  The new update will provide doctors with an earlier warning when the batteries in Abbott s implantable cardioverter defibrillators are at risk of early depletion   Abbott said it would also update the software embedded in pacemakers to reduce the risk of hacking  The company said there have been no reports of unauthorized access to any patient s implanted device and that compromising the security of the devices would require a complex set of circumstances   The FDA said it approved the update to ensure that it addresses the cyber security vulnerabilities  and reduces the risk of patient harm  The FDA and the Department of Homeland Security confirmed in January that St  Jude devices were vulnerable to hacking  But they said they knew of no cyber attacks on patients with the company s cardiac implants  The FDA said the benefits of continuing treatment outweighed cyber risks  and DHS said only an attacker  with high skill  could exploit the vulnerability  They launched the probe in August after short selling firm Muddy Waters and cyber security firm MedSec Holdings said the devices were riddled with security flaws that made them vulnerable to potentially life threatening hacks  
When Muddy Waters went public with the claims  it also disclosed it was shorting shares of St  Jude Medical  which was preparing to sell itself to Abbott  The short selling firm said it believed that disclosure of the vulnerabilities could cause the  25 billion deal to fall apart  but Abbot completed the deal in January ",2017-08-29,Reuters,https://www.investing.com/news/technology-news/abbott-releases-new-round-of-cyber-updates-for-st-jude-pacemakers-523513,523513
181355,402871,ABT,Abbott  ABT  Stock Moves  0 24   What You Should Know,opinion,"In the latest trading session  Abbott  ABT  closed at  82 66  marking a  0 24  move from the previous day  This change traded in line with S P 500  Meanwhile  the Dow lost 0 3   and the Nasdaq  a tech heavy index  lost 0 58  
Heading into today  shares of the maker of infant formula  medical devices and drugs had lost 1 61  over the past month  lagging the Medical sector s gain of 1 15  and the S P 500 s gain of 4 96  in that time 
Investors will be hoping for strength from ABT as it approaches its next earnings release  which is expected to be October 16  2019  In that report  analysts expect ABT to post earnings of  0 84 per share  This would mark year over year growth of 12   Our most recent consensus estimate is calling for quarterly revenue of  8 10 billion  up 5 81  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  3 24 per share and revenue of  31 93 billion  These totals would mark changes of  12 5  and  4 43   respectively  from last year 
Investors should also note any recent changes to analyst estimates for ABT  Recent revisions tend to reflect the latest near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate remained stagnant  ABT is currently sporting a Zacks Rank of  3  Hold  
Looking at its valuation  ABT is holding a Forward P E ratio of 25 56  For comparison  its industry has an average Forward P E of 26 8  which means ABT is trading at a discount to the group 
Also  we should mention that ABT has a PEG ratio of 2 33  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Medical   Products industry currently had an average PEG ratio of 2 6 as of yesterday s close 
The Medical   Products industry is part of the Medical sector  This group has a Zacks Industry Rank of 85  putting it in the top 34  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
You can find more information on all of these metrics  and much more  on Zacks com ",2019-09-26,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-stock-moves-024-what-you-should-know-200468519,200468519
181356,402872,ABT,Abbott  ABT  Earnings Expected To Grow  What To Know Ahead Of Next Week s Release,opinion,"The market expects Abbott  ABT  to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended September 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on October 16  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This maker of infant formula  medical devices and drugs is expected to post quarterly earnings of  0 84 per share in its upcoming report  which represents a year over year change of  12  
Revenues are expected to be  8 10 billion  up 5 8  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Abbott 
For Abbott  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Abbott will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Abbott would post earnings of  0 80 per share when it actually produced earnings of  0 82  delivering a surprise of  2 50  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Abbott doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-08,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release-200471925,200471925
181357,402873,ABT,Abbott Forms Alliance With Omada Health For Diabetes Care,opinion,Abbott Laboratories   NYSE ABT   announced that it is collaborating with Omada Health to integrate Abbott s FreeStyle Libre system with Omada s revolutionary digital care program  This aims at creating a new paradigm for Type 2 diabetic patients Abbott s management believes that given the positive outcome of FreeStyle Libre  it will be successful in providing a customized treatment  combining Abbott s flagship FreeStyle Libre system  and Omada s professional coaching and digital platform With the partnership  Abbott aims to further consolidate its position in the global continuous glucose monitoring  CGM  technology market  Few Words on FreeStyle LibreThe FreeStyle Libre system is a CGM device  which is globally used to monitor real time glucose levels in diabetic patients  It is connected with a secure cloud based diabetes management system  LibreView   thus obtaining clear and comprehensive health reports Rationale Behind the PartnershipCurrently  more than 30 million Americans are diabetic  of which approximately 95  have been diagnosed with Type 2 diabetes  These patients look for simple ways to manage their conditions and overall health How Does This Work Per the agreement  eligible Type 2 diabetic patients will be guided through a personalized experience  which includes an online physician consultation  obtaining a prescription of Freestyle Libre and a welcome kit   including the CGM system and a wireless scale The integrated solution to be provided will have the respective company s mechanisms  which in turn  will be linked to the patient s smartphones for better health management  The program includes features that will help in tracking and managing the disease Recent DevelopmentsAbbott collaborated with biopharmaceutical major  Sanofi   NASDAQ SNY    in September 2019  where Freestyle Libre will be integrated with glucose sensing and insulin delivery technologies of Sanofi  thus augmenting patient care Abbott also received public reimbursement in the two largest provinces of Canada  namely Ontario and Quebec  in September 2019  With the reimbursement approval  FreeStyle Libre became the first sensor based glucose monitoring system to be listed by any provincial health plan in Canada In June 2019  the company was upbeat while announcing a favorable outcome on the analysis on hemoglobin A1c  HbA1c  levels in patients with Type 2 diabetes who are undergoing intensive insulin therapy Industry ProspectsPer a report by   the global CGM market size is estimated to reach approximately  1 325 9 million by 2025  seeing a CAGR of 15 8  between 2019 and 2025  The major factors driving growth of the market are the increasing incidences of diabetes around the world and the subsequent awareness about the same Given the current market prospects about diabetes management  the collaboration has come at just the right time Share Price PerformanceThe company has gained 12 5  in the past year against the  s decline of 2 5   The S P 500 index rallied 4 9  during the same period Zacks Rank   Stocks to ConsiderCurrently  Abbott carries a Zacks Rank  3  Hold   A few better ranked stocks from the broader medical space are Owens   Minor  Inc   NYSE OMI   and GW Pharmaceuticals PLC   NASDAQ GWPH   Owens   Minor  with a Zacks Rank  1  Strong Buy   has a projected third quarter 2019 earnings growth rate of 300   You can see GW Pharmaceuticals estimates third quarter earnings growth rate to be 70 2   It currently carries a Zacks Rank  2  Buy  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-14,Zacks Investment Research,https://www.investing.com/analysis/abbott-forms-alliance-with-omada-health-for-diabetes-care-200473554,200473554
181381,402897,ABT,Illinois court finds AbbVie liable for birth defects related to Depakote   15M in compensatory damages,news,Bloomberg reports that a jury in Illinois has awarded the plaintiff  15M in compensatory damages related claims that AbbVie s  ABBV  1 1   epilepsy med Depakote  divalproex sodium  caused birth defects when taken during pregnancy  Punitive damages have yet to be determined Several months ago  a jury in Ohio found that the company  including  Abbott Laboratories   NYSE ABT  since the drug was originally sold by its pharmaceutical division  was not responsible for said effects There are more than 800 lawsuits against Abbott AbbVie over the issue  The first verdict  in the plaintiff s favor  was rendered in June 2015 in Missouri  The compensatory damages were  15M and the punitive damages were  23M  An appeal is in process Now read ,2017-06-09,Seeking Alpha,"https://www.investing.com/news/stock-market-news/illinois-court-finds-abbvie-liable-for-birth-defects-related-to-depakote,-$15m-in-compensatory-damages-493956",493956
181382,402898,ABT,Exclusive  Ahead of Modi visit  U S  lawmakers ask India to rethink price cap on stents,news,"By Aditya Kalra NEW DELHI  Reuters    A group of U S  lawmakers has backed medical device makers by urging India to reconsider its decision to cap prices of heart stents  raising the issue ahead of Prime Minister Narendra Modi s visit to the United States later this week  In a letter sent to the Indian ambassador to Washington last month  and seen by Reuters  18 members of Congress said they were  troubled  by the price cap  warning that it could deter firms from launching new medical products in India  Modi s government has in recent years capped prices of hundreds of life saving drugs to make them more affordable  And in February  it imposed a 75 percent price cut for certain heart stents   wire mesh tubes used to treat blocked arteries   The government justified its action by citing  huge unethical markups   But global medical device makers have protested the new cap  with some saying it would force them to sell below cost  The U S  lawmakers warned that people would be denied access to the latest medical advances if companies backed away from India s  5 billion medical technology market   The sudden and unprecedented nature of the decision threatens citizens  access to the newest and most innovative medical technologies and raises strong concerns about the business environment in India   they said in the May 22 letter  which has not previously been made public  The Indian embassy in Washington did not respond to a request for comment  The U S  Department of Commerce is likely to raise the issue with Modi during his visit on June 25 26  according to an industry source aware of the plans   It s one of the biggest pain points   the source said   BE PREPARED TO QUIT  An aide to Modi said companies were being asked to bring down prices of medical devices  or be prepared to quit  the country  and a bureaucrat who works closely with the prime minister s office said raising the matter to diplomatic levels would not influence India s position  U S  based companies such as Boston Scientific Corp  NYSE BSX  and  Abbott Laboratories   NYSE ABT  sell heart stents in India  while Johnson   Johnson  NYSE JNJ  sells other devices  Following the February decision  Abbott moved to withdraw one of its stents from India  but its plea was rejected by Modi s government   Boston Scientific   which also has a research base near New Delhi   sought a higher price for one of its stents but a government panel declined the request   Such decisions  the group of U S  Congress members wrote  had forced companies to sell  leading edge technology in India at a loss   Signatories to the letter included Indiana Republican Jackie Walorski  and Ron Kind  a Wisconsin Democrat  Both are members of the House Ways and Means Committee  Before the pricing order  for example  Boston Scientific was selling its high end Synergy stent for about  3 000 in India  well above its  750 cost  according to a company document seen by Reuters  The new cap reduces the price to  450  and the company says it would result in losses of at least  7 million this year   Indian health activists have lauded the government decision to cap heart stent prices  saying it is in the public interest   It was found that huge unethical mark ups are charged at each stage in the supply chain of coronary stents resulting in irrational  restrictive and exorbitant prices in a failed market system   the Indian government said in February  A month later  India s federal drug pricing regulator privately asked the health ministry to add at least four more medical devices to a list of essential medicines  opening the way for them to be made subject to price controls   In their letter  the U S  lawmakers echoed concerns raised by the medical device industry  saying India s interventionist policy on pricing would hamper innovation and jeopardize investment  
 We are especially worried that comments by government officials signal the intention to double down on this dangerous policy and expand price cuts to other medical devices   they wrote in their letter ",2017-06-19,Reuters,"https://www.investing.com/news/world-news/exclusive:-ahead-of-modi-visit,-u.s.-lawmakers-ask-india-to-rethink-price-cap-on-stents-496716",496716
181383,402899,ABT,Alere shareholders OK amended merger with Abbott,news,In a special meeting today  shareholders in Alere  ALR  0 2   voted to approve an amended merger deal with  Abbott Laboratories   ABT  1    About 72 5  of outstanding shares  or about 63M votes  were in favor of the deal  At closing  Alere shareholders will receive  51 share in cash and Alere will become an Abbott subsidiary  After hours  ABT  0 2   ALR is flat at  50 35  Now read ,2017-07-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/alere-shareholders-ok-amended-merger-with-abbott-503400,503400
181384,402900,ABT,Abbott Sees Hammer Chart Pattern  Time To Buy ,opinion,Abbott Laboratories   NYSE ABT   has been struggling lately  but the selling pressure may be coming to an end soon  That is because ABT recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom What is a Hammer Chart Pattern A hammer chart pattern is a popular technical indicator that is used in candlestick charting  The hammer appears when a stock tumbles during the day  but then finds strength at some point in the session to close near or above its opening price  This forms a candlestick that resembles a hammer  and it can suggest that the market has found a low point in the stock  and that better days are ahead Other FactorsPlus  earnings estimates have been rising for this company  even despite the sluggish trading lately  In just the past 60 days alone 9 estimates have gone higher  compared to none lower  while the consensus estimate has also moved in the right direction Estimates have actually risen so much that the stock now has a Zacks Rank  2  Buy  suggesting this relatively unloved stock could be due for a breakout soon  This will be especially true if ABT stock can build momentum from here and find a way to continue higher of off this encouraging trading development  You can see 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2019-09-10,Zacks Investment Research,https://www.investing.com/analysis/abbott-sees-hammer-chart-pattern-time-to-buy-200463709,200463709
181385,402901,ABT,Abbott Partners With Sanofi To Upgrade Diabetes Management,opinion,Abbott Laboratories   NYSE ABT   recently entered a collaboration with biopharmaceutical major  Sanofi   NASDAQ SNY    Under the terms of the agreement  the companies will integrate glucose sensing and insulin delivery technologies  which would help to further simplify the management of diabetes The companies are planning to adopt a pioneering approach to connected care by developing tools  which combine the revolutionary FreeStyle Libre technology with Sanofi s insulin dosing information for future smart pens  insulin titration apps and cloud software Abbott  a major player in the continuous glucose monitoring  CGM  business  believes that diabetes is an information rich condition  with various streams of data from various devices  Given this scenario  the company plans to utilize this opportunity to help patients by developing new and improved tools for diabetes care and management The partnership is expected to improve Abbott s foothold in the global CGM market   Rationale Behind the PartnershipThrough this partnership  the companies aim to build a digital ecosystem around FreeStyle Libre  thus consolidating how patients access their data  This can be done by simplifying user experience through Abbott s digital health tools  and working with other diabetes and technology leaders How Does This Work Abbott plans to utilize the non exclusive alliance to enable data sharing in the initial phase  with the user s consent  The data will be shared between Abbott s FreeStyle Libre mobile app and cloud software  and Sanofi s connected insulin pens  apps and cloud software  which are currently in the development stage  The data sharing will help patients with diabetes as well as doctors to make better decisions regarding their treatment  nutrition and lifestyle Sanofi  which already has a robust portfolio of medicines  has been in the diabetes care business for quite a long time  The association with Abbott helps it move a step closer to providing better control and quality of life decision for patients through customized glycemic management of diabetes Recent Developments in Abbott s FreeStyle LibreThe company has been hogging the limelight for developments in its flagship  sensor based CGM system   FreeStyle Libre System  United States Centers for Medicare   Medicaid Services   CMS   granted FreeStyle Libre for Medicare coverage  Post this approval  FreeStyle Libre became the only no user calibration CGM device under the Medicare coverage  available for around 30 million diabetic patients in the United States  At present  in the United States alone  FreeStyle Libre is reimbursed for approximately 75  of people with private pharmacy benefit insurance With this reimbursement approval  FreeStyle Libre becomes the first sensor based glucose monitoring system to be listed by any provincial health plan in Canada  The company also announced the receipt of national reimbursement for FreeStyle Libre in the U K  This marked another milestone for Abbott With its proven accuracy and easy to use features  the FreeStyle Libre system seems a perfect substitute for traditional blood glucose monitoring and allows patients to dose insulin based on the results Industry ProspectsPer a report by Polaris Market Research published in   the global CGM market size is estimated to reach approximately  1 325 9 million by 2025  at a CAGR of 15 8  between 2019 and 2025  The major factor  driving growth of the market  is increasing incidences of diabetes around the world and the subsequent awareness about the same Given the current market prospects about diabetes management  the collaboration has come at just the right time Share Price PerformanceThe company has gained 21 9  in the past year against the  s decline of 1 3   The S P 500 index rallied 2 2  during the same period Zacks Rank   Stocks to ConsiderCurrently  Abbott carries a Zacks Rank  3  Hold   A few better ranked stocks from the broader medical space are Capricor Therapeutics  Inc    NASDAQ CAPR   and GW Pharmaceuticals PLC   NASDAQ GWPH   Capricor  with a Zacks Rank  2  Buy   has a projected third quarter 2019 earnings growth rate of 28 2   You can see GW Pharmaceuticals estimates third quarter earnings growth rate to be 72 9   It currently sports a Zacks Rank  1 5 Stocks Set to DoubleZacks experts released their picks to gain  100  or more in 2020  One is a famous cutting edge food company that is  hiding in plain sight   Swamped with competitors and ignored by Wall Street  its stock price floundered  Now  suddenly  it acquired a company that gives it an advantage none of its peers have ,2019-09-17,Zacks Investment Research,https://www.investing.com/analysis/abbott-partners-with-sanofi-to-upgrade-diabetes-management-200465265,200465265
181407,402923,ABT,Abbott Laboratories may see boost from St  Jude s acquisition  Barron s,news,"NEW YORK  Reuters     Abbott Laboratories   N ABT  is likely to see its shares rise again after trading range bound for nearly a year on the back of its  25 billion acquisition of medical device maker St  Jude Medical  Barron s said on Sunday   The global healthcare company  based in Abbott Park  Illinois  has seen its stock trade between  37 and  45 for a year  as investors remain concerned over currency headwinds given the company s global business and its St  Jude acquisition   However  the uncertainty has also created an opportunity to buy inexpensive shares of a company with a  proven track record and a good shot at continuing its double digit earnings growth   the report said  adding that a 20 percent return is credible over a year  The St  Jude deal  which closed last month  has weighed on the stock  with some investors questioning whether Abbott overpaid for a company that s seen a history of delayed product launches  However  the acquisition pushes Abott s profile more towards the U S  market  which should ease concerns about the strength of the dollar  
Also  a number of St  Jude legacy products are expected to win federal approval later this year following the green light on its Assurity MRI pacemaker earlier this month ",2017-02-12,Reuters,https://www.investing.com/news/stock-market-news/abbott-laboratories-may-see-boost-from-st.-jude's-acquisition:-barron's-459447,459447
181408,402924,ABT,Abbott agrees to buy Alere at lower price from earlier offer,news," Reuters    Diversified healthcare company  Abbott Laboratories   N ABT  on Friday agreed to buy  Alere Inc   N ALR  at a lower price than it had previously offered  after raising concerns about the accuracy of various representations  warranties and covenants made by Alere in the earlier agreement  Abbott s revised offer values Alere s equity around  5 3 billion  down from the about  5 8 billion announced in February last year  the companies said in a statement  ending a prolonged legal battle over Abbott s plan to acquire the diagnostic testing company  Abbott will now pay  51 per share for Alere  compared with its earlier offer of  56  The new price was a much better outcome than what Alere s shareholders had priced in  given that Alere s shares closed at  42 31 on Thursday on the New York Stock Exchange  While the new deal values Alere at 26 84 times forward earnings  Alere s peers are on average valued at 37 9 times  according to Thomson Reuters data   The new  51 per share deal price is in the middle of the initial  49 to  53 per share range that Abbott had indicated it would be willing to pay for Alere when it first discussed an acquisition in December 2015  according to Alere s proxy statement to its shareholders   Abbott at the time had not carried out due diligence on Alere  and subsequent negotiations led to a deal being agreed early last year  However  the deal ran into trouble within months of being announced  as Alere received a grand jury subpoena from the U S  Department of Justice in March last year seeking documents relating to the company s sales practices  and delayed filing its annual report  Both the companies ended up suing each other last year  with Alere forcing Abbott to move ahead with the deal  and Abbott wanting to back out of the deal citing a  substantial loss  in the value of the diagnostics company   The renegotiated price is in the realm of investor expectations and seems to reflect the impact from some of the challenges witnessed in Alere s business over the last 12 months   Raymond James analyst Nicholas Jansen told Reuters   Alere has also delayed filing its 2016 annual report and has not yet fixed material weaknesses with respect to its revenue recognition practices disclosed in its 2015 annual report   We think the new merger agreement now includes all of the known issues that have developed so would not expect any risk to the future of the deal unless something else emerges as of today s date   Jansen said   Abbott and Alere said on Friday that the companies had agreed to dismiss their respective lawsuits  and the deal is expected to close by the end of the third quarter of 2017  Waltham  Massachusetts based Alere  which makes tests for infections such as HIV  tuberculosis  malaria and dengue  while Abbott Park  Illinois based Abbott sells medical devices  nutritional products and baby formula  The deal will help Abbott expand in point of care diagnostic testing  a market that is growing as physicians increasingly adopt rapid tests that speed up treatment  Point of care tests provide results to doctors in a matter of minutes and can be conducted in the physician s office  an ambulance or even at home  The news about the revised deal was first reported by the Financial Times  citing people close to the matter     
Up to Thursday s close Alere shares had risen 8 6 percent this year while Abbott had increased 11 1 percent to  42 67 ",2017-04-14,Reuters,https://www.investing.com/news/stock-market-news/abbott-agrees-to-buy-alere-at-lower-price-from-earlier-offer-474444,474444
181409,402925,ABT,Abbott Labs Q1 earnings beat estimates ,news,Investing com    NYSE Abbott Laboratories  reported first quarter earnings that beat estimates The U S pharmaceutical posted adjusted diluted Q1 EPS of  0 48 vs  estimate of  0 43 and  0 41 a year earlier Revenues rose 29 7  on a reported basis from a year earlier to  6 3 bn Abbott shares were up 2 92  at  44 70 in pre market trade ,2017-04-19,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-q1-earnings-beat-estimates-475354,475354
181410,402926,ABT,Abbott sees Alere as challenging  fixer upper  after revised deal,news,By Natalie Grover and Akankshita Mukhopadhyay  Reuters     Abbott Laboratories   NYSE ABT  said it was looking to close the recently revised deal to buy Alere Inc in the coming months  calling the diagnostics company  a bit of a fixer upper   Abbott  which reported first quarter sales and profit ahead of analysts  estimates on Wednesday  first revealed an agreement to buy Alere in February 2016  But the deal ran into trouble as issues related to Alere s accounting and sales practices came to light  However  last week  Abbott agreed to the takeover at a price of around  5 30 billion down from  5 80 billion  ending the prolonged legal tussle  Alere has had some challenges and closing the deal is going to be a bit unpredictable  because Alere still needs to file its annual report and Abbott is required to divest some businesses for regulatory approvals  Abbott CFO Brian Yoor said on a post earnings conference call  The Alere deal is now expected to close in the third quarter  and will help Abbott expand in point of care diagnostic testing  a market that is rapidly growing as physicians increasingly adopt tests that speed up treatment  Abbott has been considerably active on the M A front  Last year  it agreed sell its medical optics division to Johnson   Johnson  NYSE JNJ  for  4 3 billion  and closed its  25 billion acquisition of St  Jude Medical this January  The company s first quarter net sales rose 3 2 percent on an operational basis to  6 34 billion  above the average analyst estimate of  6 15 billion  according to Thomson Reuters I B E S  While sales in its diagnostics  medical devices and branded generic pharmaceuticals divisions grew in the quarter ended March 31  Abbott s nutrition business continued to suffer  Global nutrition sales dipped 1 percent on an operational basis  hurt mainly by continued challenges in the Chinese infant formula market  New food safety regulations in China require manufacturers to re register baby formulas with the government   As the government transitions through these new regulations  I think that s going to be a little bumpy and it has been    but I think we feel pretty good about China for the long term   Abbott CEO Miles White said  Excluding items  Abbott earned 48 cents per share  beating the average analyst estimate by 5 cents  Shares of the diversified healthcare company  which also maintained its 2017 forecast  were little changed in afternoon trading  As of yesterday s close  Abbott s stock had risen nearly 15 percent since it announced the Alere deal in February last year ,2017-04-19,Reuters,https://www.investing.com/news/stock-market-news/abbott-posts-29.7-percent-rise-in-quarterly-sales-475351,475351
181411,402927,ABT,Abbott  ABT  Down 4 4  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Abbott  ABT   Shares have lost about 4 4  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Abbott due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Abbott Posts Q2 Earnings Beat on Strong Segmental SalesAbbott  reported second quarter 2019 adjusted earnings from continuing operations of 82 cents per share  beating the Zacks Consensus Estimate by 2 5   The bottom line improved 12 3  year over year and remained above the company s guided range of 79 81 cents  Reported earnings from continuing operation in the quarter came in at 56 cents  a 36 6  surge from the year ago quarter Second quarter worldwide sales came in at  7 98 billion  up 2 7  year over year on a reported basis  The top line missed the Zacks Consensus Estimate by 0 1  On an organic basis  adjusting for the impact of foreign exchange as well as certain acquisitions and divestments   sales increased 7 5  year over year in the reported quarter Quarter in DetailAbbott operates through four segments  namely Established Pharmaceuticals Division  EPD   Medical Devices  Nutrition and Diagnostics In the second quarter  EPD sales dropped 1 8  on a reported basis  improved 6 1  on an organic basis  to  1 11 billion  This included a 7 9  adverse impact from currency fluctuations  Sales in the key emerging markets declined 1 4  year over year on a 9 3  adverse impact of foreign exchange  Organically  sales improved 7 9  in this market The Medical Devices business sales increased 6 4  on a reported basis to  3 08 billion  On an organic basis  sales grew 10 5  Cardiovascular and Neuromodulation sales reportedly  up 5 6  on an organic basis  rose 2 1  on double digit growth in Electrophysiology  Heart Failure and Structural Heart  In Electrophysiology  growth was led by strong performance in cardiac diagnostic and ablation catheters Heart Failure sales growth was 24 6  organically  driven by strong market adoption of Abbott s HeartMate 3 left ventricular assist device following its FDA approval as a destination therapy in late 2018 Within Structural Heart  the company registered 16 6  organic growth on a year over year basis driven by strong performance in several product areas across Abbott s broad portfolio  including MitraClip device Diabetes Care sales improved 23 9   up 35 3  organically   buoyed consistent consumer uptake of FreeStyle Libre  the revolutionary continuous glucose monitoring system of Abbott Nutrition sales were up a marginal 0 9  year over year on a reported basis  up 5 1  on an organic basis  to  1 88 billion  Pediatric Nutrition sales increased 2 9  on an organic basis  Adult Nutrition sales were up 7 9  organically Diagnostics sales were up 1 7  year over year on a reported basis  up 6 2  on a comparable operational basis  to  1 91 billion  Core Laboratory Diagnostics sales grew 9 4  while Molecular Diagnostics slipped 9 3   on an organic basis  Point of Care Diagnostics sales were up 5 7   Rapid Diagnostics sales improved 2 8  on an organic basis in the second quarter led by infectious disease testing in developed markets and cardio metabolic testing globally 2019 GuidanceFor the full year  adjusted earnings from continuing operations have been raised to a new band of  3 21  3 27 from the earlier provided range of  3 15  3 25  The Zacks Consensus Estimate of  3 22 remains within this projected range  The company also projects 2019 organic sales growth of 7 8  The company has also provided third quarter 2019 adjusted earnings per share outlook  It expects to report adjusted earnings from continuing operations in the range of 83 85 cents  The consensus mark of 85 cents falls at the upper end the predicted range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in estimates revision 
VGM Scores
At this time  Abbott has an average Growth Score of C  though it is lagging a bit on the Momentum Score front with a D  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision has been net zero  Notably  Abbott has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-down-44-since-last-earnings-report-can-it-rebound-200455844,200455844
181412,402928,ABT,Has Abbott Laboratories  ABT  Outpaced Other Medical Stocks This Year ,opinion,"Investors focused on the Medical space have likely heard of Abbott Laboratories  NYSE ABT   but is the stock performing well in comparison to the rest of its sector peers  A quick glance at the company s year to date performance in comparison to the rest of the Medical sector should help us answer this question 
Abbott Laboratories is one of 866 individual stocks in the Medical sector  Collectively  these companies sit at  4 in the Zacks Sector Rank  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months  The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks  ABT is currently sporting a Zacks Rank of  2  Buy  
Over the past three months  the Zacks Consensus Estimate for ABT s full year earnings has moved 0 79  higher  This is a sign of improving analyst sentiment and a positive earnings outlook trend 
Based on the most recent data  ABT has returned 13 27  so far this year  Meanwhile  stocks in the Medical group have gained about 0 83  on average  This shows that Abbott Laboratories is outperforming its peers so far this year 
Breaking things down more  ABT is a member of the Medical   Products industry  which includes 79 individual companies and currently sits at  68 in the Zacks Industry Rank  This group has gained an average of 14 53  so far this year  so ABT is slightly underperforming its industry in this area 
Going forward  investors interested in Medical stocks should continue to pay close attention to ABT as it looks to continue its solid performance ",2019-08-25,Zacks Investment Research,https://www.investing.com/analysis/has-abbott-laboratories-abt-outpaced-other-medical-stocks-this-year-200458555,200458555
181429,402945,ABT,EpiPen maker Mylan to restructure and cut its workforce,news," Reuters    Generic drugmaker Mylan NV  O MYL   which has been under fire for its price hikes on the life saving EpiPen allergy treatment  said on Wednesday that it would restructure and expected to cut less than 10 percent of its global workforce as it integrates acquisitions  Mylan  whose shares were down more than 4 percent at midday  has been under investigation by the U S  government  and its chief executive officer was called before Congress to testify on raising the price of a pair of EpiPens to more than  600 from  100 in 2008  The company said in a regulatory filing that it would implement restructuring programs in certain locations  At Tuesday s market close  its shares had fallen 25 percent since August  when it first came under public scrutiny by former U S  presidential candidate Hillary Clinton  Mylan  which has about 35 000 employees  said in the filing that it would take cost cutting measures  including workforce actions  after making a significant number of acquisitions  It bought Sweden s Meda earlier this year and Abbott Laboratories   N ABT  branded specialty and generics business in non U S  developed markets in 2015  The company said it would disclose details of its restructuring efforts  including their cost  as it finalizes the plans  Mylan spokeswoman Nina Devlin declined to comment further   Wells Fargo   NYSE WFC  analyst David Maris said in a research note that he did not believe the company had previously discussed a restructuring but added that it had talked about  optimizing  its platform  Mylan has been criticized for classifying EpiPen as a generic product  which led to its paying significantly smaller rebates to state Medicaid programs for the poor than it would have if the drug were classified as branded   In October  Mylan said it would pay  465 million to settle questions of whether it underpaid U S  government healthcare programs including Medicaid  The U S  Department of Justice has not confirmed that it has reached a settlement   Mylan  one of the largest U S  makers of generic medicines  reported a third quarter loss last month as it set aside money to pay for the settlement  It said it was still working on completing the deal   The Canonsburg  Pennsylvania based company said it expected EpiPen to account for 6 percent of total sales in 2017  It plans to introduce a generic version that will sell for  300 for a two pack  
Drug price increases were a hot political topic among U S  presidential candidates during the past two years  President elect Donald Trump in a Time magazine article published early on Wednesday said   I m going to bring down drug prices  I don t like what s happened with drug prices  ",2016-12-07,Reuters,https://www.investing.com/news/stock-market-news/epipen-maker-mylan-says-may-cut-jobs-446217,446217
181430,402946,ABT,St  Jude releases cyber updates for heart devices after U S  probe,news,"By Jim Finkle  Reuters     Abbott Laboratories   N ABT  moved to protect patients with its St  Jude heart implants against possible cyber attacks  releasing a software patch on Monday that the firm said will reduce the  extremely low  chance of them being hacked  The company disclosed the moves some five months after the U S  government launched a probe into claims the devices were vulnerable to potentially life threatening hacks that could cause implanted devices to pace at potentially dangerous rates or cause them to fail by draining their batteries   The Food and Drug Administration and the Department of Homeland Security said that St  Jude s software update addresses some  but not all  known cyber security problems in its heart devices  The patch that Abbott began pushing out to patients on Monday addresses vulnerabilities that present the greatest risk to patients and prevent hackers from accessing the device  said FDA spokeswoman Angela Stark    The patch is intended to reduce the risk of unauthorized individuals exploiting the vulnerability and support patient safety   she said   The FDA has maintained this focus on addressing patient safety first and foremost throughout its investigation    A Department of Homeland Security spokesman said he had no immediate comment on the remaining problems   St  Jude spokeswoman Candace Steele Flippin declined to identify specific problems  but said   The cybersecurity landscape is evolving  St  Jude Medical has worked with  and continues to work with  the FDA and DHS to update and improve the security of our technology    MedSec Chief Executive Justine Bone said in a statement that  a multitude of severe vulnerabilities  were not fixed in the security update   They include the ability to issue an unauthorized command to a cardiac implant from a device other than St  Jude s Merlin Home device  Bone said   Monday marked the first time that the FDA and DHS had confirmed that St  Jude devices were vulnerable to hacking  They said they knew of no cyber attacks on patients with the company s cardiac implants   The FDA said that the benefits of continuing treatment outweighed cyber risks  DHS said only an attacker  with high skill  could exploit the vulnerability  They launched the probe in August after short selling firm Muddy Waters and cyber security firm MedSec Holdings said the devices were riddled with security flaws that made them vulnerable to potentially life threatening hacks   When Muddy Waters went public with the claims  it also disclosed it was shorting St  Jude Medical  which was preparing to sell itself to Abbott   The short selling firm said it believed that disclosure of the vulnerabilities could cause the  25 billion deal to fall apart  but Abbott last week completed its acquisition of St  Jude  one of the world s biggest makers of implantable cardiac devices  Muddy Waters founder Carson Block said he felt the release of the software patch  effectively vindicates  the research produced by his firm and MedSec   As St  Jude announced the security patch  it declined comment on a lawsuit it filed against Muddy Waters and MedSec in September  It accused them of perpetrating a  willful and malicious scheme to manipulate the securities markets for their own financial windfall   MedSec said St  Jude has not dropped the lawsuit   
Abbott shares closed down 0 1 percent at  40 74  The S P 500  by comparison  dipped 0 3 percent ",2017-01-09,Reuters,https://www.investing.com/news/stock-market-news/abbott-releases-cyber-updates-for-st.-jude-devices-after-government-probe-451978,451978
181431,402947,ABT,Johnson   Johnson s sales miss  seeks options for diabetes care unit,news," Reuters    Johnson   Johnson  N JNJ  reported a smaller than expected rise in fourth quarter sales  hurt by slowing demand for its pharmaceutical products and a strong dollar  and said it was looking at strategic options for its diabetes care division  Shares of the diversified healthcare company  which also forecast 2017 earnings and revenue below estimates  slipped 1 2 percent in premarket trading on Tuesday  J J is seeking strategic options for its diabetes care division  specifically LifeScan Inc  Animas Corp and Calibra Medical Inc  as the company looks to rejuvenate its aging legacy portfolio  The division falls within J J s medical device business  which is the company s second biggest division  The diabetes unit accounted for 2 5 percent of total sales in the latest quarter  J J s total sales rose 1 7 percent to  18 11 billion in the fourth quarter  but missed analysts  average estimate of  18 28 billion  according to Thomson Reuters I B E S  A slower than expected rise in sales in the company s pharmaceutical business weighed on the quarter   Sales of its cancer drugs  Imbruvica and Velcade  were below consensus estimates  according to Jefferies analysts   Another drag was a drop in sales of Remicade  the company s top seller  Sales of the autoimmune drug fell 3 3 percent in the quarter  dropping for the first time in 2016  but was in line with consensus estimates  The drug now faces competition in the United States from  Pfizer  Inc s  N PFE  biosimilar  Inflectra  which was launched on Nov  21  midway through the quarter  at a 15 percent lower price   Sales in the latest quarter took a hit of 0 6 percent due to a strong dollar and another 4 8 percent due to additional shipping days in the year ago quarter  the company said   This is a tepid quarter for J J  and most of its disappointments came from the U S  market  both before and after currency  Leerink analysts said   Excluding items  the band aid maker earned  1 58 per share  beating analysts  average estimate by 2 cents  helped by lower taxes  J J forecast 2017 adjusted earnings of  6 93  7 08 per share and revenue of  74 1 billion  74 8 billion  Analysts on average were expecting a profit of  7 11 per share and revenue of  75 10 billion   The company is currently in exclusive talks to buy Actelion Ltd  S ATLN   Europe s biggest biotech  and last September agreed to pay  4 33 billion to buy Abbott Laboratories   N ABT  eye care business  
J J s report  the first among major pharmaceutical companies  comes on the heels of President Donald Trump s scathing remarks on drug price gouging ",2017-01-24,Reuters,"https://www.investing.com/news/stock-market-news/johnson--amp;-johnson-fourth-quarter-sales-up-1.7-percent,-plans-to-divest-diabetes-care-division-455266",455266
181432,402948,ABT,Abbott Labs Q4 EPS  0 65 in line with estimates as revenues fall short ,news,Investing com    NYSE Abbott Labs  fourth quarter earnings in line with estimates as revenues fell short Abbott reported a 4 8  rise in diluted Q4 EPS to  0 65 on a year on year rise of 2 8  in revenues to  5 33 bn The consensus forecast for the U S  pharmaceutical firm s revenues was  5 42 bn Full year diluted EPS was up 2 3  at  2 20 as revenues rose 2 2  to  20 85 bn Abbott issued guidance for full year diluted EPS of  2 40  2 50 Abbott s shares were down 0 77  at  40 00 in pre market trade ,2017-01-25,Investing.com,https://www.investing.com/news/stock-market-news/abbott-labs-q4-eps-$0.65-in-line-with-estimates-as-revenues-fall-short-455577,455577
181433,402949,ABT,EU clears Abbott acquisition of Alere subject to divestments,news,"BRUSSELS  Reuters    European Union antitrust regulators cleared Abbott Laboratories   N ABT  proposed  5 8 billion acquisition of diagnostic test maker Alere  N ALR  on Wednesday  subject to the divestment of some of Alere s operations  However  Abbott said last month it had moved to terminate the proposed acquisition citing a  substantial loss  in the value of Alere since they struck a deal a year ago  The European Commission  which is in charge of competition policy in the European Union  said there were overlaps in analyzers used in testing of blood gases and cardiac markers  The Commission said it had accepted Abbott s offer to divest Alere s global Epoc  Triage and BNP reagents businesses  
 Doctors and patients worldwide rely on fast and accurate tests to detect and monitor medical conditions  Today s decision ensures that they will continue to benefit from choice and competitive prices in the fast developing market for small and portable test analyzers   EU Competition Commissioner Margrethe Vestager said in a statement ",2017-01-25,Reuters,https://www.investing.com/news/stock-market-news/eu-clears-abbott-acquisition-of-alere-subject-to-divestments-455597,455597
181434,402950,ABT,Abbott pauses on deals  to focus on St  Jude integration,news,"By Natalie Grover  Reuters     Abbott Laboratories   N ABT  said it planned to focus on slashing its debt and integrating its  25 billion acquisition of St  Jude Medical in 2017  in a break from the hectic pace of dealmaking last year The company in 2016 also agreed to buy  Alere Inc   N ALR  for  5 8 billion and to sell its medical optics division to Johnson   Johnson  N JNJ  for  4 3 billion as it sheds its slow growth  low margin businesses and fortifies its presence in cardiovascular devices and diagnostics  Abbott will also hold back on share repurchases  Chief Executive Miles White said on a post earnings conference call on Wednesday   The company  which is looking to abort the Alere deal  took on  15 billion in debt to finance the St  Jude deal and also assumed the heart device maker s debt  Abbott reported fourth quarter sales just shy of estimates  largely due to a strong dollar and waning demand for its nutrition products in China  Global sales of nutrition products  which account for roughly a quarter of Abbott s net sales  fell 3 7 percent to  1 73 billion in the quarter  including a 1 1 percent hit from a strong dollar   The decline was mainly due to changes in food safety regulations in China that require manufacturers to reregister their baby formulas with the government   This has caused an oversupply in the Chinese market  White said  adding that nutrition growth in the country will be relatively flat in the first quarter but improve over the course of 2017   Abbott also forecast first quarter adjusted earnings from continuing operations in the range of 42 cents to 44 cents per share  below the average analysts  estimate of 50 cents   The forecast reflects continued weak nutrition and getting St  Jude up and running  but these are transitory issues  Edward Jones  analyst John Boylan said  St  Jude s traditional cardiac rhythm management  CRM  business  which sells pacemakers and defibrillators  continued to struggle in the quarter  as it loses out to rivals with MRI compatible devices in the United States  Abbott said  Similar approvals for St  Jude are expected shortly  the company said   Abbott also forecast 2017 adjusted earnings from continuing operations in the range of  2 40  2 50 per share  Analysts on average were expecting  2 46   The company s net sales of  5 33 billion in the fourth quarter ended Dec  31  came in just below the Thomson Reuters I B E S estimate of  5 38 billion   Abbott s shares were marginally down at  40 50 in afternoon trading  recovering from a drop to  39 25 earlier on Wednesday  
The stock was the biggest drag on the S P 500 healthcare index  SPXHC  ",2017-01-25,Reuters,"https://www.investing.com/news/stock-market-news/abbott-pauses-on-deals,-to-focus-on-st.-jude-integration-455638",455638
181435,402951,ABT,Abbott  ABT  Q2 Earnings Surpass Estimates,opinion,"Abbott  ABT  came out with quarterly earnings of  0 82 per share  beating the Zacks Consensus Estimate of  0 80 per share  This compares to earnings of  0 73 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 2 50   A quarter ago  it was expected that this maker of infant formula  medical devices and drugs would post earnings of  0 61 per share when it actually produced earnings of  0 63  delivering a surprise of 3 28  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Abbott  which belongs to the Zacks Medical   Products industry  posted revenues of  7 98 billion for the quarter ended June 2019  missing the Zacks Consensus Estimate by 0 10   This compares to year ago revenues of  7 77 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Abbott shares have added about 15  since the beginning of the year versus the S P 500 s gain of 19 8  
What s Next for Abbott 
While Abbott has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Abbott was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 85 on  8 09 billion in revenues for the coming quarter and  3 22 on  31 93 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Products is currently in the top 33  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-q2-earnings-surpass-estimates-200440923,200440923
181436,402952,ABT,Abbott  ABT  Upgraded To Strong Buy  What Does It Mean For The Stock ,opinion,"Abbott  ABT  appears an attractive pick  as it has been recently upgraded to a Zacks Rank  1  Strong Buy   An upward trend in earnings estimates    one of the most powerful forces impacting stock prices    has triggered this rating change 
The sole determinant of the Zacks rating is a company s changing earnings picture  The Zacks Consensus Estimate    the consensus of EPS estimates from the sell side analysts covering the stock    for the current and following years is tracked by the system 
Since a changing earnings picture is a powerful factor influencing near term stock price movements  the Zacks rating system is very useful for individual investors  They may find it difficult to make decisions based on rating upgrades by Wall Street analysts  as these are mostly driven by subjective factors that are hard to see and measure in real time 
As such  the Zacks rating upgrade for Abbott is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  has proven to be strongly correlated with the near term price movement of its stock  The influence of institutional investors has a partial contribution to this relationship  as these big professionals use earnings and earnings estimates to calculate the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their transaction of large amounts of shares then leads to price movement for the stock 
Fundamentally speaking  rising earnings estimates and the consequent rating upgrade for Abbott imply an improvement in the company s underlying business  Investors should show their appreciation for this improving business trend by pushing the stock higher 
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  so it could be truly rewarding if such revisions are tracked for making an investment decision  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Abbott
This maker of infant formula  medical devices and drugs is expected to earn  3 22 per share for the fiscal year ending December  2019  which represents a year over year change of 11 8  
Analysts have been steadily raising their estimates for Abbott  Over the past three months  the Zacks Consensus Estimate for the company has increased 0 3  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Abbott to a Zacks Rank  1 positions it in the top 5  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-upgraded-to-strong-buy-what-does-it-mean-for-the-stock-200441297,200441297
181443,402959,ABT,St  Jude forms cyber panel after claims of heart device bugs,news,"By Jim Finkle  Reuters    Medical device maker St  Jude Medical Inc said on Monday that it planned to set up a medical advisory board focused on cyber security issues affecting patient care and safety  St  Jude said in a statement that the group  known as the Cyber Security Medical Advisory Board  would provide advice on cyber security standards for medical devices  The St  Paul  Minnesota based company is establishing the group as the U S  Food and Drug Administration investigates claims that St  Jude heart devices are riddled with defects that make them vulnerable to fatal cyber hacks   The FDA launched that probe in August after short seller Muddy Waters and cyber research firm MedSec Holdings said they had placed bets that St  Jude shares would fall after they discovered the alleged vulnerabilities   We take the cyber security of our devices very seriously and creating the Cyber Security Medical Advisory Board is one more demonstration of our ongoing commitment to advancing standards of patient care around the world without comprising safety and security   St  Jude Chief Medical Officer Mark Carlson said in a statement   The board  whose membership has yet to be finalized  will work with technology experts at St  Jude Medical as well as external researchers to help  maintain and enhance cyber security and patient safety   Carlson said   Suzanne Schwartz  a senior official in the FDA s Center for Devices and Radiological Health  said the agency supports efforts by medical device manufacturers to prioritize cyber security   Doing so in collaboration with other stakeholders such as cyber security researchers  health care providers  patients and government agencies  means cyber security vulnerabilities are more likely to be identified  assessed and fixed in a timely manner before they can cause patient harm   she said in a statement  St  Jude agreed in April to sell itself for  25 billion to  Abbott Laboratories   NYSE ABT   
The company last week said it would recall some of its 400 000 implanted heart devices due to risk of premature battery depletion  a condition linked to two deaths in Europe ",2016-10-17,Reuters,https://www.investing.com/news/technology-news/st.-jude-forms-cyber-panel-after-claims-of-heart-device-bugs-432925,432925
181445,402961,ABT,Abbott s third quarter earnings edge past Street,news, Reuters     Abbott Laboratories   NYSE ABT   which is acquiring St  Jude Medical Inc for  25 billion  reported a quarterly profit that edged past estimates as strength in its medical devices business more than offset a decline in its nutrition unit  The company has been focusing on its device and diagnostics businesses this year  Apart from the St  Jude deal  Abbott is buying molecular diagnostic company Alere Inc for  5 80 billion  The Abbott Park  Illinois based company s stock was down about 2 percent in premarket trading on Wednesday  St  Jude  which also reported its quarterly results  posted a quarterly adjusted profit of 99 cents  missing the average Wall Street estimate by 2 cents  St  Jude is facing multiple challenges including an investigation by the U S  Food and Drug Administration over claims that its heart devices are riddled with defects that make them vulnerable to fatal cyber hacks  The company has sued short seller Muddy Waters and cyber research firm MedSec Holdings after the two firms brought the alleged vulnerabilities to light  St  Jude Chief Executive Michael Rousseau  on a post earnings conference call  said he expected Muddy Waters to continue to  mislead  investors and patients about the cyber safety of its devices  Last week  the company said it would recall some of its 400 000 implanted heart devices due to risk of premature battery depletion  a condition linked to two deaths in Europe  Muddy Waters released several videos on Wednesday morning that claimed to be demonstrations of how attacks could be launched on St  Jude s implanted heart devices    Reuters was unable to independently confirm claims in the videos  which were posted on a new website set up by Muddy Waters    A St  Jude spokeswoman said the company had not verified the claims in the new videos  St  Jude continues to expect the Abbott deal will be completed by the end of the year  The two companies on Tuesday announced a  1 12 billion deal to sell some of their devices to Japan based Terumo Corp  an important step toward completing the acquisition  Abbott s Alere deal is also in trouble with Alere suing the company  alleging that Abbott was dragging its feet on key antitrust submissions to sabotage the acquisition  Abbott reported a net loss from continuing operations of  329 million  or 24 cents per share  primarily due to an adjustment of 66 cents per share associated with Abbott s equity investment in Mylan  NASDAQ MYL  NV  The company sold its generic drugs business catering to developed markets to Mylan in 2014  Excluding items  Abbott earned 59 cents per share  on sales of  5 30 billion in the third quarter ended Sept  30  Analysts on average had expected earnings of 58 cents per share and revenue of  5 29 billion  according to Thomson Reuters I B E S ,2016-10-19,Reuters,https://www.investing.com/news/stock-market-news/abbott's-third-quarter-revenue-rises-nearly-3-percent-433341,433341
181448,402964,ABT,Hired experts back claims St  Jude heart devices can be hacked,news,"By Jim Finkle  Reuters    Short selling firm Muddy Waters said in a legal filing on Monday that outside experts it hired validated its claims that St  Jude Medical Inc cardiac implants are vulnerable to potentially life threatening cyber attacks  U S  regulators responded by reiterating previous advice that patients should keep using the devices  and a St  Jude spokeswoman said the company would respond  through appropriate legal channels   Muddy Waters released a 53 page report from boutique cyber security firm Bishop Fox as part of a legal filing in federal court in Minnesota in its defense against a suit brought by St  Jude  Bishop Fox said in the report it validated the claims with help from well known specialists in cryptography  computer hardware hacking  forensics and wireless communications  and cyber research firm MedSec Holdings that St  Jude cardiac implants are susceptible to hacking   St  Paul  Minnesota based St  Jude has strongly disputed those claims  which are under investigation by the U S  Food and Drug Administration   One of the world s biggest makers of implantable cardiac devices  St  Jude filed a lawsuit against San Francisco based Muddy Waters  Miami based MedSec and individuals affiliated with those firms on Sept  7  St  Jude accused them of intentionally disseminating false information about its heart devices to manipulate its stock price  which fell 5 percent the day they went public with their claims  The FDA said in a statement it had no comment on the litigation but that based on information obtained to date it urged patients to continue using devices as directed by their physicians   The benefits of the devices far outweigh any potential cyber security vulnerabilities   the FDA said of St  Jude s cardiac implants  which the company said have been implanted in hundreds of thousands of patients  St  Jude spokeswoman Candace Steele Flippin said the company s lawyers were reviewing the documents from Muddy Waters and MedSec   We continue to feel this lawsuit is the best course of action to make sure those looking to profit by trying to frighten patients and caregivers are held accountable for their actions   she said in an email  St  Jude in April agreed to sell itself for  25 billion to  Abbott Laboratories   NYSE ABT   Short sellers like Muddy Waters make bets that stock prices will fall  selling borrowed shares so they can buy them at a lower price and profit from the difference  The defendants said that St  Jude s lawsuit is without merit  reiterating their prior claim that St  Jude s heart devices have  significant security vulnerabilities    Muddy Waters  and MedSec s statements regarding security issues in the St  Jude Medical implant ecosystem were  by and large  accurate   Bishop Fox Partner Carl Livitt said in the report  The report said the wireless communications in St  Jude cardiac devices are vulnerable to hacking  making it possible for hackers to convert the company s Merlin home patient monitoring devices into  weapons  that can cause cardiac implants to stop providing care and deliver shocks to patients   Bishop Fox said it conducted successful test attacks from 10 feet  3 meters  away  but that the range might be extended to as far as 100 feet  30 meters  with an antenna and a specialized device known as a software defined radio   The report said Bishop Fox confirmed that several different types of hacks were possible  In one instance  it said  a hacker could remotely turn off the therapeutic functions of an implantable cardioverter defibrillator  ICD   then send a T wave shock to a patient s heart  causing ventricular fibrillation  would could lead to cardiac arrest  Bishop Fox said its clients include Fortune 500 firms  global financial firms  medical institutions and law firms  
Shares in St  Jude were little changed in afternoon trading ",2016-10-24,Reuters,https://www.investing.com/news/technology-news/hired-experts-support-claims-st.-jude-heart-devices-can-be-hacked-434302,434302
181449,402965,ABT,Abbott offers EU concessions over  25 billion St  Jude deal,news,"BRUSSELS  Reuters    Medical device maker  Abbott Laboratories   N ABT  has offered concessions in an attempt to secure EU antitrust approval for its  25 billion bid for  St Jude Medical  Inc  N STJ   according to the European Commision  The move pushed back the European Commission s decision on the deal to Nov  21 from Nov  9  according to a filing on the EU competition enforcer s website on Thursday  It did not provide details  The Commission can either accept the offer  demand more or open an investigation which can take up to five months  Abbott and St Jude last month announced the sale of some of their medical devices worth about  1 12 billion to Japanese company Terumo Corp  T 4543  as part of their deal  
The deal comes as medical equipment makers come under pressure to offer a wider range of products to hospital customers ",2016-11-03,Reuters,https://www.investing.com/news/stock-market-news/abbott-offers-eu-concessions-over-$25-billion-st.-jude-deal-437389,437389
181452,402968,ABT,EU regulator conditionally approves Abbott s purchase of St Jude,news,BRUSSELS  Reuters    The European Commission on Wednesday said it has given its conditional approval to U S  medical device maker Abbott Laboratories   N ABT  bid for peer  St Jude Medical  Inc  N STJ   Reuters reported on Nov  15 that the  25 billion deal was going to be cleared in Brussels  The European Commission  the mergers regulator  said in a statement that its approval was conditional on  Abbott divesting two devices used in cardiovascular treatments  ,2016-11-23,Reuters,https://www.investing.com/news/stock-market-news/eu-regulator-conditionally-approves-abbott's-purchase-of-st-jude-443335,443335
181453,402969,ABT,Abbott  ABT  Moves To Buy  Rationale Behind The Upgrade,opinion,"Abbott  ABT  appears an attractive pick  as it has been recently upgraded to a Zacks Rank  2  Buy   This rating change essentially reflects an upward trend in earnings estimates    one of the most powerful forces impacting stock prices 
The sole determinant of the Zacks rating is a company s changing earnings picture  The Zacks Consensus Estimate    the consensus of EPS estimates from the sell side analysts covering the stock    for the current and following years is tracked by the system 
The power of a changing earnings picture in determining near term stock price movements makes the Zacks rating system highly useful for individual investors  since it can be difficult to make decisions based on rating upgrades by Wall Street analysts  These are mostly driven by subjective factors that are hard to see and measure in real time 
As such  the Zacks rating upgrade for Abbott is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  and the near term price movement of its stock are proven to be strongly correlated  That s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their bulk investment action then leads to price movement for the stock 
Fundamentally speaking  rising earnings estimates and the consequent rating upgrade for Abbott imply an improvement in the company s underlying business  Investors should show their appreciation for this improving business trend by pushing the stock higher 
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  so it could be truly rewarding if such revisions are tracked for making an investment decision  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Abbott
This maker of infant formula  medical devices and drugs is expected to earn  3 22 per share for the fiscal year ending December  2019  which represents a year over year change of 11 8  
Analysts have been steadily raising their estimates for Abbott  Over the past three months  the Zacks Consensus Estimate for the company has increased 0 4  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Abbott to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-06-12,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-moves-to-buy-rationale-behind-the-upgrade-200431245,200431245
181454,402970,ABT,J J makes takeover approach for Swiss drugmaker Actelion  Bloomberg,news," Reuters    U S  healthcare company Johnson   Johnson  N JNJ  has approached Swiss biotechnology firm Actelion Ltd  S ATLN  about a potential takeover  Bloomberg reported on Thursday  citing people it said were familiar with the matter  The report said that deliberations are still at an early stage following Johnson   Johnson s initial offer  and Actelion is working with an adviser to explore options   Johnson   Johnson Chief Executive Alex Gorsky said earlier this year that the company was interested in making deals to expand its main consumer  medical device  and pharmaceuticals segments  He noted that in recent years  J J had derived about half its revenue from acquired products  Johnson   Johnson agreed to buy Abbott Laboratories   N ABT  eye care business for about  4 33 billion in cash in September   Actelion shares have risen more than 13 percent this year  valuing it at about  17 billion  In October  Actelion raised its earnings guidance for the third time this year as sales from its new drugs Opsumit and Uptravi  which treat pulmonary arterial hypertension  PAH   for the first time surpassed those of Tracleer  its decade long mainstay that lost U S  patent protection last November  
Johnson   Johnson and Actelion were not immediately available for comment ",2016-11-24,Reuters,https://www.investing.com/news/stock-market-news/j-amp;j-makes-takeover-approach-for-swiss-drugmaker-actelion:-bloomberg-443565,443565
181462,402978,ABT,Abbott  ABT  Upgraded To Buy  What Does It Mean For The Stock ,opinion,"Abbott  ABT  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank  2  Buy   This upgrade is essentially a reflection of an upward trend in earnings estimates    one of the most powerful forces impacting stock prices 
The Zacks rating relies solely on a company s changing earnings picture  It tracks EPS estimates for the current and following years from the sell side analysts covering the stock through a consensus measure    the Zacks Consensus Estimate 
Since a changing earnings picture is a powerful factor influencing near term stock price movements  the Zacks rating system is very useful for individual investors  They may find it difficult to make decisions based on rating upgrades by Wall Street analysts  as these are mostly driven by subjective factors that are hard to see and measure in real time 
Therefore  the Zacks rating upgrade for Abbott basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  has proven to be strongly correlated with the near term price movement of its stock  The influence of institutional investors has a partial contribution to this relationship  as these big professionals use earnings and earnings estimates to calculate the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their bulk investment action then leads to price movement for the stock 
Fundamentally speaking  rising earnings estimates and the consequent rating upgrade for Abbott imply an improvement in the company s underlying business  Investors should show their appreciation for this improving business trend by pushing the stock higher 
Harnessing the Power of Earnings Estimate Revisions
As empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  tracking such revisions for making an investment decision could be truly rewarding  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Abbott
For the fiscal year ending December  2019  this maker of infant formula  medical devices and drugs is expected to earn  3 22 per share  which is a change of 11 8  from the year ago reported number 
Analysts have been steadily raising their estimates for Abbott  Over the past three months  the Zacks Consensus Estimate for the company has increased 0 4  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Abbott to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-05-09,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-upgraded-to-buy-what-does-it-mean-for-the-stock-200420191,200420191
181463,402979,ABT,Why Is Abbott  ABT  Up 3 6  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Abbott  ABT   Shares have added about 3 6  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Abbott due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Abbott Posts Q1 Earnings Beat  Reiterates  19 EPS ViewAbbott reported first quarter 2019 adjusted earnings from continuing operations of 63 cents per share  beating the Zacks Consensus Estimate by 3 3   The bottom line improved 6 8  year over year and remained above the company s guided range of 60 62 cents  Reported earnings from continuing operation in the quarter came in at 38 cents  a 65 2  surge from the year ago quarter First quarter worldwide sales came in at  7 54 billion  up 1 9  year over year on a reported basis  The top line remained above the Zacks Consensus Estimate of  7 47 billion On an organic basis  adjusting for the impact of foreign exchange as well as certain acquisitions and divestments   sales increased 7 1  year over year in the reported quarter Quarter in DetailAbbott operates through four segments  namely Established Pharmaceuticals Division  EPD   Medical Devices  Nutrition and Diagnostics In the first quarter  EPD sales dropped 4 9  on a reported basis  improved 5 4  on an organic basis  to  992 million  This included an 10 3  adverse impact from currency fluctuations  Sales in the key emerging markets declined 5 2  year over year on a 12 5  adverse impact of foreign exchange  Organically  sales improved 7 3  in this market The Medical Devices business sales increased 5 5  on a reported basis to  2 89 billion  On an organic basis  sales grew 9 5  Cardiovascular and Neuromodulation sales reportedly  up 3 6  on an organic basis  rose 0 2  on double digit growth in Electrophysiology  Heart Failure  Structural Heart and Diabetes Care  In Electrophysiology  growth was led by strong performance in cardiac mapping and ablation catheters Within Structural Heart  the company registered 15  organic growth on a year over year basis driven by strong performance in several product areas across Abbott s broad portfolio  including MitraClip device Diabetes Care sales improved 34 4   up 42  organically   buoyed consistent consumer uptake of FreeStyle Libre  the revolutionary continuous glucose monitoring system of Abbott Nutrition sales were up 2  year over year on a reported basis  up 6 7  on an organic basis  to  1 79 billion  Pediatric Nutrition sales increased 6 7  on an organic basis  Adult Nutrition sales were up 6 8  organically Diagnostics sales were up a marginal 0 2  year over year on a reported basis  up 4 4  on a comparable operational basis  to  1 84 billion  Core Laboratory Diagnostics sales grew 9 9  while Molecular Diagnostics slipped 5 1   on an organic basis  Point of Care Diagnostics sales were down 4 2   Rapid Diagnostics sales declined 1 4  on an organic basis in the first quarter affected by a difficult comparison versus the first quarter of 2018 when sales were abnormally high due to a strong flu season 2019 GuidanceAdjusting for certain net specified items for the full year  adjusted earnings from continuing operations are reiterated in the band of  3 15  3 25  The Zacks Consensus Estimate of  3 20 remains within this projected range The company has also provided second quarter 2019 adjusted earnings per share outlook  It expects to report adjusted earnings from continuing operations in the range of 79 81 cents  The consensus mark of 81 cents falls at the upper end the predicted range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
At this time  Abbott has a strong Growth Score of A  though it is lagging a bit on the Momentum Score front with a B  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Abbott has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-16,Zacks Investment Research,https://www.investing.com/analysis/why-is-abbott-abt-up-36-since-last-earnings-report-200422529,200422529
181464,402980,ABT,Abbott  ABT  Stock Moves  0 05   What You Should Know,opinion,"Abbott  ABT  closed the most recent trading day at  75 67  moving  0 05  from the previous trading session  This change was narrower than the S P 500 s 0 69  loss on the day  Elsewhere  the Dow lost 0 87   while the tech heavy Nasdaq lost 0 79  
Heading into today  shares of the maker of infant formula  medical devices and drugs had lost 4 84  over the past month  lagging the Medical sector s loss of 0 97  and the S P 500 s loss of 4 53  in that time 
Investors will be hoping for strength from ABT as it approaches its next earnings release  On that day  ABT is projected to report earnings of  0 80 per share  which would represent year over year growth of 9 59   Meanwhile  our latest consensus estimate is calling for revenue of  7 99 billion  up 2 82  from the prior year quarter 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  3 22 per share and revenue of  31 92 billion  These totals would mark changes of  11 81  and  4 4   respectively  from last year 
It is also important to note the recent changes to analyst estimates for ABT  These recent revisions tend to reflect the evolving nature of short term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  ABT is holding a Zacks Rank of  3  Hold  right now 
Digging into valuation  ABT currently has a Forward P E ratio of 23 54  This represents a discount compared to its industry s average Forward P E of 24 64 
Also  we should mention that ABT has a PEG ratio of 2 13  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  ABT s industry had an average PEG ratio of 2 22 as of yesterday s close 
The Medical   Products industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 89  which puts it in the top 35  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-05-29,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-stock-moves-005-what-you-should-know-200426285,200426285
181465,402981,ABT,Abbott  ABT  Gains But Lags Market  What You Should Know,opinion,"In the latest trading session  Abbott  ABT  closed at  77 54  marking a  1 85  move from the previous day  This change lagged the S P 500 s 2 14  gain on the day  Elsewhere  the Dow gained 2 06   while the tech heavy Nasdaq added 2 65  
Coming into today  shares of the maker of infant formula  medical devices and drugs had lost 4 25  in the past month  In that same time  the Medical sector lost 3 29   while the S P 500 lost 6 63  
Investors will be hoping for strength from ABT as it approaches its next earnings release  The company is expected to report EPS of  0 80  up 9 59  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  7 99 billion  up 2 82  from the year ago period 
ABT s full year Zacks Consensus Estimates are calling for earnings of  3 22 per share and revenue of  31 92 billion  These results would represent year over year changes of  11 81  and  4 4   respectively 
Investors should also note any recent changes to analyst estimates for ABT  Recent revisions tend to reflect the latest near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate remained stagnant  ABT is currently a Zacks Rank  3  Hold  
Valuation is also important  so investors should note that ABT has a Forward P E ratio of 23 54 right now  This represents a discount compared to its industry s average Forward P E of 25 4 
Also  we should mention that ABT has a PEG ratio of 2 13  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Medical   Products was holding an average PEG ratio of 2 22 at yesterday s closing price 
The Medical   Products industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 84  which puts it in the top 33  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-06-04,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-gains-but-lags-market-what-you-should-know-200428416,200428416
181466,402982,ABT,St Jude in  39 25 million shareholder settlement over heart devices,news,By Jonathan Stempel  Reuters    St  Jude Medical Inc has reached a  39 25 million class action settlement with shareholders to resolve claims it downplayed the possible dangers associated with a product used to connect implantable defibrillators to patients  hearts  The preliminary settlement  disclosed Thursday with the U S  District Court in Minneapolis  requires a judge s approval  It resolves claims that St  Jude inflated its stock price by concealing risks revealed in a November 2012 U S  Food and Drug Administration report about its Durata lead  a cable linking the heart to a defibrillator  St  Jude used a material called Optim to insulate Durata and help preserve its ability to deliver needed electric shocks  But the FDA report raised questions about whether St  Jude had properly tested Durata  and whether the lead could face problems similar to what prompted a 2011 recall of Riata  a lead that was prone to failure because the insulation wore away  St  Jude s share price fell more than 12 percent on Nov  21  2012  the day after the FDA report was released  wiping out roughly  1 3 billion of its market value  The St  Paul  Minnesota based company denied liability in agreeing to the settlement  which averted a February 2017 trial  St  Jude had no immediate comment on Friday  In a May 4 regulatory filing  it said it had not taken a charge for a possible settlement  The company reported  880 million of profit on net sales of  5 54 billion for 2015   Abbott Laboratories   NYSE ABT  agreed in April to buy St  Jude for about  25 billion  Forsta AP Fonden of Sweden and Danske Invest Management A S of Denmark led the class action on behalf of St  Jude shareholders from Feb  5  2010 to Nov  20  2012  Their law firms  Kessler Topaz Meltzer   Check and Motley Rice  plan to request up to  9 81 million in legal fees plus up to  2 9 million for costs  Gregory Castaldo  from Kessler Topaz  and Gregg Levin  from Motley Rice  on Friday said they were pleased to settle  The case is Forsta AP Fonden et al v  St  Jude Medical Inc et al  U S  District Court  District of Minnesota  No  12 03070 ,2016-07-08,Reuters,https://www.investing.com/news/stock-market-news/st-jude-in-$39.25-million-shareholder-settlement-over-heart-devices-413286,413286
181467,402983,ABT,Abbott sales beat on higher demand for medical devices,news,"By Amrutha Penumudi  Reuters     Abbott Laboratories   NYSE ABT  reported better than expected quarterly sales and profit as strong sales in its medical device business more than made up for the hit from an economic turmoil in Venezuela  Abbott is one of the major U S  companies to be affected by troubled operations in Venezuela  The Latin American nation s economy contracted by 4 5 percent in the first nine months of last year as plunging oil prices  and what critics of President Nicolas Maduro see as policy missteps  took an increasing toll  Venezuela s official annual inflation rate was the world s highest at 141 5 percent in the nine months  Abbott  which rakes in two thirds of its revenue from outside the United States  said emerging market sales increased 1 1 percent but would have risen 4 8 percent excluding the impact of Venezuelan operations  The company s results  however  beat Wall Street estimates  largely helped by its booming medical device business  where sales rose 6 4 percent to  1 37 billion in the second quarter  Abbott s device unit develops products for heart  diabetes and eye patients and has been helped by launches including glucose monitor FreeStyle Libre and MitraClip  which repairs heart valves less invasively  Abbott is in the process of acquiring St  Jude Medical Inc for  25 billion  St  Jude on Wednesday reported second quarter earnings and revenue roughly in line with Wall Street estimates  Miles White  chief executive of Abbott  said he had still expected to close the transaction before year end  as the company prepares to respond to a second request of information from the U S  Federal Trade Commision  Abbott s acquisition of diagnostic company Alere Inc however  continues to see challenges  especially after Alere was subpoenaed by the U S  Department of Justice over its sales practices  Alere rejected a request by Abbott to terminate the deal for a breakup fee in April   To be honest  no matter what kind of teeth grinding and gnashing we go through with them    one thing I m certain of is that they are trying to do everything they can  in their way to address the challenges   Miles said on a conference call with analysts  On an adjusted basis  Abbott earned 55 cents per share in the quarter ended June 30  above the average analyst estimate of 53 cents  according to Thomson Reuters I B E S   The company s net sales rose 3 2 percent to  5 33 billion  beating analysts  estimate of  5 24 billion     
Abbott s shares were up 2 3 percent at  42 76 in mid morning trading ",2016-07-20,Reuters,https://www.investing.com/news/stock-market-news/abbott-labs-reports-3.2-percent-rise-in-sales-415434,415434
181468,402984,ABT,St  Jude says report by short sellers  false and misleading ,news,"By Jim Finkle  Reuters    Medical device manufacturer St  Jude Medical Inc  N STJ  said on Friday a report by short selling firm Muddy Waters and a cyber security researcher alleging its heart devices were riddled with bugs was  false and misleading    The report  which caused St  Jude shares to fall 5 percent after its release on Thursday  alleged there were significant security bugs in the company s Merlin home device for monitoring implanted heart devices   St  Jude chief technology officer Phil Ebeling on Thursday said  the allegations are absolutely untrue  but provided no specific examples of errors  St  Jude on Friday said most of the observations in the report applied to older versions of its Merlin home devices  which had not been patched with security upgrades that the company automatically pushes out to customers    We want to reassure our patients that our systems meet the highest international security requirements  as required by regulatory authorities and international standards organizations   St Jude said  Muddy Waters late on Friday said it plans to publicly refute the response of St  Jude  which in April agreed to sell itself for  25 billion to  Abbott Laboratories   N ABT    This was a missed opportunity for St  Jude to take responsibility for their flawed devices   the short seller said in a statement   MedSec executives could not be reached for comment  Muddy Waters had no immediate response to St Jude s claim that the testing was done on older versions of its devices with unpatched software   We continue to stand by the report and are pleased the company has actually decided to respond to the allegations   St  Jude shares closed marginally higher on Friday after the company released its statement following a halt in trading  Earlier they had traded as low as  75 34 in heavy trade  Muddy Waters founder Carson Block said on Thursday he decided to short the stock after MedSec approached Muddy Waters about three months ago with results of research it had conducted into its medical device security  The two struck a deal under which Block agreed to hire the cyber security firm as a consultant  pay it a licensing fee for the research and a percentage of any profits from the investment  Block said  In its rebuttal on Friday  St Jude said the researchers used a  flawed test methodology on outdated software   demonstrating  lack of understanding of medical device technology   Beau Woods  a medical device security expert with the non profit Atlantic Council  said that while he had no knowledge of MedSec s research methodology  St  Jude s explanation sounded reasonable  
 It makes sense that they would not have the current versions of software  that rings true to me   said Woods  He said that medical device makers typically push out regular updates to their software  which include security patches ",2016-08-26,Reuters,https://www.investing.com/news/technology-news/st.-jude-says-report-by-short-sellers-'false-and-misleading'-422632,422632
181470,402986,ABT,Alere lawsuit accuses Abbott of  buyer s remorse  in proposed merger,news,"By Carl O Donnell  Reuters     Alere Inc   N ALR  alleges  Abbott Laboratories   N ABT  is trying to stymie its planned  5 8 billion takeover of the diagnostics company by purposefully delaying key submissions to anti trust regulators  according to a lawsuit made public on Tuesday  Alere claims in its complaint that Abbott has avoided responding to a second request by the Federal Trade Commission in a bout of  buyer s remorse  spurred by a desire to free up capital for Abbott s other major planned deal   a  24 billion acquisition of rival St  Jude Medical  N STJ   Abbott denied the allegations  arguing that Alere s financial problems and related delays in filing its financial statements had slowed the deal s progress  Abbott also said it had been approached by a whistleblower who alleges that Alere is deliberately hiding information about its Indian operations   Alere s complaint is nonsense and without merit   Abbott said in a statement   Their description of events is fiction and nothing but a publicity stunt  Abbott is compliant with its obligations under the merger agreement    Alere s planned deal with Abbott ran into trouble when it revealed that it was under investigation by the U S  Department of Justice for some of its foreign sales practices and that it would not be able to provide certain key regulatory filings on time  Prior to the deal  Alere already had revealed that its accounting practices had been under scrutiny by the Securities and Exchange Commission   Abbott agreed to acquire Alere in February  In late April  Abbott struck an even bigger deal to buy St  Jude to position itself as the dominant player in the market for cardiovascular devices   After the second deal was announced  Alere said in a filing that it had declined an offer from Abbott to pay it up to  50 million to break off their merger agreement   Alere said last week that it had sued Abbott in Delaware Chancery Court but the complaint was only made public on Tuesday  In its lawsuit  Alere said Abbott s chief executive officer  Miles White  said he would make life a  living hell  for everyone in Alere if it did not agree to walk away from the deal  The suit claims that Abbott  inundated  Alere with about 175 document requests and asked for more than 40 interviews in an attempt to find evidence of a breach of its agreement   It said Abbott s allegedly slow response to requests from anti trust regulators was a fall back attempt to prevent the deal from closing  In a response to Alere s lawsuit filed Wednesday  Abbott said the timing of its response to regulators amounts to  a tactical disagreement among the parties about how to best secure antitrust clearance    Abbott noted the current deal agreement does not expire for at least eight months and that a court intervention into its dealings with regulators at this stage would likely be unprecedented  
Abbott also said in its response to the lawsuit that it had received the tip from a whistleblower  who alleged that Alere had been obstructing its attempt to investigate possible legal violations by Alere in India by coaching witnesses to provide false information ",2016-08-31,Reuters,https://www.investing.com/news/stock-market-news/alere-lawsuit-accuses-abbott-of-'buyer's-remorse'-in-proposed-merger-423491,423491
181471,402987,ABT,Delaware judge expedites Alere lawsuit against Abbott,news,NEW YORK WILMINGTON  Del   Reuters    A Delaware judge on Friday granted a motion to expedite Alere Inc s  N ALR  lawsuit against  Abbott Laboratories   N ABT   which seeks to ensure that Abbott lives up to the terms of its  5 8 billion takeover of the diagnostics company  representatives for Alere said   Alere filed suit last week in the Delaware Court of Chancery  arguing that Abbott is trying to stymie the deal by purposefully delaying key submissions to anti trust regulators  Abbott denies the charges  Delaware Vice Chancellor Sam Glasscock did not say when a trial would be held and did not address hearing dates  Instead he ordered the parties to go back to their clients and ask if they would consider mediation   Former Chancellor William Chandler is available to be a mediator  according to the judge   The judge s suggestion that the parties work together is helpful and we look forward to engaging in that process   Abbott said in a statement   Abbott continues to be compliant with its obligations under the merger agreement   An Alere spokesperson said the company was pleased with the court s decision  Abbott agreed to acquire Alere in February  In late April  Abbott struck an even bigger deal to buy St  Jude Medical  N STJ  to position itself as the dominant player in the market for cardiovascular devices   After the St  Jude deal was announced  Alere said in a filing that it had declined an offer from Abbott to pay it up to  50 million to break off their merger agreement   Alere claims in its complaint that Abbott is motivated to end its deal with Alere in order to free up capital for its  24 billion takeover of St  Jude  Abbott has said it is in compliance with the deal and that Alere s financial problems and related delays in filing its financial statements had slowed its progress ,2016-09-02,Reuters,https://www.investing.com/news/stock-market-news/delaware-judge-expedites-alere-lawsuit-against-abbott-424007,424007
181472,402988,ABT,St  Jude sues short seller over heart device allegations,news,"By Ransdell Pierson and Ankur Banerjee  Reuters    St  Jude Medical Inc on Wednesday filed a lawsuit against short selling firm Muddy Waters and cyber security company MedSec Holdings Ltd  saying they intentionally disseminated false information about its heart devices to manipulate its stock  St  Jude s shares fell sharply on Aug  25 after Muddy Waters  run by Carson Block  said it had taken a short position in company s stock after uncovering security flaws in its devices   Block said last week his firm s position was motivated by research from MedSec  which asserted that St  Jude s heart devices were vulnerable to cyber attacks and were a risk to patients  MedSec has acknowledged that it would share in gains from Muddy Water s short investment   Short sellers borrow shares and sell them in expectation the price will fall  When it does  the short sellers buy back the shares  return them to the lender  pay borrowing fees and pocket the difference  St  Jude said it had filed the lawsuit to protect the reputation of its implantable pacemakers and defibrillators  which are used to regulate heart rhythm or treat cardiac arrest  It is seeking damages and for the defendants to give up any profits they made off their investment  The lawsuit said Muddy Waters had created a short selling scheme meant to secure a quick and illegal financial windfall  It was not immediately clear how big the short seller s position was or how much it may have made when St  Jude s stock fell   A Muddy Waters spokesman responded to the lawsuit in an emailed statement that  It is not unusual for a company like this to try to silence its critics and we are always prepared to vigorously defend our right to criticize a company that puts its profits before its patients   Muddy Waters alleged last month it and MedSec found security flaws in St  Jude s Merlin home device for monitoring implanted heart devices  They said the flaws potentially could enable hackers to easily take control of the devices and either speed them up or drain their power   In its lawsuit  St  Jude said the accusations were defamatory and that its devices have numerous features that protect against cyberattacks  It accused the short sellers of false advertising  conspiracy and manipulation of the stock market  University of Michigan researchers last week said their own experiments had undermined allegations of security flaws in St  Jude s implantable devices  St  Jude agreed in April to sell itself to  Abbott Laboratories   NYSE ABT  for  25 billion  MedSec did not immediately respond to requests for comment  St  Jude s shares rose 0 8 percent in morning trading on the New York Stock Exchange  The stock has fallen about 4 percent since Muddy Waters disclosed its position   
The case is St  Jude Medical vs  Muddy Waters  MedSec Holdings et al  in the United States District Court for the District of Minnesota  No  16 cv 03002 ",2016-09-07,Reuters,https://www.investing.com/news/stock-market-news/st.-jude-sues-short-seller-over-heart-device-allegations-424748,424748
181475,402991,ABT,Abbott to sell its eye care business to J J for about  4 33 billion,news," Reuters     Abbott Laboratories   N ABT  said it would sell its eye care business to Johnson   Johnson  N JNJ  for about  4 33 billion in cash to focus on cardiovascular devices and diagnostics business   The company expanded its medical device and diagnostics businesses this year with a  25 billion deal for St  Jude Medical Inc  N STJ  and a  5 8 billion deal for  Alere Inc   N ALR   Abbott Medical Optics  which the company acquired for nearly  1 4 billion in 2009  reported sales of  1 1 billion for 2015  J J said on Friday  The Wall Street Journal earlier reported that Abbott was in talks to sell the business to J J   We ve been actively and strategically shaping our portfolio  which has recently focused on developing leadership positions in cardiovascular devices and expanding diagnostics   Abbott Chief Executive Miles White said   The Alere deal has run into rough weather with the target company filing a lawsuit in August  accusing Abbott of dragging its feet on key antitrust submissions to sabotage the deal  To make matters worse  St  Jude is facing allegations that its pacemakers and defibrillators have cyber security flaws that hackers could exploit to harm patients  The company has sued short selling firm Muddy Waters and cyber security firm MedSec Holdings Inc who raised the allegations   Wells Fargo analysts said Abbott was likely selling the eye care business because it was less of a strategic fit once it acquired St Jude and the company would need to reduce debt after the two deals   Abbott had long term debt of about  6 billion as of June 30  For Johnson   Johnson  the deal would help expand its eye care portfolio with products in cataract surgery  laser refractive surgery and consumer eye health units  The World Health Organization estimates that about 20 million people are blind from age related cataracts and that there are at least 100 million eyes with compromised visual acuity caused by cataracts  J J said  Friday s deal  which is expected to close in the first quarter of 2017  is expected to modestly add to J J s earnings immediately   J J s vision care unit  which includes Acuvue brand contact lenses  generated revenue of  685 million in the second quarter   
Abbott shares closed up 1 8 percent at  41 87 on Friday  J J shares closed down 0 3 percent at  118 25 ",2016-09-16,Reuters,https://www.investing.com/news/stock-market-news/j-amp;j-to-buy-abbott's-eye-care-business-for-about-$4.33-billion-426761,426761
181485,403001,ABT,Abbott Labs to buy diagnostics company Alere for  5 8 billion,news,"By Ankur Banerjee and Rosmi Shaji  Reuters     Abbott Laboratories   N ABT  said it would buy  Alere Inc   N ALR  for  5 8 billion to become a leader in point of care testing  a fast growing market as physicians increasingly adopt rapid tests that speed up treatment  Point of care tests provide results to doctors in a matter of minutes as they can be conducted in the physician s office  an ambulance or even at home  Waltham  Massachusetts based Alere  which has annual sales of  2 5 billion  makes tests for infections such as HIV  tuberculosis  malaria and dengue  The deal comes at a time when deadly viruses such as Zika are spreading alarmingly across the globe  putting the spotlight on diagnostic test makers and vaccine developers  It was not immediately clear if Alere or Abbott were involved in making tests for Zika  which has been linked to severe birth defects in babies   We view the deal positively as we think point of care testing is the fastest growing segment in the diagnostic market   S P Capital IQ analyst Jeffrey Loo said  The global diagnostics industry  which is roughly  60 billion in size  is growing at a rate of 5 percent  according to Goldman Sachs  N GS   Abbott will pay  56 per share in cash  a premium of about 51 percent to Alere s Friday closing  Alere shares were trading at  53 95 on Monday  Abbott was down 0 7 percent  Abbott  which makes products ranging from Similac infant formula to Ensure beverages for adults  has struggled to boost sales growth after it sold its developed markets generics business to Mylan NV  O MYL  in 2014  The company  which spun out  AbbVie Inc   N ABBV  in 2013  reported lower than expected quarterly revenue for the first time in four quarters last week  Canaccord Genuity analyst Mark Massaro said the deal helps Abbott become the undisputed global leader in point of care diagnostics and help diversify its business  Abbott  whose 2015 worldwide diagnostics sales were  4 6 billion in 2015  said its total diagnostics sales would exceed  7 billion after the close of the deal  The deal will immediately add to Abbott s earnings per share upon close and contribute significantly thereafter  the companies said  
Alere s net debt  currently  2 6 billion  will be assumed or refinanced by Abbott  Evercore is the financial adviser to Abbott  while Kirkland   Ellis LLP is legal counsel  JP Morgan is Alere s financial adviser  while Cravath  Swaine   Moore is legal counsel ",2016-02-01,Reuters,https://www.investing.com/news/economy-news/abbott-labs-to-buy-diagnostics-company-alere-for-$5.8-billion-382743,382743
181486,403002,ABT,Mylan to buy Swedish drugmaker Meda in  7 2 billion deal,news,"By Natalie Grover  Reuters    Generic drugmaker Mylan NV  O MYL  said it would acquire  Meda AB   ST MEDAa  in a  7 2 billion cash and stock deal in its third attempt to buy the Swedish company  The move comes three months after Mylan gave up on its seven month long pursuit of smaller rival Perrigo  N PRGO   Mylan s stock fell about 8 pct in extended trading  after it announced the 165 Swedish crowns per share offer  That works out to be nearly twice Meda s last traded price  which had some analysts questioning the high premium   The deal may be earnings accretive  but Mylan is paying a huge premium in a deteriorating market   Clinical Assistant Professor Erik Gordon  from the Ross School of Business at the University of Michigan  told Reuters   The announcement of the takeover came alongside the company s fourth quarter results  which underwhelmed analysts  estimates both in terms of profit and revenue  Mylan is still on the prowl for deals  Chief Executive Heather Bresch indicated over a post earnings conference call with analysts   Meda makes branded  over the counter and generic drugs  It already handles European sales of EpiPen  Mylan s emergency shot for severe allergic reactions and its biggest selling branded product  Mylan said the offer  recommended by Meda s board  valued the company at  9 9 billion  including debt  Meda s two largest shareholders  who own about 30 percent of the specialty pharmaceutical s outstanding shares  have accepted the offer  Mylan added  In 2014  Meda spurned takeover offers from Mylan after its biggest shareholder rejected the deal     Stena Sessan Rederi AB  controlled by the Olsson business family  is the biggest shareholder in Meda  with a 20 7 percent stake   Both companies have changed considerably since then   Meda s board chairman Martin Svalstedt told Reuters  highlighting recent acquisitions made by both drugmakers  Last year  Mylan completed its purchase of Abbott Inc s  N ABT  specialty and generics business in developed markets outside the United States  which helped it shift its tax address to the Netherlands   Meda in July 2014 unveiled its biggest deal ever   the  3 1 purchase of Rottapharm   weeks after the Italian firm scrapped flotation plans   We have now a stronger business fit  but the industrial landscape is the biggest change since 2014   said Svalstedt  Mylan said it would finance the cash portion of the offer via a bridge credit facility arranged by  Deutsche Bank   DE DBKGn  and Goldman Sachs  N GS   The transaction  due to be completed by the third quarter  should immediately add to Mylan s earnings  the company said  Mylan shares traded at  46 60 in after market trading  They closed at  50 54 Wednesday on the Nasdaq  while Meda s shares closed at 86 05 crowns  
Centerview Partners was Mylan s financial adviser and Cravath  Swaine   Moore LLP  Vinge  and NautaDutilh its legal advisers  Rothschild   Co served as Meda s financial adviser ",2016-02-10,Reuters,https://www.investing.com/news/stock-market-news/mylan-to-buy-swedish-drugmaker-meda-in-$7.2-billion-deal-384170,384170
181489,403005,ABT,India s codeine cough syrup ban hits Pfizer  Abbott units,news,"By Zeba Siddiqui and Aditya Kalra MUMBAI NEW DELHI  Reuters     Pfizer  Inc  N PFE  and  Abbott Laboratories   N ABT  on Monday said they would comply with a ban on a popular cough syrup in India after it was added to a local list of prohibited drugs  sending shares in the U S  firms  Indian subsidiaries tumbling  Pfizer s Corex brand syrup and Abbott s identical Phensedyl contain the narcotic codeine  That brought them to the attention of authorities combating addiction and smuggling  who had been privately pressuring the drugmakers to better police supply chains  Reuters reported last year   We are happy that this will end the misuse of the medicine   said Akun Sabharwal  drugs controller for the southern state of Telangana  that last year detected an  illegal diversion  of Phensedyl worth about  8 5 million  Shares of  Pfizer Ltd   NS PFIZ  fell as much as 8 percent after the drugmaker said it stopped selling its version of the medicine  Shares of  Abbott India Ltd   NS ABOT  fell as much as 3 percent after the firm said it would comply with the ban  INDUSTRY SALES HIT The medicine   a combination of chlorpheniramine maleate and codeine syrup   was among 344 fixed dose combination drugs that Indian regulators banned at the weekend after a panel of experts found they lacked  therapeutic justification   Market researcher AIOCD AWACS estimated the total ban could cut sales in the local pharmaceutical industry by up to  522 million  with Pfizer and Abbott among the worst hit  Pfizer said Corex sales totaled about  26 million in the nine months through December  Abbott s Phensedyl commands around a third of the local cough syrup market and makes up over 3 percent of the company s  1 billion in Indian revenue  Pfizer said of the ban that it was  exploring all possible options   OPPI  a lobby group for multinational drugmakers  said regulators had used  a very broad brush  when imposing the ban  The Indian Pharmaceutical Alliance  which represents Indian drugmakers  said review process was not transparent  Health ministry bureaucrat K L  Sharma told Reuters on Monday that he disagreed  saying   We are not prepared to tolerate anything that will affect patients   COURT BATTLE The sale of combination drugs requires the approval of central government  However  the 344 listed at the weekend entered the market based only on local approval  Regulators have made intermittent efforts to prevent drugs reaching the market without central government clearance  They issued an order in 2007 requiring states to recall about 300 combination drugs  Drugmakers challenged the order in court  which put it on hold     In 2014  regulators set up a review of combination drugs that had not received central government approval  Regulators have assessed over 6 000 such drugs and asked makers to prove their safety and efficacy  
While it has banned 344  the review process is ongoing  the health ministry s Sharma said ",2016-03-14,Reuters,"https://www.investing.com/news/stock-market-news/pfizer,-abbott-india-shares-fall-as-regulator-bans-codeine-cough-syrups-389674",389674
181492,403008,ABT,Sanofi launches  9 3 billion fight for U S  cancer firm Medivation,news,"By Ben Hirschler and Leigh Thomas LONDON PARIS  Reuters    French drugmaker Sanofi  PA SASY  went public with a  9 3 billion offer to buy Medivation on Thursday  setting up what could be a lengthy takeover battle after the U S  cancer firm rebuffed its approaches  The decision to target Medivation marks a return to the biotech takeover trail for Sanofi  which is looking to new cancer treatments to bolster its portfolio and help offset declining sales of mainstay diabetes drug Lantus  Sanofi s non binding proposal is to buy Medivation for  52 50 per share in cash  representing a 50 percent premium over the San Francisco based firm s two month volume weighted average share price prior to takeover rumors  It is  however  only modestly above Medivation s Wednesday closing price of  52 05 and investors signaled they expected Sanofi to dig deeper  with the shares trading above  56 on Thursday  Reuters reported last month that Medivation had been working with investment bank J P  Morgan to handle interest from companies regarding a potential acquisition  but it had no plans to sell itself  Bryan Garnier analyst Eric Le Berrigaud said Sanofi could now face a prolonged takeover fight with other players potentially getting involved  including Japan s Astellas Pharma  Medivation s partner on its prostate cancer drug Xtandi  Britain s AstraZeneca has also been reported to have looked at Medivation  Officials at Astellas and AstraZeneca declined to comment  although one person close to the British company said it was unlikely to enter a bidding war  Medivation  which has limited takeover defenses  said it would respond to Sanofi s offer following a board meeting on Thursday  with input from financial advisers Evercore and J P  Morgan  Sanofi  which is being advised by  Morgan Stanley   NYSE MS   has a track record of pushing through unsolicited deals  after buying Genzyme for  20 billion in 2011  Sanofi s move comes on the same day that  Abbott Laboratories   NYSE ABT  agreed to buy medical device maker St  Jude Medical for  25 billion and AbbVie announced a  5 8 billion deal for cancer firm Stemcentrx  highlighting a pattern of healthcare companies snapping up smaller rivals  LOOKING FOR DEALS The French company  whose shares slipped 1 percent  said there was no certainty the deal would get done  but that if it did  it would boost earnings immediately   Deutsche Bank   DE DBKGn  analysts said Sanofi likely had  significant flexibility  to raise its offer  given the current low cost of debt  while Bernstein calculated the deal would still lift earnings from 2017 even at  62 40 a share  or 20 percent above Wednesday s close  The premium to the unaffected price offered by Sanofi is below some other recent large biotech deals  with Roche paying a 63 percent premium for Intermune in 2014 and Alexion 140 percent for Synageva last year  Stepping up acquisitions fits with the strategy of Sanofi Chief Executive Olivier Brandicourt  who took over a year ago  He told Reuters in January that he was looking for deals to broaden its reach in areas such as oncology and could consider deals of up to  20 billion  France s biggest drugmaker is going through a tough patch  due to falling sales of Lantus  prompting it to warn of no meaningful profit growth over the next two years  Oncology is currently the hottest area of pharmaceutical research  thanks to advances in understanding the biological drivers of the disease  Sanofi has a long history in selling chemotherapy drugs but has been less successful at developing modern cancer medicines    COMPELLING  PROPOSAL Brandicourt first contacted Medivation about a deal on March 25 but he said Chief Executive Officer David Hung had declined to meet him and had told him the U S  company s board was not interested in discussing a transaction  Sanofi then set out its  52 50 a share offer in an April 15 letter to Hung  to which Medivation only acknowledged receipt without commenting on its contents   We do not understand the delay in responding to our letter  The price we put forth represents a very substantial premium  and it would be all cash without any financing condition  In these circumstances we believe it is appropriate to make this letter public  which we are doing today   Brandicourt wrote in a follow up letter to Hung on April 28    We also strongly believe that Medivation shareholders would find our proposal to be compelling   Xtandi  which had worldwide sales of nearly  2 billion in 2015  is Medivation s only marketed drug  The high price of Xtandi has been criticized by some U S  lawmakers  including Democratic Party presidential hopeful Bernie Sanders  
Medivation is also conducting clinical trials on two experimental drugs  talazoparib for breast cancer and pidilizumab for blood cancers ",2016-04-28,Reuters,https://www.investing.com/news/stock-market-news/france's-sanofi-makes-$9.3-billion-bid-for-u.s.-biotech-medivation-398498,398498
181493,403009,ABT,U S  stocks struggle for gains  oil moves higher,news,"Investing com   Global markets were shocked on Thursday by the Bank of Japan s decision to not undertake a further expansion of monetary stimulus  but stocks stateside struggled near mid session to maintain gains 
At 15 21GMT  or 13 21ET  the Dow Jones slipped 10 points  or 0 05   while the S P 500 edged up 3 points  or 0 16   and the tech heavy Nasdaq Composite traded up 23 points  or 0 47  
The Nasdaq managed to avoid the red thanks to heavy gains in  Facebook Inc   NASDAQ FB   The social media company reported after the close on Wednesday that revenue jumped more than 50  thanks to a surge in mobile ad sales and its shares soared around 9  
Ford Motor Company  NYSE F  also rose by more than 3  after a 113  jump in net income led the automaker to easily beat Wall Street consensus 
Thursday s session was also ripe with M A activity as Comcast  NASDAQ CMCSA  confirmed that it would pay  3 8 billion to acquire Dreamworks Animation SKG Inc  NASDAQ DWA   while  Abbott Laboratories   NYSE ABT  announced plans to buy  St Jude Medical  Inc  NYSE STJ  for  25 billion in an effort to expand its heart device business 
Tech earnings will remain in focus on Thursday with both Amazon com and Baidu reporting after the market close 
On the economic front  the U S  economy showed worrying signs of deceleration as first quarter gross domestic product grew at its slowest pace in two years and missed consensus 
In positive news  the labor market continued to show signs of firming as initial jobless claims rose less than expected  and the four week average remained at the lowest level since 1973 
The dollar was unaffected by the data and continued to trade lower  The U S  dollar index  which measures the greenback s strength against a trade weighted basket of six major currencies  traded down 0 38  at 94 02  at 15 24GMT or 11 24AM ET
Meanwhile  oil struggled throughout the day to maintain gains after hitting highs for this year on the prior day as data showed that U S  oil supplies rose to an all time high last week  underlining concerns over a supply glut 
Both West Texas and Brent had rallied more than 70  since hitting 2016 lows in February and January  respectively  but investors looked set to maintain the bullish bets and continue the rally 
U S  crude futures gained 0 51  to  45 56 a barrel by 15 25GMT  or 11 25ET  while Brent oil traded up 0 81  to  47 31 ",2016-04-28,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-struggle-for-gains;-oil-moves-higher-398613,398613
181503,403019,ABT,Analysis   NY insider trading ruling tests prosecutors beyond Wall Street,news,"By Nate Raymond
NEW YORK  Reuters    A court ruling that sharply curtailed the ability of prosecutors including Manhattan U S  Attorney Preet Bharara to pursue insider trading cases is increasingly testing regulators  abilities across the country 
    Defendants in California and Massachusetts have sought to take advantage of a December ruling from the 2nd U S  Circuit Court of Appeals in New York that narrowed the definition of insider trading  making it harder for prosecutors to pursue their cases 
    The challenges raise the possibility that the 2nd Circuit decision  legally binding only in New York  Connecticut and Vermont  could be adopted by other jurisdictions nationally or could create a split among the federal courts 
    The ruling reversed the convictions of Todd Newman  a former portfolio manager at Diamondback Capital Management  and Anthony Chiasson  co founder of Level Global Investors 
    A three judge panel held that prosecutors need to prove a trader knew the original source of a tip received a benefit in exchange for the information  It also narrowed what constitutes a benefit  saying it must be of  some consequence  and cannot be only friendship 
    Samuel Lieberman  a defense lawyer involved in a similar challenge  said judges across the country often look to the 2nd Circuit for guidance   
     The 2nd Circuit is the leading appeals court for insider trading   he said   So disregarding it comes with some peril  
    While the pace of prosecutions had looked set to slow from the pace of recent years  the appeals court s ruling could slam the brakes on authorities  efforts to pursue future cases  The decision s effect was quickly felt in New York  where Bharara s office on Friday filed papers asking the court to reconsider the ruling 
    Bharara s office has charged 92 people with insider trading since October 2009 and had won guilty pleas or trial convictions of 86 of them  including Galleon Group hedge fund founder Raj Rajaratnam and former SAC Capital Advisors trader Mathew Martoma  before the 2nd Circuit ruling 
    Many of those cases are unlikely to be affected by the ruling  because the benefits were financial and known to the traders  But some defendants have already sought to vacate guilty pleas and reverse trial convictions in light of it 
    In the first decision to follow the 2nd Circuit ruling  a federal judge in Manhattan on Thursday threw out the guilty pleas of four men accused of illegally dealing in shares ahead of an IBM Corp acquisition 
     A spokeswoman for Bharara declined comment  but in court papers Friday  his office argued the 2nd Circuit ruling  threatens the effective enforcement of the securities laws  
 
    RIPPLE EFFECTS
    The ruling is having ripple effects beyond New York  U S  Securities and Exchange Commission data shows that 52 of the 66 people charged with insider trading civilly or criminally in the 2014 fiscal year were pursued outside of New York 
    In Boston  for example  authorities charged a group of friends who they said exchanged non public information about American Superconductor Corp 
    One of the men  Eric McPhail  learned secret information about the company from one of its senior executives  who belonged to a country club where McPhail was a member 
    Despite being told the information in confidence  McPhail tipped off other golfing buddies  including attorney Douglas Parigian  who reaped  300 000 in illegal profits  authorities say 
    McPhail and Parigian were indicted in July  after earlier being sued by the SEC  which reached settlements with four of the friends for  145 309 
    Both men have moved to dismiss the SEC s case and plan to do the same in the criminal case in light of the 2nd Circuit ruling  said Allison Koury  Parigian s lawyer 
    In court papers  they argue no allegations exist that the executive received what would constitute a benefit under the 2nd Circuit s decision  and that authorities failed to allege Parigian knew about the benefit 
    The U S  Attorney s Office in Boston did not respond to requests for comment  But the SEC has argued since the information was misappropriated  it has to prove a benefit flowed to McPhail  who acted as the tipper 
    The SEC said McPhail had made it clear he  was looking forward to getting paid back   Prosecutors on Wednesday meanwhile filed a superseding indictment that added a line saying he received a benefit from Parigian and others 
    In Santa Ana  California  former Advanced Medical Optics Inc CEO James Mazzo and three co defendants charged with insider trading filed papers arguing prosecutors failed to establish there was a tangible quid pro quo for allegedly tipping ex Baltimore Orioles third baseman Douglas DeCinces about a deal 
    Prosecutors say Mazzo  a close friend of DeCinces  tipped him in advance of Abbott Laboratories   1 36 billion acquisition of the company  enabling him to make  1 3 million in illicit profits 
    DeCinces  in turn  told five other people about the deal  including his business partner David Parker and real estate lawyer Fred Jackson  who made  347 920 and  140 259 respectively trading ahead of the deal  prosecutors say 
    In court papers  prosecutors said the 2nd Circuit ruling is  inconsistent  with the law of the U S  Supreme Court and the 9th U S  Circuit Court of Appeals  which covers California and other Western states  They argue that insider trading includes making a  gift  of confidential information to a relative or friend 
    Before the 2nd Circuit ruling  U S  District Judge Andrew Guilford in Santa Ana previously denied a motion to dismiss by DeCinces that made similar arguments  Late on Friday  he denied the defendants  latest motions  saying with little explanation that he was upholding his earlier decision     Lawyers for the defendants either declined comment or did not respond to requests for comment on Sunday 

But at a Jan  12 hearing  Guilford warned prosecutors that if he did not dismiss the indictment  they needed to be prepared to  pursue their strongest claims   since the issue could still affect the case at the Feb  3 trial or in any appeal ",2015-01-26,Reuters,https://www.investing.com/news/stock-market-news/analysis---ny-insider-trading-ruling-tests-prosecutors-beyond-wall-street-325077,325077
181506,403022,ABT,Drugmaker Abbott says not pursuing an offer for St Jude Medical,news,"By Vidya L Nathan
 Reuters    Drugmaker  Abbott Laboratories   N ABT   knocking down a report in the Financial Times  denied on Thursday that it was preparing a bid for medical device maker  St Jude Medical  Inc  N STJ  
The FT  citing people familiar with the matter  reported that Abbott has been working with advisers for several weeks to line up financing for a  25 billion cash and stock bid for St  Paul  Minnesota based St Jude  St Jude s shares  which jumped 15 percent premarket trading following the report  were up 3 4 percent at  71 72 in early trading 
The company had a market value of about  19 5 billion as of Wednesday s close 
 I can tell you that we are not pursuing an offer for St Jude   Abbott spokesman Scott Stoffel told Reuters 
St Jude did not immediately respond to a request for comment 
A source familiar with Abbott s thinking said he did not believe a deal was seriously contemplated  while Evercore ISI analyst Vijay Kumar said Abbott was more likely to do medium sized deals than a big transaction 
Abbott Chief Executive Miles White said last month that he was interested in acquisitions  including in the device sector  but would be cautious because a flurry of deals in the healthcare industry had pushed up valuations 
Abbott had cash on hand of almost  4 billion as of June 30 
RBC Capital Markets analyst Glenn Novarro said last month that a deal in the region of  5 billion for a device maker was more likely than something larger 
Kumar and  Wells Fargo   NYSE WFC  Securities  Larry Biegelsen said on Thursday they expected Abbott to strike a deal in either the medical device or generic drug industries 
Abbott shares  which had fallen about 2 percent this year up to Wednesday s close  were up 1 8 percent at  44 75 
 This version of the story was refiled to correct syntax in paragraph 5 ",2015-08-27,Reuters,https://www.investing.com/news/stock-market-news/drugmaker-abbott-says-not-pursuing-an-offer-for-st-jude-medical-358009,358009
181516,403032,ABT,Top Ranked Income Stocks To Buy For April 29th,opinion,"Here are four stocks with buy rank and strong income characteristics for investors to consider today  April 29th 
Core Mark Holding Company  Inc   CORE   This fresh and broad line supply solutions marketer has witnessed the Zacks Consensus Estimate for its current year earnings increasing 73 6  over the last 60 days Core Mark Holding Company  Inc  Price and Consensus   This Zacks Rank  1  Strong Buy  company has a dividend yield of 1 2   compared with the industry average of 0   Its five year average dividend yield is 1 1  Core Mark Holding Company  Inc  Dividend Yield  TTM    Ambev S A   ABEV   This beverages and food products manufacturer has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4 8  over the last 60 days Ambev S A  Price and Consensus   This Zacks Rank  2  Buy  company has a dividend yield of 2 7   compared with the industry average of 0 2   Its five year average dividend yield is 2  Ambev S A  Dividend Yield  TTM    Abbott Laboratories  NYSE ABT   ABT   This health care products manufacturer has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 6  over the last 60 days Abbott Laboratories Price and Consensus   This Zacks Rank  2 company has a dividend yield of 1 6   compared with the industry average of 0   Its five year average dividend yield is 2 1  Abbott Laboratories Dividend Yield  TTM    Delta Air Lines  NYSE DAL   Inc   DAL   This scheduled air transportation provider has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1 7  over the last 60 days Delta Air Lines  Inc  Price and Consensus   This Zacks Rank  2 company has a dividend yield of 2 5   compared with the industry average of 0   Its five year average dividend yield is 1 6  Delta Air Lines  Inc  Dividend Yield  TTM    See the  
Find more top income stocks with  
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-04-28,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-income-stocks-to-buy-for-april-29th-200412506,200412506
181522,403038,ABT,Delphi to contest pressure to file U S  taxes despite UK tax base,news," Reuters    Auto parts supplier Delphi Automotive Plc  N DLPH  said it would  vigorously contest  pressure by U S  tax authorities to file taxes in the United States as a domestic company  when its tax base is in the UK 
Delphi  which operates out of Detroit  is one among several American companies locked in a battle with the Internal Revenue Service over the use of offshore tax shelters 
Mylan Inc  O MYL  said on Thursday it would go ahead with the purchase of some non U S  businesses from Abbott Laboratories  N ABT  despite the political opposition to tax inversion deals 
The IRS told Delphi in June that it would be taxed as a U S  company due to the sale of its assets to Delphi Holdings LLP after it emerged from bankruptcy in 2009  Delphi said in a regulatory filing on July 31    
Delphi said it was reincorporated in the UK as a limited liability partnership  which allows it to save tax  The company said it had filed U S  federal partnership tax returns between 2009 and 2011 
 We will continue to prepare and file our financial statements on the basis that neither Delphi Automotive LLP nor Delphi Automotive Plc is a domestic corporation for U S  federal income tax purposes   the company said in the filing 
U S  President Barack Obama and Congressional Democrats have proposed measures to stem the flow of so called  inversions  
The IRS contends that U S  based companies operating globally are manipulating tax laws 
Under the U S  tax code  domestic companies must pay tax on total global income  including income generated in other countries  The workaround for companies is to incorporate in those countries 
Earlier  companies chose Caribbean Islands or Switzerland to set up their tax bases  but Britain is becoming increasingly attractive to companies after the country changed its laws to keep profits reported in other countries out of its tax ambit 
Delphi has also been in the news in recent months because it supplied to General Motors Co  N GM  the defective ignition switches that were linked to at least 13 deaths 

Delphi s shares were up about 1 percent at  67 87 in late morning trading on the New York Stock Exchange on Friday 
 Reporting by Sagarika Jaisinghani and Sweta Singh in Bangalore  Editing by Kirti Pandey ",2014-08-08,Reuters,https://www.investing.com/news/stock-market-news/delphi-to-contest-pressure-to-file-u.s.-taxes-despite-uk-tax-base-302208,302208
181524,403040,ABT,Abbott Labs Profits Up On Growing Nutrition Business,news,"By    Abbott Laboratories NYSE ABT saw its third quarter revenue rise 5 8 percent to  5 1 billion thanks to strong sales of branded pharmaceuticals and nutrition goods  along with a boost in its vision care products  Meanwhile  the drugmaker s profit fell 44 percent to  538 million  or 36 cents per share  from  966 million  or 61 cents per share  in the same period a year ago 
Excluding special items  the company s adjusted earnings were 62 cents per share  which beat analysts  expectations of 59 to 61 cents 
In Wednesday s early trading  Abbott s shares fell 22 cents  or less than one percent  to  42 18 

The company revised its full year adjusted earnings from between  2 19 and  2 29 to between  2 25 to  2 27 
Abbott s nutrition sector  which includes products such as the supplemental drink Ensure  saw a 10 1 percent increase in the last quarter  the Abbott Park  Illinois based health care technology manufacturer announced on Wednesday  More than half of Abbott s sales are in emerging markets 
Abbott has been making big changes to its business recently  Last year  it created AbbVie Inc   which has recently cancelled plans for a  54 billion takeover of Dublin based pharma company Shire PLC amid stricter American tax rules   In July  it made a  5 3 billion agreement to sell its generic drug business to Mylan Inc  according to Bloomberg  In September  it acquired CFR Pharmaceuticals  which increased its presence in Latin America ",2014-10-22,International Business Times,https://www.investing.com/news/stock-market-news/abbott-labs-profits-up-on-growing-nutrition-business-313899,313899
181525,403041,ABT,AbbVie says strong results lessen need for big deal,news,"By Ransdell Pierson   Reuters    AbbVie  which this month abandoned its planned  55 billion purchase of Dublin drugmaker Shire  L SHP   reported impressive quarterly earnings on demand for its Humira arthritis drug and said it could deliver strong long term growth without rushing into another big merger attempt    The underlying growth prospects of AbbVie don t require us to do a deal of that size   AbbVie Chief Executive Richard Gonzalez said in conference call  but added the company was keen on smaller acquisitions  particularly of treatments involving rare diseases  cancer and hepatology   AbbVie shares rose 3 5 percent to  63 35 in morning trading   The Chicago drugmaker  which significantly boosted its full year earnings forecast  said it had earned  506 million  or 31 cents per share  in the third quarter  That compared with  964 million  or 60 cents per share  a year earlier   Excluding special items  including charges for the attempted Shire deal  AbbVie earned 89 cents per share  Analysts on average expected 77 cents  according to Thomson Reuters I B E S   Sales rose 7 8 percent to  5 02 billion   200 million above forecasts    We see today s results as reinforcing our view that AbbVie shares remain well positioned heading into 2015   said JPMorgan analyst Chris Schott  He said AbbVie could win U S  marketing approval within weeks for a combination treatment for hepatitis C that may bolster earnings next year and beyond   AbbVie  spun off early last year from Abbott Laboratories  N ABT   is also testing treatments for cancer  Parkinson s Disease  endometriosis and other diseases   The company had hoped to buy Shire and locate the combined company in Britain to take advantage of the nation s lower tax rate  But AbbVie walked away after tax law changes announced by the U S  Treasury made the tax inversion deal less attractive   Sales of Humira  the world s top selling drug  jumped almost 18 percent to  3 26 billion  They accounted for 65 percent of total sales  underscoring the company s need for other products to broaden its portfolio   Gonzalez attributed Humira s sales growth to the wide range of approved uses of the drug  including for Crohn s disease and psoriasis  and because it is still being introduced in more countries 12 years after its U S  launch   Although Humira s U S  patent lapses in late 2016  AbbVie has said it will take years for other drugmakers to develop and win approval for their own generic versions   A few other AbbVie brands showed strong growth in the quarter  including thyroid hormone replacement drug Synthroid  whose sales rose 24 percent to  200 million   But others declined  including cholesterol treatments and AndroGel testosterone gel  whose sales have been hurt by safety concerns for the drug class   
AbbVie raised its 2014 profit forecast to between  3 25 and  3 27 per share from its prior view of  3 06 to  3 16     Reporting by Ransdell Pierson  Editing by Chizu Nomiyama  James Dalgleish and Lisa Von Ahn ",2014-10-31,Reuters,https://www.investing.com/news/stock-market-news/abbvie-says-strong-results-lessen-need-for-big-deal-315014,315014
181526,403042,ABT,Johnson   Johnson s  7 2 billion claim against Boston Scientific now with U S  judge,news,"By Joseph Ax NEW YORK  Reuters    For more than eight years  Johnson   Johnson  N JNJ  has pursued billions of dollars in damages against Boston Scientific Corp  N BSX  after the latter won a controversial   and ultimately ill fated   bidding war for device maker Guidant  Now the dispute lies in the hands of a federal judge after lawyers for both companies made final presentations on Wednesday at the close of a non jury trial in New York federal court  J J is seeking more than  7 2 billion in damages and interest from Boston Scientific as Guidant s successor  an amount that one analyst has characterized as a  major near term risk  for a company with a market capitalization of about  19 billion as of Wednesday  U S  District Judge Richard Sullivan  who oversaw the trial  did not indicate when he would rule  The dispute stems from 2005  when J J agreed to buy Guidant for  21 5 billion  Under the deal  Guidant was permitted to consider unsolicited competing bids  In late 2005  Boston Scientific announced its intention to make an offer  which was contingent on selling some of Guidant s assets to Abbott Laboratories  N ABT  to satisfy antitrust concerns  J J claims Guidant knowingly violated their contract by providing due diligence directly to Abbott  Without that breach  J J argues  Abbott would have walked away from the deal  scuttling Boston Scientific s bid and leaving Guidant with no competing offers   What made the breach material was that Boston Scientific was not going to make an offer if Abbott was not involved   said Harold Weinberger  a lawyer for J J  David Boies  a lawyer for Boston Scientific  said Guidant relied on the advice of its attorneys in sharing information with Abbott  Boston Scientific eventually acquired Guidant for  27 billion and paid J J a  705 million termination fee  The deal has since been widely panned as too expensive  prompting Boston Scientific to argue that J J dodged a bullet by failing to complete the acquisition and cannot now claim any damages  even if a breach occurred   They have not presented any evidence that they would have been better off   Boies said  Sullivan pressed both sides during more than two hours of closing arguments  At one point  he questioned why J J did not aggressively challenge Guidant as soon as they became aware that Abbott had been given information in January 2006  instead of making subsequent higher bids   There s a glaring absence of the sorts of emails and documents you would expect if you thought you had just been hosed on a multibillion dollar deal   he said  Weinberger said J J was not fully aware of what had occurred until weeks later  after the bidding war ended  Sullivan also told Boies it seemed likely Guidant shareholders would have had no other option but to accept J J s bid absent a formal offer from Boston Scientific  Boies argued  however  that the deal might still have fallen through  citing dissatisfaction among some shareholders over the price  
The case is Johnson   Johnson v  Guidant Corporation  U S  District Court for the Southern District of New York  No  06 7685 ",2015-01-21,Reuters,https://www.investing.com/news/stock-market-news/johnson--amp;-johnson's-$7.2-billion-claim-against-boston-scientific-now-with-u.s.-judge-324535,324535
181539,403055,ABT,Is Abbott Laboratories  ABT  Stock Outpacing Its Medical Peers This Year ,opinion,"Investors interested in Medical stocks should always be looking to find the best performing companies in the group  Has Abbott Laboratories  NYSE ABT  been one of those stocks this year  Let s take a closer look at the stock s year to date performance to find out 
Abbott Laboratories is a member of the Medical sector  This group includes 848 individual stocks and currently holds a Zacks Sector Rank of  3  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months  The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks  ABT is currently sporting a Zacks Rank of  2  Buy  
Over the past three months  the Zacks Consensus Estimate for ABT s full year earnings has moved 0 73  higher  This is a sign of improving analyst sentiment and a positive earnings outlook trend 
Based on the most recent data  ABT has returned 2 20  so far this year  Meanwhile  the Medical sector has returned an average of 0 85  on a year to date basis  This shows that Abbott Laboratories is outperforming its peers so far this year 
To break things down more  ABT belongs to the Medical   Products industry  a group that includes 77 individual companies and currently sits at  150 in the Zacks Industry Rank  This group has gained an average of 5 08  so far this year  so ABT is slightly underperforming its industry in this area 
Investors in the Medical sector will want to keep a close eye on ABT as it attempts to continue its solid performance ",2019-04-18,Zacks Investment Research,https://www.investing.com/analysis/is-abbott-laboratories-abt-stock-outpacing-its-medical-peers-this-year-200408718,200408718
181557,403073,ABT,Wall Street opens up on M A  Citi earnings,news,"By Chuck Mikolajczak NEW YORK  Reuters    U S  stocks opened higher on Monday  boosted by the latest flurry of merger activity as well as strong earnings from Citigroup Inc 
The Dow Jones industrial average rose 69 48 points or 0 41 percent  to 17 013 29  the S P 500 gained 6 98 points or 0 35 percent  to 1 974 55 and the Nasdaq Composite added 24 69 points or 0 56 percent  to 4 440 18 

Citigroup rose 3 3 percent to  48 57 in early trading 
 Reporting by Ryan Vlastelica  Editing by Nick Zieminski ",2014-07-14,Reuters,"https://www.investing.com/news/stock-market-news/wall-street-opens-up-on-m-amp;a,-citi-earnings-294676",294676
181558,403074,ABT,Mylan to buy some Abbott drug assets in  5 3 billion deal,news," Reuters    Generic drugmaker Mylan Inc  O MYL  said it would buy Abbott Laboratories   N ABT  specialty and branded generics business in developed markets outside the United States in an all stock transaction valued at about  5 3 billion 
Mylan s shares were up 7 percent in premarket trade after the announcement of the deal that gives it access to Abbott s key products such as gastroenterology drug Creon  pain drug Brufen and influenza vaccine Influvac 
The deal has also been structured to help Mylan reduce its tax bill by moving its tax address outside the United States  a practice known as tax inversion that has become popular among healthcare companies 
Under the deal  Abbott will transfer the assets to a new public company organized in the Netherlands  after which Mylan will merge with a wholly owned unit of the new company 
Abbott will receive 105 million shares of the combined company  giving it about 21 percent ownership stake 
Reuters had reported on Friday that Mylan was in advanced talks to buy a multi billion dollar portfolio of established products from Abbott 
The deal gives Mylan a portfolio of more than 100 specialty and branded generic pharmaceutical products in five major therapeutic areas including cardio metabolic and gastrointestinal 
Mylan expects the deal to add about  1 9 billion in annual revenue 
Abbott s non U S  specialty and branded generics business has a strong presence in Europe  Japan  Canada  Australia and New Zealand 

Mylan s shares closed at  50 20 on the Nasdaq on Friday  Abbott s shares closed at  41 30 
 Reporting by Shailesh Kuber  Editing by Sriraj Kalluvila ",2014-07-14,Reuters,https://www.investing.com/news/stock-market-news/mylan-to-buy-some-abbott-drug-assets-in-$5.3-billion-deal-294679,294679
181559,403075,ABT,Obama Government Seeks Legislation To Curb Corporate Tax Flight,news,"By    The Barack Obama administration on Tuesday called for immediate legislation to prevent U S  based companies from re incorporating overseas for lower taxes  the Wall Street Journal reported Tuesday 
Treasury Secretary Jacob Lew wrote a letter to Senate Financing Committee Chairman Ron Wyden on Tuesday and called for a  new sense of economic patriotism   urging Congress to clamp down on the  abuse of our tax system   He also stated that U S  based companies should not be allowed to indulge in  inversion  transactions solely for the purpose of changing their tax status 
The White House had earlier proposed similar steps in the budget and called for broad reforms in corporate taxation  In his letter  Lew added that the  President had called for undertaking business tax reforms as a way of improving the investment climate in the U S   He also stated that there was a need to lower the corporate tax rate in the country to make the investment climate in the country more  business friendly  
Many companies seek to reduce their tax burden by relocating to countries with a lower tax rate  They do so by either buying another company in the target country and adopting its domicile  or by establishing a new company in the target country  This process  known as  inversion   has been popular among many pharmaceutical companies in the U S   which have overseas cash they don t want to subject to the 35 percent corporate tax rate prevalent in the U S   which is the highest in the world 
In his letter  Lew also demanded that a legislation to limit corporate tax inversions be implemented retroactively from May 
It isn t yet clear whether the Obama administration is targeting inversion deals that were signed before but not closed by May  or only deals agreed upon since then  Such a law would apply to U S drug maker AbbVie Inc s  NYSE ABBV  deal with Ireland based Shire Plc  NASDAQ SHPG  and Mylan Inc s  NASDAQ MYL  pending deal for Abbott Laboratories   NYSE ABT  overseas generics business 

Fearing unfavorable legislation  many companies have reportedly been adding clauses to merger agreements that would allow them to walk away without paying a penalty if the tax advantage is suddenly taken away  About 50 U S  firms have reincorporated overseas through inversions in the last 10 years  the Journal reported 
Another report from the Journal  citing the findings of a Congressional research panel  stated that the U S  would have received an additional  20 billion over the past decade through corporate taxes  if inversions had not taken place ",2014-07-16,International Business Times,https://www.investing.com/news/economy-news/obama-government-seeks-legislation-to-curb-corporate-tax-flight-295281,295281
181561,403077,ABT,Abbott  ABT  Surpasses Q1 Earnings And Revenue Estimates,opinion,"Abbott  ABT  came out with quarterly earnings of  0 63 per share  beating the Zacks Consensus Estimate of  0 61 per share  This compares to earnings of  0 59 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 28   A quarter ago  it was expected that this maker of infant formula  medical devices and drugs would post earnings of  0 81 per share when it actually produced earnings of  0 81  delivering no surprise 
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Abbott  which belongs to the Zacks Medical   Products industry  posted revenues of  7 54 billion for the quarter ended March 2019  surpassing the Zacks Consensus Estimate by 0 91   This compares to year ago revenues of  7 39 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Abbott shares have added about 5 6  since the beginning of the year versus the S P 500 s gain of 16  
What s Next for Abbott 
While Abbott has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Abbott was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 81 on  7 93 billion in revenues for the coming quarter and  3 20 on  31 79 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Products is currently in the top 37  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-04-16,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-surpasses-q1-earnings-and-revenue-estimates-200407642,200407642
181581,403097,ABT,UPDATE 2 Solvay sees higher 2011 profit as Q1 tops forecast,news,"  REBIT 197 million euros  vs forecast 148 million
   Sales 1 67 billion euros  vs forecast 1 57 billion
   Expects higher chemicals  plastics profits in 2011
 
  Adds detail 
 By Aaron Gray Block
 AMSTERDAM  May 9  Reuters    Belgian chemicals group Solvay
 reported a 79 percent jump in first quarter operating profit 
beating estimates thanks to improved demand and price hikes  and
forecast higher full year 2011 earnings 
  In the context of the globally favourable business climate
and based on its strategy of sustainable and profitable
growth  Solvay expects to improve its annual operating result 
both in chemicals and plastics activities in 2011   it said 
 Recurring earnings before interest and taxes from continuing
operations  REBIT  was 197 million euros   275 million  
compared with a forecast for 148 million in a Reuters poll in
which the highest estimate was 165 million 
 Solvay was wxpected to report full year REBIT of 794 million
euros  ING analyst Jan Hein de Vroe said both the consensus and
his 750 million euro forecast will need to be raised in light of
the first quarter figures 
 Global chemicals firms have reported solid first quarter
earnings reflecting strong demand  especially in Asia  and
because they have been able to raise prices for chemicals and
plastics to more than offset higher costs for raw materials 
such as crude oil  used in many chemicals products 
 Industry leader BASF beat estimates after demand from
carmakers picked up  while French specialty chemicals group
Rhodia  which Solvay is buying for 3 4 billion euros  raised its
2011 forecast 
 Solvay group sales from continuing operations were 1 67
billion euros  up 23 percent from a year ago restated 1 36
billion euros  and against a forecast 1 57 billion euros 
 Solvay said sustained demand had allowed it to raise its
selling prices across its business to offset increased costs of
energy and some raw materials  adding volumes rose 10 percent
and it had raised prices 12 percent 
  The main good news is in caustic soda  where sales improved
41 percent   ING s De Vroe said  Caustic soda is used to make
detergents as well as in the pulp and paper industry 
  They are also talking about improved sales volumes for
vinyls  which is not too bad  although some of this might have
been a bit of restocking ahead of price increases  
 Solvay s plastics unit reported REBIT of 116 million euros 
beating a forecast for 83 5 million  thanks to higher volumes
for both specialty plastics and polyvinyl chloride  PVC   which
is used in construction 
 The PVC market has been problematic for Solvay in recent
quarters due to sluggish construction markets  increased
competition and higher costs 
 In the chemicals unit  record operating profit of 101
million euros also beat estimates of 78 million 
 Solvay s agreed buy out of Rhodia will lift its exposure to
fast growing markets such as China and Brazil to 40 percent and
allow it to further tap into higher margin specialty chemicals 
 Solvay s shares have risen 18 percent since it announced the
deal  as it removed persistent worries over the type of
acquisition the company might make following the sale of its
drugs unit to Abbott Laboratories in February 2010 
  Reporting by Aaron Gray Block  Editing by Sara Webb and Dan
Lalor 
   1   0 7158 euro ",2011-05-10,Reuters,https://www.investing.com/news/commodities-news/update-2-solvay-sees-higher-2011-profit-as-q1-tops-forecast-214495,214495
181582,403098,ABT,U S  futures mixed  focus on Fed decision  Dow Jones down 0 33 ,news,Investing com   U S  stock futures pointed to a mixed open on Wednesday  as markets awaited the Federal Reserve s rate decision later in the day while concerns over the restructuring of Greek debt weighed on investor confidence   Ahead of the open  the Dow Jones Industrial Average futures pointed to a fall of 0 33   S P 500 futures signaled a 0 29  decline  while the Nasdaq 100 futures indicated a 0 58  gain Concerns over a potential Greek default persisted as talks on a deal to help restructure the country s sovereign debt stalled on Tuesday Sentiment briefly found support after data showed that German business confidence improved more than expected in January  moving higher for the third consecutive month  Apple was expected to be in focus as the company s quarterly results were significantly better than  expected after U S  consumers bought near unprecedented numbers of iPhones and iPads  Apple shares surged 7 22  in pre market trade  Meanwhile  aircraft makers were also slated to be active as Nordic budget carrier Norwegian Air Shuttle ordered 222 narrow body aircraft worth a total of USD21 5 billion  It split its order between Airbus and Boeing  which was due to report fourth quarter earnings later in the day Elsewhere  U S  oil giant Exxon Mobil resumed work on Wednesday at its USD15 7 billion liquefied natural gas project in Papua New Guinea  a day after a landslide swept through two nearby villages killing at least four people  Exxon shares edged up 0 08  in after hour trading Also in corporate news  Roche Holding is offering USD5 7 billion in cash to buy U S  gene sequencing company Illumina Inc in a hostile takeover bid that marks a major play by the Swiss drug maker into the gene technology field Other stocks in focus included United Technologies  Textron  Abbott Laboratories and Xerox  all due to release earnings reports later in the day Across the Atlantic  European stock markets were sharply lower  The EURO STOXX 50 plunged 1 05   France s CAC 40 tumbled 0 81   Germany s DAX dropped 0 58   while Britain s FTSE 100 declined 0 81  During the Asian trading session  Hong Kong s Hang Seng Index was closed due to the Chinese Lunar New Year holiday  while Japan s Nikkei 225 Index rallied 1 12  ,2012-01-25,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-futures-mixed,-focus-on-fed-decision;-dow-jones-down-0.33-229533",229533
181586,403102,ABT,What Makes Abbott  ABT  A New Buy Stock,opinion,"Abbott  ABT  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank  2  Buy   This upgrade primarily reflects an upward trend in earnings estimates  which is one of the most powerful forces impacting stock prices 
The sole determinant of the Zacks rating is a company s changing earnings picture  The Zacks Consensus Estimate    the consensus of EPS estimates from the sell side analysts covering the stock    for the current and following years is tracked by the system 
Since a changing earnings picture is a powerful factor influencing near term stock price movements  the Zacks rating system is very useful for individual investors  They may find it difficult to make decisions based on rating upgrades by Wall Street analysts  as these are mostly driven by subjective factors that are hard to see and measure in real time 
Therefore  the Zacks rating upgrade for Abbott basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  and the near term price movement of its stock are proven to be strongly correlated  That s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their bulk investment action then leads to price movement for the stock 
Fundamentally speaking  rising earnings estimates and the consequent rating upgrade for Abbott imply an improvement in the company s underlying business  Investors should show their appreciation for this improving business trend by pushing the stock higher 
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  so it could be truly rewarding if such revisions are tracked for making an investment decision  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Abbott
This maker of infant formula  medical devices and drugs is expected to earn  3 20 per share for the fiscal year ending December 2019  which represents a year over year change of 11 1  
Analysts have been steadily raising their estimates for Abbott  Over the past three months  the Zacks Consensus Estimate for the company has increased 0 3  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Abbott to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-03-19,Zacks Investment Research,https://www.investing.com/analysis/what-makes-abbott-abt-a-new-buy-stock-200399192,200399192
181587,403103,ABT,Is Abbott Laboratories  ABT  Outperforming Other Medical Stocks This Year ,opinion,"Investors focused on the Medical space have likely heard of Abbott Laboratories  NYSE ABT   but is the stock performing well in comparison to the rest of its sector peers  By taking a look at the stock s year to date performance in comparison to its Medical peers  we might be able to answer that question 
Abbott Laboratories is one of 833 individual stocks in the Medical sector  Collectively  these companies sit at  2 in the Zacks Sector Rank  The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups 
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks  This system has a long record of success  and these stocks tend to be on track to beat the market over the next one to three months  ABT is currently sporting a Zacks Rank of  2  Buy  
Within the past quarter  the Zacks Consensus Estimate for ABT s full year earnings has moved 0 28  higher  This signals that analyst sentiment is improving and the stock s earnings outlook is more positive 
Based on the most recent data  ABT has returned 10 55  so far this year  In comparison  Medical companies have returned an average of 10 46   As we can see  Abbott Laboratories is performing better than its sector in the calendar year 
Looking more specifically  ABT belongs to the Medical   Products industry  which includes 77 individual stocks and currently sits at  74 in the Zacks Industry Rank  Stocks in this group have gained about 13 70  so far this year  so ABT is slightly underperforming its industry this group in terms of year to date returns 
Investors in the Medical sector will want to keep a close eye on ABT as it attempts to continue its solid performance ",2019-03-19,Zacks Investment Research,https://www.investing.com/analysis/is-abbott-laboratories-abt-outperforming-other-medical-stocks-this-year-200399399,200399399
181610,403126,ABT,US STOCKS Dow nears 10 000 on strong profits,news,"  JPMorgan  Intel results boost investor confidence
    September retail sales better than expected
    Dow up 1 2 pct  S P 500 up 1 3 pct  Nasdaq up 1 2 pct
  Updates to late morning  changes byline 
 By Angela Moon
 NEW YORK  Oct 14  Reuters    The Dow Jones industrials
neared the 10 000 milestone on Wednesday for the first time in
a year as robust results from JPMorgan Chase   Co and Intel
Corp boosted the outlook for earnings 
 Major indexes gained more than 1 percent  and the Dow s
reclaiming the psychological 10 000 level could convince some
doubters of the durability of the stock market s seven month
rally 
 JPMorgan  the first major U S  bank to report quarterly
earnings  said profit rose sharply as underwriting revenue at
its investment bank offset deeper losses on credit cards and
other consumer loans 
  We are seeing new highs  thanks to Intel last night and
JPMorgan this morning  People are more comfortable with seeing
this market rally further   said Steve Goldman  market
strategist at Weeden   Co in Greenwich  Connecticut 
 JPMorgan s shares rose 3 8 percent to  47 37 and chip maker
Intel s shares added 3 percent to  21 10 
 The Dow Jones industrial average was up 114 12 points  or
1 16 percent  at 9 985 18  The Standard   Poor s 500 Index   
 rose 13 42 points  or 1 25 percent  at 1 086 61  The Nasdaq
Composite Index  was up 25 93 points  or 1 21 percent  at
2 165 82 
 The Dow came within 10 points of 10 000 and was last at
that level in October 2008 
 The CBOE Volatility Index  a measure of anticipated
volatility using options  fell 2 83 percent to its lowest level
since early September 2008  which was just before the collapse
of investment bank Lehman Brothers 
 Underscoring optimism that the worst of the recession was
over  a government report showed sales at U S  retailers fell
by a less than expected 1 5  percent in September  Economists
in a Reuters poll had forecast a 2 1 percent drop 
 The S P retail index rose 1 5 percent 
 Shares of Johnson   Johnson  however  fell 0 9 percent to
 60 49  after rival Abbott Laboratories Inc posted
better than expected third quarter profit  Abbott rose 3 2
percent to  51 25 
 Oil rose for a fifth straight day on Wednesday to a 2009
high above  75 a barrel  boosted by a weak U S  dollar and
surprisingly strong trade data in China  the world s
second largest oil user 
 The Federal Reserve s minutes from its meeting of Sept 
22 23 will be released at 2 p m   1800 GMT   with investors
looking for signs of the Fed s thinking on the prospects for
inflation 
  Reporting by Angela Moon  Editing by Kenneth Barry ",2009-10-14,Reuters,"https://www.investing.com/news/equities-news/us-stocks-dow-nears-10,000-on-strong-profits-94056",94056
181628,403144,ABT,UPDATE 1 Nycomed  Japan firm circle Solvay drug unit source,news,"  Nycomed  Japanese suitor looking at whole unit  source
   Abbott interested in TriCor  other parts  source
   Process in early second round  source
  
  adds detail  background  shares 
 By Quentin Webb
 LONDON  July 15  Reuters    Private equity owned Nycomed and
a Japanese drugs company are in the early second round of an
auction for all of Solvay s pharmaceuticals business  a person
familiar with the matter said on Wednesday 
 Analysts reckon the Belgian chemicals and drug maker s
Solvay Pharmaceuticals unit could fetch 5 billion euros   7
billion  or more  although Solvay has said it is open to other
options such as a partnership or flotation 
 Abbott Laboratories  Solvay s partner for its
cholesterol fighting blockbuster TriCor  is not seeking to buy
the whole unit  but the U S  drugmaker is interested in
acquiring TriCor and possibly other parts of Solvay s drugs
business  the person added 
 Solvay hopes to conclude a deal by the end of the European
summer  the person said  but has yet to set a deadline for
binding  second round bids  The person declined to identify the
Japanese suitor 
 Shares in Solvay rose 6 percent by 1107 GMT to 61 92 euros a
share 
 The Financial Times earlier reported Solvay had whittled
down its list of bidders to two    Nycomed  and Abbott  which
was bidding only for TriCor 
 Bidders have begun due diligence and have held initial
meetings with management  and will continue to investigate the
business  including making site visits  the first source and a
second person  also familiar with the matter  said 
 For Nycomed  whose biggest owner is Nordic Capital  Solvay
could offer big possible cost savings through European
synergies  A Japanese bidder would gain a European platform 
 Nycomed declined to comment  Abbott was not immediately
available to comment  Solvay reiterated it was conducting a
strategic review of the business but declined to comment
further 
 In Japan  spokesmen for Astellas Pharma Inc and Eisai Co Ltd
 declined to comment  A Takeda Pharmaceutical Co Ltd spokesman
referred to a May 29 statement that the company would not bid
for the Solvay unit 
 additional reporting by Philip Blenkinsop in Brussels  Sam
Cage in Zurich  and Ritsuko Shimizu in Tokyo  Editing by Erica
Billingham  John Stonestreet ",2009-07-15,Reuters,"https://www.investing.com/news/equities-news/update-1-nycomed,-japan-firm-circle-solvay-drug-unit-source-71737",71737
181629,403145,ABT,US STOCKS Markets advance on increased M A activity,news,"  Xerox will acquire ACS for about  6 4 billion
   Abbot to buy Solvay s drugs unit for  6 6 billion
   DJIA headed for best quarter since 1998
   Dow up 1 3 pct  S P up 1 6 pct  Nasdaq up 2 pct
  Updates to midday  changes byline 
 By Ryan Vlastelica
 NEW YORK  Sept 28  Reuters    U S  stocks rallied on Monday
after three straight days of losses as several mergers lifted
investor confidence 
 An uptick in mergers and acquisitions is considered a
bullish sign as it suggests companies are more optimistic about
the economy and see values in the market 
 A number of companies announced large takeover deals  Xerox
agreed to buy Affiliated Computer Services Inc for  6 4 billion
while Covidien said it would buy Aspect Medical for about  210
million 
 Affiliated shares climbed 14 percent to  53 92 while Aspect
soared 55 percent to  11 90 
 With Monday s gains  the Dow Jones industrial average is up
nearly 16 percent in the quarter so far  which would make it
its best such period since the fourth quarter of 1998 
 Abbott Laboratories gained 3 1 percent to  48 80 after it
said it would pay  6 6 billion for the drugs unit of Solvay 
The purchase gives Abbott full control of its Belgian
development partner s cholesterol treatments and exposure to
emerging markets 
  Its encouraging that companies are taking these actions 
even if it is in an environment of cheap money   said Joseph
Battipaglia  market strategist at Stifel Nicolaus in Yardley 
Pennsylvania 
  Plus  we had some pretty solid moves to the downside last
week  so it doesn t surprise me that we re getting a bounce
today  
 A Jewish holiday observed Monday and the end of the third
quarter two days later could translate into thin volume and
volatility as fund managers reposition their assets amid fewer
market participants  investors said 
 The Dow Jones industrial average gained 128 33 points  or
1 33 percent  to 9 793 52  The Standard   Poor s 500 Index rose
17 06 points  or 1 63 percent  to 1 061 44  The Nasdaq
Composite Index climbed 42 38 points  or 2 03 percent  to
2 133 30 
 The Dutch biotechnology firm Crucell said Johnson   Johnson bought 14 6 million new Crucell shares for over  400 million
as part of a flu vaccine development deal 
 Crucell shares fell 5 6 percent to  22 37 on the Nasdaq 
 China Unicom said it would sell Apple Inc s iPhone in
China  starting in October  France Telecom s Orange also said
it would sell the product later this year 
 Shares of Apple rose 1 9 percent to  185 80 
 Gander Mountain shares surged 35 percent to  5 16 after it
said it intends to go private  Under the terms of the deal  two
of Gander s largest shareholders will buy out stakes held by
the remaining holders 
 The Federal Reserve Bank of Chicago said its National
Activity Index was minus 0 9 in August  but its three month
moving average of economic indicators improved for the seventh
straight month  rising to its highest level since June 2008 ",2009-09-28,Reuters,https://www.investing.com/news/equities-news/us-stocks-markets-advance-on-increased-m-a-activity-90421,90421
181640,403156,ABT,Why Is Abbott  ABT  Up 6  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Abbott  ABT   Shares have added about 6  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Abbott due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Abbott Posts In Line Q4 Earnings  Provides  19 ViewAbbott reported fourth quarter 2018 adjusted earnings from continuing operations of 81 cents per share  in line with the Zacks Consensus Estimate  The bottom line improved 9 5  year over year and fell within the company s guided range of 80 82 cents  Reported earnings from continuing operation in the quarter came in at 37 cents against the year ago loss of 48 cents per share Full year adjusted EPS was  2 88  a 15 2  improvement from the year ago period  However  it missed the Zacks Consensus Estimate by a penny Fourth quarter worldwide sales came in at  7 77 billion  up 2 3  year over year on a reported basis  The top line remained slightly below the Zacks Consensus Estimate of  7 79 billion On an organic basis  adjusting for the impact of foreign exchange as well as certain acquisitions and divestments   sales increased 6 4  year over year in the reported quarter For 2018  sales were  30 6 billion  up 11 6  on a reported basis and up 7 3  on an organic basis from 2017  The top line remained in line with the Zacks Consensus Estimate Quarter in DetailAbbott operates through four segments  namely Established Pharmaceuticals Division  EPD   Medical Devices  Nutrition and Diagnostics In the fourth quarter  EPD sales dropped 4 8  on a reported basis  improved 3 6  on an organic basis  to  1 09 billion  This included an 8 4  adverse impact from currency fluctuations  Sales in the key emerging markets declined 6 2  year over year on a 10 5  adverse impact of foreign exchange  Organically  sales improved 4 3  in this market The Medical Devices business sales increased 6 7  on a reported basis to  2 92 billion  On an organic basis  sales grew 9  Cardiovascular and Neuromodulation sales reportedly  up 4 8  on an organic basis  rose 6 7  on double digit growth in Electrophysiology and Structural Heart In Electrophysiology  growth was led by strong performance in cardiac mapping and ablation catheters  Within Structural Heart  growth was driven by several product areas across Abbott s broad portfolio  including AMPLATZERPFO Occluder and MitraClip Diabetes Care sales improved 28 3   up 32 4  organically   buoyed consistent consumer uptake of FreeStyle Libre  the revolutionary continuous glucose monitoring system of Abbott Nutrition sales were down 0 4  year over year on a reported basis  up 3 6  on an organic basis  to  1 78 billion  Pediatric Nutrition sales increased 3 7  on an organic basis  Adult Nutrition sales were up 3 5  organically Diagnostics sales were up 2 9  year over year on a reported basis  up 7 4  on a comparable operational basis  to  1 96 billion  Core Laboratory Diagnostics sales grew 9 4  while Point of Care Diagnostics slipped 5 1   on an organic basis  Molecular Diagnostics sales were up 3 8  banking on strong growth in the infectious disease testing business  Rapid Diagnostics recorded sales of  548 million  driven by solid contributions from cardiometabolic testing 2019 GuidanceAbbott has initiated its 2019 guidance Adjusting for certain net specified items for the full year  adjusted earnings from continuing operations are expected in the band of  3 15  3 25  The Zacks Consensus Estimate of  3 19 remains within this projected range  Organic sales growth is expected in the range of 6 5   7 5   The Zacks Consensensus Estimate for the top line is pegged at  32 03 billion The company has also provided first quarter 2019 adjusted earnings per share outlook  It expects to report adjusted earnings from continuing operations in the range of 60 62 cents  The consensus mark of 66 cents falls outside the predicted range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  5 72  due to these changes 
VGM Scores
Currently  Abbott has a nice Growth Score of B  a grade with the same score on the momentum front  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Abbott has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-02-21,Zacks Investment Research,https://www.investing.com/analysis/why-is-abbott-abt-up-6-since-last-earnings-report-200391536,200391536
181644,403160,ABT,US STOCKS Wall St rises  led by financials and commodity shares,news,"  Technology shrs up  healthcare  consumer staples down
   Goldman rises after broker comment
   Dow up 0 4 pct  S P 500  Nasdaq both up 0 9 pct
  Updates to mid afternoon  changes byline 
 By Rachel Chang
 NEW YORK  July 9  Reuters    U S  stocks rose on Thursday
as investors snapped up beaten down technology and commodity
shares  while a positive broker comment on Goldman Sachs
boosted the financial sector 
 Investors bought shares of technology and commodity related
companies as they moved out of defensive shares  including
healthcare and consumer staples  which had led the market
higher recently due to uncertainty about the economy 
  It s a reversal of what we ve seen the last couple days 
It s a little bit of sector rotation evening things up   said
Paul Nolte  director of investments at Hinsdale Associates in
Hinsdale  Illinois 
 Within the tech sector  KLA Tencor Corp shot up 5 1 percent
to  26 43 after the chipmaker was upgraded to  overweight  by
Barclays  The PHLX semiconductor index gained 3 5 percent 
 Nolte said the comment on Goldman Sachs Group Inc added a
positive tone to the market 
 Goldman rose 4 3 percent to  144 46 after its stock was
upgraded to  buy   and earnings estimates were raised by Banc
of America Securities Merrill Lynch  The S P financial sector
led the S P 500 with a gain of 2 2 percent 
 The Dow Jones industrial average was up 36 12 points  or
0 44 percent  at 8 214 53  The Standard   Poor s 500 Index rose
7 68 points  or 0 87 percent  at 887 24  The Nasdaq Composite
Index added 15 36 points  or 0 88 percent  at 1 762 53 
 Stocks briefly pared gains following results from a
Treasury bond auction that capped a week of strong demand for
the growing government debt 
 Energy shares rose  with the S P energy index up 1 7
percent as crude oil futures edged up  Oil giant Chevron Corp
was up 1 percent to  63 34  The oil giant is expected to report
interim quarterly results later Thursday 
 Shares of healthcare companies were the biggest drag  with
Dow component Merck   Co Inc down 3 3 percent to  27 13 on
speculation its Zetia cholesterol drug fared poorly in a
clinical trial comparing it to a drug from Abbott Laboratories ",2009-07-09,Reuters,"https://www.investing.com/news/equities-news/us-stocks-wall-st-rises,-led-by-financials-and-commodity-shares-70318",70318
181645,403161,ABT,US STOCKS SNAPSHOT Tech  commodity stocks lift S P 500  Nasdaq,news,"NEW YORK  July 9  Reuters    The S P 500 and the Nasdaq
rose on Thursday as investors rotated into beaten down
technology and commodity shares from healthcare and consumer
staples  while a positive broker comment on Goldman Sachs
boosted the financial sector 
   But the Dow industrials were flat  weighed by Merck   Co
Inc  which fell 3 7 percent to  27 01 on speculation its Zetia
cholesterol drug fared poorly in a clinical trial comparing it
to a drug from Abbott Laboratories 
   The Dow Jones industrial average rose 4 76 points  or
0 06 percent  at 8 183 17  The Standard   Poor s 500 Index
gained 2 97 points  or 0 34 percent  at 882 53  The Nasdaq
Composite Index added 5 38 points  or 0 31 percent  at
1 752 55 
  Reporting by Chuck Mikolajczak  Editing by Leslie Adler ",2009-07-09,Reuters,"https://www.investing.com/news/equities-news/us-stocks-snapshot-tech,-commodity-stocks-lift-s-p-500,-nasdaq-70348",70348
181646,403162,ABT,European Markets Advance For The Third Consecutive Day,news,"The Forex Trader Portal
Current Futures  Dow  33 00  S P  3 50  NASDAQ  17 20European markets are trading in the green as a number of companies reported better than expected results throughout the second quarter  However  the S P futures traded almost flat during the overnight session  after absorbing a 1  move higher in the after market on Tuesday  S P futures had a 3 points range  0 3   during the overnight session  trading near to Tuesday s high  Despite this  the S P futures market had a very strong momentum during the late U S  session  surging by almost 1  after Intel reported better than expected earnings throughout the second quarter  This lifted the Asian markets  and helped the technology stocks become the top gainers in Europe  something that does not happen too often in the current economic climate The German Dax had only one component in decline  while in the U K   the FTSE only had six companies that were trading in the red  out of the 102 members  In addition  both European indexes advanced for the third consecutive day  something not seen over the last few weeks Later in the day  the following U S  companies will report  AMR Corporation  Abbott Laboratories  Crown Holdings  Landstar System  W W  Grainger  Wolverine World Wide and Xilinx Overnight  the U K  FTSE advanced 51 97 points  1 23   to 4 289 65  while t he German Dax gained 70 69 points  1 48   to 4 852 38Crude oil for August delivery was recently trading at  60 20 per barrel  up by  0 70  Wednesday is the fourth consecutive day in which crude oil has swung around the  60 benchmarkGold for August delivery was recently trading higher by  6 10 to  928 90  Gold is trading just below a trend line that connects the Jun 10 09 and the Jul 01 09 highsTeamLFB provides forex related market analysis and trade signals",2009-07-15,LFB Forex,https://www.investing.com/news/forex-news/european-markets-advance-for-the-third-consecutive-day-71717,71717
181650,403166,ABT,Johnson   Johnson  JNJ  To Acquire Auris Health For  3 4B ,opinion,"Johnson   Johnson s   NYSE JNJ   robotic surgery and medical device division  Ethicon entered into a definitive agreement to acquire Auris Health  Inc   a developer of robotic technologies focused on lung cancer  for approximately  3 4 billion in cash  If certain milestones are achieved  Auris could also receive as much as  2 35 billion more from the deal  The transaction is expected to close by the end of the second quarter of 2019  subject to customary closing conditions  
J J s stock has gained 6 5  in the past year compared with growth of 9 9  recorded by the 

 
With this acquisition  J J will gain access to robotics along with potential for growth and expansion into other interventional applications  According to J J  Auris s technology will help the former develop a digital solution addressing different parts of patients  lung cancer treatment  Auris developed the Monarch Platform  a medical device that can help physicians access nodules in patients  lungs to diagnose and target treatments 
Upon completion of the deal  Frederic Moll  M D   CEO and Founder of Auris Health  and a visionary in the field of surgical robotics  will be joining J J 
J J will continue to make investments to make the surgical experience better by connecting digital solutions  In this endeavor  Auris s technology will support J J s vision of becoming a world leader across the continuum of surgical approaches  including open  laparoscopic  robotic and endoluminal 
J J previously forayed into surgical robotics by forming Verb Surgical  a joint venture with Alphabet s Verily unit  in 2015  Last year  J J acquired Orthotaxy  a privately held developer of robotic assisted surgery software 
J J struck several deals  which should boost the top line  In June 2017  J J acquired Swiss biotech Actelion for  30 billion  which diversified its revenues in the pulmonary arterial hypertension  PAH  category and will bolster long term growth  In February 2017  J J acquired Abbott s   NYSE ABT   vision care business  Abbott Medical Optics for  4 325 billion  which has strengthened the former s Medical Device segment Johnson   Johnson Price

    
Zacks Rank and Stocks to Consider
J J currently has a Zacks Rank  3  Hold  
Some better ranked stocks from the same space are GlaxoSmithKline   NYSE GSK   and Bristol Myers Squibb   NYSE BMY    While GlaxoSmithKline sports a Zacks Rank  1  Strong Buy   Bristol Myers carries a Zacks Rank  2  Buy   You can see  
GlaxoSmithKline s earnings per share estimates have increased from  2 86 to  2 95 for 2019 and from  2 94 to  3 01 for 2020 in the past 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters  with average of 3 74  
Bristol Myers earnings per share estimates have increased from  4 07 to  4 16 for 2019 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 14 26  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ",2019-02-14,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-to-acquire-auris-health-for-34b-200388465,200388465
181660,403176,ABT,Here s Why Momentum Investors Will Love Abbott  ABT ,opinion,"Momentum investing is all about the idea of following a stock s recent trend  which can be in either direction  In the  long  context  investors will essentially be  buying high  but hoping to sell even higher   And for investors following this methodology  taking advantage of trends in a stock s price is key  once a stock establishes a course  it is more than likely to continue moving in that direction  The goal is that once a stock heads down a fixed path  it will lead to timely and profitable trades 
Even though momentum is a popular stock characteristic  it can be tough to define  Debate surrounding which are the best and worst metrics to focus on is lengthy  but the Zacks Momentum Style Score  part of the Zacks Style Scores  helps address this issue for us 
Below  we take a look at Abbott  ABT   a company that currently holds a Momentum Style Score of B  We also talk about price change and earnings estimate revisions  two of the main aspects of the Momentum Style Score 
It s also important to note that Style Scores work as a complement to the Zacks Rank  our stock rating system that has an impressive track record of outperformance  Abbott currently has a Zacks Rank of  2  Buy   Our research shows that stocks rated Zacks Rank  1  Strong Buy  and  2  Buy  and Style Scores of A or B outperform the market over the following one month period 
You can see the current list of Zacks  1 Rank Stocks here    
Set to Beat the Market 
In order to see if ABT is a promising momentum pick  let s examine some Momentum Style elements to see if this maker of infant formula  medical devices and drugs holds up 
A good momentum benchmark for a stock is to look at its short term price activity  as this can reflect both current interest and if buyers or sellers currently have the upper hand  It s also helpful to compare a security to its industry  this can show investors the best companies in a particular area 
For ABT  shares are up 1 7  over the past week while the Zacks Medical   Products industry is up 0 91  over the same time period  Shares are looking quite well from a longer time frame too  as the monthly price change of 6 15  compares favorably with the industry s 4 66  performance as well 
Considering longer term price metrics  like performance over the last three months or year  can be advantageous as well  Over the past quarter  shares of Abbott have risen 3 68   and are up 30 32  in the last year  In comparison  the S P 500 has only moved  3 05  and 6 96   respectively 
Investors should also pay attention to ABT s average 20 day trading volume  Volume is a useful item in many ways  and the 20 day average establishes a good price to volume baseline  a rising stock with above average volume is generally a bullish sign  whereas a declining stock on above average volume is typically bearish  ABT is currently averaging 6 200 330 shares for the last 20 days 
Earnings Outlook
The Zacks Momentum Style Score also takes into account trends in estimate revisions  in addition to price changes  Please note that estimate revision trends remain at the core of Zacks Rank as well  A nice path here can help show promise  and we have recently been seeing that with ABT 
Over the past two months  7 earnings estimates moved higher compared to 1 lower for the full year  These revisions helped boost ABT s consensus estimate  increasing from  3 19 to  3 20 in the past 60 days  Looking at the next fiscal year  4 estimates have moved upwards while there have been 1 downward revision in the same time period 
Bottom Line
Taking into account all of these elements  it should come as no surprise that ABT is a  2  Buy  stock with a Momentum Score of B  If you ve been searching for a fresh pick that s set to rise in the near term  make sure to keep Abbott on your short list ",2019-02-10,Zacks Investment Research,https://www.investing.com/analysis/heres-why-momentum-investors-will-love-abbott-abt-200386300,200386300
181661,403177,ABT,Top Ranked Momentum Stocks To Buy For February 11th,opinion,"Here are three stocks with buy rank and strong momentum characteristics for investors to consider today  February 11th Apartment Investment and Management Company  AIV   This real estate investment trust has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 4  over the last 60 days Apartment Investment and Management Company Price and Consensus   Apartment Investment s shares gained 8 9  over the last one month more than S P 500 s gain of 4 9   The company possesses a  of B 
Apartment Investment and Management Company Price   ABIOMED  Inc   ABMD   This developer and seller of medical devices has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 2  over the last 60 days 
ABIOMED  Inc  Price and Consensus   ABIOMED s shares gained 8 2  over the last one month  The company possesses a Momentum Score of A 
ABIOMED  Inc  Price   Abbott Laboratories  NYSE ABT   ABT   This developer and manufacturer of health care products has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 3  over the last 60 days 
Abbott Laboratories Price and Consensus   Abbott Laboratories  shares gained 7 4  over the last one month  The company possesses a Momentum Score of B 
Abbott Laboratories Price   See the 
Learn more about the  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-02-11,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-momentum-stocks-to-buy-for-february-11th-200386426,200386426
181670,403186,ABT,Abbott  ABT  Upgraded To Buy  Here s Why,opinion,"Investors might want to bet on Abbott  ABT   as it has been recently upgraded to a Zacks Rank  2  Buy   This rating change essentially reflects an upward trend in earnings estimates    one of the most powerful forces impacting stock prices 
A company s changing earnings picture is at the core of the Zacks rating  The system tracks the Zacks Consensus Estimate    the consensus measure of EPS estimates from the sell side analysts covering the stock    for the current and following years 
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts  since these are mostly driven by subjective factors that are hard to see and measure in real time  In these situations  the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near term stock price movements 
As such  the Zacks rating upgrade for Abbott is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  and the near term price movement of its stock are proven to be strongly correlated  That s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their bulk investment action then leads to price movement for the stock 
Fundamentally speaking  rising earnings estimates and the consequent rating upgrade for Abbott imply an improvement in the company s underlying business  Investors should show their appreciation for this improving business trend by pushing the stock higher 
Harnessing the Power of Earnings Estimate Revisions
As empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  tracking such revisions for making an investment decision could be truly rewarding  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Abbott
This maker of infant formula  medical devices and drugs is expected to earn  3 20 per share for the fiscal year ending December 2019  which represents a year over year change of 11 1  
Analysts have been steadily raising their estimates for Abbott  Over the past three months  the Zacks Consensus Estimate for the company has increased 0 3  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Abbott to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-01-27,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-upgraded-to-buy-heres-why-200379983,200379983
181678,403194,ABT,Is A Surprise Coming For Abbott  ABT  This Earnings Season  ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories   NYSE ABT   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Abbott is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for ABT in this report In fact  the Most Accurate Estimate for the current quarter is currently higher than the broader Zacks Consensus Estimate of 81 cents per share  This suggests that analysts have very recently bumped up their estimates for ABT  giving the stock a Zacks Earnings ESP of  0 25  heading into earnings season Abbott Laboratories Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that ABT has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Abbott  and that a beat might be in the cards for the upcoming report Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-17,Zacks Investment Research,https://www.investing.com/analysis/is-a-surprise-coming-for-abbott-abt-this-earnings-season-200377137,200377137
181679,403195,ABT,What Lies Ahead For Abbott  ABT  Stock This Earnings Season ,opinion,Abbott Laboratories   NYSE ABT   is slated to report fourth quarter 2018 results  before the market opens on Jan 23  In the last reported quarter  the company s earnings per share exceeded the Zacks Consensus Estimate by 1 35   Moreover  Abbott delivered positive surprises in the trailing four reported quarters  the average being 1 82  Let s see how things are shaping up for this announcement Factors at PlayOver the past few quarters  Abbott has been riding high on a healthy growth curve within its Diabetes Care business  The company has been hogging the limelight for developments in the flagship  sensor based continuous glucose monitoring  CGM  system   FreeStyle Libre System In the United States  the company received an FDA approval for a 14 day sensor with a shorter one hour warm up  making Libre the longest lasting wearable glucose sensor available  Meanwhile in Europe  the company obtained a CE Mark for FreeStyle Libre 2 system  Both developments should contribute strongly to the company s top line in the yet to be reported quarter Abbott Laboratories Price and EPS Surprise   Per a recent data  the strength of Libre users has now crossed 1 million across the globe  representing an unprecedented level of patient adoption in the industry  This in turn  has firmly boosted the company s top line numbers in recent times  above 30  growth for the last four consecutive reported quarters         The Zacks Consensus Estimate of  544 million for Diabetes Care revenues indicates a surge of 31 7  from the year ago period s level In sync with the prior reported quarter  Abbott is anticipated to gain from a strong performance by the Established Pharmaceuticals Division  EPD  business  which has been recording operational sales growth over the last few quarters  According to Abbott  its EPD business is growing at a faster pace than the market rate across several of its priority countries including India and China  Management expects mid single digit sales growth during the fourth quarter 2018  reflecting a difficult comparison in non core other business segment in relation to the year ago quarterly figure when sales strongly soared to double digits growth Currently  the Zacks Consensus Estimate of  1 13 billion for EPD revenues shows a 1 7  slip from the year earlier period s number We are upbeat about the consistently sturdy Diagnostics business  courtesy of solid contributions from all sub segments  namely Core Laboratories Diagnostics  Molecular Diagnostics and Point of Care  We are impressed by the accelerated pace of the company s Alinity launch in Europe  driven by strong competitive win rates and even more robust retention rates  This business is growing more rapidly than its market rate  Per Abbott  it is well positioned for sustainable growth in years to come based on the company s rollout of the full suite of Alinity systems across additional geographies including the United States Moreover  management estimates Rapid Diagnostics to contribute more than  2 billion in 2018  The Zacks Consensus Estimate for Core Laboratory Diagnostic revenues of  1 14 billion depicts a 3 6  improvement from the registered figure in the comparable quarter last year We also encouragingly note that Nutrition is Abbott s most speedily growing business owing to aging population  increasing rate of chronic diseases and the rise of the middle class in the emerging markets  Furthermore  Abbott s pediatric nutrition business continues to thrive in the United States  For the fourth quarter  the company currently projects low to mid single digit sales growth What the Model SuggestsOur proven Zacks model clearly shows that a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive Earnings ESP  You can uncover the best stocks to buy or sell before they re reported with our Earnings ESP Filter Abbott has a Zacks Rank  3  which increases the predictive power of ESP  and an Earnings ESP of  0 25   This combination implies that the company is likely to beat on earnings this reporting cycle  The Zacks Consensus Estimate for the bottom line of 81 cents translates into 9 5  growth year over year Other Stocks Worth a LookHere are a few other medical stocks worth considering from the same space as these too comprise the right combination of elements to surpass expectations this time around Chimerix  Inc    NASDAQ CMRX   has an Earnings ESP of  13 89  and a Zacks Rank  2  You can see  MacroGenics  Inc    NASDAQ MGNX   has an Earnings ESP of  24 79  and a Zacks Rank of 2 NanoString Technologies  Inc    NASDAQ NSTG   has an Earnings ESP of  4 64  and a Zacks Rank of 1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-18,Zacks Investment Research,https://www.investing.com/analysis/what-lies-ahead-for-abbott-abt-stock-this-earnings-season-200376958,200376958
181680,403196,ABT,Abbott  ABT  Meets Q4 Earnings Estimates,opinion,"Abbott  ABT  came out with quarterly earnings of  0 81 per share  in line with the Zacks Consensus Estimate  This compares to earnings of  0 74 per share a year ago  These figures are adjusted for non recurring items 
A quarter ago  it was expected that this maker of infant formula  medical devices and drugs would post earnings of  0 74 per share when it actually produced earnings of  0 75  delivering a surprise of 1 35  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Abbott  which belongs to the Zacks Medical   Products industry  posted revenues of  7 77 billion for the quarter ended December 2018  missing the Zacks Consensus Estimate by 0 29   This compares to year ago revenues of  7 59 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Abbott shares have lost about 1 2  since the beginning of the year versus the S P 500 s gain of 5  
What s Next for Abbott 
While Abbott has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Abbott was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 65 on  7 61 billion in revenues for the coming quarter and  3 19 on  31 99 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Products is currently in the top 36  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-01-22,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-meets-q4-earnings-estimates-200378372,200378372
181700,403216,ABT,Abbott  ABT  Stock Moves  0 12   What You Should Know,opinion,"Abbott  ABT  closed at  69 41 in the latest trading session  marking a  0 12  move from the prior day  This change was narrower than the S P 500 s daily loss of 0 76   At the same time  the Dow lost 0 82   and the tech heavy Nasdaq lost 0 9  
Coming into today  shares of the maker of infant formula  medical devices and drugs had lost 2 06  in the past month  In that same time  the Medical sector lost 0 16   while the S P 500 lost 1 41  
ABT will be looking to display strength as it nears its next earnings release  which is expected to be January 23  2019  On that day  ABT is projected to report earnings of  0 81 per share  which would represent year over year growth of 9 46   Meanwhile  our latest consensus estimate is calling for revenue of  7 79 billion  up 2 64  from the prior year quarter 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  2 88 per share and revenue of  30 61 billion  These totals would mark changes of  15 2  and  11 74   respectively  from last year 
Investors should also note any recent changes to analyst estimates for ABT  Recent revisions tend to reflect the latest near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 04  higher  ABT is currently sporting a Zacks Rank of  3  Hold  
Looking at its valuation  ABT is holding a Forward P E ratio of 24 11  This valuation marks a discount compared to its industry s average Forward P E of 25 7 
Meanwhile  ABT s PEG ratio is currently 2 07  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  The Medical   Products was holding an average PEG ratio of 2 29 at yesterday s closing price 
The Medical   Products industry is part of the Medical sector  This group has a Zacks Industry Rank of 92  putting it in the top 36  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-11-14,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-stock-moves-012-what-you-should-know-200359346,200359346
181701,403217,ABT,Abbott  ABT  Up 3 8  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Abbott  ABT   Shares have added about 3 8  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Abbott due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Abbott Beats on Q3 Earnings  Narrows  18  EPS ViewAbbott reported third quarter 2018 adjusted earnings from continuing operations of 75 cents per share  a penny ahead of the Zacks Consensus Estimate  The bottom line improved 13 6  year over year and remained at the upper end of the company s guided range of 73 75 cents  Reported earnings from continuing operation in the quarter came in at 31 cents per share  a 3 1  drop year over year Third quarter worldwide sales came in at  7 66 billion  up 12 1  year over year on a reported basis  The top line remained slightly below the Zacks Consensus Estimate of  7 67 billion On an organic basis  adjusting for the impact of foreign exchange as well as certain acquisitions and divestments  sales increased 7 8  year over year in the reported quarter Quarter in DetailAbbott operates through four segments  namely Established Pharmaceuticals Division  EPD   Medical Devices  Nutrition and Diagnostics EPD sales dropped 0 9  on a reported basis  improved 5 9  on an organic basis  to  1 16 billion  This included a 6 8  adverse impact of from currency fluctuations  Sales in the key emerging markets declined 2 1  year over year on an 8 9  adverse impact of foreign exchange  Organically  sales improved 6 8  driven by double digit growth in India and China The Medical Devices business sales increased 8 4  on a reported basis to  2 82 billion  On an organic basis  sales grew 9 8  Cardiovascular and Neuromodulation sales reportedly  up 4 8  on an organic basis  rose 3 6  on double digit growth in Electrophysiology and Structural Heart  In Electrophysiology  growth was led by strong performance in cardiac mapping and ablation catheters as well as strong growth of Abbott s Confirm Rx Insertable Cardiac Monitor  ICM   Within Structural Heart  growth was driven by several product areas across Abbott s broad portfolio  including AMPLATZERPFO Occluder and MitraClip Diabetes Care sales improved 37 4   up 39 8  organically   buoyed consistent consumer uptake of FreeStyle Libre  the revolutionary continuous glucose monitoring system of Abbott Nutrition sales were up 4  year over year on a reported basis  up 6 1  on an organic basis  to  1 84 billion  Pediatric Nutrition sales increased 8 5  on an organic basis  Adult Nutrition sales were up 3 2  organically Diagnostics sales soared 42 6  year over year on a reported basis  up 7 5  on a comparable operational basis  to  1 82 billion  Core Laboratory Diagnostics and Point of Care Diagnostics sales grew 8 1  and 4   respectively  on an organic basis  Molecular Diagnostics sales were up 6 1  banking on strong growth in the infectious disease testing business  Rapid Diagnostics recorded sales of  481 million  driven by solid contributions from cardiometabolic testing Full Year GuidanceAbbott has narrowed its 2018 adjusted earnings per share guidance  Adjusting for certain net specified items for the full year  adjusted earnings from continuing operations are now expected in the band of  2 87  2 89 as compared to the earlier projected range of  2 85  2 91  The Zacks Consensus Estimate of  2 88 remains within this projected range The company has also provided fourth quarter 2018 adjusted earnings per share outlook  It expects to report adjusted earnings from continuing operations in the range of 80 82 cents  The consensus mark of 81 cents falls within the predicted range  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
Currently  Abbott has a strong Growth Score of A  though it is lagging a bit on the Momentum Score front with a B  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Abbott has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-11-15,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-up-38-since-last-earnings-report-can-it-continue-200360024,200360024
181703,403219,ABT,Abbott  ABT  Stock Sinks As Market Gains  What You Should Know,opinion,"Abbott  ABT  closed the most recent trading day at  68 53  moving  0 77  from the previous trading session  This change lagged the S P 500 s 0 3  gain on the day  Elsewhere  the Dow 0   while the tech heavy Nasdaq added 0 92  
Prior to today s trading  shares of the maker of infant formula  medical devices and drugs had gained 0 71  over the past month  This has outpaced the Medical sector s loss of 2 51  and the S P 500 s loss of 4 37  in that time 
ABT will be looking to display strength as it nears its next earnings release  which is expected to be January 23  2019  On that day  ABT is projected to report earnings of  0 81 per share  which would represent year over year growth of 9 46   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  7 79 billion  up 2 64  from the year ago period 
ABT s full year Zacks Consensus Estimates are calling for earnings of  2 88 per share and revenue of  30 61 billion  These results would represent year over year changes of  15 2  and  11 74   respectively 
Investors should also note any recent changes to analyst estimates for ABT  These revisions help to show the ever changing nature of near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 02  higher  ABT is currently a Zacks Rank  3  Hold  
In terms of valuation  ABT is currently trading at a Forward P E ratio of 23 96  This valuation marks a discount compared to its industry s average Forward P E of 24 53 
Also  we should mention that ABT has a PEG ratio of 2 05  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  Medical   Products stocks are  on average  holding a PEG ratio of 2 24 based on yesterday s closing prices 
The Medical   Products industry is part of the Medical sector  This group has a Zacks Industry Rank of 93  putting it in the top 36  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-11-21,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-stock-sinks-as-market-gains-what-you-should-know-200361592,200361592
181704,403220,ABT,8 Top Active ETFs Of 2018,opinion,"The year 2018 has been rocky for equities withSPDR S P 500 ETF  NYSE SPY    AX SPY   losing 3 1   as of Dec 14  2018   SPDR Dow Jones Industrial Average  NYSE DIA  ETF   V DIA   shedding about 2 7  and Invesco QQQ Trust  gaining only 1 6  
Resurfacing global growth worries  nagging trade tensions between the United States and China  constant volatility in the oil patch and a flattening yield curve in the United States have invoked recessionary fears 
Against this background  investors and fund managers had to be prudent with the changing dynamics of the market  And in order to do so  several investors resorted to active ETFs  An actively managed ETF does have a benchmark index  but managers  or shift from the index constituents if they consider appropriate  per investopedia 
Investors should note that active funds are arguably expensive as these involve research expenses associated with the manager s due diligence and additional cost in the form of a wide bid ask spread beyond the expense ratio 
Still  there has been a surge of actively managed ETFs lately  Actively managed ETFs have been outperforming the passive ones as the average year to date returns for the passively managed funds are negative 6 5  this year while the figure for the actively managed ones is negative 3 74  
Below we highlight some top performing active ETFs of 2018 that breezed past the S P 500  as of Dec 14  2018   read    
AdvisorShares Dorsey Wright Short ETF    Up 18 7 
The fund is actively managed with an investment focus that involves buying securities that have appreciated in price more than the other securities in the investment universe  and holding those securities until they underperform  read    
iShares Evolved US Healthcare Staples ETF    Up 13 2 
The fund looks to offer access to U S  companies with healthcare staples exposure  The expense ratio is pretty low at 18 bps a year  The fund is heavy on Unitedhealth Group  15 16   followed by Abbott Laboratories  NYSE ABT   5 44   and CVS Health Corp  NYSE CVS   4 58   
Reaves Utilities ETF   SI UTES     Up 11 7 
The fund targets the utility sector and charges 95 bps in fees  Nextera Energy takes 15 57  of the fund  while DTE Energy takes 8 39  of the portfolio 
ARK Innovation ETF   KW ARKK     Up 8 3 
The fund provides thematic exposure to all sectors of innovation  The securities in ARKK offer the best risk reward opportunities from ARK s innovation based themes  while providing less volatility  The fund charges 75 bps in fees 
ARK Web x 0 ETF    Up 8 0 
The fund seeks long term growth of capital  It is an actively managed ETF that invests primarily at least 80  of its assets in domestic equity securities and U S  exchange traded foreign equity securities of companies that are relevant to the fund s investment theme of Web x 0  It s expense ratio of 0 75  
WisdomTree Bloomberg US Dollar Bullish ETF   Up 7 1 
The fund looks to provide total returns that exceed the performance of the Bloomberg Dollar Spot Index  It charges 50 bps in fees  read    
ClearBridge Large Cap Growth ESG ETF    Up 4 3 
The fund seeks to achieve long term capital appreciation through investments in large capitalization companies with positive ESG attributes that have the potential for high future earnings growth  read    
Invesco Multi Strategy Alternative ETF    Up 3 6 
The fund seeks to achieve positive total returns with low correlation to the broader securities  markets by investing in a combination of equity securities  financial futures contracts  forward currency contracts and other securities  The expense ratio is 0 98   read  
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2018-12-18,Zacks Investment Research,https://www.investing.com/analysis/8-top-active-etfs-of-2018-200369258,200369258
181705,403221,ABT,The Zacks Analyst Blog Highlights  Chimerix  MacroGenics  Rockwell Medical  TG Therapeutics And Valeritas,opinion,For Immediate ReleaseChicago  IL  December 19  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Chimerix  Inc    NASDAQ CMRX    MacroGenics  Inc    NASDAQ MGNX    Rockwell Medical  Inc    NASDAQ RMTI    TG Therapeutics  Inc    NASDAQ TGTX   and Valeritas Holdings  Inc    NASDAQ VLRX   Here are highlights from Tuesday s Analyst Blog  5 Beaten Down Medical Product Stocks to Rebound Next YearIn terms of market size  the U S  health care market is the largest in the world  America s unparalleled purchasing power  massive demand for medical services  equipment  cosmetic surgeries and opportunity for innovation have lent it a competitive edge  However  macroeconomic issues  volatility in oil prices  trade war with China  geopolitical conflict with North Korea and Iran  three interest hikes by Fed and a soft global economy have been denting the economy as a whole  just at the threshold of 2019 The Zacks  industry  which was once acclaimed for its high paying jobs  and research and development opportunities  is also no exception here  The industry lost 1 8  on a year to date basis Thus  it is essential for the investors who are willing to park their money in the healthcare sector  to find the means that can dilute these woes  But before understanding how to make prudent investments for the year  let s take a look at the various developments that have taken place within the space Not So Happy New Year for Medical Product Trade War FiascoThe medical product space is confronted by short term hurdles associated with the U S  China trade war  According to a survey conducted by the Medical Imaging   Technology Alliance  MITA   the tariffs will cost medical product companies nearly  138 million every year Cyber Security RisksA recent survey report by KPMG revealed that around 81  of health care organizations experienced data breach over a two year period beginning 2015 end  per an article published on 24x7  For instance  in April  the FDA had to issue a Safety Communication to inform the patients about the availability of an additional firmware update to combat the confirmed cybersecurity risks discovered in Abbott Labs  NYSE ABT  implantable cardiac product along with managing rapid battery depletion Regulatory HurdlesThe Unique Device Identification  UDI  system by the FDA has been quite costly and difficult to implement for medical product manufacturers Adding to the woes  the medical device tax repeal amendment is just a temporary relief for manufacturers  The tax will be back in effect on Jan 1  2020 Screening StocksBuoyed by these trends  there are a few medical product companies that had a rather weak 2018  However  with a Zacks Rank  1  Strong Buy  or 2  Buy   these stocks hold immense promise for long term growth You can see  5 Possible Outperformers of 2019Chimerix  Inc This Zacks Rank  2 company lost 35 2  on a year to date basis The company has been progressing well with its oral and IV brinci platform  the small pox program  Further  Chimerix s newest molecule   CMX521   for norovirus has been providing it with a competitive edge in the niche space Per management  Chimerix s substantial work over the past three years has set the stage for 2019 to be a transformational year for the company MacroGenics  Inc This Zacks Rank  2 company lost 35 2  on a year to date basis However  MacroGenics has achieved major milestones with Margetuximab in the SOPHIA breast cancer trial  The company s solid progress in the Phase 1b 2 gastric cancer study is encouraging Management also announced clinical advancement of MGA012 platform for its potential in treating solid tumor cancers  Additionally  the company has two bispecific DART molecule programs in progress We expect share prices of MacroGenics to soar in 2019 based on its exclusive products and solutions Rockwell Medical  Inc This Zacks Rank  2 company lost 50 9  on a year to date basis The company is gaining prominence in the global renal space particularly in North America  Latin America and Asia Pacific  Rockwell Medical is also expected to gain from its Triferic platform  the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia The company also plans to launch its dialysates Triferic formulation in the United States  in the first half of 2019 TG Therapeutics  Inc This Zacks Rank  2 company lost 45 7  on a year to date basis Headquartered in New York  TG Therapeutics is a biopharmaceutical company that focuses on commercialization of novel treatments for B cell malignancies and autoimmune diseases in the United States Management at TG Therapeutics has formulated an early stage pipeline to power the next generation proprietary triple and quad combinations  This unique pipeline will harness the immune system with PD L1 inhibitor  and the anti CD47 and anti CD19 bispecific antibodies Valeritas Holdings  Inc This Zacks Rank  2 company lost 87  on a year to date basis Valeritasis trying to expand its direct to patient marketing efforts  The company is a commercial stage medical technology company  focusing on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China The company s clinical team continues to produce meaningful clinical and pharma economic data  demonstrating the benefits of its flagship V Go platform over conventional insulin injection therapy In addition to the stocks discussed above  would you like to know about our 10 top tickers to buy and hold for the entirety of 2019 These 10 are painstakingly handpicked from over 4 000 companies covered by the Zacks Rank  They are our primary picks poised to outperform in the year ahead  Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-12-19,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-chimerix-macrogenics-rockwell-medical-tg-therapeutics-and-valeritas-200369456,200369456
181706,403222,ABT,Don t Be A Victim Of The Stock Market ,opinion,"Introduction
The primary objective of this article is to help the reader put this recent bad market in perspective and simultaneously provide lessons in valuation and how to think about stock prices  There have been many sage pieces of wisdom that have been provided to investors by investing greats  For example  in 1995 Peter Lynch wrote this in Worth Magazine 

 what makes stocks valuable in the long run isn t the market  It s the profitability of the shares in the companies you own  Corporations become more valuable and sooner or later  their shares will sell for a higher price  

Nevertheless  my own personal anecdotal experience indicates to me that people react to stock price movement and rarely  if ever  compare that movement to the profitability of the companies they own  I consider this a mistake  but also at the same time recognize that it is only human nature 
Consequently  the emotional response to the stock market is extremely strong  When markets are rising people are likely to get more confident and unfortunately even complacent  In contrast  when markets are falling people are likely to become fearful with doom and gloom scenarios replacing  sugar plums dancing in their heads  even during the holiday season  However  it is my contention that it is rarely as simple as prices are rising or prices are falling  Most importantly  I make it a practice to never react to price action  Instead  my approach is always to analyze and evaluate whether price volatility is justified   or not  In other words  my approach is intellectual rather than emotional 
As a registered investment advisor with more than 45 years  experience  I have often lamented that I live in money manager hell  When my clients are giddy with enthusiasm about the market  I tend to be morose and gloomy  In contrast  when my clients are miserable and frightened  I tend to be ecstatically optimistic  My experience has taught me that bull markets eventually bring risk  while bear markets bring opportunity  Therefore  instead of being caught up in the moment  I tend to be focused on what the future is likely to bring  Bad markets bring long term profits  good markets bring risk and overvaluation  Consequently  I love bad markets and hate good ones  However  my approach and attitude are predicated on understanding  within reason  what the true value of each of the companies I own truly is  Therefore  I can recognize both rational and irrational market behavior as it occurs  In my opinion  nothing is more calming during turbulent times 
I Just Don t Understand Why Investors Get So Upset by A Market Behaving Badly
Because of my perspective  I often find it difficult to understand why long term oriented prudent investors get so concerned when the market is down like it has been this December  From my perspective as a long term investor in great dividend paying stocks  short term price volatility seems totally irrelevant  Why  The answer is simple  if I do not intend to sell my dividend growth stocks today  or for that matter for many years to come  why should I worry about what the prices of the stocks are today  Nevertheless  a falling stock market  like we are seeing this December  causes a significant amount of investor angst 
Furthermore  this worry seems especially irrelevant to me when the dividend growth stocks I own continue growing their earnings and raising their dividends  People tend to be overly concerned about the performance of their portfolios based solely on price action even when their businesses are performing fantastically  Somehow  they only consider the price movement as indicative of how their portfolios are performing 
In my experience  most investors seem incapable of even considering the operating performance of the businesses they are long term investors in  In other words  their businesses can be doing great and their dividend income increasing  but if the prices are down  the investors are upset  To me this is backwards  because I only care about how my businesses are performing because I am confident that in the long run this is the only thing that will produce the rewards that I am seeking through investing in great dividend paying businesses 
To summarize  measuring the performance of my portfolio or any of my individual holdings based solely on what the price has recently done or is doing is just wrong in my opinion  Nevertheless  this is precisely what most investors do  I can t tell you how many times I ve had an angry or concerned client call me complaining about how poor a certain stock is performing when  from my perspective  it is performing fabulously  The client is measuring price action  whereas I am measuring earnings  dividend and revenue growth  To me  the only performance that truly matters is how the business is doing 
AbbVie  NYSE ABBV   a Case in Point 
The biotechnology giant and spin off from Abbott Labs  NYSE ABT  represents an excellent case in point  For all of 2018  the stock price is down almost 14   From its peak in the spring of 2018  AbbVie s  ABBV  stock price is down more than 30   Consequently  most investors would call AbbVie a performance dog for calendar year 2018  However  from my perspective as a shareholder  I consider it one of the best performing stocks that I own for 2018  The company s earnings are forecast to increase approximately 40  by the consensus of leading analysts following the stock  and thus far they have beat estimates of both earnings and revenues for each of the last three completed quarters 
Additionally  AbbVie announced that they increased their dividend by 35 2  on February 15  2018  Consequently  their 2018 quarterly dividends of  0 96 a share are on track to produce a  3 84 dividend for fiscal 2018 which is approximately 46  higher than the  2 63 dividend they paid in 2017  To me  this is simply spectacular performance   and I couldn t be happier with my holding  The fact that the price is down for the year is just typical market foolishness to me  In other words  I am ecstatic with my AbbVie holding and its true performance for fiscal year 2018  Nevertheless  it never ceases to amaze me how blinded people are regarding their true portfolio performance when short term prices are weak 

Not all Price Drops Are the Same
Another important aspect regarding short run stock price volatility is the reality that not all price drops are the same  Investors need to understand and consider that some price drops are justified while others are not  Sometimes the company s stock price falls simply because the market was pricing the fundamental value of the company too high  This is one example of a justified price drop  In another case  a company s stock price might fall because the company s fundamentals have deteriorated  This would be another example of a justified price drop 
In contrast  a company s stock price can be fairly valued or even attractively valued and drop nevertheless because of a major market selloff  This would represent an example of an unjustified price drop that is  in reality  an opportunity rather than a crisis  In other words  a great company that has gone on sale  These are important distinctions that most investors seem either incapable of or unwilling to make or consider  The price drops  the investor panics   and that is typically the end of the story 
CVS Health Corporation  NYSE CVS   a Case in Point 
In the summer of 2015  CVS Health Corporation s  CVS  stock price was significantly overvalued as seen on the following earnings and price correlated graph  Earnings growth was very strong for 2012  2013  2014 and 2015  Nevertheless  the headwinds of overvaluation soon took its toll and by October 2016  CVS s stock price fell approximately 25   However  based on previous overvaluation  I believe the correction was clearly justified 
Then along came 2017  which delivered very anemic growth relative to recent history  Consequently  with investor sentiment already negative for the past year and ca half or so  CVS s stock price has continued to slide another 18  on top of the original 25  drop  With earnings growth reemerging in 2018 stock price has recovered somewhat  Nevertheless  I would consider this company significantly undervalued based on current and expected future operating results 

It s a Market of Stocks Not a Stock Market
Recently I ve been hearing a lot of  wow the market is tanking   what do you think it s going to do   My answer is always the same  I think it will continue to fluctuate as it always has  However  I think the most important message that I want to convey is that it is a market of stocks and not a stock market  Just as all price drops are the same  not all stocks in the market are the same  They all have different operating histories and potentials  different valuations  and different reasons for whatever their prices are doing  Of course  it is certainly true that a rising tide lifts all boats and a falling tide sinks all boats   at least in the short run 
The following earnings and price correlated graph with valuation references on the S P 500 clearly illustrates that this market index has been significantly overvalued since 2014  Consequently  the recent correction has not been a surprise to me  because I have been expecting it for some time  Moreover  I think the S P 500 is now reasonably priced after this correction  However  that is not to say that it won t overshoot in to undervaluation territory if sentiment remains negative 

FAST Graphs Analyze out Loud Video Summary
The following video summarizes and elaborates on the important messages I am offering with this article 


Conclusions
If you are a long term investor  then my advice is to never let the stock market or short term price volatility impact your investment decisions  However  I understand the difficulty of watching your portfolio value get smaller even if it s only temporary  In my experience  for most people their financial situation comes only second to the health and welfare of their families  In other words  a person s financial security is extremely important  Consequently  it s easy to be a victim of volatile markets 
Therefore  it is also my experience that more people have had their financial situation severely impacted by reacting emotionally to markets  In other words  in too many cases I have seen people sell when they should buy and buy when they should sell  The powerful emotional responses of fear and greed are powerful adversaries to our financial health  However  when we can understand and embrace the reality that   as it relates to investing in stocks   operating performance is significantly more important than price action  only then can we protect ourselves from volatile markets  Healthy earnings  cash flows  revenues and dividend growth will eventually lead to healthy returns  Don t be a stock market victim 
Disclosure  Long ABBV and CVS 
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2018-12-21,Chuck Carnevale,https://www.investing.com/analysis/dont-be-a-stock-market-victim-200370096,200370096
181707,403223,ABT,Why Abbott  ABT  Could Beat Earnings Estimates Again,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Abbott  ABT   which belongs to the Zacks Medical   Products industry 
This maker of infant formula  medical devices and drugs has an established record of topping earnings estimates  especially when looking at the previous two reports  The company boasts an average surprise for the past two quarters of 2 08  
For the last reported quarter  Abbott came out with earnings of  0 75 per share versus the Zacks Consensus Estimate of  0 74 per share  representing a surprise of 1 35   For the previous quarter  the company was expected to post earnings of  0 71 per share and it actually produced earnings of  0 73 per share  delivering a surprise of 2 82  
Price and EPS Surprise

For Abbott  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Abbott has an Earnings ESP of  0 25  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on January 23  2019 
Investors should note  however  that a negative Earnings ESP reading is not indicative of an earnings miss  but a negative value does reduce the predictive power of this metric 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2018-12-23,Zacks Investment Research,https://www.investing.com/analysis/why-abbott-abt-could-beat-earnings-estimates-again-200370725,200370725
181729,403245,ABT,Abbott  ABT  Outpaces Stock Market Gains  What You Should Know,opinion,"In the latest trading session  Abbott  ABT  closed at  69 30  marking a  1 91  move from the previous day  This change outpaced the S P 500 s 1 09  gain on the day  Meanwhile  the Dow gained 0 97   and the Nasdaq  a tech heavy index  added 2 01  
Heading into today  shares of the maker of infant formula  medical devices and drugs had lost 7 87  over the past month  outpacing the Medical sector s loss of 10 02  and lagging the S P 500 s loss of 7 81  in that time 
Investors will be hoping for strength from ABT as it approaches its next earnings release  which is expected to be January 23  2019  The company is expected to report EPS of  0 81  up 9 46  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  7 79 billion  up 2 64  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  2 88 per share and revenue of  30 61 billion  which would represent changes of  15 2  and  11 74   respectively  from the prior year 
It is also important to note the recent changes to analyst estimates for ABT  These recent revisions tend to reflect the evolving nature of short term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 03  higher within the past month  ABT is holding a Zacks Rank of  3  Hold  right now 
In terms of valuation  ABT is currently trading at a Forward P E ratio of 23 58  For comparison  its industry has an average Forward P E of 24 92  which means ABT is trading at a discount to the group 
We can also see that ABT currently has a PEG ratio of 2 02  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Medical   Products industry currently had an average PEG ratio of 2 29 as of yesterday s close 
The Medical   Products industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 106  which puts it in the top 42  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow ABT in the coming trading sessions  be sure to utilize Zacks com ",2018-10-31,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-outpaces-stock-market-gains-what-you-should-know-200352681,200352681
181730,403246,ABT,Abbott  ABT  Q3 Earnings Top Estimates,opinion,"Abbott  ABT  came out with quarterly earnings of  0 75 per share  beating the Zacks Consensus Estimate of  0 74 per share  This compares to earnings of  0 74 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 1 35   A quarter ago  it was expected that this maker of infant formula  medical devices and drugs would post earnings of  0 74 per share when it actually produced earnings of  0 75  delivering a surprise of 1 35  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Abbott  which belongs to the Zacks Medical   Products industry  posted revenues of  7 66 billion for the quarter ended December 2018  missing the Zacks Consensus Estimate by 0 12   This compares to year ago revenues of  7 59 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Abbott shares have added about 22 9  since the beginning of the year versus the S P 500 s gain of 2 5  
What s Next for Abbott 
While Abbott has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Abbott was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 66 on  7 66 billion in revenues for the coming quarter and  3 19 on  32 05 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Products is currently in the top 38  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-q3-earnings-top-estimates-200353840,200353840
181731,403247,ABT,Abbott  ABT  Gains As Market Dips  What You Should Know,opinion,"Abbott  ABT  closed the most recent trading day at  72 96  moving  0 63  from the previous trading session  This move outpaced the S P 500 s daily loss of 0 25   Elsewhere  the Dow gained 0 04   while the tech heavy Nasdaq lost 0 53  
Prior to today s trading  shares of the maker of infant formula  medical devices and drugs had gained 5 19  over the past month  This has outpaced the Medical sector s loss of 1 06  and the S P 500 s loss of 2 35  in that time 
Wall Street will be looking for positivity from ABT as it approaches its next earnings report date  This is expected to be January 23  2019  The company is expected to report EPS of  0 81  up 9 46  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  7 79 billion  up 2 64  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  2 88 per share and revenue of  30 61 billion  These totals would mark changes of  15 2  and  11 74   respectively  from last year 
Any recent changes to analyst estimates for ABT should also be noted by investors  These recent revisions tend to reflect the evolving nature of short term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Our research shows that these estimate changes are directly correlated with near term stock prices  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 07  higher  ABT is holding a Zacks Rank of  3  Hold  right now 
In terms of valuation  ABT is currently trading at a Forward P E ratio of 25 15  This valuation marks a discount compared to its industry s average Forward P E of 25 86 
It is also worth noting that ABT currently has a PEG ratio of 2 16  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Medical   Products was holding an average PEG ratio of 2 4 at yesterday s closing price 
The Medical   Products industry is part of the Medical sector  This group has a Zacks Industry Rank of 101  putting it in the top 39  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow ABT in the coming trading sessions  be sure to utilize Zacks com ",2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-gains-as-market-dips-what-you-should-know-200357231,200357231
181750,403266,ABT,Why Is Abbott  ABT  Up 2  Since Its Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Abbott Laboratories   NYSE ABT    Shares have added about 2  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is ABT due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers 
Recent EarningsAbbott reported first quarter 2018 adjusted earnings from continuing operations of 59 cents per share  beating the Zacks Consensus Estimate by a cent  The bottom line also improved 22 9  year over year and met the high end of the company s guided range of 57 59 cents  Moreover  reported earnings in the quarter came in at 23 cents per share compared with the year ago figure of 22 cents First quarter worldwide sales came in at  7 39 billion  up 16 6  year over year on a reported basis  The top line also exceeded the Zacks Consensus Estimate of  7 26 billion by 1 8  On an organic basis  adjusting for the impact of foreign exchange and certain divestments  sales increased 6 9  year over year in the reported quarter Quarter in DetailAbbott operates through four segments  namely Established Pharmaceuticals Division  EPD   Medical Devices  Nutrition and Diagnostics EPD sales rose 9 9  on a reported basis  up 6 8  on an organic basis  to  1 04 billion  This included a positive impact of 3 1  from currency fluctuations  Sales in the key emerging markets increased 8 7   up 6 8    driven by double digit growth in India  China and Brazil The Medical Devices business sales increased 14 6  on a reported basis to  2 74 billion  On an organic basis  sales grew 9 4  Cardiovascular and Neuromodulation sales reportedly  up 6 2  on an organic basis  rose 10 5  on double digit growth in Electrophysiology and Neuromodulation Vascular product sales  however  declined 6  on a reported basis  up 1 6    Within Rhythm Management  the company saw a sales increase of 4 7  on a reported basis  a decline of 1 2   Diabetes Care sales improved 44 2   up 32 9    buoyed by double digit international sales growth  led by a consistent consumer uptake of FreeStyle Libre  the revolutionary continuous glucose monitoring system of Abbott Nutrition sales were up 7  year over year on a reported basis  up 4 7  on an organic basis   Foreign exchange drove sales by 2 2   Pediatric Nutrition sales increased 7 3  on an organic basis  Adult Nutrition sales were up 4 3  organically Diagnostics sales soared 58 7  year over year on a reported basis  up 5 5  on a comparable operational basis   Core Laboratory and Point of Care Diagnostics sales grew 6 3  and 4   respectively  on an organic basis  Molecular Diagnostics sales were up a nominal 1 3  as strong growth in the infectious disease testing business was partially offset by the planned scale down in other testing areas  primarily in the United States  Rapid Diagnostics recorded sales of  559 million  driven by solid contributions from infectious disease testing including flu and strep testing Full Year GuidanceAbbott has reiterated its 2018 earnings per share guidance  Adjusting for certain net specified items for the full year  adjusted earnings from continuing operations are still expected in the band of  2 80  2 90  The Zacks Consensus Estimate of  2 86 remains within this projected range The company has also provided second quarter 2018 adjusted earnings per share outlook  It expects to report adjusted earnings from continuing operations in the range of 70 72 cents  The consensus mark of 71 cents falls within but near the lower end of the predicted range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There has been one revision higher for the current quarter compared to three lower Abbott Laboratories Price and Consensus    VGM Scores
At this time  ABT has a great Growth Score of A  though it is lagging a lot on the momentum front with a C  The stock was also allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is more suitable for growth investors than those looking for value and momentum 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  ABT has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-17,Zacks Investment Research,https://www.investing.com/analysis/why-is-abbott-abt-up-2-since-its-last-earnings-report-200317356,200317356
181776,403292,ABT,Abbott  ABT  Beats On Earnings And Revenues In Q1,opinion,Abbott Laboratories   NYSE ABT   is an Illinois based company focused on bringing a diverse line of healthcare products to the market Abbott reports its diversified business in four segments   namely Established Pharmaceuticals Division  EPD   Medical Devices  Diagnostics and Nutrition  The company has reshaped its portfolio through strategic acquisitions divestitures in recent times In Feb 2015  Abbott completed the sale of its branded generics pharmaceuticals business in developed markets  Realignment of the EPD division through acquisitions in Latin America and Russia  along with business divestitures in developed markets  has positioned the company well for the coming quarters Abbott Laboratories Price and EPS Surprise   The company rides on its strong EPD business and strategic buyouts  In 2017  Abbott completed the acquisition of Alere  which is expected to enhance the company s stance in healthcare  However  foreign currency headwinds raise major concerns for the company  since a considerable percentage of Abbott s revenues come from outside the United States Abbott has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4 5  Currently  Abbott has a Zacks Rank  3  Hold   but that could definitely change following the company s first quarter 2018 earnings report which was just released   You can see   We have highlighted some of the key stats from this just revealed announcement below Earnings  Abbott  first quarter 2018 adjusted earnings per share from continuing operations of 59 cents outpaced the Zacks Consensus Estimate by a penny Revenues  Abbott posted first quarter worldwide revenues of  7 39 billion beating the Zacks Consensus Estimate for revenues by 1 8  Key Stats  Worldwide revenues increased by 6 9  on organic basis and by 16 7  on year over year basis  The revenues for Nutrition segment came in at  1 76 billion  up 7  year over year  Diagnostics segment reported sales worth  1 84 billion  up 58 7  on year over year basis  Established Pharmaceuticals revenues were  1 04 billion  up  9 9  from the year ago quarter  Medical Devices revenues came in at  2 74 billion  up 14 6  from the year ago quarter Major Factors  The company expects full year earnings per share to be in the range of  2 80 to  2 90  reflecting 14  growth at midpoint  Several new products launched by the company have contributed to a strong growth  Furthermore  in January  Abbott announced U S  FDA approval of for magnetic resonance  MR  conditional labeling for its Quadra Assura and Quadra Assura MP devices Stock Price  Following the earnings release  share prices decreased by 1 4  during the pre market trading session The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-04-17,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-beats-on-earnings-and-revenues-in-q1-200306522,200306522
181777,403293,ABT,Centene  CNC  Q1 Earnings   Revenues Top   18 View Lowered,opinion,Centene Inc    NYSE CNC   reported first quarter 2018 adjusted net income per share of  2 17  which beat the Zacks Consensus Estimate by 13   Also  the bottom line improved 93  year over year For the first quarter  total revenues rose 13  to  13 2 billion from the year ago period  primarily driven by growth in the Health Insurance Marketplace business in 2018 as well as expansions and new programs across many states in both 2017 and this year  Moreover  the top line slightly surpassed the Zacks Consensus Estimate by 0 01  Quarterly Operational UpdateAs of Mar 31  2018  managed care membership came in at 12 8 million  a 6  increase over March 31  2017 Health Benefit Ratio  HBR  for the first quarter was 84 3  compared with 87 6  in the prior year quarter  This reflects a year over year deterioration of 330 basis points  bps   stemming from membership growth in the Health Insurance Marketplace business  lower medical costs in Medicaid business and the reinstatement of the health insurer fee in 2018 Adjusted Selling  General   Administrative  SG A  expense ratio of 10 3  for the first quarter of 2018 compared with 9 3  for the first quarter of 2017  This represents a deterioration of 100 basis points year over year  arising from growth in the Health Insurance Marketplace business  operating at a higher SG A expense ratio Centene Corporation Price  Consensus and EPS Surprise    Financial Update  As of Mar 31  2018 Centene had cash and cash equivalents of  5 7 billion  up 39  from 2017 end Total assets of  25 2 billion grew 15  Centene s long term debt totaled  5 2 billion  up 10  At the end of the first quarter of 2018  cash inflow from operations was  1 8 billion  up 48  year over year 2018 Guidance UpdatedCentene expects adjusted earnings per share in the range of  6 75  7 15  down from the previous projection of  6 95  7 35 Total revenues are anticipated in the band of  58 2  59 0 billion  down from the earlier forecast of  60 6  61 4 billion HBR is estimated at 85 9 86 4  compared with the past view of 86 2 86 7 Adjusted SG A expense ratio is predicted at 9 4 9 8   up from the former outlook of 9 2 9 7   Zacks Rank and Performance of PeersCentene carries a Zacks Rank  3  Hold   You can see  Among other players in the Medical sector having reported first quarter earnings so far  Novartis AG   NYSE NVS    UnitedHealth Group Incorporated   NYSE UNH   and Abbott Laboratories   NYSE ABT   surpassed the respective Zacks Consensus Estimate Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/centene-cnc-q1-earnings--revenues-top-18-view-lowered-200308548,200308548
181778,403294,ABT,Merck Vs  Pfizer  Which Stock Looks Better Post Q1 Earnings ,opinion,Both Merck   Co   Inc    NYSE MRK   and Pfizer  Inc    NYSE PFE   reported upbeat first quarter results on May 1  In fact  both pharma giants managed to outpace their earnings estimate but missed on the revenue front  However  the companies  top and bottom lines rose year over year Merckhas a Zacks Rank  2  Buy   while Pfizer possesses a Zacks Rank  3  Hold   Now  but let s see which stock is better positioned in terms of fundamentals  post earnings  You can see  Other major earnings came from other pharma giants like Abbott   NYSE ABT   and Johnson   Johnson   NYSE JNJ   Q1 Earnings PerformanceIn the first quarter  Merck reported adjusted earnings per share of  1 05  surpassing the Zacks Consensus Estimate by six cents  The bottom line increased 19 3  from the year ago period  Meanwhile  the company s revenues of  10 04 billion fell short of the Zacks Consensus Estimate of  10 12  but increased 6  year over year   Read More    Pfizer posted first quarter earnings of 77 cents per share  beating the Zacks Consensus Estimate by only 3 cents  Earnings advanced 12  from the year ago period  due to lower tax rates and share count  Moreover  revenues increased 1  year over year to  12 91 billion but missed the Zacks Consensus Estimate of  13 09 billion   Read More   Price PerformanceMerck has witnessed a rise of 5 8  in the past three months  while Pfizer has advanced only 2 6   So Merck is a clear winner in this respect with better returns than both rival Merck and the broader   which declined 2  during the same period ValuationThe most appropriate ratio to evaluate these two drug makers is perhaps EV EBITDA  This metric is usually used to compare two stocks in the same industry  It is superior to other metrics such as P E because it is not affected by the different capital structures of the two companies Coming to the two pharma majors  Pfizer with an EV EBITDA ratio of 15 63 is overvalued than the broader industry  which has an EV EBITDA value of 11 32  On the other hand  with an EV EBITDA ratio of 8 19  Merck is underpriced than both Pfizer and the industry Net MarginThe pharmaceutical industry enjoys higher profit margins than several other sectors  This is possibly one of the reasons why critics of the sector continually draw attention to exorbitant drug pricing  which helps the sector maintain its steep margins With a net margin value of 31 44   Pfizer performs better than rival Merck  which has a net margin value of 27 85   In comparison  the broader industry has a net margin value of 26 86  Debt to Equity RatioThe debt to equity  D E  ratio is a good indicator of the financial health of a company and a good proxy for its debt servicing capacity  In the context of a capital intensive industry like pharma  this is an indicator of a company s long term sustainability Merck s debt to equity ratio of 61 8  is significantly high compared with the industry s D E ratio of 56    With a comparatively lower D E ratio of 46 8   Pfizer evidently has a better leverage condition Earnings History and Estimate RevisionsMerck delivered positive surprises in all the last four quarters  with an average earnings surprise of 8 55   In comparison  Pfizer delivered an earnings beat in all the trailing four quarters and posted an average positive earnings surprise of around 5 23  When considering estimate revisions  Merck s earnings estimate for the current year has improved 1 2  over the past 30 days  Meanwhile  Pfizer s earnings estimate has declined by 0 3  over the same period  ConclusionIn our comparative analysis  we found that both the two pharma giants have certain positives  Pfizer holds a better leverage position and has a higher net margin  However  in terms of valuation  Merck is more underpriced than Pfizer  Further  Merck has comparatively higher price performance than Pfizer Moreover  Merck also holds an edge over Pfizer when considering its average positive earnings surprise and estimate revisions  What clinches the case in favor of Merck at this point of time is that it has a better Zacks Rank than Pfizer  In this respect  our analysis clearly indicated that Merck is better positioned than Pfizer and thus calls for investors  attention post earnings Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-05-10,Zacks Investment Research,https://www.investing.com/analysis/merck-vs-pfizer-which-stock-looks-better-post-q1-earnings-200315506,200315506
181779,403295,ABT,Traders Bet On Abbott Laboratories Joining Healthcare Slide,opinion,"President Donald Trump is expected to announce a plan to  today  which should put healthcare sector in focus on Wall Street  This group has struggled in 2018  illustrated by a recent email sent out by Schaeffer s Quantitative Analyst Chris Prybal showing the extreme underperformance of the 20 names that we cover in our  Pharmaceuticals and Biotechnology  category 
Prybal notes that this group s collective market cap has seen the biggest decrease in 2018 by far out of all the sectors we track  with only four of the 20 companies seeing their market caps climb year to date  One pharmaceutical stock that s managed to hold gains so far in 2018 is Abbott Laboratories  NYSE ABT   but data shows bears are moving in 
ABT stock was last seen trading up 0 6  at  60 92  pacing for a third straight win and its highest close since March 26  The shares took a sharp bounce off their 160 day moving average earlier this month  and have since pushed through recent resistance at the  60 level  Overall  the healthcare giant is up 6 7  year to date 

Analysts are extremely bullish on Abbott  with 17 of the 20 brokerage firms in coverage saying to buy the shares  Plus  the average 12 month price target is  68 56  representing a 12 7  premium to current levels and record high territory  Looking elsewhere  however  shows increasing negativity around the stock 
In fact  short interest has been surging on the stock  rising almost 53  in the last reporting period alone    one of the biggest increases among all stocks that trade more than one million shares per day or trade weekly options  At the same time  less than 1  of the total float is sold short 
But options traders have also been showing bearish tendencies  ABT s 10 day put call volume ratio across the International Securities Exchange  ISE   Chicago Board Options Exchange  CBOE   and NASDAQ OMX PHLX  PHLX  stands at 1 10  ranking in the 83rd annual percentile  This suggests put buying has been unusually popular in recent weeks  relative to call buying ",2018-05-13,Schaeffer's Investment Research,https://www.investing.com/analysis/traders-bet-on-abbott-laboratories-joining-healthcare-slide-200315760,200315760
181816,403332,ABT,Is Big Pharma Using Corporate Tax Savings To Lower Drug Costs ,opinion,"With the passing of the new tax bill  the corporate tax rate has come down from 35  to 21  which is likely to boosts profit margins  Moreover  the cash repatriation window allowed in the bill will help companies to bring in cash stashed in foreign locations at a one time tax rate of 10   leaving these companies with extra spending power Most big pharma companies discussed their plans to use the extra cash they save from the new tax bill at their fourth quarter conference calls  The extra cash will mostly be invested in capital expenditures  products pipeline  in licensing or acquisition deals or rewarding shareholders through higher dividends and share buybacks  However  the majority of companies did not mention any effort regarding lowering of prescription drug costs Last week  Senator Tina Smith in letters to five big pharma companies  expressed concern about how big pharma companies plan to used billions of dollars they will save from the tax cut offered under the tax bill passed in December 2017  She is concerned about the fact that the companies are favoring investors instead of using the savings to bring down prescription drug costs  Major life saving drugs which are protected by patents are steeply priced  Thus  making these drugs affordable will help consumers  as it will lower their medical costs The Senator has sent letters to CEOs of Pfizer Inc    NYSE PFE    Merck   Co   Inc    NYSE MRK    Johnson   Johnson   NYSE JNJ    AbbVie Inc    NYSE ABBV   and Abbott Laboratories   NYSE ABT   to provide the details of how they intend to utilize major savings from the tax overhaul The prices of major prescription drugs have skyrocketed over the past years  pinching hard U S  citizens as their medical bills have soared  Moreover  the government also has to pay higher costs for the drugs that are covered under Medicare  The concern of the senator is thus justified  A move to restrict the use of tax savings for boosting shareholders will be a welcome move for consumers Moreover  large players from every other industry have similar plans  which have undercut President Donald Trump s plans to create jobs and boost wages Senator Smith is also working toward making cheaper generic drugs available in the market faster by introducing a new legislation  as reported by KDAL Large Cap Pharmaceuticals Industry 5YR   Return
 Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-03-09,Zacks Investment Research,https://www.investing.com/analysis/is-big-pharma-using-corporate-tax-savings-to-lower-drug-costs-200296924,200296924
181838,403354,ABT,HCA Healthcare s  HCA  Q4 Earnings  Revenues Beat Estimates  Revised ,opinion,"HCA Healthcare  Inc    NYSE HCA   reported fourth quarter 2017 adjusted earnings of  2 12 per share  which surpassed the Zacks Consensus Estimate of  1 86 by 14   The bottom line also rose nearly 12 2  year over year 
The company reported net income per share of  1 30 in the fourth quarter that includes a non cash increase in the company s provision for income taxes of 83 cents per share  stemming from the impact of the Tax Cuts and Jobs Act  This reflects 45  year over year decline 
For 2017  the company reported net income per share of  5 95  down 18  year over year 
HCA Healthcare generated revenues of  11 6 billion in the fourth quarter that surpassed the Zacks Consensus Estimate by 3 5   The reported figure was up 8 6  from the year ago quarter  The upside was primarily driven by an increase of 2 3  in same facility equivalent admissions and an increase of 3 5  in same facility revenue per equivalent admission compared to the year ago quarter 
For 2017  the company reported revenues of  43 6 billion  up 5  year over year 
Quarterly Details
Adjusted EBITDA totaled  2 4 billion  up 7 1  year over year 
Same facility equivalent admissions inched up 2 3  year over year  while same facility admissions jumped 1 4   Same facility revenue per equivalent admission increased 3 5  
Total operating expenses increased 12  year over year to  10 2 billion 
As of Dec 31  2017  HCA Healthcare ran 179 hospitals and 120 free standing surgery centers 
HCA Holdings  Inc  Price  Consensus and EPS Surprise
   Financial Update
As of Dec 31  2017  the company had cash and cash equivalents of  732 million  total long term debt of  32 8 billion and total assets of  36 6 billion 
During the reported quarter  capital expenditures totaled  982 million  excluding acquisitions  Cash flow provided by operating activities totaled  1 7 billion  up 2 1  year over year 
Share Repurchase Update
The company repurchased 7 2 million shares of its common stock for  576 million in the fourth quarter 
For 2017  the company repurchased 25 1 million shares of its common stock for  2 051 billion 
The company plans to increase its three year capital expenditures program to pursue growth opportunities in its existing markets  The new capital investment program is expected to be of roughly  10 5 billion  up from the previous three year spend of nearly  8 2 billion 
Dividend Update
HCA Healthcare has declared a quarterly cash dividend of 35 cents per share on the company s common stock  The dividend will be paid on Mar 30  2018 to stockholders of record at the close of business on Mar 1 
The initiation of quarterly dividends reflects the company s financial strength 
2018 Guidance
The company expects 2018 revenues in the range of  45  46 billion  adjusted EBIDTA of  8 45  8 75 billion  EPS of  8 50  9 00 and capital expenditures of about  3 5 billion 
Zacks Rank and Performance of Other Stocks
HCA Healthcare carries a Zacks Rank  3  Hold   You can see  
Among other players in the Medical sector that have reported their fourth quarter earnings so far  AbbVie Inc    NYSE ABBV    UnitedHealth Group Inc    NYSE UNH   and Abbott Laboratories   NYSE ABT   have surpassed their respective Zacks Consensus Estimate 
Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly 
 We are reissuing this article to correct a mistake  The original article  issued on Jan 30  2018  should no longer be relied upon  ",2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/hca-healthcares-hca-q4-earnings-revenues-beat-estimates-revised-200285087,200285087
181839,403355,ABT,Zoetis  ZTS  Q4 Earnings   Revenues Surpass Estimates,opinion,Florham Park  NJ based Zoetis Inc    NYSE ZTS   is one of the leading global animal health companies focused on the discovery  development  manufacture and commercialization of animal health medicines and vaccines  with a focus on both livestock and companion animals  The company came into existence following Pfizer s decision to spin off its animal health business in 2013 Zoetis  diversified portfolio of products for livestock and companion animals should continue to drive top line growth at the company  The company s top line should benefit from the addition of products acquired from Abbott Laboratories  NYSE ABT   February 2015   Pharma  November 2015   Nexvet  July 2017  as well as from the performance of Apoquel and other key brands  In this scenario  investor focus remains on top and bottom line numbers Zoetis  track record has been impressive with the company beating earnings estimates consistently  In fact  Zoetis  earnings surpassed expectations in three of the last four quarters  with an average positive surprise of 4 51  Currently  Zoetis has a Zacks Rank  2  Buy  but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings In line  Zoetis reported earnings per share of 69 cents beating the Zacks Consensus Estimate of 66 cents in fourth quarter of 2017 Revenues Beat   Zoetis posted revenues of  1 5 billion surpassing the Zacks consensus estimate of  1 40 billion Key Stats   During the fourth quarter  Zoetis continued to expand the availability of its oral flea and tick medication  Simparica into new markets  with additional approvals in Chile  Panama  the Philippines and Switzerland  Simparica also received approval in the European Union for the treatment of two additional types of skin mites In the United States  the company enhanced its medicated feed additives portfolio with an expanded claim for Lincomix  lincomycin hydrochloride   a popular feed medication  2018 Outlook  Zoetis provided its outlook for 2018  In 2018  the company expects adjusted earnings in the range of  2 96 to  3 10 per share on revenues of  5 675 billion and  5 800 billion  The Zacks Consensus Estimate for earnings is  2 94 per share on revenues of  5 64 billion Share Price Impact  Shares of the company were up 0 7  in pre market trading Check back later for our full write up on this ZTS earnings report later  Zoetis Inc  Price and EPS Surprise   Zacks  Top Investment Ideas for Long Term ProfitHow would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ,2018-02-14,Zacks Investment Research,https://www.investing.com/analysis/zoetis-zts-q4-earnings--revenues-surpass-estimates-200290843,200290843
181840,403356,ABT,Abbott  ABT  Down 6 7  Since Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Abbott Laboratories    NYSE ABT     Shares have lost about 6 7  in that time frame  underperforming the market 
Will the recent negative trend continue leading up to its next earnings release  or is ABT due for a breakout  Before we dive into how investors and analysts have reacted of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts 
Recent EarningsAbbott reported fourth quarter 2017 adjusted earnings from continuing operations of 74 cents per share  beating the Zacks Consensus Estimate by a penny  Earnings improved 13 8  year over year and met the high end of the company s guided range of 72 cents to 74 cents However  reported loss in the quarter came in at 50 cents per share  as against year ago earnings of 51 cents  Notably  this includes anticipated net expense of  1 46 billion as an impact of U S  tax reform Full year 2017 adjusted earnings came in at  2 50 per share  in line with the Zacks Consensus Estimate  However  the figure beat the year ago number by 13 6  Fourth quarter worldwide sales came in at  7 59 billion  up 42 3  year over year on a reported basis  The figure also beat the Zacks Consensus Estimate of  7 37 billion by 2 9  On a comparable operational basis  adjusting the impact of foreign exchange  certain acquisitions and divestments   sales increased 7 7  year over year in the reported quarter Worldwide sales in the full year came in at  27 39 billion  up 31 3  year over year on a reported basis  The figure also surpassed the Zacks Consensus Estimate of  27 15 billion Quarter in DetailAbbott operates through four segments   Established Pharmaceuticals Division   EPD    Medical Devices  Nutrition and Diagnostics EPD sales were up 17  on a reported basis  up 14  on comparable operational basis  to  1 15 billion  This included a positive impact of 3  from currency fluctuations  Sales in key emerging markets increased 15   up 12 5    driven by double digit growth in Latin America  India and China The Medical Devices business sales rose 102 2  on a reported basis to  2 74 billion  On a comparable operational basis  sales increased 9 6  Cardiovascular and Neuromodulation sales soared 222 5  on a reported basis  up 6 9  on comparable operational basis  on double digit growth in Electrophysiology  Structural Heart  Heart Failure and Neuromodulation Vascular product sales  however  declined 1 9  on a comparable operational basis  Within Rhythm Management  the company saw a sales drop of 8  on a comparable operational basis  However  the company received FDA approval for magnetic resonance  MR  conditional labeling for its Quadra Assura and Quadra Assura MP cardiac resynchronization therapy defibrillator  CRT D  devices and its Fortify Assura implantable cardioverter defibrillator  ICD  in the quarter under review Diabetes Care sales improved 27 6  on a comparable operational basis  buoyed by double digit international sales growth  led by continued consumer uptake of FreeStyle Libre   the revolutionary continuous glucose monitoring system of Abbott Nutrition sales were up 3  year over year on a reported basis  2  on a comparable operational basis   Foreign exchange drove sales by 1   Pediatric Nutrition sales increased 1 5  on a comparable operational basis  Adult Nutrition sales were up 2 8  on a comparable operational basis Diagnostics sales rose 51 7  year over year on a reported basis  up 6 7  on a comparable operational basis   Core Laboratory and Point of Care Diagnostics sales grew 7 2  and 6 8   respectively  on a comparable operational basis  Molecular Diagnostics sales were up a nominal 2 4  as strong growth in the infectious disease testing business was partially offset by the planned scale down of the genetics business  Rapid Diagnostics recorded sales of  540 million  driven by solid contributions from infectious disease testing  including flu and strep testing GuidanceAbbott issued full year 2018 guidance  Adjusting for certain net specified items for the full year  adjusted earnings per share from continuing operations are expected in the band of  2 80  2 90  The current Zacks Consensus Estimate is pegged at  2 83  near the low end of the projected range The company also provided first quarter 2018 adjusted earnings per share guidance  It expects to report adjusted earnings from continuing operations in the range of 57 cents to 59 cents in the quarter  The current Zacks Consensus Estimate of 56 cents is below the projected range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  There has been one revision higher for the current quarter 
Abbott Laboratories Price and Consensus    VGM Scores
At this time  ABT has a strong Growth Score of A  though it is lagging a bit on the momentum front with a B  The stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is primarily suitable for growth investors while also being suitable for those looking for momentum and to a lesser degree value 
Outlook
Estimates have been trending upward for the stock and the magnitude of this revisions also looks promising  Interestingly  ABT has a Zacks Rank  3  Hold   We expect in line returns from the stock in the next few months ",2018-02-23,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-down-67-since-earnings-report-can-it-rebound-200293744,200293744
181855,403371,ABT,Opening Bell  Gold  Bitcoin Struggle  Oil Remains Above  60,opinion,"Key Events
Yesterday  in what some may see as an auspicious sign for markets  on the first official trading day of 2018 all four major US indices rallied to start the new year  Three the S P 500  NASDAQ Composite and Russell 2000 even posted fresh records 
On Friday  the final trading day of 2017  stocks were sold off and gains made during at least 8 previous sessions were erased  Yesterday  however  investors replenished lost value  then continued to break new ground  suggesting Friday s selloff was not the first move in a trend reversal  but rather  nothing more sinister than profit taking after a spectacular year  the best since 2013 
While the strong opening session of 2018 trade may suggest that this year will bring more of the same  market internals tell a different story  Since September  fewer and fewer stocks have been participating in the headline grabbing rallies  forming a series of negative divergences  a possible prelude to a full market correction 

The S P 500 gained 0 83 percent  making both an all time high and a record close  The Dow climbed 0 43 percent  the  laggard  among the US indices and the only one to not post a new record  The NASDAQ outperformed major averages  jumping 1 51 percent  posting both a record high and close  finishing above 7 000 for the first time  while the NASDAQ 100 climbed 1 8 percent  the biggest gain for the index since October 27  Finally  the Russell 2000 advanced 1 07 percent  hitting dual records  both high and close 
On a more granular level  the Energy sector led the rally  up 1 63 percent  followed closely by Consumer Discretionary shares  which were boosted 1 49 percent  Materials   1 42 percent and Technology  which gained 1 24 percent  The weak dollar helped lift energy and material shares  which are priced in USD  The currency s weakness also affected multinational technology companies  whose products become cheaper on a softer greenback 
Among defensive stocks  Utilities led the decline  falling 0 93 percent  Healthcare was the only defensive sector that advanced  by a whopping 1 12 percent  Some individual healthcare stocks fared even better  Abbott  NYSE ABT  shares advanced 3 percent after JP Morgan upgraded them to overweight and raised their target price 
The only growth sector that lagged was Financials  which eked out a 0 04 advance  This essentially extends Friday s 0 71 decline of the sector  which led the pre weekend selloff 
As we mentioned here  albeit in a different context related to trading gold  investors seem to be betting against continued US growth and therefore rising rates  even as Fed policy makers have forecast another three hikes during the coming year 
Global Financial Affairs
Of interest given the recent slide in US financial sector shares  while financials traded on most Asian and European markets advanced this morning amid overall European market declines  Canada s financial sector shares fell 0 13 percent suggesting they may be more aligned with the US 
Energy shares were buoyed by the price of oil  which closed for the second time in three days above  60  trading near its two year high and enjoying the strongest new year opening for the commodity since 2014 

As of this writing  oil has been maintaining yesterday s gains  as it continues to sit above  60 for a third day  This can be credited to five fundamental causes 

Saudi Arabia s seriousness about production cuts and the need to maintain price stability ahead of Saudi Aramco s IPO 
The sagging dollar which makes the cost of oil cheaper 
Unchanged rig counts which remained at 747 for a second week  after US drillers paused production 
Unlike in Libya  where social unrest has affected the country s export capacity  the current  ongoing political protests in Iran OPEC s third largest producer have not had an effect on the country s exports  nor are they likely to impact production  As a rule  political unrest in oil producing countries effects sentiment  However  some speculate that should the protests escalate and become more violent  additional oil market risk could ensue  Worth paying attention to though  is the continued tension with Saudi Arabia which could escalate  thereby increasing the potential for actual supply interruption  However  with each country s economy and ruling regime completely dependent on oil exports  the conflict is unlikely to escalate beyond the current posturing 
US stockpiles extended drawdowns for a seventh week and nationwide crude supplies are forecast to decline by 5 million barrels 

This morning  investors in Asia followed their US counterparts  spurring major indices including the Shanghai Composite and KOSPI higher  Hong Kong s Hang Seng closed higher by 0 2  after earlier having hit a new intraday high 
As with US stocks  which were buoyed by a weak dollar  softer regional currencies led by South Korea s won pushed local stocks higher  Japanese markets remain closed for holidays 

European investors followed Asian bullishness as the region s MiFID II investment regulations finally take effect  Investors in Europe are expected to trade more cautiously today  as the biggest shake up to European regulation in a decade begins  The MiFID II regulations are one of the most seismic regulatory shifts in history  effecting everything from investment research to trade execution 
The Stoxx Europe 600 climbed this morning  led by retailers and healthcare stocks 

The euro fell for the first time in six days  Both European bonds and US Treasuries steadied 

Similarly  gold retreated from a near four month high  in line with a return move following an upside breakout  The recent rally in the precious metal offers some gold rush trading opportunities 

Bitcoin is moving higher right now  after the cryptocurrency fell from  15 428  pushed back below the  15 000 key level  A close within the current price level would form a bearish shooting star 
Up Ahead

US Construction Spending and ISM Manufacturing data are due later today 
FOMC December Meeting Minutes are also expected 

Market Moves
Stocks

The Stoxx Europe 600 gained 0 4 percent as of 8 13 London time  3 13 EST  to the highest in a week 
The U K  s FTSE 100 rose less than 0 05 percent 
Germany s DAX increased 0 4 percent 
The MSCI Asia Pacific Index increased 0 2 percent to the highest on record 
The MSCI Emerging Markets Index jumped 0 4 percent to the highest in almost seven years 
S P 500 Futures climbed 0 1 percent to the highest on record 

Currencies

The Dollar Index increased 0 1 percent 
The euro declined 0 2 percent 
The British pound rose less than 0 05 percent to  1 3593  the strongest in almost 16 weeks 
The Japanese yen decreased less than 0 05 percent to 112 34 per dollar 

Bonds

The yield on 10 year Treasuries rose less than one basis point to 2 47 percent  the highest in more than a week 
Germany s 10 year yield dipped one basis point to 0 46 percent 
Britain s 10 year yield decreased one basis point to 1 279 percent 

Commodities

West Texas Intermediate crude rose less than 0 05 percent to  60 38 a barrel 
Gold decreased 0 3 percent to  1 314 18 an ounce 
Copper dipped 0 6 percent to  3 26 a pound  the lowest in more than a week ",2018-01-03,Pinchas Cohen/Investing.com,https://www.investing.com/analysis/opening-bell-200277206,200277206
181856,403372,ABT,Abbott  ABT  Beats Earnings And Revenue Estimates In Q4,opinion,"Abbott   NYSE ABT   is an Illinois based company focused on bringing a diverse line of healthcare products to the market Abbott reports its diversified business in four segments   namely Established Pharmaceuticals Division  EPD   Medical Devices  Diagnostics and Nutrition  The company has reshaped its portfolio through strategic acquisitions divestitures in recent times  It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R D  which has resulted in numerous new product launches across its businesses In Feb 2015  Abbott completed the sale of its branded generics pharmaceuticals business in developed markets  Realignment of the EPD division through acquisitions in Latin America and Russia  along with business divestitures in developed markets  has positioned the company well for the coming quarters  However  unfavorable movement in foreign currency rates is affecting the top line adversely Abbott Laboratories Price and EPS Surprise    Abbott has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4 67  Currently  Abbott has a Zacks Rank  3  Hold   but that could definitely change following the company s second quarter 2017 earnings report which was just released   You can see   We have highlighted some of the key stats from this just revealed announcement below Earnings  The Zacks Consensus Estimate remained steady at 73 cents per share over the last 60 days  Abbott  fourth quarter 2017 earnings per share from continuing operations of 74 cents outpaced this estimate by a penny  Revenues  Abbott posted fourth quarter revenues of  7 59 billion beating the Zacks Consensus Estimate for revenues of  7 36 billion Key Stats   Worldwide Nutrition sales increased 2  on a reported basis in the fourth quarter to  1 78 billion while worldwide Diagnostics sales increased 6 7  on a reported basis to  1 9 billion while total Established Pharmaceuticals sales increased 14  on a reported basis to  1 14 billion  Revenues of Worldwide Medical Devices increased 9 6  on a reported basis to  2 73 billion  Major Factors  Abbott issued earnings outlook for 2018  reflecting strong double digit growth  The company banks on new product approvals and launches  Notably  Abbott received FDA clearance for its Confirm Rx Insertable Cardiac Monitor in October  Also  the company won FDA approval for magnetic resonance  MR  conditional labeling for its Quadra Assura and Quadra Assura MP cardiac resynchronization therapy defibrillator  CRT D  devices and its Fortify Assura implantable cardioverter defibrillator  ICD  Stock Price  Following the earnings release  share prices rose 1 77  during the pre market trading session 
Check back later for our full write up on this Abbott earnings report The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-23,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-beats-earnings-and-revenue-estimates-in-q4-200283036,200283036
181868,403384,ABT,3 Income Stocks That Are Saving Lives ,opinion,"I m a long term investor  Like Warren Buffett  I d love to hold a stock forever  Even if that s not likely  I do expect to keep a stock in my portfolio for five years minimum   preferably 10 
So not only do I look for great businesses  but I want to be invested in sectors with strong long term fundamentals 
I can t think of a stronger sector than healthcare 
Sure  technology is vital to our economy and is a source of growth  I like technology 
But can you think of a sector whose products will be more in demand over the coming decades than healthcare 
You may have heard this statistic  In the United States  roughly 10 000 people turn 65 every day 
One thing we know is that the older we get  the more healthcare we consume  Whether it s from doctor visits  prescriptions or artificial joints  older people and their insurance companies spend a lot on healthcare 
In fact  the average retired couple will spend more than a quarter of a million dollars out of pocket on healthcare  And Medicare and other insurance providers will spend a lot more 
It s not an understatement when we say your health is the most important thing 
So it makes sense to find the best healthcare companies to invest in for the long term  And since I m the dividend guy  I want these top companies to pay dividends as well 
Let s take a look at a few different areas within healthcare for some ideas on where to make money over the long term 

Biotech Pharma
Bristol Myers Squibb Company  NYSE BMY  was founded eight years before the invention of the radio and is one of the leading biopharmaceutical companies in the world 
It has 30 products on the market  including blood thinners Coumadin and Eliquis  cancer fighters Opdivo and Yervoy  and hepatitis B therapy Atripla  Additionally  it has 35 compounds being studied in clinical trials 
Bristol Myers Squibb recently scored big wins with new drugs  including Opdivo and Yervoy  that should keep revenue growing for years  That will not only reward shareholders but fund future research 
The stock yields 2 5  


Medical Devices
Though it still has pharmaceuticals in its product portfolio  Abbott Laboratories  NYSE ABT  is focusing more on medical devices  diagnostics and consumer products 
Its consumer products division makes Ensure  a nutritional drink for adults that is often used to supplement the diet of a person who is ill 
Its vascular unit has a variety of drug eluting stents  guide wires and other products 
And Abbott s diagnostic tools are used in oncology  genetic testing and infectious diseases 
The company has been around for 125 years  The stock yields 1 9  

Services
Omega Healthcare Investors Inc  NYSE OHI  is one of my favorite companies in healthcare 
It owns real estate that is leased by nursing homes and assisted living facilities  It s important to understand that Omega Healthcare doesn t operate the nursing homes  it is the nursing homes  landlord 
It is expected that roughly one third of all baby boomers will spend time in a nursing home or assisted living facility at some point in their lives 
Demand for beds in these places will be huge  Omega is poised to profit on this enormous trend 
The stock has a fat 9 3  yield and has raised its dividend for 15 years in a row 
Healthcare stocks should definitely have a place in your long term portfolio  The  silver tsunami  is one of the most significant trends that will affect the markets and the economy over the next several decades 
These stocks and others will thrive as seniors spend more on feeling good and feeling better 
And you ll feel great generating profits and dividends from these and other healthcare stocks ",2017-11-19,Investment U,https://www.investing.com/analysis/three-income-stocks-that-are-saving-lives-200266481,200266481
181915,403431,ABT,Centene  CNC  Tops Q3 Earnings   Revenues  Raises  17 View,opinion,Centene Inc    NYSE CNC   reported third quarter 2017 adjusted net income per share of  1 35  which beat the Zacks Consensus Estimate by 8   Earnings also improved 20 5  year over year  primarily on the back of higher revenues Operational UpdateFor the quarter  total revenues grew 10  to  11 9 billion year over year  primarily driven by growth in the Health Insurance Marketplace business in 2017 and expansions and new programs in many states in 2016 and 2017 This was partially offset by the moratorium of the Health Insurer Fee in 2017 and lower membership in the commercial business in California  Revenues surpassed the Zacks Consensus Estimate of  11 8 billion by 1  At the end of the quarter  managed care membership of 12 3 million reflected an increase of 8  from the third quarter of 2016 Health Benefit Ratio  HBR  for the quarter was 88  compared with 87  in the prior year quarter  This improvement of 100 basis points  bps  was a result of new and expanded health plans with higher HBR  an increase in higher acuity members and a premium rate reduction for California Medicaid Expansion effective Jul 1  2017 In the third quarter  adjusted selling  general and administrative expenses ratio was 8 9   down 20 bps year over year  This improvement reflects the leveraging of expenses over higher revenues in 2017  Total operating expenses of  11 5 billion increased 9 5  from the prior year quarter Centene Corporation Price  Consensus and EPS Surprise   Financial UpdateAs of Sep 30  2017  Centene had cash and cash equivalents of  4 3 billion  up 8 9  from 2016 year end  Total assets of  22 billion grew 8 9  from 2016 year end As of Sep 30  2017  Centene s long term debt totaled  4 7 billion  up 1 4  from 2016 year end For the first nine months of 2017  cash inflow from operations was  1 039 million compared with  259 million in the prior year period 2017 GuidanceCentene expects adjusted earnings per diluted share to be in the range of  4 86  5 04 against the previously guided range of  4 70  5 06 Total revenues are expected to be in the range of  47 4 48 2 billion compared with the earlier guidance of  46 4  47 2 billion HBR is expected in the range of 87 87 4   unchanged from the previous guidance Adjusted Selling  General   Administrative expense ratio is expected in the range of 9 3 9 7   unchanged from the previous guidance Diluted shares outstanding is expected be between 176 3 million and 177 3 million Zacks Rank and Performance of Other PeersCentene currently sports a Zacks Rank  1  Strong Buy   You can see  Among other players in the Medical sector that have reported their third quarter earnings so far  Abbott Laboratories    NYSE ABT    Johnson   Johnson    NYSE JNJ   and UnitedHealth Group Incorporated   NYSE UNH   beat their respective Zacks Consensus Estimate Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/centene-cnc-tops-q3-earnings--revenues-raises-17-view-200220659,200220659
181944,403460,ABT,Abbott  ABT  Beats Earnings And Sales In Q3  Tweaks View,opinion,Abbott   NYSE ABT   is an Illinois based company focused on bringing a diverse line of healthcare products to the market Abbott Labs reports its diversified business in four segments   namely Established Pharmaceuticals Division  EPD   Medical Devices  Diagnostics and Nutrition  The company has reshaped its portfolio through strategic acquisitions divestitures in recent times  It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R D  which has resulted in numerous new product launches across its businesses In Feb 2015  Abbott completed the sale of its branded generics pharmaceuticals business in developed markets  Realignment of the EPD division through acquisitions in Latin America and Russia  along with business divestitures in developed markets  has positioned the company well for the coming quarters  However  unfavorable movement in foreign currency rates is affecting the top line adversely Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4 6  Abbott Laboratories Price and EPS Surprise   Currently  Abbott Labs has a Zacks Rank  2  Buy   but that could definitely change following the company s third quarter 2017 earnings report which was just released   You can see   We have highlighted some of the key stats from this just revealed announcement below Earnings  The Zacks Consensus Estimate remained steady at 65 cents per share over the last 60 days  Abbott s third quarter 2017 earnings per share from continuing operations of 66 cents outpaced this estimate by a penny  Revenues  Abbott Labs posted third quarter revenues of  6 82 billion surpassing behind the Zacks Consensus Estimate for revenues of  6 71 billion Key Stats   Worldwide Nutrition sales increased 0 8  on a reported basis in the third quarter to  1 76 billion while worldwide Diagnostics sales increased 5 4  on a reported basis to  1 27 billion while total Established Pharmaceuticals sales increased 15 7  on a reported basis to  1 17 billion  Revenues of Worldwide Medical Devices increased 98 2  on a reported basis to  2 59 billion Major Factors  Per management  Abbott s third quarter results reflect a strong performance  The company is well positioned to achieve the upper end of the initial full year EPS guidance range  Management narrowed its full year 2017 EPS guidance which ranges from  2 48 to  2 50 now The company has received many FDA approvals recently Stock Price  Following the earnings release  share prices rose 1 7  during the pre market trading session Check back later for our full write up on this Abbott earnings report later The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/abbott-abt-beats-earnings-and-sales-in-q3-tweaks-view-200219555,200219555
182000,403516,ABT,Abbott Gets FDA Nod For FreeStyle Libre  Boosts Diabetes Arm,opinion,"Abbott   NYSE ABT   recently announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States The approval is likely to widen this Illinois based medical device major s customer base in diabetes management  The company aims at making the product commercially available to 30 million people with diabetes in the United States by the end of 2017  This flagship product will be available at major retail pharmacies for end users on a prescription basis Meanwhile  Abbott has been steadily progressing with the development of its diabetics segment  Recently  the company announced the receipt of national reimbursement for FreeStyle Libre in the U K   marking another milestone for the company  Notably  the FreeStyle Libre system is partially or fully covered in 17 countries  including France  Germany and Japan Moreover  the company recently announced receipt of Health Canada License for FreeStyle Libre Flash Glucose Monitoring System  This will drive growth in the Diabetes Care sales segment  which saw revenue growth of 18 7  in second quarter 2017 on continued consumer acceptance of FreeStyle Libre internationally  We believe the latest FDA nod will boost the company s performance in the domestic arena as well We expect Freestyle Libre to contribute to Abbott s top line as along with the U K   Japanese and Canadian developments  the French Health Ministry has approved national reimbursement for the device Per a report by Mordor Intelligence  the global market for diabetes care devices is projected to reach a value of  30 25 billion by 2021  at a CAGR of 5 93   Given the bullish market sentiments  we believe the recent regulatory approvals for FreeStyle Libre have come at an opportune moment However  the diabetes market is dominated by many well established players  Johnson   Johnson   NYSE JNJ   being the most prominent one  In this space  Johnson   Johnson also has a tie up with U S  based Animas Corporation for the development of insulin delivery systems Share Price PerformanceAbbott has been gaining investor confidence on consistently positive results  Over the last three months  Abbott s share price has outperformed the broader   The stock has gained 10 1   in contrast to the broader industry s decline of 0 7   The company has also outperformed the 3 6  gain of the S P 500 market over the same time frame  
Zacks Rank   Key PicksAbbott carries a Zacks Rank  3  Hold   A few better ranked medical stocks in the medical sector are Orthofix International N V    NASDAQ OFIX   and Owens   Minor  Inc   NYSE OMI    Orthofix International and Owens   Minor sport a Zacks Rank  1  Strong Buy   You can see Orthofix International has a long term expected earnings growth rate of 11 8   The stock has rallied roughly 3  over the last three months Owens   Minor has a long term expected earnings growth rate of 5   The stock has gained 4 4  in the last month Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-01,Zacks Investment Research,https://www.investing.com/analysis/abbott-gets-fda-nod-for-freestyle-libre-boosts-diabetes-arm-200216473,200216473
182001,403517,ABT,Abbott To Gain From Alere s Takeover Due For Oct 3 Closure,opinion,"Investors keen on the consolidation of Abbott Labs   NYSE ABT   with Alere may expect that much awaited good news to arrive soon  Per Abbott s latest update  with all the necessary regulatory clearances getting fulfilled for the closure  the company finally plans to complete the hugely contentious acquisition of Alere  Inc   on Oct 3  2017 
Notably  after a year s rollercoaster ride to overcome the regulatory hurdles  both Abbott and Alere had progressed with the merger process based on certain amended terms of the original agreement 
Per the amended agreement clauses  announced earlier in April   Abbott has agreed to pay  51 per common share to acquire Alere  a reduction from the earlier deal of  56 per common share in cash upon the transaction s conclusion  This results in an expected  new equity value of approximately  5 3 billion  lower than the originally estimated equity value of almost  5 8 billion 
Our Take
Abbott has stated that with the successful wrap up of this transaction  its total diagnostics sales should be  7 billion  The company also anticipates to emerge a lead player in the  7 billion point of care diagnostic space within the broader  50 billion in vitro diagnostics market with this takeover  The combined entity is expected to generate approximately  2 5 billion in point of care testing sales worldwide 
The buyout would also enable the company to gain an access to new channels and geographies  including entries into fast growing outlets  such as doctors  offices  clinics  pharmacies and at home testing  More to that  Alere s complementary portfolio of diagnostic products  comprising tests for infections such as HIV  tuberculosis  malaria and dengue will be added to Abbott s portfolio  Significantly  Alere develops simple  rapid tests  including Alere i   the molecular test for flu and strep   to deliver reports in less than 15 minutes 
Hence  the shared business will offer several options of tests in a broad array  for instance  infectious disease  molecular  cardiometabolic and toxicology testings  Also  this union would definitely expand Abbott Labs  platforms to include benchtop and rapid strep tests  Although Alere would hitherto generate over half its total sales from the United States alone  the company has a growing presence in key international markets with potential to strengthen Abbott s footprint ahead in these territories 
Price Performance

Over the past three months  Abbott s share price has outperformed the broader  it belongs to  The stock has gained 9 5  versus the industry s loss of 0 7  
Zacks Rank and Other Key Picks
Abbott currently carries a Zacks Rank  3  Hold   Some better ranked medical stocks are IDEXX Laboratories  Inc    NASDAQ IDXX    Luminex Corp    NASDAQ LMNX   and Masimo Corp    NASDAQ MASI    each carrying a Zacks Rank  2  Buy   You can see 
IDEXX Laboratories has a positive earnings surprise of 9 3  over the last four quarters  The stock has roughly surged 37 5  over the last year 
Luminex Corp  has a long term expected earnings growth rate of 16   The stock has gained around 22 2  over the last month 
Masimo has an expected long term adjusted earnings growth of almost 14   The stock has rallied nearly 29  year to date 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-02,Zacks Investment Research,https://www.investing.com/analysis/abbott-to-gain-from-aleres-takeover-due-for-oct-3-closure-200216531,200216531
182027,403543,ABT,iFOREX Daily Analysis   August 29  2017,opinion,"On Monday the U S  dollar fell below its 16 month low against other major currencies  Tropical storm Harvey that hit the south east of the United States hard as well as the disappointing speech by FED chair Yellen on Friday contributed to the pressure on the greenback 
U S  equity indices showed a mixed picture on Monday with energy and financial stocks down and with significant gains from biotech stocks 
Gold rallied to its highest level since December last year and passed the  1 300 barrier with ease early in the North American trading session  On the other hand oil had significant losses as traders expect that the lack of refinery capacity in the storm affected area of the U S  will drive up oil inventories  which the EIA will publish on Wednesday 
Bitcoin experienced some losses on Monday which it could mostly recover  The major cryptocurrency is still can t breach its resistance level of around  4 500  Litecoin hit a record high on Monday  while Ripple was up after falling since last Wednesday 
On Tuesday Germany will publish consumer sentiment data  while France publishes statistics about its GDP and manufactured goods consumption which will give the first insight in the economic impact of Emmanuel Macron s government  From the U S  we expect the publication of the S P Case Shiller House Price Index and consumer confidence statistics 
EUR USD
The EUR USD  i  rose further on Monday amid a disappointing speech by U S  Federal reserve chair Yellen and a positive attitude to the Euro Zone economy by ECB president Draghi at the same time 
EUR USD reached a high of 1 1985 for the first time since January 2015  The EUR USD had its low before in July 2012 at 1 2043  The U S  Dollar Index USDX fell also to a new low this year 
On Tuesday EUR USD traders will be looking at consumer sentiment data from Germany and GDP data from France  In the North American trading session data on the U S  consumer sentiment and house prices will be released 

Pivot  1 1915Support  1 1915 1 1865 1 183Resistance  1 2 1 204 1 211
Scenario 1  long positions above 1 1915 with targets at 1 2000   1 2040 in extension Scenario 2  below 1 1915 look for further downside with 1 1865   1 1830 as targets Comment  the RSI advocates for further upside 
Gold
Janet Yellen s speech on Friday was understood by traders as a signal that there would be no more rate hikes this year which in turn pushed Gold  i  finally above  1 300 on Monday  The fall of the U S  dollar to a new low on Monday also contributed to the Gold rally as Gold become comparably cheaper in other currencies than the U S  dollar 
Market participants also received no calming words from the Trump administration as fears of a possible government shutdown still worry investors 
Market participants will continue watching for news from the White House and the impact of tropical storm Harvey as to gauge what the destabilizing effects will be  U S  inflation data published on Thursday and the Nonfarm Payrolls  NFP  on Friday could also show more details about the state of the economy and move the markets 

Pivot  1297Support  1297 1293 1288Resistance  1315 1319 1324
Scenario 1  long positions above 1297 00 with targets at 1315 00   1319 00 in extension Scenario 2  below 1297 00 look for further downside with 1293 00   1288 00 as targets Comment  the RSI is bullish and calls for further upside  Prices broke above a bullish channel 
WTI Oil
Oil  i  settled lower on Monday as activities of refineries in the south east of the U S  are still disrupted by the effects of tropical storm Harvey  There are fears that the lack of oil processing capacity will lead to greater supplies and inventories of crude oil 
The U S  Bureau of Safety and Environmental Enforcement estimated that the production of oil in the Gulf of Mexico is down by about 19  but this is still not enough to make up for the lack of refinery capacities 
Storm Harvey could continue having an effect on oil prices this week  Energy Information Administration  EIA  inventory data published on Friday will give a first look into what the actual impact on the inventories will be  

Pivot  47 2Support  46 05 45 7 45 35Resistance  47 2 47 5 47 8
Scenario 1  short positions below 47 20 with targets at 46 05   45 70 in extension Scenario 2  above 47 20 look for further upside with 47 50   47 80 as targets Comment  the RSI is mixed to bearish 
US 500
U S  equity indices  i  closed on Monday mostly slightly higher with the exception of the Dow  US 30  which was down by 0 05   Traders were mostly concerned by the impact of the tropical storm Harvey which negatively impacted companies in the energy sector while financial companies still felt the effect of the speech from FED s chairwoman Janet Yellen on Friday which did not satisfy the traders  expectations 
Biotech companies were the biggest winners of the day with the US Biotech ETF being up by 1 92   Among them Abbott Laboratories  NYSE NYSE ABT  was one of the winners of the day following the FDA s approval for one of its new heart pump systems 
U S  equity trader will look forward to the publication of the S P Case Shiller House Price Index and consumer confidence data 

Pivot  2436Support  2436 2429 2422Resistance  2451 2455 2462
Scenario 1  long positions above 2436 00 with targets at 2451 00   2455 00 in extension Scenario 2  below 2436 00 look for further downside with 2429 00   2422 00 as targets Comment  the RSI is mixed to bullish ",2017-08-29,iFOREX,https://www.investing.com/analysis/iforex-daily-analysis--august-29-2017-200210071,200210071
182055,403571,ABT,Abbott  ABT  Tops Earnings Estimates In Q2  Misses On Sales,opinion,"Abbott Laboratories   NYSE ABT   is an Illinois based company focused on bringing a diverse line of healthcare products to the market Abbott Labs reports its diversified business in four segments   namely Established Pharmaceuticals Division  EPD   Medical Devices  Diagnostics and Nutrition  The company has reshaped its portfolio through strategic acquisitions divestitures in recent times  It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R D  which has resulted in numerous new product launches across its businesses In Feb 2015  Abbott completed the sale of its branded generics pharmaceuticals business in developed markets  Realignment of the EPD division through acquisitions in Latin America and Russia  along with business divestitures in developed markets  has positioned the company well for the coming quarters  However  unfavorable movement in foreign currency rates is affecting the top line adversely Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4 67  Currently  Abbott Labs has a Zacks Rank  2  Buy   but that could definitely change following the company s second quarter 2017 earnings report which was just released   You can see   We have highlighted some of the key stats from this just revealed announcement below Earnings  The Zacks Consensus Estimate remained steady at 60 cents per share over the last 60 days  Abbott Labs  second quarter 2017 earnings per share from continuing operations of 62 cents outpaced this estimate by 3 33   Revenues  Abbott Labs posted second quarter revenues of  6 60 billion lagging behind the Zacks Consensus Estimate for revenues of  6 62 billion 
Abbott Laboratories Price and EPS Surprise   Key Stats   Worldwide Nutrition sales decreased 0 6  on a reported basis in the second quarter to  1 73 billion while worldwide Diagnostics sales increased 3 8  on a reported basis to  1 27 billion while total Established Pharmaceuticals sales increased 4 1  on a reported basis to  1 02 billion  Revenues of Worldwide Medical Devices increased 89 2  on a reported basis to  2 59 billion Major Factors  Per management  Abbott s second quarter performance reflects a strong start to the year 2017  Management raised its guidance range for reported EPS from continuing operations in the range of  2 43 to  2 53    The integration of St  Jude is currently going on and its recently launched products are contributing to double digit sales growth across several areas of Abbott s Medical Devices business Stock Price  Following the earnings release  share prices rose 1 15  during the pre market trading session Check back later for our full write up on this Abbott Labs earnings report later 3 Top Picks to Ride the Hottest Tech Trend Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce d the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ",2017-07-19,Zacks Investment Research,"https://www.investing.com/analysis/abbott-(abt)-tops-earnings-estimates-in-q2,-misses-on-sales-200202354",200202354
182103,403619,ABT,Zacks com Featured Highlights  Johnson   Johnson  NantKwest  Delek US Holdings  Abbot Labs And Winnebago,opinion,"For Immediate Release

	Chicago  IL   June 21  2017   Stocks in this week s article include Johnson   Johnson  NYSE JNJ   NYSE         NantKwest  NASDAQ         Delek US Holdings  NYSE         Abbot Labs  NYSE        and Winnebago  NYSE        

Screen of the Week of Zacks Investment Research by Kevin Matras  

How to Uncover Institutional Buying

	One of the best ways to find stocks on the move that are grabbing the attention of investors is to screen for stocks with increasing volume 

	This is because increased volume shows investor interest  As more investors buy the stock  the stock s price should go higher 

	But the individual investor  while important to the market  doesn t really have the firepower to affect volume the way that big institutional investors do 

	And very few things can move a stock more than institutional buying 

	Why is that 

	For one  institutions have the ability of buying tens of millions of dollars worth of a stock and even hundreds of millions of dollars  And because their purchases are often so large  it typically takes weeks  if not months  for an institutional investor to build a position 

	Given this commitment  considering it will also take several weeks or months to get out  you can be sure that these institutional investors have done plenty of homework to feel good about the fundamental prospects of the company 

	This does not mean you can ignore your own analysis or the stock market as a whole  But screening for stocks with rising volume  along with prices of course  can put some fantastic stocks on your radar screen 

What Kind of Volume Increase to Look For

	I prefer to search for at least two weeks of increasing volume along with rising prices  And in my testing I have found that 3 weeks performs even better 

	One week volume spikes  however  will not get thru  as oftentimes those can be driven by one day events  Instead  it s the successive volume increase that shows true buying demand  giving this set up its value 

	The volume increase also doesn t have to be huge  We re not talking about a several hundred percent increase  In fact  often those massive increases prove to be turning points 

	What we re looking for are noticeable increases  like 10   20  or 50  increases  etc  But nothing outrageous  like a 10 fold increase  Remember  the last thing an institutional investor wants to do is call too much attention while he or she is in the midst of building a position  But if you know what to look for  you can see all of this happening in plain sight  And get in for the ride as they flesh out the rest of their position 

Screen Parameters

  Current Price greater than Price from 1 Week Ago
	  Price from 1 Week Ago greater than Price from 2 Weeks Ago
	  Price from 2 Week Ago greater than Price from 3 Weeks Ago 

  Weekly Volume greater than Weekly Volume from 1 Week Ago
	  Weekly Volume from 1 Wk Ago greater than Weekly Volume from 2 Wks Ago
	  Weekly Volume from 2 Wks Ago greater than Weekly Volume from 3 Wks Ago 

  Zacks Rank less than or equal to 3
	  Price greater than or equal to  5
	  Average 20 day Volume greater than or equal to 100 000 shares 

	The most important elements to this screen are the price and volume items  especially the volume   The Zacks Rank also helps to make sure that their earnings estimates are on the rise  The price item  however  is a personal preference as I generally don t buy stocks under  5  But it should also be noted that many institutions won t either  But if you re looking for lower priced stocks  you can of course remove this item  And lastly  the average volume item ensures there s enough trade activity on a daily basis to get in and out of the market easily 

Stocks

	Here are 5 stocks that passed this week s screen 

	 NYSE       Johnson   Johnson
	 NASDAQ       NantKwest
	 NYSE       Delek US Holdings
	 NYSE       Abbot Labs
	 NYSE       Winnebago

	All of these stocks look good fundamentally  But their successive increases in weekly volume suggest institutional buying  and warrant an even closer look 

	Get the rest of the stocks on this list and start screening for weekly volume increases to uncover institutional buying on your own  It s easy to do 



Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

Disclosure  Performance information for Zacks  portfolios and strategies are available at     

Zacks Restaurant Recommendations    In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  

	Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 

About Screen of the Week

	Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time    

 

 

 

 

 

	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Contact  Jim Giaquinto

	Company  Zacks com

	Phone  312 265 9268

	Email  

	Visit  

	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-06-20,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-johnson---johnson,-nantkwest,-delek-us-holdings,-abbot-labs-and-winnebago-200196566",200196566
182123,403639,ABT,Zoetis  ZTS  Tops Earnings   Sales In Q1  Keeps 2017 View,opinion,"Florham Park  NJ based Zoetis Inc    NYSE ZTS   is one of the leading global animal health companies focused on the discovery  development  manufacture and commercialization of animal health medicines and vaccines  with a focus on both livestock and companion animals  The company came into existence following Pfizer s decision to spin off its animal health business in 2013 
Zoetis  diversified portfolio of products for livestock and companion animals should continue to drive top line growth at the company  The company s top line should benefit from the addition of products acquired from Abbott Laboratories  NYSE ABT   Feb 2015   Pharmaq  Nov 2015  as well as from the performance of Apoquel and other key brands  In this scenario  investor focus remains on top and bottom line numbers 
Zoetis  track record has been impressive with the company beating earnings estimates consistently  In fact  Zoetis  earnings surpassed expectations in each of the last four quarters  with an average positive surprise of 11 48  
Currently  Zoetis has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below 
Earnings Beat  Once again  Zoetis has surpassed earnings estimates  Zoetis beat on first quarter 2017 earnings  The company reported EPS of 53 cents while our consensus called for EPS of 48 cents 
Revenues Beat   Zoetis posted revenues of  1 23 billion surpassing the Zacks consensus estimate of  1 19 billion 
Key Stats  The company strengthened its canine dermatology portfolio with the approval of Cytopoint in the European Union in April 2017 and in Canada inMarch 2017  Cytopoint is the first monoclonal antibody  mAb  therapy approved to help provide a reduction in the clinical signs associated with atopic dermatitis such as itching in dogs 
2017 Outlook Re affirmed  Zoetis reiterated its outlook for 2017  In 2017  the company expects earnings in the range of  2 26 to  2 36 per share on revenues of  5 10 billion and  5 23 billion  The Zacks Consensus Estimate for earnings is  2 32 per share on revenues of  5 17 billion 
Share Price Impact  Shares of the company were up 0 4  in pre market trading 
Check back later for our full write up on this ZTS earnings report later 
 Zoetis Inc  Price and EPS Surprise
    Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge  With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ",2017-05-03,Zacks Investment Research,"https://www.investing.com/analysis/zoetis-(zts)-tops-earnings---sales-in-q1,-keeps-2017-view-200187095",200187095
182148,403664,ABT,Will Abbott Lab  ABT  Surprise Estimates In Q1 Earnings ,opinion,"Abbott Laboratories   NYSE ABT   is scheduled to report first quarter 2017 results before the opening bell on Apr 19  Last quarter  the company s earnings exceeded the Zacks Consensus Estimate by 1 56   Also  the company posted an average beat of 3 05  in the trailing four quarters  Let s see how things are shaping up prior to this announcement Factors at PlayWe are optimistic about Abbott s strong and consistent Established Pharmaceuticals Division  EPD  and Medical Devices performances Within EPD  through a series of strategic actions  including the sale of Abbott s developed markets business  the acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia  the company already achieved double digit operational sales growth in fourth quarter and full year 2016  The company expects the same momentum to continue in the yet to be reported quarter With a leading market position in several geographies  including India  Russia and Latin America  EPD is believed to be well positioned for sustained above market growth in some of the largest and fastest growing pharmaceutical markets in the world Abbott Laboratories Price and EPS Surprise   In 2017  the company plans to execute its existing operating model which focuses on portfolio selling in core therapeutic areas which will lead to the creation of unique channel opportunities in differentiated relationships with physicians  retailers and pharmacies that are looking to offer a complete line of solutions to treat prominent local health conditions Also  Abbott has plans to beef up its development capabilities with an expanded EPD innovation center in India  The center will act as a hub  shipping products to over 30 countries that will further develop differentiated products to suit local needs  Ffirst quarter onward  we expect a few of these executions to take place successfully  resulting in a top line accretion Within medical device  we are looking forward to Abbott s ongoing integration synergy  related to the St  Jude acquisition  which closed in January  The acquisition of St  Jude represents a major strategic move that establishes Abbott as a premier medical device business comprising cardiovascular  neuromodulation and diabetes care  These represent some of the largest and fastest growing areas of healthcare  We expect to see the ongoing synergy to ramp up the top line from the first quarter itself Notably  Abbott anticipates annual pre tax synergies of  500 million by 2020  including revenue expansion opportunities as well as operational and SG A efficiencies Overall  for the first quarter 2017  the company forecast adjusted earnings per share within 42 cents to 44 cents  Comparable operational sales growth for the quarter is expected in low single digits Earnings WhispersOur proven model does not conclusively show that Abbott Laboratories is likely to beat on earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  Abbott s Earnings ESP is 0 00  since both the Most Accurate estimate and the Zacks Consensus Estimate stand at 43 cents Zacks Rank  Abbott has a Zacks Rank  4  Sell   which fails to increase the predictive power of ESP Also  we caution against stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are three companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter   Applied Materials  Inc    NASDAQ AMAT   has an Earnings ESP of  1 32  and a Zacks Rank  1  You can see  The Chemours Company   NYSE CC   has an Earnings ESP of  4 08  and a Zacks Rank  1 
You can uncover the best stocks to buy or sell before they re reported with our  Hill Rom Holdings  Inc    NYSE HRC   has an Earnings ESP of  1 27  and a Zacks Rank  2 Zacks  Best Private Investment Ideas While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-11,Zacks Investment Research,https://www.investing.com/analysis/will-abbott-lab-(abt)-surprise-estimates-in-q1-earnings-200182510,200182510
182149,403665,ABT,Earnings Season s Back  Stocks With Big Upside,opinion,"Earnings Season   Q1 17
Three major banks reported earnings before the market opened on Thursday and officially kicked off the start of the Q1 17 earnings season  JPMorgan  NYSE JPM  and Citigroup  NYSE C  both beat their revenue and EPS estimates while Wells Fargo  NYSE WFC  beat its EPS estimate but missed on revenues by  310 million  All three stocks  however  traded lower Thursday afternoon 
Investor sentiment has weakened in recent weeks as President Trump has been unable to get key parts of his economic agenda in motion  The Federal Reserve Bank of Atlanta also recently cut its Q1 17 GDP growth estimate to 0 6   down from 2 1  in Q4 16   As a result  investors are cautiously waiting for Q1 17 earnings to roll out as the early year stock rally has recently stalled 
According to   Wall Street expects S P 500 member companies to grow their profits by 10  which would be its highest level in over two years  This figure will likely need to be reached or surpassed in order for the market to regain its upward momentum 
Four Undervalued Stocks Reporting This Week
There are over 281 companies expected to report earnings next week  4 17 4 21  where finbox io calculates a fair value estimate and only a few appear to be fundamentally undervalued  Our intrinsic value data shows that only four companies have a  and 20  or more upside  Syntel Inc  NASDAQ SYNT   Skechers  NYSE SKX   USG Corporation  NYSE USG  and Abbott Laboratories  NYSE ABT  
Syntel is expected to report earnings on Thursday  4 20  before the market opens  The company s shares are trading near their 52 week low in the face of declining revenues and margins  However  these headwinds appear to be fully priced in leaving a nice margin of safety before earnings 
Nine separate analyses imply that the stock is over 35  undervalued while Wall Street s consensus price target of  21 20 implies 25  upside 
Skechers is expected to report earnings on Wednesday  4 19  after the market closes  The footwear company s stock has fallen over 50  since its August 2015 high of  51 per share as revenue growth has decelerated 
On March 24th  Cowen  shares to outperform and raised its price target from  25 to  35 noting Skecher s international wholesale growth  The new price target and bullish outlook is supported by the nine fundamental analyses below 
USG is expected to report earnings on Wednesday  4 19  before the market opens  Recently  the company s stock has fallen slightly on concerns about President Trump s stimulus promises  However  shares look very attractive on a long term fundamental basis  The low end of the fair value range is still roughly  2 above the stock s current trading price 
Abbott Laboratories  stock has an intrinsic value of approximately  53 50 implying over 20  upside before earnings  expected Wednesday   4 19   This compares favorably to the Wall Street s consensus price target of  47 85 which implies 10  upside 
The healthcare products manufacturer has beat its EPS estimate 10 out of the last 12 quarters and will look to continue this trend next week 
These stocks all have strong fundamentals and could easily trade  20  higher based on their underlying earnings  Value investors may want to take a closer look at these names prior to earnings this week ",2017-04-13,Finbox io,https://www.investing.com/analysis/earnings-seasons-back:-stocks-with-big-upside-200182867,200182867
182150,403666,ABT,Abbott Laboratories Agrees To Acquire Alere At Lower Price ,opinion,Finally the much contentious merger of Abbott Laboratories   NYSE ABT   with Alere is nearing its close  As expected  the financial terms of the deal have been amended Amended TermsPer the amended terms of the agreement  Abbott has agreed to pay  51 per common share to acquire Alere  a reduction from earlier deal of  56 per common share in cash upon the completion of the transaction  This results in a new expected equity value of approximately  5 3 billion  reduced from the originally expected equity value of approximately  5 8 billion The transaction  which was inked on 1 Feb 2016  is now expected to close by the end of the third quarter of 2017  subject to the approval of Alere shareholders and the satisfaction of customary closing conditions  including applicable regulatory approvals  Notably  the company also extended the last date of receiving necessary regulatory approvals from Apr 30  2017 to Sep 30  2017 Also  both the companies  which were engaged in legal battles with each other on issues regarding the pending merger  agreed to dismiss their respective lawsuits The Legal BattleNotably  the legal battle came into spotlight last August when for Alere filed a complaint against Abbott Labs in the Delaware Chancery Court  It wanted to force Abbott Labs to take all the necessary actions to obtain anti trust approvals and fulfill its obligations under the terms of the merger agreement Alere s accusation was based on Abbott Labs  reluctance to complete the deal  In fact  Abbott Labs even requested to call it off in Apr 2016 Abbott s version was that  it had serious concerns regarding the accuracy of various representations  warranties and covenants made by Alere in their merger agreement  It also agreed to pay the legal costs in the range of  30  50 million in respect to Alere s transaction expenses  which was rejected by the latter Against Alere s lawsuit  in December  Abbott filed a lawsuit to terminate its  5 8 billion purchase of the former quoting a substantial loss in the value of Alere s stock since they struck the deal With the legal actions finally dropped now  according to a Bloomberge article   The renegotiated price was better than many on Wall Street expected  Share Price PerformanceIn this regard we note that  Abbott s shares underperformed the Zacks classified  industry over the past month on litigation qualms with Alere  The stock lost 5 14  during this period compared with 1 65  loss of the broader industry  The resolution of the matter is likely to boost the company s stock price in the future Our TakeEarlier  Abbott Labs said that it expects its total diagnostics sales to exceed  7 billion post the closure of the transaction  The company will also become a lead player in the  5 5 billion point of care diagnostic segment We are upbeat about the fact that Alere integration will enable Abbott Labs to gain access to new channels and geographies  Although Alere generated more than half of its total sales of  2 5 billion from the U S  alone  the company has a growing presence in key international markets  which should further strengthen Abbott Labs  business in these territories  It will also add Alere s complementary portfolio of diagnostic products  which comprises tests for infections such as HIV  tuberculosis  malaria and dengue   Zacks Rank   Key PicksAbbott Labs currently carries a Zacks Rank  4  Sell   Better ranked stocks in the broader Medical space include Inogen  Inc    NASDAQ INGN    Orasure Technologies  Inc    NASDAQ OSUR   and Hill Rom Holdings  Inc    NYSE HRC    While Inogen sports a Zacks Rank  1  Strong Buy   Orasure and Hill Rom carry a Zacks Rank  2  Buy   You can see  Inogen gained 62 2  in the last one year compared with the S P 500 s gain of 15 1   The company reported a stellar four quarter positive average earnings surprise of over 49 08  Orasure surged 73 9  in the last one year compared with the S P 500 s gain  Its four quarter average earnings surprise was a positive 123 5  Hill Rom gained over 33 9  in the past one year  better than the S P 500 mark  It posted a trailing four quarter positive average earnings surprise of 12 03  Sell These Stocks  Now  Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ,2017-04-16,Zacks Investment Research,https://www.investing.com/analysis/abbott-laboratories-agrees-to-acquire-alere-at-lower-price-200183121,200183121
182151,403667,ABT,Company News For April 17  2017,opinion,     Shares of Abbott Laboratories   NYSE ABT   fell 1 9  after the company received a warning letter from Food and Drug Administration related to its implantable heart defibrillators     United Continental Holdings  Inc  s   NYSE UAL   shares declined 1 2  after the company removed a couple from a flight to Costa Rica on Saturday     Shares of Goldman Sachs Group Inc   NYSE GS   fell 1 1  after a U S  District Court judge in Manhattan rejected the company s bid to shorten a gender bias lawsuit     Pier 1 Imports  Inc  s   NYSE PIR   shares declined 9 1  after the company s quarterly revenue declined 2 6  year over year  to  528 4 million,2017-04-16,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-april-17,-2017-200183196",200183196
182152,403668,ABT,Abbott Laboratories  ABT  Tops Q1 Earnings   Sales Estimates,opinion,Abbott Laboratories   NYSE ABT   is an Illinois based company focused on bringing a diverse line of healthcare products to the market Abbott Labs reports its diversified business in four segments   namely Established Pharmaceuticals Division  EPD   Medical Devices  Diagnostics and Nutrition  The company has reshaped its portfolio through strategic acquisitions divestitures in recent times  It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R D  which has resulted in numerous new product launches across its businesses In Feb 2015  Abbott completed the sale of its branded generics pharmaceuticals business in developed markets  Realignment of the EPD division through acquisitions in Latin America and Russia  along with business divestitures in developed markets  has positioned the company well for the coming quarters  However  unfavorable movement in foreign currency rates is affecting the top line adversely Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 3 05  Currently  Abbott Labs has a Zacks Rank  3  Hold   but that could definitely change following the company s first quarter 2017 earnings report which was just released   You can see   We have highlighted some of the key stats from this just revealed announcement below Earnings  The Zacks Consensus Estimate remained steady at 43 cents per share over the last 60 days  Abbott Labs  first quarter 2017 earnings per share from continuing operations of 48 cents outpaced this estimate by 11 6   Abbott Laboratories Price and EPS Surprise   Revenues  Abbott Labs posted first quarter revenues of  6 33 billion which has surpassed the Zacks Consensus Estimate for revenues of  6 11 billion Key Stats   Worldwide Nutrition sales decreased 1 7  on a reported basis in the first quarter to  1 64 billion while worldwide Diagnostics sales increased 3 6  on a reported basis to  1 15 billion while total Established Pharmaceuticals sales increased 7 0  on a reported basis to  950 million  Revenues of Worldwide Medical Devices increased 100 2  on a reported basis to  2 39 billion  Major Factors  Per management  Abbott s first quarter performance reflects a strong start to the year 2017  Management reaffirmed its guidance range for reported EPS from continuing operations in the range of  0 92  1 02  The integration of St  Jude is currently going on and its recently launched products are contributing to double digit sales growth across several areas of Abbott s Medical Devices business Stock Price  Following the earnings release  share prices rose 2 92  during the pre market trading session Check back later for our full write up on this Abbott Labs earnings report later 5 Trades Could Profit  Big League  from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-04-18,Zacks Investment Research,https://www.investing.com/analysis/abbott-laboratories-(abt)-tops-q1-earnings---sales-estimates-200183734,200183734
182174,403690,ABT,Abbott Labs  ABT  Beats On Q3 Earnings  Narrows 2016 View,opinion,"Abbott Laboratories   NYSE ABT   reported third quarter 2016 earnings of 59 cents per share  higher than both the Zacks Consensus Estimate of 58 cents and the year ago figure of 54 cents Quarterly sales came in at  5 3 billion  up 2 9  year over year on a reported basis  and in line with the Zacks Consensus Estimate  The top line was  however  impacted by unfavorable foreign exchange movement of 1 1  Quarter in DetailAbbott Labs operates through four segments   Established Pharmaceuticals Division  EPD   Medical Devices  Nutrition and Diagnostics EPD sales were up 5 3  to  1 01 billion  including a negative impact of 3 7  due to currency fluctuations  Sales in key emerging markets increased 7  on a reported basis driven by solid growth in India as well as strong demand in several countries of Latin America due to commercial initiatives and locally relevant portfolio expansion The Medical Devices business generated sales of  1 3 billion  up 6 4  year over year  Vascular product sales were up 5 2  on the back of double digit growth in MitraClip  Diabetes Care sales increased 11 5  driven by continued consumer uptake of FreeStyle Libre  Sales of Medical Optics were up 4 4  backed by continued market uptake of cataract products in the premium intraocular lens segment  During the quarter  Abbott received FDA approval for Tecnis Symfony intraocular lenses Nutrition sales were decreased 2  year over year to  1 8 billion  Pediatric Nutrition sales decreased 4  on a reported basis  Adult Nutrition sales increased 1 4  on an operational basis led by a strong performance of Ensure Diagnostics sales increased 5  year over year to  1 2 billion  Core Laboratory sales and Point of Care Diagnostics sales were each up 5 6   Molecular Diagnostics sales were down 0 8  as growth in the infectious disease testing business was partially offset by the planned scale down of the genetics business 2016 OutlookAbbott Labs has raised the mid point and narrowed its guidance for earnings  The company now expects earnings in the range of to  2 19    2 21 per share  The current Zacks Consensus Estimate stands at  2 20 ABBOTT LABS Price
 

   Our TakeAbbott Labs  third quarter results were better than expected due to strong performance of the EPD and Medical Devices segments  Going ahead  the FDA approval of Absorb  the only fully dissolving heart stent  and Tecnis Symfony intraocular lenses for the treatment of cataracts should fuel the company s topline The company also stands to benefit from its upcoming acquisition of St  Jude Medical Inc    NYSE STJ    which will offer it an industry leading pipeline across cardiovascular  neuromodulation  diabetes and vision care  Abbott Labs entered into a definitive agreement to acquire St  Jude Medical  Inc  for  25 billion in Apr 2016  The transaction is expected to close in the fourth quarter of 2016 
Recently  the companies have agreed to sell certain products to Terumo Corporation in an all cash transaction of approximately  1 12 billion  The products include St  Jude Medical s Angio Seal and Femoseal vascular closure products  and Abbott s Vado Steerable Sheath  Abbott will  however  retain its vascular closure products Moreover  the sale of Abbott Medical Optics to Johnson   Johnson   NYSE JNJ   will help Abbott reshaping its portfolio in order to focus on gaining leadership positions in cardiovascular devices and expanding diagnostics Abbott Labs currently carries a Zacks Rank  4  Sell  A Stock to ConsiderA better ranked stock in the health care sector is Incyte Corporation   NASDAQ INCY   with a Zacks Rank  1  Strong Buy   You can see  Incyte s earnings estimates for 2016 and 2017 were up a respective 22 2  and 6 6  over the last 60 days  The company has beaten earnings estimates thrice in the last four quarters  with an average surprise of 335 16  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-19,Zacks Investment Research,"https://www.investing.com/analysis/abbott-labs-(abt)-beats-on-q3-earnings,-narrows-2016-view-200159644",200159644
182175,403691,ABT,How Is Diamond Hill Large Cap A Fund  DHLAX  Performing ,opinion,"Diamond Hill Large Cap A Fund     a Zacks Rank  2  Buy  was incepted in June 2001 and is managed by Diamond Hill Capital Management Inc  The objective of DHLAX is to seek capital growth for the long run  DHLAX invests the majority of its assets in securities of large cap companies  which are expected to be undervalued 

	This Large Blend product  as of the last filing  allocates their fund in three major groups  Large Value  Large Growth and Foreign Stock  Further  as of the last filing  State Street Navigator Securities  Pfizer Inc  NYSE PFE  and Abbott Laboratories  NYSE ABT  were the top holdings for DHLAX 

	The Diamond Hill Large Cap A fund  managed by   carries an expense ratio of 1 04   Moreover  DHLAX requires a minimal initial investment of  2 500 

	DHLAX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 8 8  and 5 year 15 5   To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds   

	DHLAX s performance  as of the last filing  when compared to funds in its category was in the top 16  over the past 1 year  in the top 39  over the past 3 years  and in the 32  over the past 5 years 

Want key mutual fund info delivered straight to your inbox 

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2016-10-27,Zacks Investment Research,https://www.investing.com/analysis/how-is-diamond-hill-large-cap-a-fund-(dhlax)-performing-200161414,200161414
182176,403692,ABT,Mylan  MYL  Stock Falls On Restructuring Plans  Layoffs,opinion,In an 8 K filing  generic drug maker Mylan N V    NASDAQ MYL   revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on the integration of acquired businesses  The company expects to cut less than 10  of its global workforce  marking the first step in a series of actions The company is currently straightening out the details of the cost saving and restructuring initiatives  and will divulge more information once these plans are finalized  We note that Mylan s global workforce comprised nearly 35 000 employees as of Dec 31  2015  This implies that the layoff could affect up to 3 500 people Note that Mylan has been on an acquisition spree since 2015  In Feb 2015  it acquired Abbott Laboratories    NYSE ABT   non U S  developed markets  specialty and branded generics business  This June  it took over the non sterile  topicals focused business of privately held Renaissance Acquisition Holdings  followed by the Aug 2016 buyout of Swedish drug manufacturer Meda Pricing   Related Issues PersistMylan s shares lost 3 8  on the restructuring announcement  The company has in fact lost a substantial 26 2  since Aug 2016  ever since it started facing criticism for the massive price hike of its lifesaving allergy treatment  EpiPen  The pricing controversy even led to a congressional hearing and drew immense flak from former U S  presidential candidate Hillary Clinton Since then  Mylan has been struggling to turn the tide through initiatives like changes in the EpiPen access programs  which included raising the savings card program from  100 to  300  doubling the eligibility of the patient assistance program  and working on the upcoming launch of a generic version of EpiPen However  all of these steps have more or less failed to mitigate the situation effectively In fact  right after the pricing issue  Mylan made it to the headlines for wrongly classifying EpiPen as a generic product in the Medicaid Drug Rebate Program  The misclassification implied that Mylan has been vastly underpaying rebates to Medicaid for the drug for a long time than it would have if the drug was classified as a branded one As a result  in Oct 2016  Mylan agreed to pay  465 million to the U S  Department of Justice  DoJ  and other government agencies in an effort to settle the disputes regarding the misclassification of EpiPen  In the third quarter of 2016  the company even booked a  465 million charge related to the settlement  which led to weaker than expected quarterly results In addition  even though the company stated on its third quarter 2016 earnings call that it was working on finalizing the deal  the DoJ is yet to confirm if it has reached a settlement with the company Mylan s shares will be under pressure in the foreseeable future with lawmakers continuing to question the company s pricing policy and concerns related to the ongoing investigations Despite these challenges  shares of the company have outperformed the Zacks categorized Medical Generic Drugs industry  albeit marginally  The industry has witnessed a decline of 26 5  since August The industry has been under pressure as the DoJ could investigate quite a few generic drug manufacturing companies like Mylan and Endo International plc   NASDAQ ENDP   over price collusion  In fact  Mylan revealed through a 10 Q filing of its receipt of subpoenas from the DoJ in Sep 2016  seeking additional information related to the marketing  pricing and sale of its four generic products Trump s Victory   Boon or Curse The post election rally in the biotech and pharma sectors came to an abrupt halt when President elect Donald Trump clarified that his intentions were misinterpreted and that he actually plans to target excessive drug price hikes  Winner of Time s  Person of the Year  title  in an interview with Time  Trump stated   I m going to bring down drug prices  I don t like what has happened with drug prices  During his campaigns  Trump was not as vocal as Clinton about drug price hikes  As a result  upon the declaration of results  shares of the biotech sector climbed 9  Note that the drug pricing issue has been weighing on the healthcare sector since last year when Clinton s Sep 2015  price gouging tweet  led to huge sell off in the pharma and biotech stocks Given the intense public  political and media focus on branded drug prices  in addition to the ongoing investigations into generic drug pricing  the healthcare sector will probably remain under pressure going ahead Mylan currently carries a Zacks Rank  5  Strong Sell  MYLAN NV Price and Consensus    A Key PickSucampo Pharmaceuticals  Inc    NASDAQ SCMP   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy   You can see  Sucampo s earnings estimates increased from  1 03 to  1 22 for 2016 and from  1 30 to  1 58 for 2017 over the last 60 days  The company posted a positive surprise in all of the four trailing quarters with an average beat of 35 55  Zacks  Best Private Investment IdeasIn addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ,2016-12-07,Zacks Investment Research,"https://www.investing.com/analysis/mylan-(myl)-stock-falls-on-restructuring-plans,-layoffs-200168947",200168947
182195,403711,ABT,The Zacks Analyst Blog Highlights  VIVUS  Geron  Achillion Pharmaceuticals  Anika Therapeutics And ANI Pharmaceuticals,opinion,"For Immediate Release

	Chicago  IL   October 05  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include VIVUS Inc     NASDAQ         Geron Corporation    NASDAQ         Achillion Pharmaceuticals  Inc     NASDAQ         Anika Therapeutics Inc    NASDAQ        and ANI Pharmaceuticals  Inc     NASDAQ         

	Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Tuesday s Analyst Blog  

Biotech Mergers Run the Show  5 Small Caps for Q4

	Healthcare merger and acquisition activity has gathered steam over the past few years  A few big mergers in the recent past include that of Pfizer  NYSE PFE  and Wyeth  Pfizer and Hospira  Novartis AG and Alcon  Sanofi  PA SASY  and Genzyme  Roche and Genentech  and AstraZeneca and MedImmune  Consolidation helps large pharma companies gain more pricing power while simultaneously curbing competition 

	Last November  Pfizer announced that it would acquire Allergan  NYSE AGN pa  for  160 billion  However  this deal fell apart in Apr 2016 due to the new U S  tax inversion rules 

	There has been a flurry of mergers and acquisitions in the healthcare space this year too  In August  Pfizer announced the acquisition of oncology focused Medivation for approximately  14 billion  The deal is expected to close this year  This was preceded by the buyout of Anacor in Jun 2016 

	Also in June  Shire acquired Baxalta to brace its rare disease portfolio further  while Aegerion Pharmaceuticals and QLT entered into a definitive merger agreement to form a new company  Novelion Therapeutics Inc 

	In April  Abbott Laboratories  NYSE ABT  announced plans to buy St  Jude Medical in a move to bolster its share in the cardiovascular device market  In fact  the month of September probably saw higher merger acquisition activity this year  Horizon Pharma announced plans to buy California based Raptor Pharmaceuticals  This acquisition  slated to close in the fourth quarter  is likely to strengthen Horizon s orphan business in the U S  and expand it in Europe and key important markets 

	After months of negotiations  German pharmaceutical maker  Bayer AG  DE BAYGN  last month announced a definitive merger agreement to acquire Monsanto  NYSE MON  in an all cash deal worth  66 billion 

	Allergan announced a string of small bolt on acquisitions last month  It announced a definitive deal to acquire Tobira Therapeutics  a clinical stage biotechnology company focused on drugs to treat non alcoholic steatohepatitis  NASH  and other liver diseases at a massive premium of 500   Also  Allergan said it will be acquiring clinical stage biotech company  Vitae  to boost its dermatology pipeline 

	Last month  Allergan also bought privately held Akarna Therapeutics to add the latter s lead product candidate AKN 083  a preclinical stage FXR agonist  being evaluated for the treatment of NASH  Allergan also added the lead gene therapy development program RST 001 of privately held  clinical stage biotechnology company RetroSense Therapeutics to its eye care pipeline last month 

	In licensing activities and collaborations for the development of pipeline candidates have also increased significantly  Several pharma companies are focusing on in licensing  mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time 
	Small biotech companies are open to such deals as most of them find it challenging to raise cash  thereby facing difficulty in surviving and continuing with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash 

	Merger and acquisitions  especially small bolt on acquisitions  as well as aggressive in licensing activities and collaborations are expected to increase  going forward  This in turn puts the spotlight on small cap biotech stocks 

	Biotech companies with new therapies or interesting pipeline candidates can be strong takeover targets 

	Here we have narrowed down the list of choices by focusing on five stocks with a favorable Zacks Rank of  1  Strong Buy  or  2  Buy   Also  these are small cap biotech companies with a market cap of less than  1 billion  These stocks are well positioned in today s market environment and could see considerable upside riding on the aforementioned trends 

VIVUS Inc     NASDAQ       

	Mountain View  CA based VIVUS  Inc  focuses on developing compounds to treat obesity  sleep apnea  diabetes and sexual health  VIVUS  key product  Qsymia  targets the highly lucrative obesity market with huge commercial potential 

	VIVUS delivered positive earnings surprises in three of the past four quarters  with an average beat of 39 88   Its loss estimates for 2016 and 2017 have narrowed over the past 60 days  The company s share price has increased 13  year to date  Currently  VIVUS sports a Zacks Rank  1  You can see   

Geron Corporation    NASDAQ       

	Menlo Park  CA based biopharmaceutical company  Geron Corporation focuses on the development of first in class therapeutic products for the treatment of cancer  Geron s product development programs are based on its patented core technology  telomerase  which represents significant commercial opportunity  The successful development of products that target telomeres could very well change the treatment paradigm for several diseases including oncology  which represents huge commercial potential 

	Geron  which carries a Zacks Rank  1  delivered positive earnings surprises in each of the past four quarters  with an average beat of 20 78   Its loss estimates for 2016 have narrowed from 26 cents to 24 cents in the past 60 days 

Achillion Pharmaceuticals  Inc     NASDAQ       

	Achillion Pharmaceuticals is a development stage company  focused on the development of potent and specific complement factor D inhibitors for rare and other diseases  Achillion has out licensed its HCV portfolio to Janssen  a Johnson   Johnson  NYSE JNJ  company 

	Currently  Achillion holds Zacks Rank  1  It delivered positive earnings surprises in all the past four quarters  with an average beat of 364 79   Its loss estimates for 2016 have narrowed from 66 cents to 62 cents in the past 60 days 

Anika Therapeutics Inc    NASDAQ       

	Anika Therapeutics makes therapeutic products and devices that promote the repair  protection and healing of bone  cartilage and soft tissues  Its products are based on hyaluronic acid  a naturally occurring  biocompatible polymer found in the body  The stock carries a Zacks Rank  1 

	Anika Therapeutics  earnings estimates for 2016 and 2017 have increased a respective 9 5  and 11 5  over the last 60 days  The company recorded a positive earnings surprise in each of the last four quarters  with an average beat of 42 19   Its share price has jumped 25  year to date 

ANI Pharmaceuticals  Inc     NASDAQ       

	This Zacks Rank  2 specialty pharmaceutical company witnessed an increase of 9 5  and 4 7  in its earnings estimates for 2016 and 2017  respectively  in the last 60 days  It surpassed earnings estimates twice in the last four quarters  bringing the average positive surprise to 46 85   The company s share price has surged 50 6  year to date 

Now See Our Private Investment Ideas

	While the above ideas are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum       from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors     

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-10-04,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-vivus,-geron,-achillion-pharmaceuticals,-anika-therapeutics-and-ani-pharmaceuticals-200157241",200157241
182196,403712,ABT,Celgene Agios Ink Deals With Abbott To Identify IDH Mutations,opinion,"Celgene Corporation   NASDAQ CELG   and Agios Pharmaceuticals  Inc    NASDAQ AGIO   announced that they have entered into collaboration agreements with Abbott Laboratories   NYSE ABT   to develop and commercialize diagnostic tests to identify isocitrate dehydrogenase  IDH  mutations in patients with acute myeloid leukemia  AML  The companies will use Abbott s m2000 RealTime System  a polymerase chain reaction  PCR  instrument that helps automate the PCR process to analyze results and simplify the complex and manual steps related to molecular diagnostics Celgene is developing an IDH2 inhibitor  enasidenib  for the treatment of patients with relapsed or refractory AML who have an IDH2 mutation  Currently  enasidenib is in a phase III study  IDHENTIFY  which is comparing the candidate with conventional therapy in older patients CELGENE CORP Price
    Agios is developing an IDH1 inhibitor  AG 120  for the treatment of patients with relapsed or refractory AML who have an IDH1 mutation We remind investors that Celgene had inked a discovery and development collaboration  and a license agreement with Agios focused on targeting cancer metabolism in Apr 2010  In May 2016  the collaboration agreement was amended  whereby Agios acquired full global development and commercialization rights to AG 120  Previously  Agios has held only the U S  rights to AG 120 AGIOS PHARMACT Price
    According to information provided by the company  IDH1 and IDH2 mutations occur in approximately 20  of all AML patients Celgene currently carries a Zacks Rank  3  Hold   while Agios is a Zacks Rank  4  Sell  stock A Stock to ConsiderGeron Corporation   NASDAQ GERN   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy   You can see  The company has posted a positive earnings surprise in each of the four trailing quarters  bringing the average beat to 20 78  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-12,Zacks Investment Research,https://www.investing.com/analysis/celgene-agios-ink-deals-with-abbott-to-identify-idh-mutations-200158582,200158582
182197,403713,ABT,St  Jude Medical  STJ  Q3 Earnings  What s In The Cards ,opinion,St  Jude Medical Inc    NYSE STJ   is set to report third quarter 2016 earnings results on Oct 19  Last quarter  the company posted earnings of  1 06 per share  which came in line with the Zacks Consensus Estimate We note that St  Jude surpassed the Zacks Consensus Estimate in the last four quarters  by an average of 0 82  Let s see how things are shaping up for this quarter Factors at PlayWe believe St  Jude s performance will suffer owing to a sluggish Cardiac Rhythm Management  CRM  market  The downside would come from pricing pressure  austerity measures and health care reforms in the market Foreign exchange movements are not favoring St  Jude s results  The company derives more than half of its revenues from international operations  primarily in Europe and Japan  The strong U S  dollar against the Japanese yen and euro may impede the performance in the third quarter The company also withdrew its financial guidance for fiscal 2016 as a result of its planned merger with Abott Laboratories  In this regard  St  Jude Medical is set to be acquired by Abbott Laboratories  NYSE ABT  in a  25 billion deal  St  Jude shareholders will receive  46 75 in cash and 0 8708 shares of Abbott common stock  The company is thus expected to face certain integration risks as a result of the planned merger  ST JUDE MEDICAL Price and EPS Surprise   Earnings WhispersOur proven model does not conclusively show that St  Jude is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank of  1  2 or at least 3 for this to happen  That is not the case here as you will see below Zacks ESP  St  Jude currently has an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate currently stand at  1 01 Zacks Rank  St  Jude has a Zacks Rank  4  Sell  which decreases the possibility of an earnings beat  Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few stocks worth considering that  as per our model  have the right combination of elements to post an earnings beat this quarter WellCare Health Plans   NYSE WCG   with an Earnings ESP of  5 41  and a Zacks Rank  1  Strong Buy   You can see  Achillion Pharmaceuticals  Inc    NASDAQ ACHN   with an Earnings ESP of  6 25  and a Zacks Rank  2  Buy  Ascendis Pharma   NASDAQ ASND   with an Earnings ESP of  15 49  and a Zacks Rank  2 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand    ,2016-10-16,Zacks Investment Research,https://www.investing.com/analysis/st.-jude-medical-(stj)-q3-earnings:-what's-in-the-cards-200159182,200159182
182200,403716,ABT,Abbott Labs  ABT  Beats On Earnings   Sales In Q3,opinion,"Abbott Laboratories   NYSE ABT   is an Illinois based company focused on bringing a diverse line of healthcare products to the market Abbott Labs reports its diversified business in four segments   namely Established Pharmaceuticals Division  EPD   Medical Devices  Diagnostics and Nutrition The company has reshaped its portfolio through strategic acquisitions divestitures in recent times  It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R D  which has resulted in numerous new product launches across its businesses In Feb 2015  Abbott completed the sale of its branded generics pharmaceuticals business in developed markets  Realignment of the EPD division through acquisitions in Latin America and Russia  along with business divestitures in developed markets  has positioned the company well for the coming quarters  However  unfavorable movement in foreign currency rates is affecting the top line adversely Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 3 11  ABBOTT LABS Price and EPS Surprise
    Currently  Abbott Labs has a Zacks Rank  4  Sell   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings  Our consensus called for EPS of 58 cents per share  while the company reported EPS of 59 cents  from continuing operations excluding one time items  Revenue  Abbott Labs posted revenues of  5 3 billion  in line with our expectations Key Stats  The recent launches of FreeStyle Libre and MitraClip have boosted the performance  Foreign currency exchange rate movements negatively impacted sales by 1 1   The company expects 2016 earnings per share in the range of  2 19 per share to  2 21 per share  excluding specified items  Check back later for our full write up on this Abbott Labs earnings report later Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-18,Zacks Investment Research,https://www.investing.com/analysis/abbott-labs-(abt)-beats-on-earnings---sales-in-q3-200159562,200159562
182222,403738,ABT,Bristol Myers Opdivo s Regulatory Application Validated In EU,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that its type II variation application for Opdivo has been validated by the European Medicines Agency  EMA   The company is looking to expand Opdivo s label to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma  mUC  in adults after a failure of prior platinum containing therapy  The validation marks the initiation of the EMA s centralized review process The application primarily included data from an open label  single arm phase II study  CheckMate  275  The company plans to present data from the study at the European Society for Medical Oncology Congress We are encouraged by the validation of the regulatory application for Opdivo in the EU   Per the company s press release  bladder cancer is the fifth most commonly diagnosed cancer in Europe  accounting for an estimated 151 000 new cases per year and resulting in 52 000 deaths annually  UC urothelial carcinoma is the most common type of bladder cancer  which accounts for roughly 90  of the cases Meanwhile  the company is also working on expanding the drug s label  Opdivo is currently under priority review in the U S  for the treatment of patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck  A response from the FDA is expected by Nov 11  2016  The product is also under review in the EU for the same indication Note that Opdivo has recorded worldwide sales of  1 5 billion in the first half of 2016  A label expansion in additional indications would give the product access to a higher patient population and increase the commercial potential of the drug significantly BRISTOL MYERS Price
    Zacks Rank   Key PicksBristol Myers currently carries a Zacks Rank  3  Hold   Some better ranked stocks in health care sector include ANI Pharmaceuticals  Inc    NASDAQ ANIP    Cambrex Corporation   NYSE CBM   and Abbott Laboratories   NYSE ABT    While both ANI Pharmaceuticals and Cambrex sport a Zacks Rank  1  Strong Buy   Abbott carries a Zacks Rank  2  Buy   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-20,Zacks Investment Research,https://www.investing.com/analysis/bristol-myers-opdivo's-regulatory-application-validated-in-eu-200154733,200154733
182240,403756,ABT,St  Jude Medical  STJ  Meets Q2 Earnings  Withdraws Outlook,opinion,"St  Jude Medical Inc  reported adjusted earnings of  1 06 per share in the second quarter of 2016  which was in line with the Zacks Consensus Estimate and increased almost 3  on a year over year basis  At constant currency  cc   earnings increased 7  from the year ago quarter to  1 10 
	St  Jude is set to be acquired by Abbott Laboratories  NYSE ABT    St  Jude shareholders will receive  46 75 in cash and 0 8708 shares of Abbott common stock  Due to the planned merger  St  Jude withdrew its financial guidance for fiscal 2016 Revenue Details
	Total sales improved 11  to  1 56 billion  which beat the Zacks Consensus Estimate of  1 55 billion  On a comparable basis  including Thoratec s result for both the periods  and adjusting for foreign currency  sales increased 2  on a year over year basis 
	International sales increased 11  at cc to  767 million  while U S  sales grew 12  to  795 million 







	Atrial Fibrillation  AF  sales increased 13  year over year at cc to  324 million  driven by strong adoption of FlexAbility and TactiCath ablation catheters  International sales were up 13  to  189 million  while U S  sales increased 13  to  135 million in the quarter 
	Heart Failure  HF  comprises cardiac resynchronization therapy products  ventricular assist devices and the CardioMEMS HF System products  Sales surged 48  at cc to  384 million  driven by higher sales from ventricular assist devices  On a comparable basis and adjusting for foreign currency  sales decreased 1  on a year over year basis 
	Neuromodulation sales jumped 20  year over year at cc to  140 million  driven by a 19  surge in U S  sales and 22  increase in international sales 
	Robust performance for St  Jude Medical s Burst technology in international markets and launch of Axium  Infinity DBS system and directional lead in the Europe drove results 
	Cardiovascular sales inched up 2  at cc to  319 million in the quarter  International sales climbed 3  to  198 million  while U S  sales decreased 1  to  121 million  Sales were propelled by the continued strength of the Portico Transcatheter Aortic Valve Implantation System in Europe  Increasing adoption of OPTIS optical coherence tomography products and PressureWire fractional flow reserve technology also boost sales 
	Cardiac Rhythm Management  CRM  sales decreased 7  year over year to  395 million  U S  sales fell 15  to  186 million while international sales decreased 2  to  209 million in the reported quarter 



		ST JUDE MEDICAL Price  Consensus and EPS Surprise



   


Zacks Rank   Key Picks
	Currently  St  Jude Medical has a Zacks Rank  2  Buy  
	Better ranked stocks in the same sector are NuVasive  and NxStage Medical   Both the stocks sport a Zacks Rank  1  Strong Buy  ",2016-07-19,Zacks Investment Research,"https://www.investing.com/analysis/st.-jude-medical-(stj)-meets-q2-earnings,-withdraws-outlook-200142985",200142985
182241,403757,ABT,Abbott  ABT  Beats On Earnings   Sales In Q2  Maintains View,opinion,"Abbott Laboratories   NYSE ABT   reported second quarter 2016 earnings of 55 cents per share  higher than both the Zacks Consensus Estimate of 53 cents and the year ago figure of 52 cents 

In the reported quarter  sales came in at  5 3 billion  up 3 2  year over year on a reported basis  and surpassed the Zacks Consensus Estimate of  5 26 billion  However  the top line was impacted by unfavorable foreign exchange movement of 3 2  during the quarter 
Quarter in Detail
Abbott Labs operates through four segments   Established Pharmaceuticals Division  EPD   Medical Devices  Nutrition and Diagnostics 
EPD sales were down 0 4  to  980 million  including a negative impact of 9 1  due to currency fluctuations  Sales in key emerging markets soared 15 9  on an operational basis driven by solid growth in India 
The Medical Devices business generated sales of  1 4 billion  up 6 4  year over year  Vascular product sales were up 8 3  on the back of double digit growth of MitraClip  The FDA recently approved the company s bioresorbable stent  Absorb  Diabetes Care sales increased 1 7  driven by continued consumer uptake of FreeStyle Libre 
However  sales were impacted by competitive and market dynamics in the U S  Sales of Medical Optics were up 6 2  backed by continued market uptake of cataract products in the premium intraocular lens segment  Abbott recently received FDA approval for its Tecnis Symfony intraocular lenses as well 
Nutrition sales were up 1 4  year over year to  1 7 billion  Pediatric Nutrition sales grew 3 4  on an operational basis  Growth was driven above market growth in the U S  as well as continued uptake of recently launched products including infant and toddler non GMO products and growth in Latin America and Asia  Adult Nutrition sales improved 5 5  on an operational basis led by a strong performance of Ensure and growth in international markets 
Diagnostics sales increased 4 1  year over year to  1 2 billion  Core Laboratory sales and Point of Care Diagnostics sales were up 3 4  and 11 5   respectively  Molecular Diagnostics sales grew 2 5  as growth in the infectious disease testing business was partially offset by the planned scale down of the genetics business 
2016 Outlook
Abbott Labs reiterated its earnings per share guidance in the range of  2 14 to  2 24  The current Zacks Consensus Estimate stands at  2 20 ABBOTT LABS Price and EPS Surprise
   Our Take
Abbott Labs  second quarter results were much better than expected due to the recent product launches   Eleva in China  MitraClip  Freestyle Libre in Europe and Supera peripheral stent  Going ahead  the recent FDA approval of Absorb  the only fully dissolving heart stent  and Tecnis Symfony intraocular lenses for the treatment of cataracts will fuel its performance  The company also stands to benefit from its upcoming acquisition of St  Jude Medical   NYSE STJ    which will offer it an industry leading pipeline across cardiovascular  neuromodulation  diabetes and vision care 
Abbott Labs currently has a Zacks Rank  3  Hold   Investors interested in the health care sector may consider Johnson   Johnson   NYSE JNJ   and Gilead Sciences   NASDAQ GILD    Both the stocks carry a Zacks Rank  2  Buy  ",2016-07-20,Zacks Investment Research,"https://www.investing.com/analysis/abbott-(abt)-beats-on-earnings---sales-in-q2,-maintains-view-200143092",200143092
182267,403783,ABT,Pfizer  PFE  Gets FDA Nod For Label Expansion Of Prevnar 13,opinion,Pfizer Inc    NYSE PFE   announced that the FDA has approved a label expansion of vaccine Prevnar 13  Pneumococcal 13 valent Conjugate Vaccine  Diphtheria CRM197 Protein   The vaccine can now be used for adults aged 18 to 49 years  The vaccine was previously approved for active immunization in the prevention of pneumonia and invasive disease caused by 13 Streptococcus pneumoniae  S  pneumoniae  serotypes   1  3  4  5  6A  6B  7F  9V  14  18C  19A  19F and 23F   in adults aged 50 years or older The vaccine is also approved in the EU  Its uptake has been strong among adults so far  Pfizer s vaccines division sales were up 18  to  1 6 billion in the first quarter of 2016  We believe that the latest label expansion of Prevnar will further boost sales  Moreover  the expanded age bracket aligns with the recommendations of the 2012 U S  Centers for Disease Control and Prevention s Advisory Committee on Immunizations Practices  ACIP  for use in adults 19 years of age and older with immunocompromising conditions  e g   HIV  chronic renal failure  cancer   functional or anatomic asplenia  e g   sickle cell disease   cerebral spinal fluid leak and Cochlear implants PFIZER INC Price   Pfizer has committed resources toward the development of treatments in the fields of oncology  cardiology  metabolic disorders  neuroscience  immunology  inflammation and vaccines  These are areas in which the company believes it can take leading positions  To this end  in Dec 2014  the company acquired Baxter s portfolio of marketed vaccines comprising NeisVac C and FSME IMMUN TicoVac Pfizer currently carries a Zacks Rank  2  Buy   Other favorably placed stocks in the healthcare sector include Abbott Laboratories   NYSE ABT    Roche Holdings   OTC RHHBY   and Johnson   Johnson   NYSE JNJ    All the three stocks carry the same rank as Pfizer ,2016-07-12,Zacks Investment Research,https://www.investing.com/analysis/pfizer-(pfe)-gets-fda-nod-for-label-expansion-of-prevnar-13-200141608,200141608
182268,403784,ABT,Why Is Alere Inc   ALR  Up Today ,opinion,"Alere Inc    NYSE ALR   is up 10 5  in afternoon trading on Friday after analysts saw an increased likelihood that the company s  5 8 billion acquisition by Abbott Laboratories   NYSE ABT   would close 
Based in Waltham  MA  Alere focuses on products and services for infectious diseases  cardiology  oncology  drugs of abuse  and women s health 
Abbott first announced its deal to acquire the company in the beginning of February  However  the process had been set back by Alere s choice to delay the filing of their annual 10 K report for 2015  because it was looking into the timing of revenue recognition in Africa and China during 2013  2014  and the first three quarters of 2015 
Alere plans to file its 2015 financials as soon as possible  but does not believe the revisions will make a material impact on the data  although according to their official statement did state that  the cumulative effect of reflecting these misstatements in the current year would be material to the year ended December 31st  2015  
The company also released preliminary revenue numbers  in which they indicated revenue of between  2 45 billion and  2 48 billion for 2015  Q1 2016 preliminary revenue is between  573 million and  579 million  Alere also reported preliminary net income of between  10 million to  25 million for 2015  along with between   8 million and  2 million for Q1 2016 
  Abbott made the deal with Alere in order to strengthen its presence and leadership in the global diagnostics market  This is not the only deal that Abbott has made recently  having also bought St  Jude hospital for  25 billion in late April 
Analysts have not revised earnings estimates for Alere in the last sixty days  Current estimates stand at earnings of  0 54 per share this quarter  along with earnings of  2 08 per share this fiscal year 
Alere currently sits at a Zacks Rank  3  Hold  ",2016-07-15,Zacks Investment Research,https://www.investing.com/analysis/why-is-alere-inc.-(alr)-up-today-200142192,200142192
182269,403785,ABT,Alere Updates On 10K Filing  Reports Preliminary Q1 Figures,opinion,"Alere Inc    NYSE ALR   recently provided some information about its pending 10K for the year that ended on Dec 31  2015  Over the last four months  the company has been conducting a review of its operations in Africa and China for the years 2013  2014 and 2015 The thorough review process has identified certain misstatements related to revenue recognition and other financial aspects for 2013 and 2014 and the first three quarters of 2015  Although these misstatements are not material to 2013 and 2014 financials  they are expected to affect 2015 figures Hence  Alere expects to revise its previously issued annual financial statements for 2013 and 2014 and the interim financial statements of each three quarters of 2015 in the upcoming 10K  However  Alere did not provide any time line and said that it expects to file the 10K with the SEC  as soon as practicable  Revenue Estimates Lowered for FY15Meanwhile  Alere revised down its 2015 revenue guidance  The company now expects to report revenues of almost  2 47 billion  down from  2 48 billion to  2 5 billion guided earlier  Net income from continuing operations is now expected to be in the band of  10  25 million  while adjusted EBITDA is estimated to be in the range of  505 million to  520 million  ALERE INC Price  Consensus and EPS Surprise
   As of Dec 31  2015  cash and cash equivalents are expected to be  502 million  while total debt is estimated to be  3 07 billion Preliminary Q1 FiguresAlere also provided few details about the first quarter 2016 results  The company expects to report revenues in the range of  573  593 million  Net income from continuing operations is now expected to be in the band of   8   2 million  while adjusted EBITDA is estimated to be in the range of  106 million to  116 million As of Dec 31  2015  cash and cash equivalents are expected to be  492 million  while total debt is estimated to be  3 02 billion No Immediate Relief for AlereAlere s announcement related to the 10K and the preliminary Q1 figures will certainly calm down bond holders  The figures will also be eagerly scrutinised by Abbott Laboratories   NYSE ABT    Alere s current suitor In early February  Abbott offered  5 8 billion to acquire Alere   However  the company tried to break away from the deal following the revelation of the U S  Department of Justice  DOJ  s investigation into Alere s overseas businesses  Reportedly  Abbott also offered a break up fee  which however did not interest Alere The deal continues to face issues like Alere s recent voluntary recall of the INRatio and INRatio 2 PT INR Monitoring Systems  According to Bloomberg  the recall is expected to cost Alere between  70 million and  90 million in 2016  Abbott has already expressed its disappointment and is currently reviewing the impact of the recall on Alere s financials Zacks Rank   Key PicksAlere has a Zacks Rank  3  Hold  Better ranked stocks are Boston Scientific   NYSE BSX   and NuVasive   NASDAQ NUVA    Both the stocks sport a Zacks Rank  1  Strong Buy  ",2016-07-15,Zacks Investment Research,"https://www.investing.com/analysis/alere-updates-on-10k-filing,-reports-preliminary-q1-figures-200142182",200142182
182270,403786,ABT,Abbott Labs  ABT  Q2 Earnings  Will The Stock Surprise ,opinion,Abbott Laboratories   NYSE ABT   is scheduled to report second quarter 2016 results before the opening bell on Jul 20 Abbott Labs has an impressive track record  having surpassed estimates in each of the trailing four quarters with an average earnings surprise of 3 17   Let s see how things are shaping up for this announcement Factors Influencing the QuarterStrengthening of the dollar against almost every currency adversely impacted the company s business in the past few quarters  However  strong first quarter results as well as an improving exchange rate outlook led to management raising the annual earnings guidance Earnings for the second quarter are estimated to be around 52 54 cents per share Sales in 2016 will suffer about 2  due to currency movements  Second quarter sales are expected to decline in the low single digits  reflecting a 3  negative currency impact  On a segmental basis  the company expects nutrition sales to increase in the mid to high single digits  while sales from the diagnostic unit are anticipated to grow in the mid single digits  Vascular sales are projected to remain flat on an operational basis in second quarter 2016  while the Diabetes care business may accelerate as the company strives to meet increasing demand for Libre from consumers and healthcare professionals  Sales are estimated to increase in the mid single digits  Meanwhile  sales at the established pharmaceuticals division  EPD  are expected to increase in the mid single digits as well Abbott Labs has an extremely diversified portfolio which management reshaped through strategic acquisitions divestitures in recent times  It has been taking strategic steps to expand its footprint in the growing geographies and investing in R D  which has resulted in numerous new product launches across its businesses  Realignment of the EPD division through acquisitions in Latin America and Russia  along with business divestitures in developed markets  has positioned the company well for the coming quarters What Our Model IndicatesOur proven model does not conclusively show that Abbott Labs is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to likely post an earnings beat  However  that is not the case here  as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 53 cents Zacks Rank  The combination of Abbott Labs  Zacks Rank  3 and a 0 00  ESP makes surprise prediction difficult Note that we caution against stocks with Zacks Rank  4 and  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions ABBOTT LABS Price and EPS Surprise   Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Johnson  Johnson   NYSE JNJ   has an Earnings ESP of  0 60  and a Zacks Rank  2  The company is scheduled to report second quarter results on Jul 19 Gilead Sciences Inc    NASDAQ GILD   has an Earnings ESP of  6 91  and a Zacks Rank  2  The company will report results on Jul 25 The Earnings ESP for Novartis AG   NYSE NVS    is  0 85  and it carries a Zacks Rank  3  The company is scheduled to release results on Jul 19 ,2016-07-17,Zacks Investment Research,https://www.investing.com/analysis/abbott-labs-(abt)-q2-earnings:-will-the-stock-surprise-200142453,200142453
182290,403806,ABT,Novo Nordisk  NVO  Reports Positive Trial Results On Victoza,opinion,"Novo Nordisk  CO NOVOb    NYSE NVO   announced results from the LEADER trial on Victoza at the American Diabetes Association s 76th Scientific Sessions 
Results were also published in the New England Journal of Medicine 
The trial is evaluating the long term effects of Victoza  in comparison to placebo  both in addition to the standard of care  in people with type 2 diabetes at high risk of major cardiovascular  CV  events 
Results from the multicenter  international  randomized  double blinded  placebo controlled trial showed that Victoza significantly reduced the risk of the composite primary endpoint of CV death  non fatal myocardial infarction  heart attack  or non fatal stroke by 13   compared to placebo  when added to the standard of care in adults with type II diabetes at high CV risk 
Results also showed that treatment with Victoza resulted in a 22  reduction in cardiovascular death  compared to placebo 
This means that Victoza can improve outcomes beyond glucose reduction and weight loss in reducing cardiovascular complications and death in people with type II diabetes NOVO NORDISK AS Price
   We note that Victoza is indicated in Europe for the treatment of adults with type II diabetes to achieve glycemic control as monotherapy  when metformin is considered inappropriate  and in combination with oral glucose lowering medicinal products and or basal insulin when these  together with diet and exercise  do not provide adequate glycemic control  The drug is also approved in the U S  as an adjunct to diet and exercise to improve blood glucose control in adults with type II diabetes 
These results bode well for Victoza  We note that Novo Nordisk has a strong presence in the diabetes care market  supported by one of the broadest diabetes portfolios in the industry comprising drugs like Victoza  Levemir and modern insulins 
Novo Nordisk carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector are Pfizer  Inc    NYSE PFE    Bristol Myers Squibb Co    NYSE BMY   and Abbott Laboratories   NYSE ABT    While Pfizer and Bristol Myers sport a Zacks Rank  1  Strong Buy   Abbott Labs is a Zacks Rank  2  Buy  stock ",2016-06-15,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisk-(nvo)-reports-positive-trial-results-on-victoza-200136200,200136200
182291,403807,ABT,Shire Buys Global Rights To Pfizer s Gastrointestinal Drug,opinion,"Shire plc   NASDAQ SHPG   announced that it will license global rights to all indications of Pfizer s   NYSE PFE   candidate  PF 00547659 
PF 00547659 is an investigational biologic which is being evaluated for the treatment of moderate to severe inflammatory bowel disease  IBD  in phase I and phase II trials  with phase III trials expected to begin after a consultation with global health authorities 
The IBD indication includes ulcerative colitis  UC  and Crohn s disease  CD   The candidate has been evaluated in phase II trials for the treatment of UC  TURANDOT  and CD  OPERA   Data from the TURANDOT study showed that adult patients with moderate to severe active UC  who have failed at least one previous treatment and were treated with PF 00547659  showed an increased rate of remission  response  and mucosal healing at week 12  compared to placebo  The trial had met its primary and secondary endpoints 
As per the company  IBD is estimated to affect more than 3 5 million people in the U S   Europe and Japan 
Other details of the transaction were  however  not disclosed SHIRE PLC ADR Price
   We are encouraged by Shire s efforts to develop its gastrointestinal  GI  franchise  The licensing of rights to Pfizer s candidate will strengthen the company s GI pipeline  In Feb 2015  the company had taken over NPS Pharma  adding Gattex  short bowel syndrome  and Natpara  hypoparathyroidism  to its portfolio 
Earlier this week  Shire obtained Breakthrough Therapy Designation from the FDA for two of its GI candidates   SHP621  budesonide oral suspension  or BOS  for eosinophilic esophagitis  EoE  and SHP625  maralixibat  for progressive familial intrahepatic cholestasis type 2  PFIC2   The company had acquired global rights to SHP625 through its 2014 buyout of Lumena  while the Meritage Pharma acquisition provided it with the worldwide rights to SHP621 
Shire currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the healthcare sector include Abbott Laboratories   NYSE ABT   and Johnson   Johnson   NYSE JNJ    Both stocks have a Zacks Rank  2  Buy  ",2016-06-15,Zacks Investment Research,https://www.investing.com/analysis/shire-buys-global-rights-to-pfizer's-gastrointestinal-drug-200136229,200136229
182292,403808,ABT,Aegerion  QLT Ink Merger Deal To Form Novelion Therapeutics,opinion,"Aegerion Pharmaceuticals  Inc    NASDAQ AEGR   announced that it has entered into a definitive merger agreement with QLT Inc    NASDAQ QLTI   
Terms of the Merger
Under the agreement  Aegerion will combine with a wholly owned indirect subsidiary of QLT  Post completion  each outstanding share of Aegerion s common stock will be exchanged for 1 0256 shares of QLT s common stock 
QLT will change its name upon the closing of the proposed transaction to Novelion Therapeutics Inc  The resulting entity will have its principal headquarters in Vancouver  British Columbia  where QLT is currently located  with business operations in Cambridge  MA 
The proposed merger has been approved by the boards of directors of both companies  The transaction is expected to close late third quarter 2016 or fourth quarter 2016  Meanwhile  a broad based investor syndicate is committed to invest approximately  22 million in QLT and to vote in favor of the proposed transaction  The syndicate comprises new investors as well as existing shareholders of both companies 
Post merger  QLT shareholders  including those who are investing in QLT immediately before closing  are expected to own approximately 67   while current shareholders of Aegerion will own approximately 33  of Novelion s common shares 
Moreover  Aegerion and QLT have inked a loan agreement  whereby QLT will provide a loan of up to  15 million as working capital to Aegerion 
Portfolio for a New Entity
The proposed merger will led to the formation of a global biopharmaceutical company with focus on rare diseases  It will offer a diversified portfolio primarily consisting of Aegerion s two marketed drugs   Juxtapid and Myalept   and QLT s late stage candidate  QLT091001  zuretinol   which is being developed for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes that prevent adequate functioning of the retinoid cycle leading to Leber Congenital Amaurosis  LCA  and Retinitis Pigmentosa  RP  
As per the companies  projection  zuretinol s approval will create a portfolio  including Juxtapid and Myalept  that can generate peak sales of  500 million annually 
How Does QLT Benefit 
QLT plans to use Aegerion s existing orphan product infrastructure to build a global infrastructure to maximize the value of its ophthalmology candidate  zuretinol  Given the resource requirements for this  the merger with Aegerion will allow QLT to reap benefits from a larger scale and diversification  apart from creating a more liquid stock QLT INC Price
   How Does Aegerion Benefit 
On the other hand  Aegerion is facing challenging marketing conditions  Launch of PCSK9 inhibitors in the U S  market hit Juxtapid sales severely and will continue to do so in the forthcoming quarters  The company also faced reimbursement hurdles for Myalept in the first quarter as prior authorizations are taking longer than expected and payers are requesting additional data  In fact  Myalept sales are expected to remain under pressure due to the payer mix 
Hence  Aegerion is looking to turn over a new leaf with the proposed merger with the ophthalmic biotechnology company   Aegerion is also looking to address its capital needs from the proposed merger and move forward with a regulatory filing for Juxtapid in Japan and a filing for Myalept in Europe for generalized liver dystrophy and severe partial liver dystrophy by the end of 2016 
The company will also get the time to reconfigure its core business to generate a positive operating cash flow in 2017  Moreover  the transaction structure does not trigger a repayment obligation with respect to Aegerion s outstanding convertible senior notes AEGERION PHARMA Price
   Our Take
The merger appears to combine two companies  each with its own set of challenges and each looking forward to nullify the same with the other s strengths  Zuretinol  which enjoys orphan drug status in both the U S  and Europe  is expected to be advanced to phase III development in the third quarter of 2016 
There are currently no approved treatments in the U S  or Europe for LCA or RP  As per estimates  there are approximately 2 000 to 3 000 RP patients and approximately 1 000 to 2 000 LCA patients on a global basis  reflecting significant need an unmet ophthalmologic condition 
While zuretinol does look promising  Juxtapid s growth prospects appear pretty bleak  especially with the launch of PCSK9 inhibitors in the U S  The companies have witnessed a significant decline in share prices in the recent past  The merger looks like a desperate attempt by the two parties to overcome existing challenges and build a strong portfolio 
While QLT currently carries a Zacks Rank  4  Sell   Aegerion is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the healthcare sector include Abbott Laboratories   NYSE ABT   and Johnson   Johnson   NYSE JNJ    Both stocks have a Zacks Rank  2  Buy  ",2016-06-17,Zacks Investment Research,"https://www.investing.com/analysis/aegerion,-qlt-ink-merger-deal-to-form-novelion-therapeutics-200136503",200136503
182293,403809,ABT,Epizyme Offers Early Data On Non Hodgkin Lymphoma Drug,opinion,"Epizyme  Inc    NASDAQ EPZM   reported encouraging preliminary data from its ongoing  global phase II trial on lead pipeline candidate  tazemetostat  at the American Society of Hematology Meeting on Lymphoma Biology 
Tazemetostat  a first in class EZH2 inhibitor  is currently being evaluated for the treatment of patients with relapsed or refractory non Hodgkin lymphoma  NHL  
Early data from the phase II trial showed that tazemetostat had a favorable safety profile and clinical activity consisting of objective responses in a heavily pre treated patient population  The primary endpoint of the phase II study is the overall response rate 
An Independent Data Monitoring Committee confirmed that futility was surpassed in four of the five cohorts that were being studied   diffuse large B cell lymphoma  DLBCL  with germinal center B cell  GCB  subtype and EZH2 mutations  DLBCL with GCB subtype and wild type EZH2  DLBCL with non GCB subtype  and follicular lymphoma  FL  with EZH2 mutations 
Enrollment is ongoing in the fifth cohort of patients with FL with wild type EZH2  The cohort has not reached futility assessment yet 
Meanwhile  enrollment is on track in the phase II study and is consistent with the incidence rates of all NHL subtypes  with approximately 20  of enrolled DLBCL GCB and FL patients having EZH2 mutations   Epizyme continues to enroll patients in its ongoing phase II study on NHL patients as well as in two clinical trials on patients with certain genetically defined solid tumors EPIZYME INC Price
   With no approved products in its kitty as of yet  the company s efforts to develop its lead candidate for a number of indications are impressive  Epizyme expects 2016 to be a critical year given several data readouts lined up from its trials on tazemetostat in NHL and solid tumors 
The company has also outlined a five year growth strategy and aims to launch tazemetostat globally for both NHL and genetically defined solid tumors by 2020  It also anticipates moving at least three new oncology programs into clinical development by 2020 
Epizyme currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Pfizer  Inc    NYSE PFE    Bristol Myers Squibb Company   NYSE BMY   and Abbott Laboratories   NYSE ABT    While Pfizer and Bristol Myers sport a Zacks Rank  1  Strong Buy   Abbott Labs is a Zacks Rank  2  Buy  stock ",2016-06-20,Zacks Investment Research,https://www.investing.com/analysis/epizyme-offers-early-data-on-non-hodgkin-lymphoma-drug-200137054,200137054
182294,403810,ABT,Mylan Launches Generic Version Of Glaxo s Avodart In U S ,opinion,"Mylan N V    NASDAQ MYL   announced that it has launched dutasteride capsules  0 5 mg    the generic version of GlaxoSmithKline s   NYSE GSK   Avodart    after receiving an FDA approval for an abbreviated New Drug Application  ANDA  of the drug Avodart is approved as monotherapy for the treatment of symptomatic benign prostatic hyperplasia  BPH  in men with an enlarged prostate to improve symptoms  reduce the risk of acute urinary retention and lowering the chances of surgery need  The drug can also be used in combination with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate As per IMS Health  the drug generated sales of approximately  297 2 million during the last 12 months  ended Apr 30  2016  We remind investors that Mylan currently has 248 ANDAs pending FDA approval  representing a total of  107 6 billion in annual brand sales  as per IMS Health  Of these  43 are potential first to file opportunities which representing  37 2 billion in annual sales MYLAN NV Price
   Mylan is a leading generic drug company in terms of both total and new prescriptions  The company has been making efforts to solidify its pipeline through strategic deals The company recently acquired the non sterile  topicals focused specialty and generics business of privately held Renaissance Acquisition Holdings  The deal gave Mylan access to a complementary portfolio of approximately 25 branded and generic topical products  an active pipeline of approximately 25 products  and an established U S  sales and marketing infrastructure targeting dermatologists 
The transaction is expected to be immediately accretive to the company s bottom line  In Feb 2015  Mylan acquired Abbott Laboratories    NYSE ABT   non U S  developed markets  specialty and branded generics business Mylan is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector are Bristol Myers Squibb Company   NYSE BMY   and Johnson   Johnson   NYSE JNJ    Both stocks carry a Zacks Rank  2  Buy  ",2016-06-27,Zacks Investment Research,https://www.investing.com/analysis/mylan-launches-generic-version-of-glaxo's-avodart-in-u.s.-200138520,200138520
182295,403811,ABT,Abbott Labs  Absorb Stent Gets Regulatory Approval In U S ,opinion,Abbott Laboratories   NYSE ABT   received a major boost when the FDA approved its bioresorbable heart stent  Absorb  for the treatment of coronary artery disease in the U S Approximately 15 million people in the U S  are affected by coronary artery disease  which is a leading cause of death worldwide  Traditional stents are usually made of metal  while Abbott Labs  Absorb is made of a naturally dissolving material  similar to dissolving sutures  This allows Absorb to disappear completely in approximately three years  having kept a clogged artery open and promoting healing of the treated artery segment  On the other hand  metal stents are permanent implants that restrict vessel motion throughout the rest of the patient s life  As per the company press release  Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease Naturally  an approval for Absorb offers a significant market opportunity to Abbot Labs and also indicates significant progress in the treatment of coronary artery disease We note that the Absorb bioresorbable stent had shown comparable short  and mid term outcomes to Abbott Labs  metallic drug eluting stent  Xience ABBOTT LABS Price and Consensus   The latest approval will strengthen Abbott Labs  vascular division  which recorded only modest growth in the first quarter of 2016  The stent is already approved in Europe  Abbott Labs is making consistent efforts to boost its Medical Devices business  This April  the company entered into a definitive agreement to acquire St  Jude Medical Inc    NYSE STJ    a premier medical device company with a leading position in heart failure devices  atrial fibrillation and cardiac rhythm management  The acquisition will bolster Abbott s share in the cardiovascular device market and position the company to compete in nearly every segment of a market that has an aggregate opportunity of  30 billion Abbott Laboratories currently carries a Zacks Rank  2  Buy   A couple of other favorably placed stocks in the healthcare sector include Pfizer Inc    NYSE PFE   and Johnson   Johnson   NYSE JNJ    Both the stocks carry the same rank as Abbott Labs ,2016-07-06,Zacks Investment Research,https://www.investing.com/analysis/abbott-labs'-absorb-stent-gets-regulatory-approval-in-u.s.-200140535,200140535
182296,403812,ABT,Shire  SHPG  Gets EU Nod For Label Expansion Of Revestive,opinion,"Shire plc   NASDAQ SHPG   announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug  GI  Revestive for use in the pediatric population 
Revestive 5 mg powder and solvent has been approved for the treatment of patients aged one year and above with short bowel syndrome  SBS  
An approval was on the cards given that the Committee for Medicinal Products for Human Use  CHMP  had given a positive opinion on the same in May 2016 
We remind investors that Revestive is approved in Europe for the treatment of adult patients with SBS who have become stable following a period of intestinal adaptation post surgery  The drug is also approved in the U S  as Gattex for injection in adult patients with SBS who are dependent on parenteral support 
The label expansion of Revestive for use in the pediatric population should boost its sales 
We note that Shire has a solid presence in the rare disease markets  The company acquired NPS Pharmaceuticals Inc  in Feb 2015  thereby adding Revestive Gattex and Natpara  hypoparathyroidism  to its portfolio and providing a major boost to its GI franchise SHIRE PLC ADR Price
   We are also encouraged by the company s efforts to develop its GI franchise  Last month  the company acquired global rights to Pfizer Inc  s   NYSE PFE   PF 00547659 for the treatment of moderate to severe inflammatory bowel disease  IBD   Shire also obtained Breakthrough Therapy Designation from the FDA for two of its GI candidates   SHP621  budesonide oral suspension  or BOS  for eosinophilic esophagitis  EoE   and SHP625  maralixibat  for progressive familial intrahepatic cholestasis type 2  PFIC2  
Shire currently has a Zacks Rank  3  Hold   A couple of better ranked stocks in the healthcare sector include Abbott Laboratories   NYSE ABT   and Johnson   Johnson   NYSE JNJ    Both stocks carry a Zacks Rank  2  Buy  ",2016-07-08,Zacks Investment Research,https://www.investing.com/analysis/shire-(shpg)-gets-eu-nod-for-label-expansion-of-revestive-200140851,200140851
182298,403814,ABT,Pfizer Reports Positive Data On Kidney Cancer Drug Sutent ,opinion,Pfizer Inc    NYSE PFE   announced positive results from the phase III study  S TRAC   Sunitinib Trial in Adjuvant Renal Cancer  on Sutent The randomized  double blind trial evaluated Sutent in comparison to placebo in the adjuvant setting in patients who are at high risk of renal cell carcinoma  RCC   Results showed that the trial met the primary endpoint of improving disease free survival as determined by a blinded independent central review in RCC patients with a high risk of recurrence after surgery  Adjuvant therapy is expected to lower the risk of recurrence in patients suffering from early stage cancer Pfizer expects to report full efficacy and safety data from the trial at the ESMO 2016 Congress in Oct 2016 PFIZER INC Price   We note that Sutent is approved for advanced RCC  imatinib resistant or  intolerant gastrointestinal stromal tumors and advanced pancreatic neuroendocrine tumors  As per the information provided by the company  RCC is the most common type of kidney cancer  accounting for around 90  of all kidney cancers  The product s sales increased 22  operationally  excluding currency impact  year over year in the first quarter of 2016  primarily driven by price increases in the U S   as well as strong demand in most markets The RCC market is already pretty crowded  Note that the FDA had approved Exelixis  Inc  s   NASDAQ EXEL   Cabometyx in Apr 2016 for the treatment of advanced RCC in patients who received prior anti angiogenic therapy  In Nov 2015  the FDA approved Opdivo for the same indication Pfizer currently carries a Zacks Rank  2  Buy   Other favorably placed stocks in the healthcare sector include Abbott Laboratories   NYSE ABT   and Novartis AG   NYSE NVS    Both stocks carry the same rank as Pfizer ,2016-07-10,Zacks Investment Research,https://www.investing.com/analysis/pfizer-reports-positive-data-on-kidney-cancer-drug-sutent-200141153,200141153
182329,403845,ABT,Novo Nordisk  NVO  Reports Positive Data On Diabetes Drug,opinion,Novo Nordisk  CO NOVOb    NYSE NVO   announced positive results on its pipeline candidate  semaglutide  from the phase IIIa trial  SUSTAIN 4 Semaglutide is an experimental analogue of native human glucagon like peptide 1  GLP 1  that stimulates insulin and suppresses glucagon secretion in a glucose dependent manner Data from the trial showed that treatment with semaglutide  administered once weekly  significantly improved glycemic control  compared to insulin glargine U100  in adults with type II diabetes  Results also showed that adults with type II diabetes  who were taking metformin with or without sulfonylurea  achieved statistically significant and superior improvements in HbA1c reductions of 1 2  and 1 6  when treated with 0 5 mg and 1 0 mg semaglutide  respectively  versus a 0 8  reduction with insulin glargine U100  from a mean baseline HbA1c of 8 2  These results were presented at the American Association of Clinical Endocrinologists 25th Annual Scientific and Clinical Congress  AACE   held in Orlando The company expects to file regulatory application for semaglutide in both the U S  and the EU later in 2016  We believe that an early approval and successful commercialization of the candidate will boost the company s top line significantly We note that Novo Nordisk has a strong presence in the Diabetes Care market  supported by one of the broadest diabetes portfolios in the industry comprising drugs like Victoza  Levemir and modern insulins The company expects sales to grow 5 9  in 2016  driven by continually strong performance of modern insulins Tresiba and Victoza as well as by contributions from Saxenda and Xultophy Novo Nordisk carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Abbott Laboratories   NYSE ABT    Johnson   Johnson   NYSE JNJ   and Sanofi   NYSE SNY    All three stocks hold a Zacks Rank  2  Buy  ,2016-05-31,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisk-(nvo)-reports-positive-data-on-diabetes-drug-200133373,200133373
182330,403846,ABT,Novartis  NVS  Announces Data On Leukemia Drug Tasigna,opinion,"Novartis AG   NYSE NVS   announced results from the Treatment free Remission  TFR  program on oncology drug  Tasigna 
The program comprised two open label trials   ENESTfreedom and ENESTop   that evaluated Tasigna s potential of maintaining molecular response  MR  after stopping therapy in the chronic phase in adult patients suffering from Philadelphia chromosome positive  Ph   chronic myeloid leukemia  CML  
In the ENESTfreedom trial  51 6  of eligible first line Tasigna patients maintained TFR for 48 weeks after stopping treatment  The study  however  did not meet its statistical primary endpoint  On the other hand  ENESTop met the primary endpoint  with 57 9  of eligible patients who had switched to Tasigna from Glivec maintaining TFR for 48 weeks after treatment cessation  The company expects to submit the results to regulatory authorities later in 2016 
We note that Tasigna is already approved for the treatment of chronic phase and accelerated phase Ph  CML in adult patients resistant or intolerant to at least one prior therapy 
Last week  Novartis announced that the European Commission has approved Afinitor tablets for the treatment of unresectable or metastatic  well differentiated  Grade 1 or Grade 2  nonfunctional neuroendocrine tumors  NET  of gastrointestinal  GI  or lung origin  in adults with progressive disease  An approval was on the cards as the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  had given a positive opinion for the same 
In Feb 2016  the FDA approved Afinitor for the treatment of adult patients with progressive  well differentiated nonfunctional NET of GI or lung origin  Afinitor is also approved for locally advanced  metastatic or unresectable progressive NET of pancreatic origin in both the U S  and Europe 
Approval of new drugs and label expansion of existing ones bode well for Novartis as it has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec  Additionally  its oncology drugs are facing competition from immuno oncology therapies  Moreover  its Alcon segment is facing a decline in surgical equipment sales in the U S  and emerging markets 
Novartis currently carries a Zacks Rank  4  Sell   Some better ranked stocks in the health care sector include Pfizer Inc    NYSE PFE    Johnson   Johnson   NYSE JNJ   and Abbott Laboratories   NYSE ABT    While Pfizer sports a Zacks Rank  1  Strong Buy   Johnson   Johnson and Abbott Labs carry a Zacks Rank  2  Buy  ",2016-06-06,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-announces-data-on-leukemia-drug-tasigna-200134304,200134304
182331,403847,ABT,Exelixis Up On Positive Kidney Cancer Data On Cabometyx,opinion,"Exelixis  Inc    NASDAQ EXEL    along with its partner Ipsen  announced positive data from subgroup analyses of the METEOR trial on Cabometyx  tablet formulation of cabozantinib  at the 2016 American Society of Clinical Oncology  ASCO  Annual Meeting 
The trial compared Cabometyx with Afinitor in patients suffering from advanced renal cell carcinoma  RCC  who have received prior anti angiogenic therapy 
Data from the studies showed that treatment with Cabometyx improved progression free survival  PFS  and overall survival  OS  in patients who had bone metastases at baseline 
Trial data also showed that the benefits of Cabometyx in PFS and OS were independent of the presence of bone metastases  prior anti PD 1 PD L1 therapy  and the type of prior vascular endothelial growth factor receptor  VEGFR  tyrosine kinase inhibitor  TKI  therapy  They were  in fact  consistent regardless of prior treatment  location and extent of tumor metastases 
Shares of the company gained 11 2  on the news 
We remind investors that Cabometyx was approved by the FDA in Apr 2016 for the treatment of patients with advanced RCC who have received prior anti angiogenic therapy 
The FDA approval of Cabometyx for RCC is a major boost for the company and will drive the top line in the forthcoming quarters 
Meanwhile  the European Medicines Agency  EMA  has accepted a Marketing Authorisation Application  MAA  for Cabometyx for review in the same indication  Upon a potential approval  the drug would be marketed in the EU by Ipsen  The MAA was granted accelerated assessment by the EMA s Committee for Medicinal Products for Human Use  CHMP   which translates to a review period of 150 days instead of the standard review period of 210 days 
Cometriq  the capsule form of cabozantinib is approved for the treatment of progressive  metastatic medullary thyroid cancer 
Exelixis currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Pfizer Inc    NYSE PFE    Johnson   Johnson   NYSE JNJ   and Abbott Laboratories   NYSE ABT    While Pfizer sports a Zacks Rank  1  Strong Buy   Johnson   Johnson and Abbott Labs carry a Zacks Rank  2  Buy  ",2016-06-07,Zacks Investment Research,https://www.investing.com/analysis/exelixis-up-on-positive-kidney-cancer-data-on-cabometyx-200134585,200134585
182332,403848,ABT,Merrimack Announces Positive Data On Oncology Candidate,opinion,"Merrimack Pharmaceuticals  Inc    NASDAQ MACK   announced results from the final analysis of the phase I study on pipeline candidate  MM 151  at the 2016 American Society of Clinical Oncology  ASCO  Annual Meeting held in Chicago 
MM 151 is a novel investigational oligoclonal epidermal growth factor receptor  EGFR  inhibitor in patients with refractory solid tumors 
Data from the phase I study showed positive clinical activity across multiple solid tumor types in a heavily pretreated patient population  While 21  of evaluable patients in the metastatic colorectal cancer  CRC  cohort achieved an objective response  54  of patients showed a decrease in tumor size  The CRC cohort demonstrated a median progression free survival  PFS  of four months  The candidate also showed positive clinical activity in both the EGFR treatment refractory and EGFR treatment na ve populations 
As per the American Cancer Society  CRC is the third most common type of cancer and the second leading cause of cancer related death in the U S   with an estimated 144 000 new cases to be diagnosed in 2016 
Meanwhile  MM 151 is being evaluated in two other phase I studies   one in combination with the Onivyde  irinotecan liposome injection  regimen for metastatic CRC  and a first of its kind  multi arm basket study on a combination of the candidate with three other novel agents  Both these studies were initiated this May 
Merrimack has gained FDA approval for its first product  Onivyde  in Oct 2015  Onivyde is approved for use  in combination with fluorouracil  5 FU  and leucovorin  for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following Gemzar  gemcitabine  based therapy 
Also  this makes Merrimack heavily dependent on Onivyde for growth  As a result  the company needs to work extensively on its pipeline to reduce dependence on a single product 
Merrimack Pharma carries a Zacks Rank  2  Buy   Other favorably placed stocks in the health care sector include Pfizer Inc    NYSE PFE    Johnson   Johnson   NYSE JNJ   and Abbott Laboratories   NYSE ABT    While Pfizer sports a Zacks Rank  1  Strong Buy   Johnson   Johnson and Abbott Labs carry a Zacks Rank  2  Buy  ",2016-06-07,Zacks Investment Research,https://www.investing.com/analysis/merrimack-announces-positive-data-on-oncology-candidate-200134600,200134600
182333,403849,ABT,Abbott Labs  ABT  Reports Positive Data On FreeStyle Libre,opinion,"Abbott Laboratories   NYSE ABT   announced positive results from the IMPACT trial on FreeStyle Libre  Data were presented at the American Diabetes Association s 76th Scientific Sessions 
The randomized  controlled six month trial was conducted to evaluate the effectiveness of the FreeStyle Libre system in the improvement of glycemic control for self management of type 1 diabetes as compared to self monitoring of blood glucose 
The study showed that FreeStyle Libre met the primary endpoint of a reduction in time spent in hypoglycemia  low glucose levels  defined as 1  by patients with type 1 diabetes 
Data also showed that patients using FreeStyle Libre sensor and reader system spent 38  less time in hypoglycemia  as compared to people who managed glucose with traditional self monitoring of blood glucose  SMBG  systems such as finger pricking  The study revealed that FreeStyle Libre was effective in reducing all measures of hypoglycemia without increasing HbA1c compared to SMBG  This means that FreeStyle Libre can safely and successfully replace the need for routine finger sticks as a tool for managing diabetes ABBOTT LABS Price
   We remind investors that Abbott Labs launched the FreeStyle Libre system in France  Germany  Italy  the Netherlands  Spain  Sweden and UK in 2014 
Moreover  Abbott Labs received European approval for the use of FreeStyle Libre Flash Glucose Monitoring System in children in the first quarter of 2016 
Successful uptake of FreeStyle Libre should boost sales of Abbott Labs  Diabetes Care franchise  which has been facing challenging conditions of late 
Abbott Laboratories currently carries a Zacks Rank  2  Buy   Other favorably placed stocks in the healthcare sector include Pfizer Inc    NYSE PFE    Bristol Myers Squibb Co    NYSE BMY   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    All three stocks sport a Zacks Rank  1  Strong Buy  ",2016-06-14,Zacks Investment Research,https://www.investing.com/analysis/abbott-labs-(abt)-reports-positive-data-on-freestyle-libre-200135934,200135934
182334,403850,ABT,Shire Gets Breakthrough Status For Rare Disease Candidates,opinion,"Shire plc   NASDAQ SHPG   announced that the FDA has granted Breakthrough Therapy Designation to two candidates in its rare diseases pipeline   SHP621  budesonide oral suspension  or BOS  for eosinophilic esophagitis  EoE   and SHP625  maralixibat  for progressive familial intrahepatic cholestasis type 2  PFIC2  
The FDA generally grants Breakthrough Therapy Designation to a candidate that is intended to treat a serious or life threatening disease or condition with preliminary clinical evidence indicating that the drug could demonstrate substantial improvement on one or more clinically significant endpoints over the current standard of care  This designation will enable the company to obtain intensive guidance from the FDA and be eligible for a rolling and priority review for the drug application 
Shire acquired global rights to SHP625 through its 2014 buyout of Lumena while the Meritage Pharma acquisition provided it with worldwide rights to SHP621 SHIRE PLC ADR Price
   We remind investors that the company suffered a setback when preliminary results of a phase II study  CAMEO  on SHP625 for cholestatic liver disease showed no significant reduction from baseline in serum alkaline phosphatase or other liver parameters 
Currently  SHP621 is in phase III development for EoE  while SHP625 is in phase II trials for PFIC  Successful development and commercialization of these candidates will strengthen Shire s gastrointestinal  GI  franchise significantly  The Feb 2015 takeover of NPS Pharma acquisition also boosted Shire s GI portfolio by adding Gattex  short bowel syndrome  and Natpara  hypoparathyroidism  to its portfolio 
Shire currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector are Pfizer  Inc    NYSE PFE    Bristol Myers Squibb Company   NYSE BMY   and Abbott Laboratories   NYSE ABT    While the first Pfizer and Bristol Myers sport a Zacks Rank  1  Strong Buy   Abbott Labs is a Zacks Rank  2  Buy  stock ",2016-06-14,Zacks Investment Research,https://www.investing.com/analysis/shire-gets-breakthrough-status-for-rare-disease-candidates-200135950,200135950
182351,403867,ABT,Catalyst  CPRX  Resorts To Layoffs For Firdapse Development,opinion,Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   announced that it will reduce its workforce by approximately 30   The move will primarily affect the commercial team The decision to reduce the workforce is part of Catalyst s efforts to conserve cash for completing the requirements for the submission of a new drug application  NDA  for Firdapse  amifampridine phosphate  for the treatment of Lambert Eaton myasthenic syndrome  LEMS  and congenital myasthenic syndrome  CMS  We remind investors that the company had received a  refusal to file  letter from the FDA in Feb 2015 in connection with its NDA for Firdapse  The agency determined that the NDA was insufficient after a preliminary review  The company recently met with the FDA to get better clarity on the latter s requirement of additional data to accept the NDA  The FDA informed that it needs positive results from an additional adequate and well controlled study in patients with LEMS  Moreover  the company is required to conduct additional studies as per the FDA s requirement  which will involve additional costs and a further delay in the NDA submission Since the studies involve extra costs  Catalyst is looking to reduce its operating expenses  The company expects to execute the workforce reduction with immediate effect  Management  however  believes that its currently available resources are sufficient for completing the development of and refile an NDA for Firdapse in LEMS and CMS Catalyst currently has a Zacks Rank  2  Buy   Other favorably placed stocks in the health care sector include Pfizer Inc    NYSE PFE    Johnson   Johnson   NYSE JNJ   and Abbott Laboratories   NYSE ABT    All three stocks carry the same Zacks Rank as Catalyst ,2016-05-17,Zacks Investment Research,https://www.investing.com/analysis/catalyst-(cprx)-resorts-to-layoffs-for-firdapse-development-200130732,200130732
182352,403868,ABT,Novartis  NVS  To Stop Trial On Breast Cancer Drug Early,opinion,"Novartis AG   NYSE NVS   announced that an independent Data Monitoring Committee has recommended the early stoppage of the MONALEESA 2 trial on its breast cancer candidate  LEE011 
The trial is evaluating LEE011  a CDK4 6 inhibitor  in combination with letrozole  compared to letrozole alone  in postmenopausal women who have received no prior therapy for hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   advanced breast cancer 
The committee s recommendation came after the trial met the primary endpoint  significantly extending progression free survival  PFS  compared to letrozole alone  as observed in a pre planned interim analysis  Results showed that LEE011  in combination with letrozole  led to clinically meaningful improvement in PFS in postmenopausal women who received no prior therapy 
The trial will continue to assess overall survival data  Novartis expects to present efficacy and safety data efficacy at a major medical congress 
Recently  Novartis announced that it has split its Pharmaceuticals Division into two business units   Novartis Pharmaceuticals and Novartis Oncology  These units will form the Innovative Medicines Division at the company  The change in the divisions is primarily to reflect the integration of the oncology assets acquired from GlaxoSmithKline   NYSE GSK   
We remind investors Novartis decided to realign its portfolio and move the ophthalmic pharmaceutical business and some drugs from Sandoz s portfolio to its pharmaceutical division owing to the challenges faced by the company in 2015 
Approval of new drugs and label expansion of existing ones bode well for Novartis as it has been facing stiff generic competition for some of its key drugs like Diovan  Additionally  its oncology drugs are facing competition from immuno oncology therapies  Moreover  its Alcon segment is facing a decline in surgical equipment sales in the U S  and emerging markets 
Novartis currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include Pfizer Inc    NYSE PFE   and Abbott Laboratories   NYSE ABT    Both the stocks carry a Zacks Rank  2  Buy  ",2016-05-18,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-to-stop-trial-on-breast-cancer-drug-early-200130786,200130786
182353,403869,ABT,Roche Gets Accelerated Approval For Immunotherapy Drug ,opinion,"Roche Holding  SIX ROG    OTC RHHBY   announced that the FDA has granted accelerated approval to its cancer immunotherapy drug  Tecentriq  atezolizumab   for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma  mUC   who experienced disease progression during or after platinum based chemotherapy  or whose disease has worsened within 12 months of receiving platinum based chemotherapy before or after surgery 
Under the accelerated approval program  the FDA grants conditional approval to a drug that fulfills an unmet medical need for a serious condition  based on early evidence suggesting clinical benefit  However  continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials 
Roche is also evaluating Tecentriq in a confirmatory phase III study  IMvigor 211   in comparison to chemotherapy  in patients with bladder cancer who have progressed on at least one prior platinum containing regimen 
An approval of Tecentriq will further widen Roche s already broad oncology portfolio 
Additional  the company announced positive results from a phase III study  J ALEX  on lung cancer drug  Alecensa  Results from a pre specified interim analysis study showed that Alecensa  an oral anaplastic lymphoma kinase  ALK  inhibitor  reduced the risk of disease worsening or death  progression free survival  PFS  by 66   compared to Xalkori  in Japanese patients with advanced or recurrent  ALK positive non small cell lung cancer  NSCLC  
We remind investors that Alecensa was granted accelerated approval by FDA in Dec 2015 for the treatment of patients with ALK positive NSCLC who have progressed on or are intolerant to Xalkori 
We expect investors to focus on new drug approvals  as Roche s top line could be marred by the entry of biosimilars  expected in the second half of 2017 in Europe  for its key drugs like MabThera and Herceptin  On the other hand  new drug approvals  such as those of Cotellic and Alecensa  boosted sales in 2015 
Roche currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Pfizer Inc    NYSE PFE    Johnson   Johnson   NYSE JNJ   and Abbott Laboratories   NYSE ABT    All three stocks carry a Zacks Rank  2  Buy  ",2016-05-19,Zacks Investment Research,https://www.investing.com/analysis/roche-gets-accelerated-approval-for-immunotherapy-drug-200131056,200131056
182354,403870,ABT,Merrimack Baxalta Start Study On Colorectal Cancer Drug,opinion,"Merrimack Pharmaceuticals  Inc    NASDAQ MACK   and Baxalta Inc    NYSE BXLT   announced that the companies have initiated a phase I clinical study on pipeline candidate MM 151 
The trial will evaluate the safety and tolerability of MM 151  an oligoclonal EGFR  epidermal growth factor receptor  inhibitor  in combination with Onivyde plus fluorouracil  5 FU  and leucovorin  in patients with RAS wild type metastatic colorectal cancer 
The trial will also determine the side effects of MM 151  when used in combination with Onivyde plus 5 FU and leucovorin  and a recommended dose for subsequent trials on this combination 
The phase I study will be solely funded by Merrimack and the company will be single handedly responsible for the execution of the trial 
Onivyde is approved for use in combination with fluorouracil  5 FU  and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas  after disease progression following Gemzar  gemcitabine  based therapy  Initial uptake of Onivyde has been strong and should boost the top line  going forward 
We remind investors that Merrimack and Baxalta entered into an exclusive licensing agreement to develop and commercialize Onivyde outside the U S   except for Taiwan where PharmaEngine holds the rights to commercialize the drug  Onivyde was approved in Taiwan in Oct 2015 
We note that MM 151 was previously being evaluated in a clinical trial on patients with advanced solid tumors  At present  Merrimack depends heavily on Onivyde for growth  As a result  development of other candidates is essential for the company 
Merrimack Pharma carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include Pfizer Inc    NYSE PFE   and Abbott Laboratories   NYSE ABT    Both stocks carry a Zacks Rank  2  Buy  ",2016-05-20,Zacks Investment Research,https://www.investing.com/analysis/merrimack-baxalta-start-study-on-colorectal-cancer-drug-200131283,200131283
182355,403871,ABT,Novartis  Cardiovascular Drug Gets Positive Recommendation,opinion,"Novartis AG   NYSE NVS   announced that its cardiovascular drug  Entresto  was given a class I recommendation  as per the updated clinical practice guidelines released simultaneously by the American College of Cardiology  ACC   the American Heart Association  AHA  and the Heart Failure Society of America  HFSA   as well as the European Society of Cardiology 
Consequently  Entresto is now a standard therapy for heart failure with reduced ejection fraction  HFrEF  in the U S  as an alternative to an ACE inhibitor or an angiotensin II receptor blocker  ARB  
Moreover  doctors can switch HFrEF patients with mild to moderate symptoms from ACEs or ARBs to Entresto as per the latest guidelines 
The news bodes well for Novartis as the release of the latest guidelines would propel demand for Entresto  We remind investors that Entresto s uptake was considerably slow since its launch due to access barriers 
The recommendations were based on positive results from the PARADIGM HF trial  which showed Entresto significantly lowered the occurrence of death from cardiovascular causes and heart failure hospitalizations in patients with HFrEF 
Last week  Novartis announced that it will conduct approximately 40 active or planned clinical studies in a large global clinical program  FortiHFy  to generate additional data on symptom reduction  efficacy  safety  quality of life benefits and real world evidence on Entresto 
An increase in uptake of Entresto will positively impact Novartis  top line  which is presently under pressure as the company continues to face stiff generic competition for some of its key drugs like Diovan and Gleevec  Additionally  its oncology drugs are facing competition from immuno oncology therapies  Moreover  its Alcon segment is facing a decline in surgical equipment sales in the U S  and emerging markets 
Novartis currently carries a Zacks Rank  4  Sell   Some better ranked stocks in the healthcare sector are Abbott Laboratories   NYSE ABT    Johnson   Johnson   NYSE JNJ   and Sanofi   NYSE SNY    All three stocks carry a Zacks Rank  2  Buy  ",2016-05-23,Zacks Investment Research,https://www.investing.com/analysis/novartis'-cardiovascular-drug-gets-positive-recommendation-200131676,200131676
182358,403874,ABT,Exelixis  Kidney Cancer Drug Cabometyx Positive In Phase II,opinion,"Exelixis  Inc    NASDAQ EXEL   announced positive top line data from the phase II trial  CABOSUN  on Cabometyx in patients suffering from previously untreated advanced renal cell carcinoma  RCC  
Results showed that Cabometyx led to significant improvement in progression free survival in patients with previously untreated advanced RCC  compared with sunitinib  Consequently  the trial met its primary endpoint 
Safety data from the Cabometyx arm of the study were consistent with those observed in previous studies in patients with advanced RCC 
Final results of the trial will be presented at a medical conference shortly 
We remind investors that Cabometyx  the tablet formulation of cabozantinib  was approved by the FDA in Apr 2016 for the treatment of patients with advanced RCC  who have received prior anti angiogenic therapy 
Meanwhile  the European Medicines Agency  EMA  has accepted a Marketing Authorisation Application  MAA  for Cabometyx for review in the same indication  Upon a potential approval  the drug would be marketed in the EU by Exelixis  partner  Ipsen  The MAA has been granted accelerated assessment by the EMA s Committee for Medicinal Products for Human Use  CHMP   which translates a review period of 150 days instead of the standard 210 days 
Exelixis also plans to submit results of the CABOSUN trial to regulatory authorities in order to discuss further development of Cabometyx and submission strategy for the treatment of first line advanced RCC 
As per the American Cancer Society  kidney cancer is one of the top 10 most commonly diagnosed forms of cancer in both men and women in the U S  Hence  approval of Cabometyx in first line advanced RCC will boost its growth prospects significantly 
Exelixis currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Abbott Laboratories   NYSE ABT    Johnson   Johnson   NYSE JNJ   and Sanofi   NYSE SNY    All three stocks carry a Zacks Rank  2  Buy  ",2016-05-24,Zacks Investment Research,https://www.investing.com/analysis/exelixis'-kidney-cancer-drug-cabometyx-positive-in-phase-ii-200131947,200131947
182361,403877,ABT,Novartis Filing For MabThera Biosimilar Accepted In The EU,opinion,"Novartis   NYSE NVS   announced that the European Medicines Agency  EMA  has accepted its generic arm Sandoz s Marketing Authorisation Application  MAA  for its proposed biosimilar of Roche s   OTC RHHBY   MabThera  rituximab  
We note that MabThera is approved for the treatment of non Hodgkin s lymphoma  which includes follicular lymphoma and diffuse large B cell lymphoma  chronic lymphocytic leukemia and autoimmune diseases such as rheumatoid arthritis  Sandoz is seeking approval of its biosimilar for the same indications as the reference product 
We are impressed by Sandoz s efforts to broaden its biosimilars portfolio  MabThera is one of the leading oncology drugs across the world and Sandoz s oncology portfolio already boasts two marketed products 
Sandoz currently markets three biosimilars   Omnitrope  a human growth hormone  Binocrit  an erythropoiesis stimulating agent  and Zarxio   in the U S  Backed by its deep pipeline of biosimilars  the company plans to make 10 regulatory filings over the 2015 2017 time frame  of which six applications have already been submitted 
We note that the EMA had earlier accepted Sandoz s MAA for its proposed biosimilar of Neulasta  pegfilgrastim  
Approval of new drugs  generics and biosimilars  along with the label expansion of existing ones  should bode well for Novartis as it has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec of late 
Additionally  its oncology drugs are facing competition from immuno oncology therapies  Moreover  the Alcon segment is facing a decline in surgical equipment sales in the U S  and emerging markets 
Novartis currently carries a Zacks Rank  4  Sell   A couple of better ranked stocks in the healthcare sector include Abbott Laboratories   NYSE ABT   and Johnson   Johnson   NYSE JNJ    Both the stocks carry a Zacks Rank  2  Buy  ",2016-05-24,Zacks Investment Research,https://www.investing.com/analysis/novartis-filing-for-mabthera-biosimilar-accepted-in-the-eu-200131945,200131945
182364,403880,ABT,Novo Nordisk IDegLira Recommended By FDA Advisory Committee,opinion,"Novo Nordisk  CO NOVOb    NYSE NVO   announced that the FDA s Endocrinologic and Metabolic Drugs Advisory Committee  EMDAC  voted unanimously  16 0  in favor of the approval of IDegLira for the treatment of adults with type II diabetes 
IDegLira is a once daily  single injection  fixed combination of Tresiba  insulin degludec  and Victoza  liraglutide  
Although the FDA takes the recommendations of its advisory committee into account while reviewing applications  it is not bound to follow the same 
The recommendation for approval was based on positive data from a clinical trial   DUAL  Novo Nordisk has also evaluated Tresiba and Victoza in separate clinical trials  We note that the new drug application  NDA  for IDegLira was submitted to the FDA in Sep 2015 under the agency s Prescription Drug User Fee Act V  PDUFA V  regulation 
The drug was approved in Sep 2014 in Europe and is currently sold under the brand name  Xultophy 
A potential approval of the drug in the U S  will further broaden Novo Nordisk s portfolio  the company has a strong presence in the Diabetes Care market supported by one of the broadest diabetes portfolios in the industry that comprises drugs like Victoza  Levemir and modern insulins 
The company expects sales to grow 5 9  in 2016  driven by continually strong performance of modern insulins Tresiba and Victoza as well as by contributions from Saxenda and Xultophy 
Novo Nordisk carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Abbott Laboratories   NYSE ABT    Johnson   Johnson   NYSE JNJ   and Sanofi   NYSE SNY    All three stocks carry a Zacks Rank  2  Buy  ",2016-05-25,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisk-ideglira-recommended-by-fda-advisory-committee-200132222,200132222
182380,403896,ABT,Zoetis  ZTS  Tops Q1 Earnings   Revenues  Updates Outlook,opinion,"Zoetis Inc  s   NYSE ZTS   first quarter 2016 earnings of 48 cents per share came in ahead of the Zacks Consensus Estimate of 41 cents  Earnings also increased 17  from the year ago period Total revenue increased 5  year over year to  1 162 billion in the first quarter of 2016  Revenues were also above the Zacks Consensus Estimate of  1 092 billion  Foreign currency movements impacted revenues negatively by 7  
Quarterly Details
Zoetis manages its business across two regional operating segments  the U S  and International  Within these segments  the company delivers a diverse portfolio of products for livestock and companion animals  These segment results include six additional calendar days  as the first quarter of 2016 had six additional calendar days compared with the first quarter of 2015 
In the reported quarter  sales of livestock products accounted for 58 8  of the total revenue  Approximately 40 1  of revenues in the quarter came from the sale of companion animal products  while the remaining came from contract manufacturing 
Revenues in the U S  segment increased 12  from the year ago period to  582 million  Sales of companion animal products grew 32  reflecting increased sales of Apoquel  initial sales of other products into expanded distribution relationships  and the addition of products acquired from Abbott Laboratories    NYSE ABT   Animal Health business  Livestock revenue declined 4  due to decreased sales of cattle and swine products 
Sales at the International segment were  however  down 1  to  567 million  up 13  operationally   While sales of companion animal products increased 11   up 23  operationally   sales of livestock products were down 5   up 9  operationally  in the reported quarter 
Outlook Updated
Zoetis updated its guidance for 2016 to reflect the impact of foreign exchange rates as of April and current views of its operations  For 2016  the company expects earnings in the range of  1 83 to  1 90 per share  old guidance   1 71 to  1 81 per share  on revenues of  4 775 billion and  4 875 billion  old guidance   4 65 billion and  4 775 billion   The Zacks Consensus Estimate for earnings is  1 79 per share on revenues of  4 748 billion 
The company also updated its outlook for 2017  In 2017  the company expects earnings in the range of  2 24 to  2 38 per share  old guidance   2 18 to  2 32 per share  on revenues of  5 075 billion and  5 275 billion  old guidance   4 95 billion and  5 15 billion   The Zacks Consensus Estimate for earnings is  2 26 per share on revenues of  5 069 billion 
Our Take
Zoetis  first quarter results were better than expected with the company beating on both top  and bottom line estimates  However  unfavourable currency movement continued to hurt the top line  Nevertheless  we are positive on the Nov 2015 Pharmaq acquisition  We expect to see more of such acquisitions deals at the company in the near future  as it continues to focus on its strategy of acquiring complementary businesses and products 
Zoetis carries a Zack Rank  3  Hold   A couple of better ranked stocks in the health care sector are ANI Pharmaceuticals  Inc    NASDAQ ANIP   and OncoMed Pharmaceuticals  Inc    NASDAQ OMED    both sporting a Zacks Rank  1  Strong Buy  ",2016-05-03,Zacks Investment Research,"https://www.investing.com/analysis/zoetis-(zts)-tops-q1-earnings---revenues,-updates-outlook-200127975",200127975
182383,403899,ABT,Abbott Laboratories  ABT  Is In Oversold Territory  What s Next ,opinion,"Abbott Laboratories   NYSE ABT   has been on a bit of a cold streak lately  but there might be light at the end of the tunnel for this overlooked stock  And for technical investors there is some hope when looking at ABT given that  according to its RSI reading of 24 52  it is now in oversold territory 
What is RSI 
RSI stands for  Relative Strength Index  and it is a popular indicator used by technically focused investors  It compares the average of gains in days that closed up to the average of losses in days that closed down  readings above 70 suggest an asset is overbought  while an RSI below 30 suggests undervalued conditions are present 
Other Factors
Yet  ABT s low RSI value isn t the only reason to have some optimism over a coming turnaround  as there has been plenty of positive earnings estimate revision activity as of late  This is especially true when investors take a deep dive into some of these estimate revision stats and recent changes to Abbott Laboratories  earnings consensus 
Over the past two months  investors have seen 11 earnings estimate revisions move higher  compared with none lower  at least when looking at the key current year time frame  And the consensus estimate for ABT has also been on an upward trend over the past 60 days  as estimates have risen from  2 15 share two months ago to just  2 20 share right now 
If this wasn t enough  Abbott Laboratories also has a Zacks Rank  2  Buy which puts it into rare company among its peers  So  given all of these factors  investors may want to consider getting in on this stock now  or holding on   as there are some favorable trends that could bubble up for this stock before long ",2016-05-04,Zacks Investment Research,https://www.investing.com/analysis/abbott-laboratories-(abt)-is-in-oversold-territory:-what's-next-200128322,200128322
182384,403900,ABT,Aegerion Enters Into Settlement Agreement With DoJ And SEC ,opinion,Aegerion Pharmaceuticals  Inc    NASDAQ AEGR   announced that it has reached preliminary agreements with the U S  Department of Justice  DoJ  and staff of the Securities and Exchange Commission  SEC  regarding a settlement of the ongoing investigations by the agencies into the company s sales activities and disclosures related to its lead drug  Juxtapid We remind investors that Aegerion had received a subpoena from the DoJ in late 2013  wherein the latter requested documents regarding its marketing and sale of Juxtapid in the U S  In late 2014  the company received another subpoena from the SEC for certain information related to sales activities and disclosures for Juxtapid As a result of the settlement agreement  Aegerion will pay  40 million to the DoJ and the SEC over a period of five years in following tranches   approximately  3 million upon finalization of the settlement  around  3 7 million per year  payable quarterly  for three years following finalization of the settlement  and roughly  13 million per year  payable quarterly  during the fourth and fifth year after finalization of the settlement Consequently  Aegerion increased its existing reserve related to the investigations by approximately  28 million  bringing the aggregate reserve for these matters to approximately  40 million Aegerion is also required to plead guilty for alleged marketing of Juxtapid with inadequate directions for use  and an alleged failure to comply with a requirement of the Juxtapid Risk Evaluation and Mitigation Strategies  The company will enter into a separate five year deferred prosecution agreement with regard to charges that it has violated the Health Insurance Portability and Accountability Act and engaged in obstruction of justice relating to the REMS program We note that Aegerion is currently facing challenging market conditions as the launch of PCSK9 inhibitors in the U S  market hurt Juxtapid sales significantly and will continue to do so in the forthcoming quarters Aegerion sports a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Acorda Therapeutics   NASDAQ ACOR    Abbott Laboratories   NYSE ABT   and Sanofi   NYSE SNY    All the three companies carry a Zacks Rank  2  Buy  ,2016-05-12,Zacks Investment Research,https://www.investing.com/analysis/aegerion-enters-into-settlement-agreement-with-doj-and-sec-200129786,200129786
182385,403901,ABT,Novartis  NVS  Releases Positive Data On Ultibro Breezhaler,opinion,Novartis AG   NYSE NVS   announced results from the head to head randomized  double blind  non inferiority FLAME study on Ultibro Breezhaler  The trial compared the efficacy of once daily Ultibro Breezhaler 110 50 mcg to twice daily Seretide 50 500 mcg in reducing chronic obstructive pulmonary disease  COPD  exacerbations  Results were published in the New England Journal of Medicine The FLAME study met its primary endpoint  Results from the study showed consistent superiority of Ultibro Breezhaler over Seretide across exacerbation outcomes  lung function and health related quality of life in COPD patients Data also demonstrated that Ultibro Breezhaler was effective in reducing the rate and prolonging the time to the first moderate or severe exacerbation  when compared to Seretide We note that Ultibro Breezhaler 110 50 mcg was approved in Europe in 2013 as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD   The latest results from the FLAME trial bode well for the drug The combination was also approved in the U S  under the name Utibron Neohaler in Oct 2015  Novartis  COPD portfolio currently comprises Ultibro Breezhaler  Seebri Breezhaler and Onbrez Breezhaler Arcapta Neohaler  which generated combined sales of  0 6 million in 2015  up 19  from 2014 Approval of new drugs and label expansion of existing ones bode well for Novartis as it has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec  Additionally  its oncology drugs are facing competition from immuno oncology therapies  Moreover  its Alcon segment is facing a decline in surgical equipment sales in the U S  and emerging markets Novartis currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Pfizer Inc    NYSE PFE    Johnson   Johnson   NYSE JNJ   and Abbott Laboratories   NYSE ABT    All three stocks sport a Zacks Rank  2  Buy  ,2016-05-15,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-releases-positive-data-on-ultibro-breezhaler-200130161,200130161
182386,403902,ABT,Mylan To Buy Renaissance s Topical Business For About  1B,opinion,Mylan N V    NASDAQ MYL   announced an agreement under which it will acquire the non sterile  topicals focused specialty and generics business of privately held Renaissance Acquisition Holdings  Renaissance  which is majority owned by RoundTable Healthcare Partners  will however retain its sterile focused businesses and associated manufacturing facility Mylan has agreed to pay  950 million in cash upfront and up to  50 million in additional contingent payments  The company expects to finance the transaction using a combination of cash on hand and available borrowings under existing credit facilities How will Mylan Benefit The proposed Renaissance deal will give Mylan rights to a complementary portfolio of approximately 25 branded and generic topical products  an active pipeline of approximately 25 products  and an established U S  sales and marketing infrastructure targeting dermatologists  Mylan will also gain an integrated manufacturing and development platform and a leading topicals focused contract development and manufacturing organization Mylan will have access to two high quality manufacturing sites with capabilities and capacity in creams  ointments  aerosols foams  gels  suspensions  liquids and suppositories thereby complementing Mylan s existing capabilities The to be acquired business generated about  370 million in revenues in 2015 and has roughly 1 200 employees The acquisition will also complement Mylan s pending acquisition of Swedish drug maker Meda  which also has a substantial dermatology portfolio Meanwhile  Mylan does not expect to see the Renaissance deal to have any impact on the leverage ratio of 3 8x debt to adjusted EBITDA  which the company had projected taking into account the closing of the Meda transaction  The Meda acquisition is slated to close by the end of the third quarter of 2016 We believe the Renaissance deal is in line with Mylan s strategy of strengthening its dermatology topicals portfolio  Mylan has been constantly making acquisitions to drive growth  In Feb 2015  Mylan acquired Abbott Laboratories    NYSE ABT   non U S  developed markets  specialty and branded generics business  We expect Mylan to remain active on the business development front in 2016 in order to drive long term growth Mylan is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector are ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Retrophin  Inc    NASDAQ RTRX    each sporting a Zacks Rank  1  Strong Buy  ,2016-05-16,Zacks Investment Research,https://www.investing.com/analysis/mylan-to-buy-renaissance's-topical-business-for-about-$1b-200130187,200130187
182387,403903,ABT,Aegerion  AEGR  Misses Q1 Earnings Estimates  Cuts View,opinion,Aegerion Pharmaceuticals  Inc    NASDAQ AEGR   reported a loss of  1 85 per share in the first quarter of 2016  much wider than both the Zacks Consensus Estimate of a loss of 54 cents and the year ago loss of 20 cents In the reported quarter  net product sales were  35 7 million  below the Zacks Consensus Estimate of  43 5 million and down 39 8  year over year The Quarter in DetailNet sales of Juxtapid declined 54 3  year over year to  26 2 million  including  23 6 million from prescriptions written in the U S   due to a reduction in patients on therapy in the U S   along with a delay in timing of a bulk order of Juxtapid from the Brazilian Ministry of Health  which is now shifted to the second quarter  As of Mar 31  2016  there were around 498 active commercial patients being treated with Juxtapid  approximately 490 of whom are U S  patients   down from 615 patients at the end of the previous quarter Myalept s sales increased to  9 5 million from  2 1 million in the previous quarter  As of Mar 31  2016  the company had 87 active generalized lipodystrophy  GL  patients on commercial therapy in the U S   up from 79 GL patients at 2015 end Research and development  R D  expenses were relatively flat at  9 9 million Selling  general and administrative  SG A  expenses decreased 15 4  year over year to  39 7 million mainly due to lower salary and employee related costs  and lower stock based compensation due to a reduction in headcount in both the selling and administrative functions as part of the reduction in force in Feb 2016 and changes in executives  We note that the company reduced its global workforce by approximately 25  to lower its cost base in view of a decline in Juxtapid sales in the U S  market Pipeline UpdateAegerion plans to initiate a study to evaluate Juxtapid in pediatric HoFH patients in the second quarter of 2016  The company expects a Japanese approval for Juxtapid in HoFH in the fourth quarter of 2016  anticipated launch in early 2017   The company is also planning to submit a marketing authorisation application  MAA  for Myalept for the treatment of patients with GL in the EU by the year end  Aegerion is also planning for a label expansion of Myalept to include the treatment of patients with severe partial lipodystrophy 2016 OutlookAegerion projects total sales in the range of  130 million to  150 million  down from its earlier projection of  160  190 million  Juxtapid sales are now expected in the range of  90 million to  100 million  down from the prior expectation of  120  140 million in 2016  Myalept sales are anticipated in the  40  50 million band Our TakeAegerion s first quarter results were disappointing  with the company missing on both fronts by a wide margin  Launch of PCSK9 inhibitors in the U S  market hurt Juxtapid sales and will continue to do so in the forthcoming quarters   The lowered guidance was also disappointing The company also faced reimbursement hurdles for Myalept as prior authorizations are taking longer than expected and payers are requesting additional data  In fact  Myalept sales are expected to remain under pressure due to the payer mix Moreover  the company received a setback when it reached preliminary agreements with the U S  Department of Justice  DoJ  and staff of the Securities and Exchange Commission  SEC  regarding a settlement of the ongoing investigations by the agencies into the company s sales activities and disclosures related to its lead drug  Juxtapid  Under the agreement  Aegerion will pay  40 million to the DoJ and the SEC over a period of five years in following tranches  approximately  3 million upon finalization of the settlement  around  3 7 million per year  payable quarterly  for three years following finalization of the settlement  and roughly  13 million per year  payable quarterly  during the fourth and fifth year after finalization of the settlement The dismal results could deal a blow to the company s shares Aegerion currently has a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Pfizer Inc    NYSE PFE    Johnson   Johnson   NYSE JNJ   and Abbott Laboratories   NYSE ABT    All three stocks carry a Zacks Rank  2  Buy  ,2016-05-16,Zacks Investment Research,"https://www.investing.com/analysis/aegerion-(aegr)-misses-q1-earnings-estimates,-cuts-view-200130475",200130475
182409,403925,ABT,Top Trade Ideas For The Week January 4  2016  ABT,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Abbott Laboratories  N ABT   had a 17 month run higher before the pullback in the market in August 2015  It took a large hit them and then suffered another body blow when Hillary Clinton declared war on drug pricing in September  It has since recovered the ground lost on the second point and been consolidating around resistance at 46 
The stock moved back over the 50 day SMA in lat October and retested that two weeks ago  Since it has been acting as support  tightening against the resistance at 46  The RSI remains in the bullish zone  drifting near 50 after a move over 60  The MACD is trending lower but crossed up as it hit the zero level last week 
There is resistance at 46 and a move over that would trigger a target to 53  a new high  on a Cup and Handle break out  Or you could call it an AB CD or Measured Move too  all point to 53  Support lower comes at 44 75 and 43 50 with a break under that targeting the prior low at 39 as a start  Short interest is low at 1 1  and the company is expected to report earnings next on January 27th 
Checking the options activity the January chain shows large open interest on the call side to the upside from 45 to 50 and then it tails off a bit but continues higher  The put side has high open interest at 45 and then the biggest at 40 below  Moving out to February  beyond earnings  sees a possible buffer at 43 in the put open interest with the call side showing volume from 44 to 50 above 
Abbott Labs  Ticker  ABT
Trade Idea 1  Buy the stock on a move over 46 with a stop at 45  A straight stock trade 
Trade Idea 2  Buy the January 46 Calls  offered at 23 cents late Friday  on the same trigger  Using defined risk to gain the upside 
Trade Idea 3  Buy the January 40 46 bullish Risk Reversal  17 cents   A leveraged trade for upside participation 
Trade Idea 4  Buy the February 48 Calls and sell the February 43 42 Put Spread  10 cents   A levered trade with defined risk and more time 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Thursday which  as the books closed on 2015 and we started prep for 2016 saw the equity markets showing a lack of strength at best and some weakness short term 
Elsewhere look for consolidation to rule the short term  In Gold look for consolidation in the downtrend with Crude Oil also consolidating its move lower  The US Dollar Index looks to consolidate in the uptrend while US Treasuries just continue broad consolidation sideways marking time  The Shanghai Composite looks to continue its sideways motion while Emerging Markets are biased to the downside in consolidation 
Volatility looks to remain subdued keeping the bias higher for the equity index ETF s N SPY  N IWM and O QQQ  Their charts look to move into the New Year showing further consolidation in the long run but with some weakness in the short run  especially in the SPY  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2016-01-04,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-january-4,-2016:-bonus-idea-378603",378603
182410,403926,ABT,Hungry For Stability  5 High Yield Dividend Stocks To Consider,opinion,"Recent market turmoil has reignited investor appetite for the safe and staid  Of course  when it comes to the markets  there s never a 100  guarantee of safety  but because they can be relatively stable and reliable  higher yield  3    dividend paying stocks are   According to the Wall St  Journal 

This year  stocks in the S P High Yield Dividend Aristocrats Index companies in the S P Composite 1500 that have increased their dividends every year for at least 20 years are up 1 91   including dividends  compared with a negative total return of 4 3  for the S P 500 Index  The total return on the Dow Jones U S  Dividend 100 Index  composed of stocks that offer consistent  high payouts  is negative 0 8  

Simply investing in dividend paying companies isn t a guarantee that you ll profit from the investment  And a high yield stock isn t necessarily a safe haven  Reliable is the key here  since some companies intentionally beef up their dividend yields to unsustainable levels in order to attract investors  thereby up their share price 
On the other hand  some companies are thriving  and even if their stock remains relatively flat during specific market cycles  they ve paid out and consistently raised dividends for years  That sort of past performance is a good indicator of future results 
Here s our list of the top 5 dividend stocks with high yields that have been raising dividends almost every year for at least the past 30 years 
5  AbbVie  NYSE ABBV 
AbbVie is a pharmaceuticals company focused on the research and development of biopharmaceuticals and small molecule drugs  It employs about 28 000 people and has a market cap of  90B 
Although  AbbVie has only been paying dividends for the past 3 years  it has a good excuse  it s a spin off of Abbott Laboratories  NYSE ABT   a Dividend Aristocrat that s raised its dividend payout for 20 consecutive years  And since the acorn doesn t fall far from the tree  in this case at least  it seems fair to include AbbVie on our list  since it has continued Abbott s tradition of raising its dividend annually 
AbbVie shareholders enjoy a significant dividend yield of 4 12  along with a 43 year tradition of dividends from its  parent  company  At  56 40 per share as of yesterday s close  AbbVie also trades for a reasonable P E ratio of 13 1  compared to the industry average of 38 07 

With solid growth over the past three years  including a 14  rise in revenue in 2015  and an expected blockbuster leukemia drug set to be released in 2016  as well as the ongoing success of its best selling Humira medication which is used to treat rheumatoid arthritis  ulcerative colaitis and Crohn s disease among others  AbbVie continues to look promising 
The next Ex Dividend date for AbbVie is April 13th  for a quarterly dividend of  0 57 

4  Old Republic International  NYSE ORI 
If you think you cannot possibly find reliable companies among smaller market caps  you missed this one  Old Republic International engages in the insurance underwriting  primarily in North America  The company offers a variety of insurance policies  such as automobile  travel insurance  and various specific activities 
Founded in 1887  and headquartered in Chicago  Illinois  Old Republic has a comparatively small market cap of only  4 72B  so it pales in comparison to the usual value of most Dividend Aristocrats  However  it has fully earned its place alongside them 

With an annual payout of  0 75 per share and a stock price of  18 01  the company yields 4 16   Its EPS of 1 46 also means the company sells at 12 3 times earnings  below the industry average of 15 5  The analyst consensus target price on Old Republic is  20 given potential earnings and revenue growth expectations  which would put its stock price at 10  higher than what it sells for today 
The relatively small market cap may deter some from trusting this company  but that would be a mistake  It s well worth any dividend investor s consideration 
The next Ex Dividend date for Old Republic is yet to be announced  The most recent Ex Dividend date for the quarter was March 2nd  for a quarterly dividend of  0 1875 

3  Mercury General  NYSE MCY 
Like Old Republic  Mercury General is in the insurance business  And like Old Republic  Mercury General depending on the metrics you use can be considered either a large small cap or a small mid cap with a valuation of 2 97B 
Its  3B revenue doesn t make it a powerhouse like the top two companies on this list  below   but it still has a lot to offer  How much  A 4 61  yield on its  53 85 per share price tag  It has been paying a dividend since 1986  and raising that dividend annually since the initial payout 

It has a healthy payout ratio of 95 4   meaning it is not using all its net income to fund the dividend   and though its last earnings report  released on February 8  wasn t quite as expected   0 52 EPS on expectations of  0 68   the company remains committed to its dividend raise  Luckily  the miss is expected to be a one time event  predicated on higher than expected loss frequency and severe one time events in several states  Analyst forecasts predict an EPS of  0 67 for Q1 2016  which would easily cover the dividend payout 
The next Ex Dividend date for Mercury General is March 15th  for a quarterly dividend of  0 62 

2  Chevron  NYSE CVX 
The next two companies on our list aren t really surprising  They re two of the biggest corporations in the world  First up   Chevron 
Chevron is an American multinational energy corporation  operating in more than 180 countries worldwide  It engages in everything oil and gas related  from exploration to refining through marketing and transport  With a market cap of  167 11B and revenues of   129 87B  it isn t going to disappear in the near or long term future 

But  while the company itself is here to stay  its  4 28 dividend and 4 82  yield might not be  Like the entire oil industry  Chevron has been hit hard by the recent downturn in commodity prices  The last time it hiked its dividend was in Q2 2014  and the company has said it will not raise its dividend burden until times are easier for energy companies 
For a glimpse at the possible future of this dividend payer  look no further than ConocoPhillips  NYSE COP   which recently slashed its dividend by 66   Chevron isn t much of a value buy either  since it trades at a P E ratio of 36 29  well above the industry s 28 average  Overall  Chevron s dividend probably depends on a certain recovery of oil prices  because right now its 240  payout ratio  that is  almost 2 5 times its earnings  is most certainly unsustainable 
The next Ex Dividend date is yet to be announced since the Ex Dividend date for this quarter was February 16th  for a quarterly dividend of  1 07 

1  AT T  NYSE T 
When considering yields as well as continuity and consistency  one would be hard pressed to find anything better than AT T  The telecommunications company is the second largest provider of mobile telephony in the U S  With a market cap of  24 3B it is the 12th largest company on the S P 500 
Buying AT T today would secure you a 5 04  yield  an extraordinary return given current market conditions  AT T s dividend has been spectacularly stable  rising regularly for 31 years in a row  The company itself is well priced as well  with an acceptable 16 83 P E ratio compared to 23 9 for the industry as a whole  and a Price to Sales ratio of 1 5 compared to the industry s 1 74 

The return on the stock itself isn t as impressive as the dividend  and the company has been trading sideways since mid 2012  But  if it s reliable income you re after   you could do a lot worse than AT T 
The next Ex Dividend date has yet to be announced since the Ex Dividend date for the last quarter was January 6  for a quarterly dividend of  0 48",2016-03-09,Investing.com,https://www.investing.com/analysis/5-high-yield-dividend-stocks-to-consider-200120907,200120907
182411,403927,ABT,Zoetis  ZTS   Stock Likely To Beat On Earnings In Q1 Again ,opinion,"Zoetis Inc    NYSE ZTS   is scheduled to report first quarter 2016 results on May 4  before the opening bell  Last quarter  the company easily beat expectations with a positive earnings surprise of 10 26   Let s see how things are shaping up for this announcement 
Factors to ConsiderAt the time of reporting fourth quarter 2015 earnings results  Zoetis updated its 2016 guidance to reflect the impact of the European Commission s tax rulings in Belgium  foreign exchange rates as of late January  and changes related to the company s accounting for its operations in Venezuela  For 2016  the company expects earnings in the range of  1 71 to  1 81 per share on revenues of  4 65 billion and  4 775 billion 
Meanwhile  Zoetis  robust and diversified product portfolio including products for livestock and companion animals should continue to drive top line growth at the company  The top line should also benefit from the addition of products acquired from Abbott Laboratories    NYSE ABT   Animal Health business  acquired in Feb 2015   the Nov 2015 Pharmaq acquisition as well as from the performance of Apoquel and other key brands 
However  the company expects to see a greater impact from Apoquel in the second quarter of 2016 as it increases the availability of the product in the existing markets and launches it in new markets  Moreover  Zoetis doesn t expect to see the impact from new product launches in the first quarter and anticipates these products to ramp up during the year 
Considering that Zoetis  comprehensive operational efficiency initiatives  announced in May 2015  are anticipated to be largely complete in the second half of the year  the company expects to witness the positive impact from these initiatives in the second half of the year than in the first half 
On the first quarter call  investor focus will be on the company s performance as well as on the company s update on 2016 guidance 
Surprise History
Zoetis  track record has been impressive with the company beating earnings estimates consistently  In fact  Zoetis has posted a positive earnings surprise in each of the trailing four quarters  with an average beat of 14 81  

Why a Likely Positive Surprise 
For the first quarter of 2016  our proven model also shows that Zoetis is likely to beat earnings estimates because it has the right combination of two key ingredients 
Positive Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  2 44   This is a meaningful and leading indicator of a likely positive earnings surprise for the shares 
Zacks Rank  3  Hold   Note that stocks with Zacks Ranks  1  Strong Buy    2  Buy  and  3 have a significantly higher chance of beating earnings  However  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
The combination of Zoetis  Zacks Rank  3 and  2 44  ESP makes us reasonably confident of an earnings beat this season 
Other Stocks that Warrant a Look
Here are a couple of other health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Genocea Biosciences  Inc    NASDAQ GNCA   has an Earnings ESP of  2 50  and a Zacks Rank  3  The company is scheduled to release first quarter results on May 5 
Jazz Pharmaceuticals plc   NASDAQ JAZZ   has an Earnings ESP of  4 58  and a Zacks Rank  3  The company is scheduled to release first quarter results on May 10 ",2016-05-01,Zacks Investment Research,https://www.investing.com/analysis/zoetis-(zts):-stock-likely-to-beat-on-earnings-in-q1-again-200127325,200127325
182435,403951,ABT,Profit From Emerging Market Health Care Growth With Abbott Laboratories,opinion,"Abbott Laboratories  NYSE ABT   its 2nd quarter 2015 results 
The company saw adjusted earnings per share grow 6 1  to  0 52 per share from  0 49 per share in the same quarter a year ago 
Abbott Laboratories left its adjusted earnings per share guidance for full fiscal 2015 unchanged at  2 10 to  2 20 per share  The company had adjusted earnings per share from continuing operations of  1 98 in fiscal 2014  Abbott Laboratories outlook is for earnings per share growth of between 6  and 11  for fiscal 2015 
6  to 11  earnings per share growth actually significantly understates Abbott s real underlying business growth  On a constant currency basis  the company is expecting earnings growth of 13  to 18  in fiscal 2015 
The company s management expects headwinds from currency effects of around 7  in fiscal 2015  Abbott Laboratories is experiencing strong growth despite negative currency effects 
The company s growth would be much higher if the dollar had not appreciated so much in the last year  When this trend reverses  Abbott Laboratories stands to benefit 
Business Overview
Abbott Laboratories is a diversified health care company that manufactures and sells nutrition products  medical devices and diagnostic equipment  and pharmaceuticals 
Abbott Laboratories owns the Similac  Pedialyte  and Ensure brands   making the company  1in adult nutrition globally and  1 in pediatric nutrition in the U S 
The company operates in 4 segments  Each segment is shown below along with the percentage of total revenue generated for Abbott Laboratories in its most recent quarter 
Diagnostics generated 23  of total revenue
Nutrition generated 33  of total revenue
Medical Devices generated 25  of total revenue
Branded Generic Pharmaceuticals generated 19  of total revenue
Abbott Laboratories is truly a global business  The company generated just 31  of sales in the United States in its most recent quarter  The remaining 69  of sales were from international markets 
Safety Analysis
Abbott Laboratories has invested heavily in emerging markets  These investments are paying off  Emerging market sales grew 20 6  on a constant currency basis in Abbott Laboratories  most recent quarter 
The company has had success in emerging markets because it emphasizes manufacturing in the country where goods are sold  This reduces currency fluctuation risks and builds connections with the communities  companies  and governments the company serves 
Abbott Laboratories large international business gives it an advantage over large health care businesses that focus more on the United States  Abbott Laboratories has more exposure to faster growing markets 
One would think that too much exposure to international markets would hurt Abbott Laboratories during recessions  but that is not the case 
Abbott Laboratories managed to grow revenue  earnings  and dividends each year through the Great Recession of 2007 to 2009  Consumers and governments typically do not cut back on health care expenditures regardless of the economic climate  Abbott Laboratories stock fell just 4 95  in 2008 while the S P 500 declined 38  
Abbott Laboratories carries around  7 billion in debt and has  3 billion in cash on hand  The company generated about  3 5 billion in net profit in 2014  Abbott Laboratories is conservatively financed 
Future Growth   Dividends
Abbott Laboratories has paid increasing dividends for 43 consecutive years  excluding the effects of spin offs  The company s long dividend streak makes Abbott Laboratories a Dividend Aristocrat  
Despite over 4 consecutive decades of dividend growth  Abbott Laboratories still has a long growth runway ahead 
Abbott Laboratories  emerging market penetration gives it excellent long term growth prospects  The combination of emerging market economic growth and aging populations provide a favorable macroeconomic environment for Abbott Laboratories 
The company further increased its exposure to emerging markets with its recent acquisitions of  and  in the recent past  The company is targeting constant currency adjusted earnings per share growth of around 15  in fiscal 2015 
Abbott Laboratories should continue to grow quickly over the next several years  If a global recession were to occur  management has plenty of  dry powder  to pursue further acquisitions in international markets 
Dividends should also continue to grow rapidly for Abbott Laboratories  The company has a payout ratio of just 41   Abbott Laboratories still has room to grow its dividend payments faster than overall company growth if management chooses to do so  Abbott Laboratories currently has a 1 9  dividend yield 
Valuation
Abbott Laboratories is currently trading for an adjusted price to earnings ratio of 22  This number uses adjusted earnings  not GAAP earnings  The company s adjusted earnings do not include amortization expense and other items  The adjusted earnings give a more accurate picture of Abbott Laboratories  true earnings power 
Abbott Laboratories appears to be trading at the high end of fair value  The company s price to earnings ratio is fairly high  but reflects the extreme quality of Abbott Laboratories 
The company is still growing quickly  has low debt  a shareholder friendly management  and is recession resistant  Investors should expect to pay a slight premium over the S P 500 s price to earnings multiple for a premium quality business like Abbott Laboratories 
Final Thoughts
The management teams at many publicly traded corporations talk and talk about taking advantage of emerging market growth  Abbott Laboratories  management has done much more than talk  They have positioned the company for international growth 
Over the past year  this strategy has looked somewhat foolish thanks to the rapidly appreciation United States dollar  In the long run  emerging market growth will outpace growth in the United States  Emerging markets simply have an easier path to growth and larger populations 
Abbott Laboratories has a long growth runway ahead in emerging markets  The company s shares appear to be trading near the high end of fair value  The company s stock price is up over 20  in the last year despite the strong dollar  When the dollar trend reverses  Abbott Laboratories will likely see rapid earnings per share growth 
Abbott Laboratories is among the highest quality dividend growth stocks in the health care industry  The health care industry itself is among the best industries to invest  people will always need health care  Long term thinking dividend growth investors would do well to make Abbott a core holding of their portfolio ",2015-07-26,Ben Reynolds,https://www.investing.com/analysis/profit-from-emerging-market-health-care-growth-with-abbott-laboratories-259447,259447
182457,403973,ABT,US Health Industry Manages To Hold Out,opinion,Thanks to lackluster global economic activity for most of the year and rising geo political tensions  sectors less sensitive to economic cycles  including the U S  healthcare industry  have easily managed to hold out this year   The broad Health Care S P US Sector Source  LONDON XLVS  has beaten the fund tracking the overall markets   SPDR S P 500  ARCA SPY     Though that s the case  increased mergers and acquisitions  M As  are also paving the way for stronger business and diverse offerings  Moreover  new product offerings  increased pipeline visibility and restructuring activities are fuelling confidence in the sector    A similar trend has been seen in the medical device and equipment sector   a sub sector of the healthcare industry   Several MedTech majors struggling with core businesses are looking to explore potential therapies through collaborations and alliances to focus on their areas of expertise    One of the top companies in the space  Abbott Laboratories  NYSE ABT  recently signed a deal with Mylan for the sale of its non U S  developed markets specialty and branded generics business    Medical device companies are coming up with efficient capital allocation plans  expanding their product offerings and investing in emerging geographies in order to survive in the highly regulated medical device industry  which is burdened with stringent and complex procedures    Given the stepped up M As and a shift in their business models toward a value based healthcare structure amid rising pricing pressure and other bottlenecks in the industry  a look at one of the top ranked ETFs in the space could be the way to target the best of the segment with lower levels of risk    Also  the sector might be a good defensive bet to play the current market turmoil arising from the Argentina debt default  banking problems in Europe and growing geo political tensions in Israel and Ukraine   About the Zacks ETF Rank   The Zacks ETF Rank provides a recommendation for the ETF in the context of our outlook for the underlying industry  sector  style box or asset    The aim of our models is to select the best ETFs within each risk category  We assign each ETF one of the five ranks within each risk bucket  Thus  the Zacks ETF Rank reflects the expected return of an ETF relative to other products with a similar level of risk    For investors seeking to apply this methodology to their portfolio in the health care space  we have taken a closer look at the top ranked iShares DJSU Medical Devices Index  NYSE IHI   This ETF has a Zacks ETF Rank of 2 or  Buy  and is detailed below                    IHI in Focus   Launched in May 2006  IHI provides a targeted exposure to the U S  medical device sector by tracking the Dow Jones U S  Select Medical Equipment Index  The fund manages an AUM of  687 1 million and trades in light volumes of roughly 60 000 shares a day    The fund holds a small basket of 49 stocks which are quite concentrated in its top five holdings  Abbott  Medtronic Inc and Thermo Fisher form the top three spots having a combined exposure of more than one fourth of fund assets  The product has a definite tilt toward large cap securities with 66  of assets  followed by 19  in mid caps and the rest in small caps    Sector wise  Medical Equipment occupies the bulk of exposure with three fourths allocation  followed by 15  allocation to Medical Supplies and 10  allocation to Pharmaceuticals    IHI charges a reasonable 43 basis points as expenses  The product has a modest dividend yield of 0 54  but has a good performance track record  IHI has returned 10  in the year to date frame  22  in the past one year and a compounded 67  in the past three years    Thus  given its impressive track record  solid fundamentals in the space coupled with a favorable Zacks ETF Rank  the fund is expected to continue its winning streak and outperform the broader markets in the near term  Investors can consider adding this fund to their portfolio for a more diversified approach ,2014-08-11,Zacks Investment Research,https://www.investing.com/analysis/us-health-industry-manages-to-hold-out-222291,222291
182458,403974,ABT,Wars And Failed Mergers Make For A Tricky October,opinion,"The data provider and analyst Eurekahedge  in its latest report  says that hedge funds posted negative returns in both September and October  Wars  elections  oil prices  and a change in U S  tax policy all figure into the reasons why 
Start with Numbers 
The Eurekahedge Hedge Fund Index is down 0 24  in October  although still up 3 47  year to date 
Looking at the industry by region  Eastern Europe and Russia had the worst October   2 26    The reason for that isn t difficult to grasp  war and the rumor of war  On October 1st  after all  both a school and a bus station in Donetsk took artillery hits  and 12 people died On October 10  a qualifying match between Ukraine and Belarus in Minsk was rather rudely interrupted for the arrest of about 100 fans chanting an anti Putin slogan  This is hardly an environment beloved by investors 
The Asia ex Japan index did best  up 0 55    Managers there report gains from their exposure to China s property developers  China A share investing funds scored their sixth straight month of positive returns and are now up 9 9  YTD through October 
 Parenthetically  there s much to be said for the A share s as an investing option  They give investors exposure to China s consumer names  so if you believe that consumed in China  rather than made in China  is the next Big Trend  and you want to be ahead of that curve  you might make use of this asset  
Roller Coaster Rides 
Emerging markets were down for the month  in large part due to the political success of Brazil s president 
The Eurekahedge analysis characterizes October as having been  a roller coaster ride for the financial markets  with volatility rising sharply during the month as the CBOE VIX Index reached 26 2 at its peak  while yields on 10 year treasuries briefly fell below 2   
There was a good deal of positive economic news in the second half of the month  though  including corporate earnings reports and gross domestic product numbers 
The Federal Reserve ended its quantitative easing program  but as Eurekahedge observes   central banks elsewhere remain fully committed to tackling deflation   Indeed  they do so with the  
 
Strategy
Only two of the strategy specific indices were in the black for October  CTA Managed Futures 0 26 up  and Fixed Income 0 10  The futures managers benefitted from their short energy positions as oil prices fell  Fixed income strategies may have benefited from the  divergence in economic policies between central banks  
Long short equity managers were down only slightly  They ve been reducing their long exposures of late as a matter of risk management  the report says 
Event driven funds suffered substantial losses  and merger arb funds did still worse  Some high profile attempts at merging fell through in October  hurting funds in both those categories  For example  AbbVie Inc  NYSE ABBV  tried and failed to absorb Shire PLC  AbbVie is a biopharm concern  a successor to Abbott Laboratories  and best known for Humira  Shire is a rare disease specialist  It seemed a natural combination  and certain fund managers bet heavily that it would be a completed one 
AbbVie  an American drug company  thought that it would benefit from the merger with U K  based Shire in part for tax reasons  as a so called  inversion  
AbbVie s board changed its own view of the deal on October 16th  saying  the agreed upon valuation is no longer supported as a result of the changes to the tax rules  of the Obama administration in the U S 
Multi strategy  distressed debt and arbitrage funds also had scary Octobers at 0 94   0 87  and 0 76  respectively  Macro managers were down 0 61   ",2014-12-02,AllAboutAlpha,https://www.investing.com/analysis/wars-and-failed-mergers-make-for-a-tricky-october-234330,234330
182482,403998,ABT,Market Dynamics Changing  Time To Evaluate Your Portfolio,opinion,"Being financial reporting season  it s important to discern between results that beat Wall Street consensus and real economic growth 
Abbott Laboratories  NYSE ABT  just announced better than expected first quarter earnings  but they weren t better than the comparable quarter of 2013  Operating earnings  earnings from continuing operations  and diluted earnings per share were all down significantly compared to the first quarter of 2013 
So  the illusion can definitely become real in hot markets  Investors are always better off ignoring headlines and going right to the financial statements  Managed earnings are just that managed 
One company that just produced a very good quarter was The Charles Schwab Corporation  NYSE SCHW   The stock broker s first quarter sales grew 15  to  1 48 billion on strong growth in asset management and administration fees 
Net earnings leapt 58  to  326 million  or 60  to  0 60 in diluted earnings per share  Top line growth and strong expense control were the reasons for the strong bottom line growth 
There s no real reason why Charles Schwab s share price should keep on appreciating near term  All the good news is priced into the shares  The company beat consensus earnings by  0 02 a share  while revenues were in line 
This reporting season  earnings are here to justify current share prices 
I d be very wary of buying corporate good news now  Market jitters aren t going away and all it takes is a small catalyst for institutional investors to pull the sell trigger again 
A meaningful correction or price consolidation would be a positive development for the longer run trend and a good opportunity to consider adding to blue chip positions 
A good deal of speculative fervor has come out of this market  but by no means are biotechnology stocks or initial public offerings  IPOs  now cheaply valued  There s a lot more room for meaningful downside so as to get back to reasonable pricing  It s just indeterminate as to when this will happen with the Federal Reserve being so committed to easy monetary stimulus 
The NASDAQ Composite is leading this market currently and this means that there s real potential for extra volatility  Wherever technology stocks go  so does the broader market 
The current environment is a great time to be re evaluating portfolio risk as well as identifying those companies you d like to own if valuations were more reasonable  I would still only buy genuine value in this market  the fact of the matter is that there s not a lot of it around 
Equity market dynamics are changing  The beginning of last year saw tremendous leadership from transportation stocks and dividend paying blue chips  then the rally slowly broadened out 
Speculative issues recently got a bit of a haircut and then there were gains in emerging markets  Looking for trends in the equity universe going forward  I suspect energy will continue to be a solid sector for investors  Despite recent gains  there is still value in the energy sector as earnings have done an excellent job of catching up to share prices 
The upside this year is with value plays  Price momentum might return to risk capital sectors  but I think we re in for an extended break now 
Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ",2014-04-24,Mitchell Clark,"https://www.investing.com/analysis/market-dynamics-changing,-time-to-evaluate-your-portfolio-210525",210525
182483,403999,ABT,Why This Institutional Favorite Tops My List Of Stocks,opinion,"One of my favorite companies for long term  income seeking investors is Johnson   Johnson  NYSE JNJ  
While pharmaceuticals are the company s anchor  its other business lines help with cash flow and dividend increases 
Investors have bid Johnson   Johnson shares tremendously in recent years  and it s difficult to consider buying the company now  as the position is up another 10 points since March 
But Johnson   Johnson is the kind of stock income seeking investors should keep an eye on for more attractive entry points  even though they may not come around all that often  The most recent possible entry points were in late September of last year and late January of this year 
My expectations for a mature company like this is for total annual sales to grow by the mid single digits  with earnings growth and dividends producing an approximate 10  total annual return 
With a 10  annual return on investment  your money doubles every seven years 
Johnson   Johnson is typically priced at a slight premium to the S P 500  but the company has earned its higher valuation by providing relatively consistent growth  reliable corporate outlooks  and a strong track record of dividend increases 
The company s stock chart is featured below 

Johnson   Johnson has typically been a good performer over the long term  but just like any large cap  it can sit and produce no capital gains for long periods of time 
The position broke out at the beginning of 2013 after a number of years of modest capital gains  Institutional investors  wanting the earnings safety and solid dividends that the company provided  bid the stock tremendously 
I still view the stock as an institutional favorite and the fact of the matter is that in this global economy  consistent business growth is a difficult thing to achieve 
But Johnson   Johnson is not a stock worth chasing  It s the kind of position one might take on and or add to during dips 
Investment risk with this brand name company is actually higher than you might think  and that s because in recent quarters  its only business unit that has been growing is pharmaceuticals 
And that s what you are buying if you re considering shares in this company  Consumer products and medical devices are material but slow growth business lines 
A long term  diversified equity market portfolio is well served by having exposure to the healthcare area and Johnson   Johnson would be a top pick among blue chips 
There are plenty of competitors in the marketplace from which to choose  but I like this company for its diversified business lines  even if they are mature operating units 
Abbott Laboratories  NYSE ABT  is another diversified pharmaceutical company that s broken out on the stock market 
This enterprise is a pure play pharmaceutical business with a number of other lines  including diagnostic tests  nutritional products and veterinary care products 
It s a solid  dividend paying large cap  but it s only a fifth of the size of Johnson   Johnson s market capitalization 
Second quarter earnings season is here and Johnson   Johnson reports this coming Tuesday  July 15  The company usually increases its quarterly dividend every second quarter and recently did so  payable on June 10  2014 
On any share price retrenchments  this company is worthy of consideration 
Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ",2014-07-13,Mitchell Clark,https://www.investing.com/analysis/why-this-institutional-favorite-tops-my-list-of-stocks-219208,219208
182501,404017,ABT,Near Term Catalysts  High Insider Ownership Makes GTx An Attractive Buy,opinion,Today  we are going to take a comprehensive look at a small cap biotech company with several near term catalysts  a strong cash position  and high insider ownership  I feel with all factors considered  this company can see very good price appreciation heading into its near term catalyst  GTx  GTXI  specializes in developing synthetic hormones to achieve certain therapeutic effects in the body  Hormones are extremely important in controlling certain cellular and intracellular activities in our bodies and drugs that manipulate these hormones can have a very powerful effect  Many of our body s cells have specific receptors  where certain molecules with the correct stereochemistry and conformation can activate or inhibit a response  GTx develops drugs termed  nonsteroidal selective receptor modulators  that facilitate control of androgen and estrogen receptors by binding to the receptor instead of the natural hormone  These nonsteroidal selective receptor modulators  SRMs  are important because they are able to interact with the hormone receptors that usually only allow the four fused chemical ring structure of a steroid to bind  even though they do not contain the same chemical structure  This is significant because it allows GTx s drugs to control these vital hormones and stimulate their beneficial characteristics  while also minimizing the unwanted side effects of synthetic steroidal compounds  GTx is currently in two pivotal Phase III trials  termed Power 1 and Power 2  for enobosarm  Ostarine  GTx 024   which is used for the  with non small cell lung cancer and for other muscle wasting diseases  Additionally  GTx is conducting a Phase II trial for its estrogen receptor alpha antagonist  Capesaris  GTx 758    GTx s Platform and Pipeline  Selective Receptor Modulators  SRMs  GTx s SRM platform is potentially very powerful because it s able to maximize the benefits of a drug  while minimizing the side effects  Steroidal hormones have been used for years to treat certain diseases and conditions  however  use of these hormones has been rather limited due to the unwanted side effects that steroids cause  This is of particular importance because steroid usage causes very noticeable side effects that include potential stimulation of prostate cancer  aggravation of existing benign prostatic hyperplasia  acne  hair growth  virilization  and gynecomastia  GTx s platform allows scientists to harness the power of some of our body s strongest hormones to stimulate tissue growth  development  and function  without using steroids  Whether the desired effect is to be an agonist  stimulating a biological response  or antagonist  blocking a biological response   scientists can have better control over the treatment of select tissues Enobosarm Enobosarm  also termed Ostarine or GTx 024  is in two Phase III clinical trials for the prevention and treatment of muscle wasting in patients with non small cell lung cancer  NSCLC   These trials are of the utmost importance for patients with muscle wasting because there is currently no approved treatment  Muscle wasting is a common problem for patients with non small cell lung cancer and it can be quite debilitating  In fact  88  of patients report they have difficulty doing everyday activities such as climbing stairs  This muscle loss is a common cancer symptom that can be caused by the underlying condition or the side effects of several chemotherapy drugs  Nearly half of NSCLC patients present severe muscle loss and 70  have muscle loss before death  So far  previous trials for enobosarm have gone well and met primary endpoints    To date  GTx has evaluated enobosarm in eight clinical trials involving approximately 600 subjects including three efficacy studies  A four month Phase IIb enobosarm clinical trial enrolled 159 patients with NSCLC  colorectal cancer  breast cancer  non Hodgkin s lymphoma  or chronic lymphocytic leukemia  The study met its primary endpoint of absolute change in total lean body mass  muscle  compared to placebo and the secondary endpoint of muscle function  performance   The incidence of serious adverse events  deaths and tumor progression were similar among placebo and the treatment arms  The most common side effects reported among all subjects in the trial were fatigue  anemia  nausea and diarrhea  So many NSCLC patients live with a lower quality of life  due to the fact that there is currently no approved treatment  The FDA recognizes this unmet need and gave Fast Track Designation for this indication of enobosarm  If Phase III trial results are positive  it will be a huge success for patients and investors alike  Capesaris GTx is also working on developing GTx 758  Capesaris   which is in Phase II clinical trials  Capesaris is a selective estrogen receptor alpha agonist  which is being tested for use in treating men with advanced prostate cancer  It is thought that by increasing the sex hormone binding globulin and reducing serum free testosterone  patients will see a significant decrease in prostate cancer cell growth  On March 15  2013  GTx presented its Phase II Trial Data in advanced prostate cancer at the 28th Annual European Association of Urology Congress and was selected as   Near term catalysts  GTx is expecting to release topline data from the two pivotal clinical trials termed POWER 1 and POWER 2 soon this year  Both of the pivotal trials are placebo controlled  double blind  and were fully enrolled by the 4th quarter of 2012    Chief Executive Officer of GTx  We are pleased that the DSMB  Data Safety Monitoring Board  has recommended that GTx continue as planned with our clinical studies of enobosarm under the existing protocols  The extensive safety database GTx is compiling from the numerous clinical studies of enobosarm will be a critical component of GTx s application for marketing approval  which we hope to submit following receipt of topline data from our Phase III clinical trials in the 3rd quarter of 2013  In both trials  patients with stage III or IV NSCLC were randomized at the time they began first line chemotherapy and were either treated with placebo or 3 mg of enobosarm  The study measured the response rates of enobosarm vs  placebo  on maintaining or improving total lean body mass  To test this  doctors had patients perform a stair climb to assess the individual s power at day 84 of treatment  Additionally  the study used dual x ray absorptiometry  DXM  to measure the patient s bone mineral density at five months of treatment  GTx s indication for enobosarm deals with muscle loss  however there are some big name pharmaceutical companies that produce therapies for patients with non small cell lung cancer  One of these companies is Pfizer  PFE   which currently markets Xalkori  crizontinib   Xalkori is a protein kinase inhibitor that binds to the ATP binding pocket of target kinases  About 4  of NSCLC patients have an abnormality to the anaplastic lymphoma kinase  ALK  gene  which can cause cancer growth in the lung  This approved drug causes 90  of tumors to shrink at least 30  50  in clinical trials  The purpose of this comparison is not to highlight a competing product  because GTx s indication has no current treatment and thus there is not competition   but to show that the market for products that help treat NSCLC is large and profitable  Future Catalysts  GTx also has several catalysts in the future that could drive share price significantly higher   that it would be initiating a Phase II  open label study of enobosarm to treat ER positive metastatic breast cancer  The primary endpoints for this study will be clinical benefit and will be assessed within 6 months time  Moreover  GTx is currently enrolling a  to evaluate the safety and effectiveness of lower doses of Capesaris to treat men with metastatic castration resistant prostate cancer and expects to receive topline data from this study later this year  Financial Position  GTx is in a very strong financial position for a developmental biotech company  The company engaged a public offering on June 23  2011 of 10 000 000 shares priced at  4 75 per share  totaling about  47 5 million  Currently  GTx has  56 09 million in cash  and no debt  so it s not likely the company will have a need to dilute anytime soon as its cash position should be able to last through next year  Share Structure   Similar to many of the other biotech companies that I have covered  GTx has a favorable share structure  They only have 20 57 million shares in the float  which means when the stock does move  it will move quickly and decisively  Furthermore  there is no significant outstanding warrants that would act as an overhang to limit the share price from appreciating into the anticipated release of Phase III data  Insider ownership   From the same table above  we can also see the bullish sentiment of the GTx insiders  Currently  insiders hold 69 28  of the shares  which is a large position for a developmental biotech company  Joseph Hyde  the former Chief Executive Officer of Autozone and director of the FedEx Corporation  is currently on GTx s board of directors and is the largest shareholder  He holds 9 405 014 shares of GTx  with a current market value of over  42 500 000  Jack Schuler  the former President and Chief Operating Officer of Abbott Laboratories  ABT   also owns 6 954 144 shares  with a current market value of over  31 500 000  It s important to note that neither of these heavily invested insiders has sold a single share within the last year  In fact  they have continually added  with the most recent acquisition as close as March 31  2013 by Joseph Hyde  Small cap developmental pharmas that show positive results in clinical trials dealing with unmet need markets are often acquired by larger pharmas  especially when the small cap company has former executives from large cap companies with significant insider ownership  Often times these former top executives help engage acquisition discussion as they are well  connected  with their former companies    Abbot might very well be interested in acquiring GTx if the upcoming data release is positive  Prolar Biotech  PBTH  is a recent example of a company being bought out by an insider with a large stake in the company  Opko Health  OPK  CEO Dr  Phillip Frost owned about 20  of PBTH at the time and on April 24  2013 Opko Health announced that it would be  The level of insider ownership in GTx is also similar to that of OPK  which has insiders holding 55 35  of the shares  Dr  Frost continually bought shares before the stock ran from  4 50 to  7 50  Charts and Indicators   From the above daily 50 day chart  we can see that GTXI is gaining interest as the catalyst approaches  The chart had a classic  flagging  continuation pattern  in which share price falls slightly and consolidates before the next run  Using the Fibonacci Retracement indicator  we can see that the stock retraced between the 38 2  and 50  levels and has began its next wave run  In terms of timing  this could indicate that we start to see a higher push very soon  In addition  the 20 day simple moving average crossed up through the 50 day simple moving average  This is a bullish sign for the intermediate term  as it signals that the stock might be ready for another run  From a volume standpoint  we can see from the pink average volume line that investors have begun to take their positions for the upcoming months  Looking at the indicators from the same time frame  we can see bullish sentiment going forward  The Relative Strength Index is in a general uptrend  still has a bullish reading on the scale  and is below the 70  overbought  reading  The accumulation distribution line made a vicious reversal from lows on April 15 and is now in a nice uptrend as well  The Money Flow Index also shows nearly the same trend as the RSI  indicating bullish sentiment going forward as well  With combined factors considered  GTx could have a run similar to that of Array BioPharma  ARRY   which ran from about  4 00 in mid March to about  6 20 at the end of April  Array BioPharma develops small molecule drugs to treat patients with cancer and is partnered with Novartis  NVS   InterMune  ITMN   and AstraZeneca  AZN   Array is expecting results this summer for its   Conclusion  GTXI should see a significant run in the next coming months  as investors anticipate date release from its Phase III trials  The company s strong cash position  heavy insider interest  and bullish chart are indicators of this  If GTx produces positive data here  investors will be significantly rewarded as the drugs associated with the data address large unmet need markets  My short term price target is  6 25 per share  Before data release  my target is  7  and on a good data release  I believe GXTI can reach  10 per share  Disclosure  I am long GTXI Disclaimer  This article is intended for informational and entertainment use only  and should not be construed as professional investment advice  They are my opinions only  Trading stocks is risky    always be sure to know and understand your risk tolerance  You can incur substantial financial losses in any trade or investment  Always do your own due diligence before buying and selling any stock  and or consult with a licensed financial adviser ,2013-05-08,Scott Matusow,"https://www.investing.com/analysis/near-term-catalysts,-high-insider-ownership-makes-gtx-an-attractive-buy-166069",166069
182502,404018,ABT,Why The Stock Market Is Sticking With These Two Pharma,opinion,One sector we haven t looked at in quite some time is the big pharmaceutical stocks sector  Exposure to this sector is always welcome in a long term stock market portfolio   Like every company  big pharmaceutical companies experience their own business cycles  but dividend payments within the group are significant and worthy of attention   Bristol Myers Squibb Company  BMY  was one of the higher dividend paying stocks within the group   The company got a major Wall Street upgrade from Citigroup  based on its Phase 3 development program for  Nivolumab   a new cancer treatment   The company recently experienced renewed stock market momentum after a period of consolidation  Its dividend yield is approximately three percent now because of the run up  It was closer to five percent not too long ago   I m still a fan of combo pharmaceutical companies for long term portfolios  By this I mean companies with other business lines  rather than pure play drug development stocks  I m referring to companies like Johnson   Johnson  JNJ   which has pharmaceuticals  consumer products  medical devices  and diagnostics business lines  There s also Abbott Laboratories  ABT   which sells drugs  eye care products  nutritional products  and dog food   This multifaceted business approach that includes the expensive  but also rewarding business of drug development creates a nice bit of diversification as the business cycle changes   Like virtually everything else in the large cap space  Abbott has done great on the stock market over the last couple of years  The company only experienced two long periods of flat performance since 1999  Abbott s stock chart is featured below ,2013-06-04,Mitchell Clark,https://www.investing.com/analysis/why-the-stock-market-is-sticking-with-these-two-pharma-169747,169747
182512,404028,ABT,Events In Europe Trigger Rough Patch In Markets,opinion,2013 had one of the best Januaries in recent history  only to hit a rough patch in the first week of February  Though the markets were due for a breather  events in Europe were the trigger   The two European countries most likely to cause the next phase of eurocrisis Italy and Spain both had potentially destabilizing political developments  In Italy  former prime minister  and current billionaire playboy  Silvio Berlusconi the man most responsible for Italy s financial malaise has been gaining in the polls by making promises to roll back some of the economic reforms pushed through by Mario Monti s government  These would be the same economic reforms that calmed the bond market and helped to restore confidence in Italy   And in Spain  Prime Minister Mariano Rajoy has been implicated in a corruption scandal that threatens his government at the same time that Catalonia is agitating for independence   At this point  Sizemore Capital sees this as a mild correction in the midst of a bull market that likely has several years left to run  But it may get choppy for a few weeks   Sizemore Capital made several portfolio moves in January and early February  In the Dividend Growth Portfolio  we sold our position in Spirit Realty Capital  SRC  following the announcement that it was to be acquired by Cole Credit Property Trust II  a non traded REIT  Given the legal uncertainty facing the acquisition  there are multiple lawsuits from disgruntled shareholders   taking our profits seemed the more prudent course of action   Abbott Labs  ABT  divested its pharmaceutical business as a separate stock AbbVie  ABBV   Sizemore Capital is attracted to Abbott for its collection of stable businesses in nutrition  medical devices and over the counter drugs  but the pharmaceutical spinoff was a bad fit for the Dividend Growth Portfolio  We sold our shares of AbbVie and reinvested the proceeds in additional shares of Abbott   Finally  to round out our REIT exposure  we added a position to Healthcare Trust of America  HTA   a REIT specializing in medical office buildings  Sizemore Capital is attracted to HTA s medical property portfolio  as it is supported by strong demographic trends and should actually benefit from ObamaCare   Sizemore Capital also made minor adjustments to the Tactical ETF Portfolio  We reduced our exposure to Africa via the Market Vectors Africa Index ETF  AFK  and invested the proceeds in the iShares FTSE China 25 Index Fund  FXI   Additionally  we slightly reduced our exposure to U S  large cap dividend payers via the Wisdom Tree Large Cap Dividend ETF  DLN  and initiated a new position in the iShares MSCI France ETF  EWQ    This is consistent with Sizemore Capital s view that Europe and China represent better bargains for investors at current prices   We made one addition to the Sizemore Investment Letter Portfolio  initiating a position in the tech start up fund GSV Capital  GSVC   After the drubbing Facebook  FB  took in 2012  we expect a rebound in  Web 2 0  stocks  and GSV is uniquely positioned to benefit   And finally  we replaced our bond index exposure in the Strategic Growth Allocation with active management in the form of the Pimco Total Return Bond ETF  BOND  ,2013-02-08,Charles Sizemore,https://www.investing.com/analysis/events-in-europe-trigger-rough-patch-in-markets-154453,154453
182516,404032,ABT,Top Trade Ideas  Week Of May 6  2013   The Rest,opinion,Here are the Rest of the Top 10  Abbott Laboratories  Ticker  Abbott Laboratories  ABT  is growing a symmetrical triangle after a rising out of a consolidation zone  A break of the triangle targets a  1 5 move on the pattern and continuation to the upside carries a Measured Move higher to 41  Huntington Bancshares  Ticker  HBANHuntington Bancshares  HBAN  is moving higher after falling back and finding support at the 100 day Simple Moving Average  SMA   The Relative Strength Index  RSI  is rising  The Moving Average Convergence Divergence  MACD  indicator is rising and just crossed to positive  both supporting further upside  Intuitive Surgical  Ticker  ISRGIntuitive Surgical  ISRG  is moving back higher  ending the week at the 50 day SMA  The RSI and MACD support continued upward price action  Kansas City Southern  Ticker  Kansas City Southern  KSU  is hitting resistance at the previous high after consolidating along the 50 day SMA for some time  A continued move higher breaks a broad consolidation channel and targets a move higher to 137 50  Wal Mart  Ticker  WMTWal Mart  WMT  is in a long Cup and Handle pattern and may be breaking out higher  The target on the pattern break is to 91 50  The RSI is turning higher with a MACD that may also be joining it higher After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Saturday  As we head into next week  Gold looks to continue its consolidation with a downside bias  Crude Oil works higher in the neutral zone  The U S  Dollar Index looks better lower  while U S  Treasuries are biased lower within the longer uptrend  The Shanghai Composite is at support  but looks better for a break lower while Emerging Markets are looking strong  Volatility looks to remain subdued  keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  despite their moves higher to new highs  Their charts agree and point higher  but look better on the weekly timeframe as the daily views show some signs of being extended with Friday s moves  Use this information as you prepare for the coming week and trad em well The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2013-05-05,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas:-week-of-may-6,-2013---the-rest-165735",165735
182525,404041,ABT,Best Dividend Paying Stock List As Of June 2012 ,opinion,Here is a current dividend list  from low yield to high yield paying stocks  of stocks with interesting performance and valuation figures  Stocks from that list are mid  and large caps  market capitalization of more than USD 1 billion  with double digit long term earnings growth rates  The companies are traded at AMEX  NYSE  NASDAQ and part of the Dow Jones  S P 500 or Nasdaq Composite  Date of the screen is June 01  2012  The list is selected by the following criteria and sorted by dividend yield  Market capitalization    1 Billion Price Earnings Ratio    0   100 Dividend Yield    3   20 Return on investment    10   100 Operating Margin    10   100 10 Year Revenue Growth    8   200 10 Year EPS Growth    10   100Vale  ADR   NYSE VALE  has a market capitalization of  93 33 billion  The company employs 70 785 people  generates revenues of  58 990 00 million and has a net income of  21 517 00 million  The firm s earnings before interest  taxes  depreciation and amortization  EBITDA  amounts to  34 234 00 million  Because of these figures  the EBITDA margin is 58 03 percent  operating margin 51 05 percent and the net profit margin finally 36 48 percent    Financial Analysis  The total debt representing 19 04 percent of the company s assets and the total debt in relation to the equity amounts to 31 53 percent  Due to the financial situation  a return on equity of 30 99 percent was realized  Twelve trailing months earnings per share reached a value of  3 77  Last fiscal year  the company paid  1 73 in form of dividends to shareholders  Market Valuation  Here are the price ratios of the company  The P E ratio is 4 85  P S ratio 1 69 and P B ratio 1 21  Dividend Yield  6 26 percent  The beta ratio is 1 55  Novartis AG  NYSE NVS  has a market capitalization of  126 03 billion  The company employs 123 686 people  generates revenues of  59 375 00 million and has a net income of  9 245 00 million  The firm s earnings before interest  taxes  depreciation and amortization  EBITDA  amounts to  15 751 00 million  Because of these figures  the EBITDA margin is 26 53 percent  operating margin 18 52 percent and the net profit margin finally 15 57 percent   Financial Analysis  The total debt representing 17 22 percent of the company s assets and the total debt in relation to the equity amounts to 30 72 percent  Due to the financial situation  a return on equity of 14 12 percent was realized  Twelve trailing months earnings per share reached a value of  3 55  Last fiscal year  the company paid  2 25 in form of dividends to shareholders  Market Valuation  Here are the price ratios of the company  The P E ratio is 14 66  P S ratio 2 40 and P B ratio 1 90  Dividend Yield  4 77 percent  The beta ratio is 0 52  CNOOC Limited  NYSE CEO  has a market capitalization of  80 10 billion  The company employs 5 377 people  generates revenues of  37 899 77 million and has a net income of  11 050 90 million  The firm s earnings before interest  taxes  depreciation and amortization  EBITDA  amounts to  18 571 11 million  Because of these figures  the EBITDA margin is 49 00 percent  operating margin 37 60 percent and the net profit margin finally 29 16 percent    Financial Analysis  The total debt representing 9 89 percent of the company s assets and the total debt in relation to the equity amounts to 14 45 percent  Due to the financial situation  a return on equity of 29 36 percent was realized  Twelve trailing months earnings per share reached a value of  24 64  Last fiscal year  the company paid  5 80 in form of dividends to shareholders   Market Valuation  Here are the price ratios of the company  The P E ratio is 7 28  P S ratio 2 15 and P B ratio 1 94  Dividend Yield  3 80 percent  The beta ratio is 1 43  Abbott Laboratories  NYSE ABT  has a market capitalization of  97 22 billion  The company employs 91 000 people  generates revenues of  38 851 26 million and has a net income of  4 728 45 million  The firm s earnings before interest  taxes  depreciation and amortization  EBITDA  amounts to  8 795 84 million  Because of these figures  the EBITDA margin is 22 64 percent  operating margin 14 81 percent and the net profit margin finally 12 17 percent   Financial Analysis  The total debt representing 25 57 percent of the company s assets and the total debt in relation to the equity amounts to 63 07 percent  Due to the financial situation  a return on equity of 20 07 percent was realized  Twelve trailing months earnings per share reached a value of  3 23  Last fiscal year  the company paid  1 92 in form of dividends to shareholders  Market Valuation  Here are the price ratios of the company  The P E ratio is 19 12  P S ratio 2 50 and P B ratio 3 97  Dividend Yield  3 30 percent  The beta ratio is 0 31  Take a closer look at the full table of best dividend paying stocks in June 2012  The average price to earnings ratio  P E ratio  amounts to 12 03 while the dividend yield has a value of 4 82 percent  Price to book ratio is 3 52 and price to sales ratio 2 55  The operating margin amounts to 29 67 percent  Earnings per share grew by 19 52 yearly over the past decade   Compared to the previous month  there are nine additional stocks on the best dividend paying stock list  in total 29  The highest yield is still realized by MFA Financial  MFA  who has a yield of 12 55 percent  Southern Copper  SO  was referred by Alliance Resource Partners  ARLP  to rank three  Here is the full table with some fundamentals  TTM  Related Stock Ticker Symbols MFA  ARLP  SCCO  HEP  VALE  MBT  SID  YZC  PBR  STO  MMP  NVS  SSL  STRA  MCHP  CHL  TLK  BBL  CEO  GRMN  CVX  BHP  RIO  ABT  GD  PEP  ABV  VCO  RES,2012-06-01,Dividend Yield,https://www.investing.com/analysis/best-dividend-paying-stock-list-as-of-june-2012-125125,125125
182527,404043,ABT,How Not to Get Big Pharma To Change Its Ways,opinion,Earlier this week the Justice Department announced a  3 billion settlement of criminal and civil charges against pharma giant GlaxoSmithKline  GSK    the largest pharmaceutical settlement in history   for improper marketing prescription drugs in the late 1990s to the mid 2000s The charges are deadly serious  Among other things  Glaxo was charged with promoting to kids under 18 an antidepressant approved only for adults  pushing two other antidepressants for unapproved purposes  including remedying sexual dysfunction  and  to further boost sales of prescription drugs  showering doctors with gifts  consulting contracts  speaking fees  even tickets to sporting events  3 billion may sound like a lot of money  but during these years Glaxo made  27 5 billion on these three antidepressants alone  according to IMS Health  a data research firm   so the penalty could almost be considered a cost of doing business  Besides  to the extent the penalty affects Glaxo s profits and its share price  the wrong people will be feeling the financial pain  Most of today s Glaxo shareholders bought into the company after the illegal profits were already built into the prices they paid for their shares Not a single executive has been charged   even though some charges against the company are criminal  Glaxo s current CEO came on board after all this happened  Glaxo has agreed to reclaim the bonuses of any executives who engaged in or supervised illegal behavior  but the company hasn t officially admitted to any wrongdoing   and without legal charges against any of executive it s impossible to know whether Glaxo will follow through The Glaxo case is the latest and biggest in a series of Justice Department prosecutions of Big Pharma for illegal marketing prescription drugs  In May  Abbott Laboratories settled for  1 6 billion over its wrongful marketing of an antipsychotic  And an agreement with Johnson   Johnson is said to be imminent over its marketing of another antipsychotic  which could result in a fine of as much as  2 billion The Department says the prosecutions are well worth the effort  By one estimate it s recovered more than  15 for every  1 it s spent But what s the point if the fines are small relative to the profits  if the wrong people are feeling the financial pinch  and if no executive is held accountable  The only way to get big companies like these to change their behavior is to make the individuals responsible feel the heat An even more basic issue is why the advertising and marketing of prescription drugs is allowed at all  when consumers can t buy them and shouldn t be influencing doctor s decisions anyway  Before 1997  the Food and Drug Administration banned such advertising on TV and radio  That ban should be resurrected Finally  there s no good reason why doctors should be allowed to accept any perks at all from companies whose drugs they write prescriptions for  It s an inherent conflict of interest  Codes of ethics that are supposed to limit such gifts obviously don t work  All perks should be banned  and doctors that accept them should be subject to potential loss of their license to practice ,2012-07-06,Robert B. Reich,https://www.investing.com/analysis/how-not-to-get-big-pharma-to-change-its-ways-128749,128749
182530,404046,ABT,Short Squeeze   Speculation Could Push Onyx And Ligand Higher,opinion,When I last covered Onyx Pharmaceuticals  NASDAQ ONXX  on June 19th  the company was trading at a market capitalization of approximately  3 billion dollars ahead of a review of Kyprolis  carfilzomib  by the FDA s Oncologic Drugs Advisory Committee  ODAC   Anyone who read the article and was bold enough to get long in anticipation of a favorable vote by ODAC was rewarded with a 43  rally the next day based on the 11 0 vote in favor of approval  Onyx s business partner for Kyprolis  Ligand Pharmaceuticals  LGND   also saw a massive rally  about 28   over the next two trading days In the other article  I also mentioned the 11  of shorts that were likely betting on an unfavorable ODAC decision  The short interest is now down to about 9 3  of float  which still allows for big short squeeze potential after the recent FDA approval for carfilzomib in the treatment of multiple myeloma for patients who had failed two previous therapies The FDA decision  which was issued on July 20th  limits the downside of Onyx  and partner Ligand  due to the lack of alternatives in the treatment of multiple myeloma  There is also ever present takeover speculation for Onyx  which may grow now that Kyprolis has its approval in hand  We are expecting Bayer to be the buyer  if it happens  due to the existing partnership for the drug regorafenib between the companies  Regorafenib has also recently received FDA priority review designation  which establishes the PDUFA action date four months close  to October 2012 instead of February 2013  Multiple myeloma  which is a particularly nasty and fatal plasma cell cancer that is very rare  with about 1 4 cases per 100 000  has historically been very difficult  and unprofitable  to treat  This is why we are expecting Kyprolis to have great drug penetration rates and bring Onyx  and Ligand  some better financial figures when the drug gets brought into the market In addition to Kyprolis  Onyx has the   300 000 year oncology drug Nexavar which has been approved for the treatment of liver and kidney cancer in the US and EU  Onyx is working towards expansion of its clinical applications  with phase III trials still underway in thyroid and breast cancer   which provides more catalysts down the road for the company to grow in value Even after major jumps in ONXX and LGND following developments in Kyprolis  there could be some additional upside left in the near term for traders who are willing to wait for shorts to shake out of their positions  which seems quite likely   These companies are both beginning to enter the  profitability  zone  and the 5 9 million shares betting against ONXX and the 1 3 million short on LGND are likely stuck in the red hoping something goes wrong Speaking of Ligand Pharmaceuticals  NASDAQ LGND   there was important news for the stock during Wednesday s session  Ligand announced that its partner GlaxoSmithKline   NYSE GSK  has been granted priority review from the FDA for the supplemental new drug application for Promacta  to treat thrombocytopenia caused by the hepatitis C  HCV  virus  Thrombocytopenia is a shortage of platelet cells  which help with blood clotting and as biotech investors know  stocks tried to the treatment of hepatitis C have seen valuations increase dramatically during the past year given that the hepatitis epidemic continues to spread The bullish Hepatitis space s activity  including moves from Gilead Sciences  Inc   NASDAQ GILD  paying  11 billion in cash for Pharmasset and Bristol Myers Squibb  NYSE BMY  snagging Inhibitex for  2 5 billion in cash  The strong volatility seen for hepatitis c players Idenix Pharmaceuticals  NASDAQ IDIX  Achillion Pharmaceuticals  NASDAQ ACHN   Abbott Laboratories  NYSE ABT   Vertex Pharmaceuticals  NASDAQ VRTX  and Merck   Co   NYSE MRK  is understandable given the suspected infection cases in more than 5 million people in the United States  and perhaps as many as 200 million around the world This priority review designation is given to drugs that if approved  offer major advances in treatment  or provide a treatment where no adequate therapy exists  Under the Prescription Drugs User Fee Act  the goal for completing a Priority Review is six months Recently  Cantor Fitzgerald reiterated a Buy rating on LGND and raised its price target from  19 to  24  It will be interesting to see if that firm increases their price target on the stock given the latest developments Earlier the same day  the firm had announced that it plans to report second quarter 2012 financial results on Wednesday  August 8  2012  Recently  Ligand  reaffirmed fiscal 2012 revenue guidance to be approximately  30 million and we know that one of Ligand s core goals is to produce a bottom line that supports a sustainably profitable business Technically speaking  LGND shares have a real opportunity to break past some resistance that has kept prices in check lately  As followers of the stock point out  the shares appear poised to say goodbye to the teens  but the  18 to  18 15 mark has proven tough to break through  It has withstood some positive news events  but is worth watching because the stronger the resistance  the greater the reaction when the resistance is crossed  In turn  that resistance usually becomes strong support All of these factors makes us particularly bullish about LGND in the short and long term ,2012-07-29,Myriad Equity,https://www.investing.com/analysis/short-squeeze---speculation-could-push-onyx-and-ligand-higher-131247,131247
182535,404051,ABT,Top Trade Ideas For The Week Of September 10  2012  The Rest,opinion,Abbott Labs  ABT Abbott Labs  ABT  is moving higher and at resistance after consolidating at the 50 day Simple Moving Average  SMA   The Relative Strength Index  RSI  is bullish and rising with a Moving Average Convergence Divergence indicator  MACD  that has crossed to positive  and SMA s all pointing higher  The Measured Move higher takes it to 68  but the 3 box reversal Point and Figure chart  PnF  has a price objective of 94  well above that BB T  BBT BB T  BBT  is breaking the triple top at 32 60 with a RSI that is bullish and rising and a MACD that at is positive to support further upside price movement  It has a target on a Measured Move higher to 37 30 and a PnF price objective at 57 50 above that  DSW  DSW DSW  DSW  moved above a double top two weeks ago and has been consolidating in a bull flag since  It has a RSI that is bullish and a MACD that is negative  but shallow and not unexpected in a bull flag  A move over the top of the flag carries a Measured Move to 70 25 with the PnF price objective at 92 above that  Elevated short interest near 8  could also fuel a move higher  FirstMerit  FMER FirstMerit  FMER  broke above a triple top at 16 70 Friday and is near resistance from March at 17 15  Above that brings a wide angle target of 23 on a weekly timeframe Measured Move  The PnF price objective is above that even at 25 50  The rising and bullish RSI and positive MACD support further upside as well  iRobot  IRBT iRobot  IRBT  is moving up near resistance at 26 40 and now over the 200 day SMA  Through resistance higher carries a Measured Move to 30 40 and the PnF sees it even higher with a price objective of 39  The RSI is bullish and the MACD  although negative  is improving  to support a move higher  The short interest near 9  could help it higher as well  Up Next  Bonus IdeaAfter reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Saturday which  with the full workforce returning from vacation the markets are looking very bullish Gold looks to continue its uptrend while Crude Oil may consolidate with in the current uptrend  The US Dollar Index is wounded and heading lower and US Treasuries look to follow it lower as well  The Shanghai Composite is ready for a continued bounce in the downtrend and Emerging Markets are looking higher in the broad range  Volatility looks to remain very low making for an environment for the equity index ETF s SPY  IWM and QQQ  to continue higher  And all three charts on both the daily and weekly timeframes are set up to comply  Use this information as you prepare for the coming week and trade m well Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2012-09-10,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-of-september-10,-2012:-the-rest-135782",135782
182536,404052,ABT,Sucampo Pharmaceuticals Initiation Of Coverage ,opinion,Prostone PioneerSucampo s investment case rests on its ability  with its partner Takeda  to protect and boost sales of constipation drug Amitiza  lubiprostone  in the US in the face of fresh competition from Ironwood Forest s Linzess  linaclotide   The entrance of Linzess in Q412 and a reinvigorated promotional effort behind Amitiza should help to grow the US market for the use of prescription drugs to treat constipation disorders  currently just 6 8    while Amitiza s proven track record provides a key differentiating factor Proven Track RecordOver six million prescriptions have been filled in the US for Amitiza since it gained FDA approval in 2006  Until the recent approval for Linzess  Amitiza was the only available FDA approved prescription drug for chronic idiopathic constipation  CIC  and irritable bowel syndrome with constipation  IBS C   Given historical safety issues with using Rx drugs for the estimated ten million US patients seeking alternatives to dietary lifestyle changes and OTC therapies  Amitiza s established track record is a key selling point Promotional Piggy Back And Line ExtensionsSucampo believes US Amitiza sales  FY11  226m  are well below par  due to an inadequate promotional effort so far by Takeda  particularly in raising awareness of Amitiza among patients  the basis of its recently failed attempt to regain US rights   The launch of Linzess in Q412 could therefore benefit Amitiza  which holds further potential in opioid induced constipation  FDA approval in H113   as well as near term commercial opportunities in Japan  launch by Abbott Laboratories by end 2012  and Europe  UK approval for CIC in Sep 2012 and potential to secure new partners  Rescula OpportunitySucampo is planning to launch Rescula  unoprostone  in the US by the end of 2012 as a treatment to reduce intra ocular pressure  IOP  in glaucoma patients  an important milestone in building Sucampo s commercial abilities in a burgeoning ophthalmology sector and expanding the use of its prostone based products Valuation   304m With Upside PotentialWe value Sucampo at  304m  or  7 25 per share  based on a sum of the parts DCF valuation  This assumes Amitiza s current US sales run rate is maintained and includes risk adjusted new opportunities in OIC in the US and Japan for CC  as well as a successful launch for Rescula in the US  Our base case valuation represents clear upside to Sucampo s market capitalisation of  193m and  4 60 share price To Read the Entire Report Please Click on the pdf File Below ,2012-09-28,Edison,https://www.investing.com/analysis/sucampo-pharmaceuticals-initiation-of-coverage-138055,138055
182554,404070,ABT,DCF Model Confirms,opinion,RECOMMENDATION  Reiterate  STRONG BUY    MINIMUM PT   1 01  58  upside   Just yesterday  Gould Partners  investor to aggressively buy shares in      This bullish call was reiterated by other analysts and now  in our view  confirmed by favorable business momentum   The developer of lab sample equipment recently entered into a JV agreement with Sage N Research to create software for Pressure BioSciences  innovative pressure cycling technology  PCT   This news comes off of two other favorable announcements  namely that  1  the company is ramping up its distributors and  2  partnering with the Henry C  Lee Institute of Forensic Sciences to evaluate PCT  We view  2  as putting the company into play  since  around 3 weeks ago  Abbott Labs    entered into an agreement with the University of North Texas Science Center to evaluate a forensic solution  Scientists at the University of North Texas and Florida International University have already expressed how PCT has helped them improve DNA yields  And more than 100 independent publications have backed this positive consensus  As Pressure BioSciences begins to aggressively commercialize operations through increasing marketing staff  international distributors  and partnerships  it is well positioned to surge in value  A discounted cash flow analysis of the stock demonstrates that Pressure BioSciences is on the verge of heading skyward  It is only a matter of time before investors pick up on the fundamentals The company finished 2010 with  1 34M in revenue  In the second half of 2011  the top line spiked 66  off of the first half  Fourth quarter consumable sales were up 77  sequentially  Despite these impressive figures  for the sake of being safe  Gould Partners conservatively models a 12 8  per annum growth rate in revenue over the next six years  This projection is in line with consensus expectations for peer company Thermo Fisher Scientific Inc  TMO   But  since Thermo Fisher has a much larger base to grow off of  our projection significantly understates PBIO s potential Cost of goods sold has also fallen drastically over the last reported three years  from 47 1  of revenue in 2008 to 28 4  in 2010  We expect this figure to trend from 25  to 20  over the next six years as R D hovers around 6  to 1   and SG A holds steady at 27  We then factor in taxes  net increases in working capital  and debt while adjusting for depreciation  Taking a perpetual growth rate of 2 5  and discounting backwards by an overly high rate of 15   our bearish price target for PBIO is  1 01  This implies 58  upside  As noted above  this calculation is overly reserved on revenue projections and the discount rate  Reason thus calls for a  strong buy  recommendation With the stock trading 10  book value  we believe firms like Abbott and Thermo Fisher are most likely considering a takeover  Pressure BioSciences already has over 150 customers under its belt  demonstrated the efficacy of its products  and proven supportive demand  Access to a wider client base would significantly catalyze revenue  If an outright buyout does not emerge  we anticipate the firm to receive multiple partnership requests  It should be noted that these partnerships could  in turn  develop into an acquisition With  910K capital backing from leading federal agencies  ie  NIH and DoD  in 2011  a strong IP profile  critical diversification in three different markets  ie  mass spectrometry  forensics  histology   and industry acclaim  PBIO may very well be the hottest stock of 2012 This is a company that  again  we see  at a minimum  yielding double digit returns  When the Street picks up on all of this  and we hope to alert professionals   understand that this stock is heading up DISCLAIMER  The distributor of this research report    is not a licensed investment adviser or broker dealer  Investors are cautioned to perform their own due diligence as information contained within this report has been derived from public sources and cannot be guaranteed by us to be fully accurate  We are a consultant to a third party EAG  representing Pressure BioSciences and have received one thousand dollars for independent research  Always discuss investments with a licensed professional before making any financial decision  Statements made herein are often  forward looking statements  as stipulated under Section 27A of the Securities Act of 1933  Section 21E of the Securities Act of 1934  and the Private Securities Litigation Reform Act of 1995  Since these statements are uncertain  actual results may be materially different from those expected ,2012-03-26,Takeover Analyst,https://www.investing.com/analysis/dcf-model-confirms-118141,118141
182555,404071,ABT,U S  Stocks Close Higher  Boosted by Bernanke Speech  Overlook Housing Data,opinion,After Hours  U S  Stocks Close Higher  Boosted by Bernanke Speech  Overlook Housing Data4 09 PM  Mar 26  2012    U S  stocks soared in Monday s session after Federal Reserve Chairman Ben Bernanke signaled the central bank is committed to a monetary policy that will help buoy the stock market In an address to the National Association for Business Economics  Bernanke also offered a positive take on current unemployment problems in the U S   saying today s high jobless rate is the result of cyclical problems rather than more permanent causes Bernanke s comments kept stocks trading higher despite soft data released today on home sales  The National Association of Realtors said on Monday its Pending Home Sales Index  based on contracts signed in February  slipped 0 5 percent to 96 5  continuing a string of lower sales for the month following an unexpectedly strong January  Economists polled by Reuters had expected signed contracts to climb 1 0  last month In company news  Verenium Corp   VRNM  surged after the farm biotechnology company sold  37 million of food enzymes and oilseed processing licenses to Dutch firm Royal DSM NV Healthcare stocks led today s market advance  as the Supreme Court began reviewing the U S  Healthcare Act  Pfizer  PFE   Johnson   Johnson  JNJ   Abbott Laboratories  ABT   and Merck   Co   MRK  were all higher Gold surged following Bernanke s statements  Gold for April delivery advanced  23 20  or 1 4   to  1 685 60 an ounce on the Comex division of the New York Mercantile Exchange  its highest settlement in nearly two weeks  Crude oil futures for May delivery gained 16 cents and closed at  107 03 a barrel Here s where the markets stood at end of day Dow Jones Industrial Average up 160 90   1 23   to 13 241 63S P 500 up 19 40   1 39   to 1 416 51NASDAQ Composite up 54 65   1 78   to 3 122 57GLOBAL SENTIMENTNikkei 225 up 0 07  to 10 018 24 Hang Seng Index flat China Shanghai Composite Index up 0 05  FTSE 100 up 0 82  UPSIDE MOVERS    BJRI  Wedbush raised its rating for the restaurant stock to Outperform from Neutral     OVRL  said its SnapServer DX Series of products won the Hardware Product of the Year award at the 2012 Network Computing awards     GRVY  Ragnork Online II was launched in Korea DOWNSIDE MOVERS    SWY  Credit Suisse cut rating to Neutral from Outperform and lowered price target to  20 a share     CALM  Q3 earnings slid 22  from year ago levels as higher costs hurt margins     KBH  Reported loss on Friday ,2012-03-27,Midnight Trader,"https://www.investing.com/analysis/u.s.-stocks-close-higher;-boosted-by-bernanke-speech,-overlook-housing-data-118240",118240
182556,404072,ABT,Best And Worst Sector ETFs  And Mutual Funds ,opinion,The best ETFs and mutual funds have high quality holdings and low costs  There are few funds that have both good holdings and low costs  There are lots of cheap funds  but there are too few funds with high quality holdings    I think there are at least two causes for this disconnect  First  there is  in general  a lack of independent research on ETFs and funds  Second  I think it is fair to say that there is a severe lack of quality research into the holdings of mutual funds and ETFs  There should not be such a large gap between the quality of research on stocks and funds  which are simply groups of stocks    After all  investors should care more about the quality of a fund s holdings than its costs because the quality of a fund s holdings is the single most important factor in determining its future performance    The following is a summary of my top picks and pans for all sector funds  I will follow this summary with a detailed report on each sector    Figures 1 shows the best ETF or mutual fund in each sector as of April 13  2012    For a full list of all ETFs and mutual funds for each sector ranked from best to worst  see my free     Figure 1  Best ETF or Mutual Fund by Sector Source  New Constructs  LLC and company filingsOnly one sector fund gets my Very Attractive rating  Health Care Select Sector SPDR  XLV   Over 30  of this fund is allocated to Very Attractive stocks  including Merck   Co   Inc   MRK  and Abbott Laboratories  ABT   Another 35   is allocated to Attractive stocks  About 28  is in Neutral stocks while less than 3  is in Dangerous or worse rated stocks One of the fund s top holding is MRK  With positive and rising economic earnings and a valuation that implies at permanent 10  decline in profits  MRK offers teriffic risk reward Figure 2 shows the worst ETF or mutual fund for each sector as of April 13  2012 Dangerous or worse rated funds have a combination of low quality portfolios  i e  they hold too many Dangerous or worse rated stocks  and high costs  they charge investors too much for the  lack of  management they provide  Figure 2  Worst ETF or Mutual Fund by SectorSource New Constructs  LLC and company filings   Fidelity Advisors Series VII  Fidelity Advisor Biotechnology Fund  FBTAX  is the worst health care fund and gets my Very Dangerous rating  The Portfolio Management rating for this fund is Dangerous and the Total Annual Cost Rating is Dangerous  resulting in a lose lose value proposition for investors  The managers at FBTAX have a lot of nerve charging an investor over 8  per year over 3 years    One of my least favorite stocks in this fund is SIGA Technologies  Inc   SIGA   It gets my Very Dangerous rating because of misleading earnings and an expensive valuation  The company s ROIC is     28   well below its cost of capital  To justify its valuation  the stock at  3 implies the company will grow its profits at 50  compounded annually for 15 years  Good luck    Traditional mutual fund research has focused on past performance and low management costs  The quality of a fund s holdings has been ignored  Our Portfolio Management Rating examines the fund s holdings in detail and takes into account the fund s allocation to cash  Our models are created with data from over 50 000 annual reports  This kind of due diligence is necessary for understanding just what you are buying when you invest in a mutual fund or an ETF    Figure 3 shows the best ETF or mutual fund based on our Portfolio Management Rating for each sector as of April 13  2012    Attractive or better rated funds own high quality stocks and hold very little of the fund s assets in cash   investors looking to hold cash can do so themselves without paying management fees  Only 2  of funds receive our Attractive or Very Attractive Portfolio Management ratings  so investors need to be cautious when selecting a mutual fund or ETF   there are thousands of Neutral or worse rated funds    Figure 3  ETF or Mutual Fund With Highest Quality Holdings by Sector  Source  New Constructs  LLC and company filingsFigure 4 shows the worst ETF or mutual fund based on our Portfolio Management Rating for each sector as of April 13  2012 Even ignoring costs  many ETFs and mutual fund do a poor job investing money for their clients  These funds are not worth owning at any cost Figure 4  ETF or Mutual Fund With Lowest Quality Holdings by Sector Source   New Constructs  LLC and company filings   Investors should care about all of the fees assocated with a fund in addition to the quality of the fund s holdings  The best ETFs and mutual funds have both low costs and quality holdings   and there are plenty of low cost funds available to investors    Figures 5 shows the best ETF or mutual fund in each sector according to our Total Annual Costs Rating    Total Annual Costs incorporates all expenses  loads  fees  and transaction costs into a single value that is comparable across all ETFs and mutual funds  Passively managed ETFs and index mutual funds are generally the cheapest funds    Figure 5  ETF or Mutual Fund With Lowest Costs by Sector  Source   New Constructs  LLC and company filings   The most expense fund for each sector has a Very Dangerous Total Annual Costs Rating  Guggenheim Investments Electronics Fund   RYELX   the most expensive Industrials mutual fund  charges investors a Total Annual Cost of 7 7   Investors should avoid these funds and other funds with a Very Dangerous Total Annual Costs Ratings because they charge investors too much  For every fund with a Very Dangerous Total Annual Costs Rating there is an alternative fund that offers similar exposure and holdings at a lower cost  Investors have plenty of alternatives to these over priced funds    Figures 6 shows the worst fund in each sector according to our Total Annual Costs Rating    Figure 6  ETF or Mutual Fund With Highest Costs by Sector  Source  New Constructs  LLC and company filingsDisclosure  I receive no compensation to write about any specific stock  sector or theme ,2012-04-18,David Trainer,https://www.investing.com/analysis/best-and-worst-sector-etfs-(and-mutual-funds)-120480,120480
